Novel β-hairpin peptidomimetic inhibitors of protein-RNA interactions in BIV/HIV-1 and in bacterial RNase P by Patora-Komisarska, Krystyna
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2008
Novel ￿-hairpin peptidomimetic inhibitors of protein-RNA interactions in
BIV/HIV-1 and in bacterial RNase P
Patora-Komisarska, Krystyna
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-163806
Dissertation
Published Version
Originally published at:
Patora-Komisarska, Krystyna. Novel ￿-hairpin peptidomimetic inhibitors of protein-RNA interactions in
BIV/HIV-1 and in bacterial RNase P. 2008, University of Zurich, Faculty of Science.
   
Novel !-Hairpin Peptidomimetic Inhibitors of Protein-RNA 
Interactions in BIV/HIV-1 and in Bacterial RNase P 
 
 
Dissertation 
 
 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat) 
 
 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
 
 
von 
Krystyna Patora-Komisarska 
aus Polen 
 
 
 
 
Promotionskomitee 
Prof. Dr. John A. Robinson (Vorsitz) 
Prof. Jay S. Siegel 
 
 
 
Zürich 2008 
 
 
 Summary -1- 
Summary 
 
 
The aim of the research described in this thesis is the development of novel 
antiviral and antibacterial !-hairpin peptidomimetics. The focus has been on the 
inhibition of the critical protein-RNA interactions between the viral regulatory proteins 
Tat and Rev and their target RNAs TAR and RRE, respectively, and the RNA and 
protein subunits of bacterial RNase P. RNA and its interactions with proteins has grown 
greatly in importance during the last decade. The increasing resistance against antiviral 
and antibacterial drugs puts these novel targets into a favourable light, as it is generally 
thought that pathogens will find it difficult to mutate RNAs that fulfill essential 
functions. Efforts have been made to mimic the native RNA binding domains of the 
above-mentioned proteins using cyclic peptides containing a heterochiral diproline 
template. These peptides are an interesting class of protein mimetics due to the strong 
!-hairpin inducing properties of the D-Pro-L-Pro template. They can be made 
efficiently using commercially available building blocks and standard solid-phase and 
solution synthesis methods. 
The interaction between the viral protein Tat and its cognate transactivator 
response element (TAR) RNA is critical for the life cycle of the virus. The bovine 
immunodeficiency virus (BIV) Tat arginine-rich RNA binding domain is found to 
adopt a !-hairpin conformation upon binding to TAR RNA. Previous studies on BIV 
Tat peptidomimetics allowed the identification of one highly potent BIV Tat-TAR 
inhibitor, called BIV2. Its stable !-hairpin conformation and high affinity to BIV TAR 
RNA enabled determination of the structure of its complex with BIV TAR by NMR 
techniques. In this work, extensive structure-activity relationship (SAR) studies on 
these 12-mer loop BIV Tat peptidomimetics were carried out, which yielded further 
highly potent and selective ligands. Furthermore, the BIV Tat-TAR interaction was 
employed as a model from which important information about RNA recognition was 
derived and exported to human immunodeficiency virus type-1 (HIV-1) Tat-TAR, 
facilitating the design of novel !-hairpin peptidomimetic inhibitors of HIV Tat. From 
assaying an extensive library of BIV Tat peptidomimetics, some potent and selective 
ligands for HIV-1 TAR RNA have been identified, the best of which L2-15, exhibits a 
dissociation constant of Kd~75 nM and an IC50~100 nM for inhibition of ADP-1 
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binding to TAR. Analogous to the BIV system, the HIV-1 Tat protein binds to the 
bulge region of the TAR RNA stem-loop structure. However, in order to function, a 
ternary complex between Tat-TAR and cyclin T1 must be formed, in which cyclin T1 
interacts with Tat and the tip of the RNA TAR loop. Guided by computational 
modelling and SAR studies, novel 16-mer loop HIV-1 Tat peptidomimetics were 
developed, which exhibit a stable !-hairpin conformation in aqueous solution, bind 
with high affinities to TAR RNA and are able to inhibit the Tat-TAR interaction. The 
best peptide in this class, L5-11, exhibits a dissociation constant of Kd~25 nM in the 
presence of a large excess of tRNA, and Kd~0.5 nM in the absence of the competitor 
RNA. Since the structure of the HIV-1 Tat-TAR complex is not yet available, extensive 
SAR studies on the 16-mer loop mimetics have been performed, in order to deepen 
understanding of the recognition principles in this protein-RNA interaction. Further 
studies on HIV Tat peptidomimetics established their ability to internalise through the 
cell membrane and their stability in biological settings. 
A second critical step for viral replication is binding of Rev protein to Rev 
response element (RRE) RNA, which facilities successful transport of full length or 
partially spliced mRNA from the nucleus into the cytoplasm. The RNA-binding domain 
of Rev protein was found previously to form an "-helical structure upon binding to its 
target RNA. In the second part of this thesis, a novel approach is presented to mimic 
this "-helical structure using a !-hairpin peptidomimetic, which provides a robust 
scaffold upon which the groups critical for RRE recognition are displayed. First, 
assaying the already available related !-hairpin peptidomimetics based on BIV Tat-
derived peptide, and then designing a new series of peptides based on the sequence of 
the RNA-binding domain of Rev, gave a set of potent RRE ligands, with Kd’s 
comparable to that of the native Rev peptide. The hairpin conformation of the peptides 
was stabilized by introducing a disulfide cross-link, resulting in a very active Rev 
peptidomimetic, R2-14, with a stable !-hairpin structure in aqueous solution.  
A similar approach is also described for the design of novel peptidic inhibitors 
of E. coli RNase P, a ribonucleoprotein, which facilitates the maturation of precursor 
tRNA in all three domains of life. The extensive biochemical studies on two related 
bacterial strains, E. coli and B. subtilis, revealed that "-helical, highly conserved and 
arginine-rich regions of the protein subunit of RNase P interact with the catalytically 
active RNA subunit. By assaying peptides from the Rev library, exhibiting sequence 
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similarities to the RNA-binding domain of RNase P protein, two potent antimicrobial 
agents acting selectively on E. coli were discovered. Combining the information from 
these lead compounds and preparing a computational model of a !-hairpin 
superimposed on the helical epitope of interest, led to the discovery of highly active 
inhibitors of RNase P in E. coli, the best of which, P2-05, possessed a MIC value of 
0.06 µg/ml. This class of peptides has proved to have favourable in vitro 
pharmacological properties including low haemolytic activity and high stability in 
plasma, which makes them interesting as prospective antimicrobial agents. 
All three above-mentioned approaches to inhibitors of protein-RNA interactions 
resulted in the discovery of very potent and selective antiviral and antibacterial agents 
that are very attractive starting points for drug development. In addition to their 
pharmaceutical potential, the extensive SAR studies provide important information 
about the chemistry and principles governing RNA recognition by these structurally 
and conformationally constrained peptidomimetics, which might aid the optimisation of 
other known RNA ligands, and in the future, the development of agents targeting other 
functional RNAs. 
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1. INTRODUCTION 
 
 
1.1. RNA - a target for drug discovery 
 
The growing awareness of the remarkable variety of biochemical roles of RNA 
in all living organisms is leading to an increasing appreciation that cellular and viral 
RNAs provide inviting targets for the treatment of both infectious and chronic diseases. 
Since the emergence of drug resistance is an ever-increasing therapeutic problem in 
traditional antibacterial and antiviral therapies, exploiting a new class of molecules that 
are chemically distinct from protein-based targets, namely RNA, offers a promising 
strategy to overcome this problem.  
RNA has for a long time been a validated drug target for antibacterial treatment. 
Antibiotics that have been in clinical use for decades (e.g. erythromycin) bind 
ribosomal RNA.1 Furthermore, in the last decade, RNA interference (RNAi), a 
technique that utilizes small interfering RNAs (siRNAs) to specifically knock-down the 
expression of targeted genes at the post-transcriptional level, has gained a lot of 
interest. This methodology not only has broad application in basic biomedical research, 
but is also being used in the development of therapeutic agents.2 A milestone in this 
field was the approval of a first antisense drug in 1998, Vitravene, to treat a condition 
called cytomegalovirus (CMV) retinitis in people with AIDS. 
Most functions of RNA require an interaction with RNA-binding proteins. 
Therefore protein-RNA complexes are not only important for understanding RNA 
recognition, but also protein-binding sites in RNA are potential targets for drug 
discovery. Prominent examples are interactions critical for virus replication in human 
immunodeficiency virus (HIV) between the regulatory proteins Tat and Rev and their 
cognate RNAs, TAR and RRE, respectively. 
 
 
1.1.1. RNA-binding proteins 
 
Specific RNA-protein interactions play crucial roles in gene regulation through 
transcriptional control, RNA processing, RNA transport and translation. During 
transcription, RNA structures mediate several important regulatory mechanisms, such 
 Introduction -8- 
as transcription termination by the eubacterial mRNA-binding Rho factor,3 the tRNA-
dependent transcription anti-termination in eubacteria,4 and the trans-activation of viral 
genome transcription in HIV and related retroviruses.5 Primary RNA transcripts 
undergo a variety of different processing and localization events, depending on the type 
of RNA (mRNA, rRNA, tRNA, etc.) and organism. The three main post-transcriptional 
modifications of mRNA in eukaryotic cells are: 5'-capping, 3'-polyadenylation, and 
RNA splicing.6 In the nucleus, pre-mRNA is associated with a variety of proteins in 
complexes known as heterogeneous ribonucleoprotein particles (hnRNPs).7 
Spliceosomes, to mention just one example of such pre-mRNA-protein complexes, are 
essential to remove internal non-coding regions of pre-mRNA (introns) and to join the 
remaining segments (exons) into mRNA before translation.8 After maturation, mRNA 
has to be transported from the nucleus to the cytoplasm, where translation can take 
place. This process is facilitated by nuclear pores, large protein complexes that cross 
the nuclear envelope. In HIV-1, for example, the genomic RNA is exported with the 
help of the Rev protein, which has a specific binding site for the RRE motif present in 
unspliced and partially-spliced HIV-1 RNA and an NES motif (nuclear export signal), 
which interacts with exportin-1. Another essential RNA-protein complex common for 
all the life kingdoms is RNase P. This ribonuclease catalyses endonucleotic cleavage of 
the 5’-leader sequence of precursor tRNAs, producing a mature 5’-phosphate at the end 
of the tRNA.  
The activity of the family of RNA-binding proteins is mediated by the specific 
recognition of sequences and structural elements within the mRNA transcripts. RNA is 
normally single stranded but often forms secondary structures, such as hairpins (stem-
loops), bulges and internal loops through pairing of complementary stretches within a 
strand. These secondary structural elements are often used as binding sites for proteins. 
Characterization of these RNA binding proteins resulted in the identification of several 
RNA-binding motifs, including RNA-recognition motifs (RRMs), K-homology 
domains (KH), Zinc finger (ZnF), double-stranded RNA binding domains (dsRBD), 
and arginine–rich motifs.9,10  
The RNA-recognition motif (RRM, also referred to as RNA binding domain 
(RBD) or RNP-motif) is by far the most common and best characterised of the RNA-
binding molecules. It is usually composed of 80-90 amino acids that form a four 
stranded antiparallel !-sheet with two helices packed against it, and follows a general 
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pattern of !#"#!#!#"#!. In the approximately 20 known structures of RRM-RNA 
complexes, RNA recognition usually occurs on the surface of the first !-sheet. Binding 
is mediated in most cases by three conserved residues: an Arg or Lys residue that forms 
a salt bridge to the phosphodiester backbone and two aromatic residues that make 
stacking interactions with the nucleobases. These three amino acids reside in the two 
highly conserved motifs, RNP motif-1 (RNP1) and RNP2, and define these motifs at 
the sequence level and are located in the two central !-strands.11,12  
K-homology (KH) protein is a domain that binds both single-stranded DNA and 
RNA and is ubiquitous in eucaryotes, eubacteria and archea. The domain is composed 
of 60-70 amino acids with a functionally important signature sequence of 
(I/L/V)IGXXGXX(I/L/V) near the centre of the domain. The KH-domain contains 
three antiparallel !-sheets, which are packed against three "-helices on one face of the 
!-sheet (!#"#"#!#!#" or "#!#!#"#"#!) The loops between !2/!3 or "2/!2 as well 
as a GXXG motif are important for recognizing about four nucleotides in single 
stranded RNA (ssRNA).13,14  
The double-stranded RNA binding domain, dsRBD, is another small domain 
composed of 60-70 amino acids, which folds into a structure where two "-helices lie on 
the face of a three-stranded antiparallel #-sheet ("#!#!#!#"). Such domains are found 
in both bacteria and eucaryotes. Helix "1, the N-terminal portion of "2-helix and the 
loop between !1 and !2 are important for the shape-specific recognition of the minor-
major-minor groove of dsRNA through contacts to the sugar-phosphate backbone.15  
Zinc-fingers (ZnF) are one of the most versatile binding motifs, first known as 
DNA-binding domains, but now also known to have additional activities such as the 
recognition of RNA and other proteins. They are characterized by a Cys- and His-rich 
domain that chelates a zinc ion. Different classes of zinc-finger proteins contain 
different combinations of metal binding amino-acids: CCHH (Cys-Cys-His-His), 
CCCH or CCHC. Structural studies of ZnF complexes reveal considerable diversity in 
terms of protein partners, binding modes and affinities, and highlight the often 
underestimated versatility of the ZnF structure and function (Figure 1).16,17 
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!
Figure 1. RNA-binding proteins: RRM-Structure of the N-terminal RNA-recognising motif of human 
U1A bound to RNA;12 KH-domain of Nova-2 bound to 5’-AUCAC-3’;18 dsRNA-binding domain from 
yeast Rnt1 bound to an RNA helix;19 two ZnF of TlS11d bound to an AU-rich RNA element.20  
 
In contrast to the prefolded RNA-binding domains described above, short 
arginine-rich domains, called also arginine-rich motifs (ARM), adopt stable 
conformations only upon binding to their target RNAs. Proteins containing ARMs 
function in transcription, translation, RNA trafficking and packaging and are present in 
anti-termination bacteriophage proteins (bacteriophage $ N protein),21,22 viral 
regulatory proteins (Tat, Rev, Rex), ribosomal proteins23 and in naturally occurring 
antimicrobial peptides.24 
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! ! ! !
 
Figure 2. Arginine-rich binding domains, populate a variety of conformations. NMR structures of 
peptide-RNA complexes: HIV Rev-RRE interaction,25 bovine immunodeficiency virus (BIV) Tat-TAR 
interaction,26 bacteriophage $ N peptide-Box B RNA,27 human T-cell leukemia virus (HTLV-1), Rex-
RNA aptamer.28 
 
The ARMs are usually 20-30 amino acids long and, while unfolded or weakly 
structured in the absence of RNA, have been shown to bind RNA in "-helical, !-
hairpin and other conformations (Figure 2). Although it is not surprising that highly 
positively charged peptides derived from this class of RNA-binding proteins can bind 
RNA with a high affinity, it is remarkable that they bind with relatively high 
specificity. This, apparently, is possible because RNAs form distinct binding pockets 
that help to induce peptide conformations and make specific interactions including salt 
bridges, charge-stabilized and neutral hydrogen bonding, weakly polar and %#stacking 
interactions and precise apposition of van der Waals interactions. Adaptive binding of 
peptide secondary structures is associated with widening of the RNA major groove to 
accommodate the ligand. The molecular mechanisms of the major-groove widening are 
different for each complex but share the use of non-canonical RNA elements.  
 
 
1.1.2. RNA-binding domains as attractive targets for drug design 
 
The ability of RNA molecules to fold into complex three-dimensional 
structures, and the importance of RNAs to many biological processes, have generated 
great interest in designing sequence-specific RNA binding molecules. One advantage of 
targeting RNA over traditional protein targets might be slower development of drug 
resistance. The RNA functional domains, potential drug targets, are more highly 
conserved, and it is expected that pathogens will find it more difficult to mutate their 
RNA. The complexity of RNA structure, including double-stranded duplexes, hairpins, 
HIV Rev-RRE RNA    BIV Tat-TAR RNA    $ N-box B RNA Rex-RNA aptamer 
      "-helix          !-hairpin       bent "-helix  extended conformation 
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internal loops, bulged bases, and pseudo-knotted structures, makes it difficult to design 
ligands for sequence-specific RNA recognition. However, de novo design can be very 
useful for testing our understanding of the basic principles of nucleic acid recognition, 
as well as developing new types of drugs to treat both infectious and chronic diseases. 
So far, RNA is a validated drug target for antibacterial treatment. Antibiotics, such as 
aminoglycosides (streptomycin, tombramycin, neomycin), polyketides (tetracycline) 
and macrolides (erythromycin), were all discovered in the ca. 1950’s and target 
bacterial ribosomal subunits, thus inhibiting bacterial protein synthesis.1,29 Furthermore, 
RNA is the genetic material of pathogenic viruses such as HIV or hepatitis C virus 
(HCV), so it provides numerous opportunities for the discovery of new drugs to treat 
these diseases. Finally, the complex functions of RNA in the control of gene expression 
in humans opens many new opportunities to target specific RNAs for the treatment of 
numerous chronic health conditions. To date, many of the RNA targets have been 
approached by modifying existing ribosomal antibiotics. However, new technologies 
such as antisense oligonucleotide agents, siRNA molecules to induce gene silencing by 
RNA interference, have been extensively exploited. However, drawbacks of antisense 
technology are the poor pharmacological profile, unspecific protein binding, inefficient 
metabolic stability and poor cellular uptake. In addition, many RNA sequences are not 
accessible to antisense agents because they are highly structured or bound to cellular 
proteins.30,31  
Among many RNA targets used for drug design, in this work the focus is on 
RNA interacting with arginine-rich domains, including viral BIV/HIV-1 Tat-TAR RNA 
and HIV Rev-RRE RNA interactions, and bacterial RNase P holoenzyme. These targets 
provide good scaffolds for inhibitor design, since the proteins concerned are short, 
conformationally diverse, but well studied from a structural viewpoint and they bind to 
RNA with high affinities and specificities. In the literature, mostly two strategies have 
been taken towards the design of RNA-protein interaction inhibitors: i) by 
modifications of known RNA-binding natural products, such as aminoglycosides, or ii) 
imitating the structure of a native binding domain by short, usually constrained 
peptides. Aminoglycosides seem to be a very attractive starting point, since several 
structures of aminoglycoside-RNA complexes have been solved and the interactions 
with RNA have been well defined, particularly for 16S and 30S ribosomal bacterial 
RNA.1,32 Although, there are examples of aminoglycosides inhibiting RNase P, or viral 
Tat-TAR and Rev-RRE interactions, the structures of the RNA-ligand complexes have 
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been only poorly studied, which makes further optimisation difficult.33 Furthermore, the 
poor oral absorption of highly positively charged aminoglycosides, the growing 
resistance to them, their toxicity and their chemical complexity are drawbacks in the 
use and development of aminoglycosides and their derivatives. Much effort has been 
made to develop other RNA-binding small molecules with lower structural complexity 
than aminoglycosides, and with better pharmacological properties, including 
oxazolidines, the only fully synthetic antibiotics that target rRNA of the bacterial 
ribosome, and phenyl-furan derivatives.29 
Another strategy, the design of relatively small peptidomimetics that can mimic 
the structure and/or function of the active sites within proteins, is gaining popularity at 
present. Peptidomimetics are useful for detailed studies of protein folding, structure and 
function. The main potential application of peptidomimetics is to block protein-protein 
or protein-nucleic acid interactions involved in undesired biological processes. Being 
relatively small, peptidomimetics often solve some of the problems associated with the 
use of proteins as drugs, such as antigenicity. However, low bioavailability and rapid 
enzymatic degradation remain major problems. The properties of the parent binding-
domain must be retained when designing peptidomimetics, including the bioactive 
conformation of the desired active site, and a certain degree of conformational freedom 
to allow an induced fit. Linear peptides are not optimal candidates to mimic proteins, 
because they equilibrate between multiple conformations and their adaptation to the 
bioactive conformation incurs an entropic cost. Introduction of conformational 
constraints into the peptide is, therefore, often needed to generate a successful 
peptidomimetic. Being relatively small and conformationally constrained, cyclic 
peptides are excellent candidates to serve as potential inhibitors of protein-RNA 
interactions.34,35  
 
 
1.1.3. Specificity and stereospecificity of RNA-ligand binding 
 
A major challenge in the development of RNA-targeted therapeutics is to design 
molecules binding selectively to a desired RNA target and not to a multitude of other 
cellular RNAs.36 A deeper understanding of RNA folding, structure and recognition of 
specific targets is necessary to enable the successful design of target-selective 
molecules. Aminoglycosides are among the most commonly used broad-spectrum 
antibiotics in the clinic. Since the initial discovery of streptomycin in 1944, a series of 
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aminoglycoside antibiotics, including kanamycin, neomycin B, gentamicin, and 
tobramycin have been successfully introduced as treatments for serious systemic 
infections, and have been used for a variety of topical applications.1 Due to their broad 
use in clinical applications the aminoglycosides are the most studied RNA-ligands. 
Aminoglycoside antibiotics are highly selective in their preferential binding of RNA 
over DNA, but exhibit much less discrimination between different RNA molecules. 
Aminoglycosides bind to a wide range of unrelated RNAs, including simple duplex 
RNA,37 16S and 18S rRNAs,38,39 mRNA transcripts,40 tRNA,41 and a variety of 
catalytic RNAs.42 The poor RNA-target selectivity of the aminoglycosides has been 
attributed to two major factors, i) their highly charged nature, which is responsible for 
their electrostatically driven binding to the major groove of duplex RNA, and ii) their 
conformational flexibility. The mutual electrostatic attraction between multi-positively 
charged groups of aminoglycosides and the negatively charged RNA backbone may 
also lead to base pairing disruption. They may also bind less extensively to human 18S 
rRNA causing severe toxicity.1,43,44  
A comparison of the selected, clinically used aminoglycosides that can inhibit 
the interactions of viral RNAs TAR and RRE with their native ligands is summarised in 
Table 1. Aminoglycoside antibiotics bind their therapeutic target-bacterial rRNA in the 
sub-nanomolar/low micromolar range, but due to their low specificity they also 
interfere with human rRNA, causing toxicity.45,46 As shown in Table 1 they also bind to 
other RNA domains, including HIV TAR and RRE RNAs. It is reasonable to suggest 
that the inherent flexibility of RNA and the aminoglycosides may allow for a myriad of 
different binding solutions, which lead to the same functional consequences and as a 
result to low selectivity.  
 
Inhibitory activity Aminoglycoside Clinical Use Target 
HIV Tat-TAR HIV Rev-RRE  
Neomycin (1) Excellent against Gram-
positive; partially against  
Gram-negative,  
skin infections 
Binds to the 16S 
subunit of the 
bacterial ribosome 
IC50 $ 1 µM IC50 $ 0.1 µM 
Streptomycin (2) Gram-negative bacteria,  
tuberculosis 
Binds to the 16S 
subunit of the 
bacterial ribosome 
IC50 $ 10 µM IC50 % 100 &M 
Gentamicin (3) Gram-negative bacteria Binds the 30S 
subunit of the 
bacterial ribosome 
IC50 $ 45 µM IC50 $ 10 &M 
Table 1. The comparison of aminoglycoside antibiotics in clinical use interfering with viral RNAs. Also 
shown are inhibitory values (IC50) reported for Tat-TAR RNA from Krebs,
47 and for RRE-Rev from 
Zapp.48 
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Figure 3. Structures of the aminoglycosides that bind to A-site of bacterial rRNA as well as to other  
unrelated RNAs: neomycin (1), streptomycin (2), gentamicin (3), neamine (4). 
 
The cited results indicate that aminoglycoside-based ligands are capable of high 
affinity binding to RNA and therefore are interesting compounds for drug discovery, 
but achieving high site specificity remains a challenging objective. 
The same conclusions were drawn from experiments performed with L- and D-
neamine (4, Figure 3),49 HIV-1 D/L-Tat peptides50,51 and D/L-Rev peptides,52 which 
showed very low, if any, stereospecificity in binding to the target RNA (Table 2). The 
enantiomeric forms of these ligands show similar binding modes, including binding to 
the bulge region of RNA and widening of the major groove.  
 
Ligand Target Kd [nM] 
D-neamine A-site bacterial rRNA 501.7±14.2 
L-neamine A-site bacterial rRNA 1039.5±29.1 
L-Tat peptide TAR RNA 130±80 
D-Tat peptide TAR RNA 220±50 
L-Rev peptide RRE RNA 14.4±0.6 
D-Rev peptide RRE RNA 14.6±0.3 
Table 2. A comparison of binding affinities of enantiomeric forms of neamine, HIV-1 Tat and Rev 
peptides to their target RNAs.49,50,52 
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These findings strongly support the view that both partners in the ligand-RNA 
interaction are mouldable. Thus, rather than being modelled as a rigid key-and-lock, or 
even as a hand-in-glove fitting, it is suggested that both RNA and ligand undergo 
conformational changes by a mutual induced-fit process.  
In an attempt to circumvent this conformational flexibility and the resulting 
RNA target promiscuity, conformationally constrained molecules seem to be one of the 
potential solutions. Freezing the ligand conformation may, under ideal circumstances, 
have advantages including, i) in increased affinity to the desired target due to limited 
entropy losses upon binding and, ii) in increased selectivity by locking the ligand 
skeleton in an unfavourable orientation for binding to competing targets. This approach 
has been taken already in the design of conformationally constrained aminoglycosides53 
and peptidomimetics.54 These studies show that designing a constrained compound that 
binds with the same affinity as the parent natural protein is not a trivial task, however, 
by developing structure-activity-relationships it has proven possible to increase the 
selectivity, as shown also in the course of this thesis work. 
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2. PEPTIDOMIMETICS OF THE VIRAL TAT PROTEIN 
 
2.1. Introduction 
 
2.1.1. The importance of the Tat protein-TAR RNA interaction for viral 
transcription 
 
 The interaction between the viral transactivator protein Tat and the trans-
activation responsive element (TAR) RNA plays a critical role in the replication of 
immunodeficiency viruses and has emerged in the last decade as an important target in 
antiviral therapy. The arginine-rich binding domain of the Tat protein binds to its 
cognate TAR RNA stem-loop structure located at the 5’-end of the viral mRNA, 
resulting in enhanced processivity of RNA polymerase II.  
 The non-phosphorylated RNA polymerase II (RNAPII) is recruited to the core 
promoter in proviral DNA, at the TATA box in the long terminal repeat (LTR), through 
its interaction with transcription factor IID (TFIID) and other components of the basal 
transcription apparatus, and so forms a pre-initiation complex (PIC). The carboxy-
terminal domain (CTD) of the RNA polymerase II is then phosphorylated by cyclin-
dependent kinase 7 (CDK7) found in TFIIH, and the modified polymerase clears then 
the promoter and begins the transcription of RNA (Figure 4). 
 
 
 
Figure 4. Model for activation of RNA polymerase II by Tat and cellular co-factors.55 
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 Following promoter clearance, and before entering productive elongation, the 
processivity of RNAPII is controlled by the action of both negative (NELFs, DSIF) and 
positive elongation factors (P-TEFs). NELFs and DSIF have been proposed to be 
responsible for premature stopping and termination of the initiated polymerase, 
resulting in generation of short abortive transcripts. P-TEFs, such as p-TEFb, are 
known to mediate the transition from abortive into productive elongation by 
phosphorylating the CTD of polymerase II. P-TEFb is composed of two subunits, the 
catalytic subunit, cyclin dependent kinase CDK9, and the regulatory subunit, cyclin T1.  
 
 
 
Figure 5. Transactivation mechanism of Tat protein. Only if the viral protein Tat is present and binds to 
the bulge of TAR the cellular transcription elongation factor p-TEFb is recruited. Upon phosphorylation 
of RNA polymerase II, NELF and DSIF by the kinase component CDK9 of p-TEFb, anti-termination 
takes place and TAR can be elongated to the full length viral RNA. 
 
The complex of Tat with autophosporylated p-TEFb binds to the upper bulge 
and loop structures of the nascent RNA chain corresponding to the TAR RNA 
transcript, thereby positioning CDK9 to phosphorylate, i) the negative elongation 
factors, which repress transcription by binding to the lower stem in TAR, and ii) the 
CDT of RNAPII (hyperphosphorylation). These phosphorylation events result in the 
release of the transcriptional elongation block and the transcription elongation is 
promoted (Figure 5).56,57 
The HIV-1 transactivator protein Tat consists of 101 amino acids in most HIV-1 
isolates. There are four domains defined in the Tat protein sequence, an N-terminal 
proline rich/acidic region (amino acids 1-21), a region containing seven cysteines (22-
37), a core region (38-48), a basic region enriched with arginine and lysine residues 
(49-57) that is highly conserved among different strains, and a cell-adhesion C-terminal 
region. Based on mutational analysis, Tat can be divided into two functional domains, 
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i) a functionally autonomous transcription-activation domain (amino acids 1-48), which 
is thought to be involved in metal ion binding, and ii) a conserved basic domain (47-
59), essential for TAR recognition and binding. The basic domain is also important for 
translocation through the cell membrane.58,59 
The Tat-mediated transactivation mechanism is a particularly attractive target 
for the development of new antiretroviral drug therapies, because Tat is required for 
viral gene expression not only during the exponential growth of the virus but also 
during the activation of the integrated proviral genomes that give rise to drug-resistant 
strains of HIV-1.55 
 
 
2.1.2. A comparison between the HIV and BIV Tat transcriptional elements 
 
Among the most studied RNA targets for the treatment of infectious diseases are 
the Tat RNA regulatory elements from HIV-1 and related viruses. The associated 
regulatory/accessory proteins are important features that differentiate lentiviruses from 
other retroviruses.  
Since structural information about the HIV-1 Tat-TAR complex is not yet 
available, it was decided here to use the corresponding interaction from bovine 
immunodeficiency virus (BIV) to study TAR recognition by peptidomimetic ligands. 
Both viruses use similar transcriptional activation mechanisms and their Tat and TAR 
elements share structural and sequential similarities. Most importantly, the three-
dimensional structure of BIV TAR in a complex with a Tat-derived peptide has been 
determined, revealing that BIV Tat forms a !-hairpin conformation in a complex with 
its cognate TAR RNA (Figure 6). These observations make BIV an ideal model for 
studying this interaction, with the possibility to export the information derived from 
BIV into the HIV system. 
 
Figure 6. The BIV Tat peptide (green) adopts a !-hairpin conformation upon binding to TAR RNA 
(PDB 1MNB). 
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BIV, first isolated in 1969, causes lymphocytosis, lymphadenopathy, 
progressive weakness, and central nervous system disorders in infected cattle. It 
belongs to the unique genus Lentivirinae, which share structural, genetic, biological 
and/or pathological properties and infect monocyte/macrophage cells. BIV is the most 
complex of non-primate lentiviruses and bears a strong resemblance to primate viruses 
including HIV-1 and HIV-2, as well as simian immunodeficiency virus (SIV). Besides 
genes encoding the obligate retroviral Gag, Pol, and Env polyproteins, BIV encodes six 
non-structural/accessory proteins, which are called Tat, Rev, Vif, Vpy, Vpw, and Tmx. 
These proteins play a critical role in the viral replicative cycle and contribute 
significantly to the pathogenesis of BIV.60 
BIV Tat protein contains five structural domains similar to those in primate 
lentiviruses, an acidic amino terminal, a cysteine-rich, a highly conserved core, a basic 
and a carboxy-terminal region. The functional domains include an activation domain 
and an RNA-binding domain.  
BIV Tat protein residues directly interacting with the RNA form a basic, 
arginine-rich domain, and include Arg70, Gly71, Thr72, Arg73, Arg77 and Ile79, while 
the Gly74 and Gly76 play an important conformational role (Figure 7). The BIV Tat-
derived peptide adopts a !-hairpin structure defined by an antiparallel !-sheet. The turn 
of the !-hairpin occurs between Arg73 and Arg77, while two Gly residues (74 and 76) 
facilitate the turn. The Tat peptide penetrates deep into the major groove and the tight 
fit results in substantial widening of the groove (from approximately 10Å to 
16Å).26,61,62 
 
Figure 7. RNA-binding domain of BIV Tat protein in a !-hairpin conformation. 
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Binding to HIV-1 TAR RNA is mediated by residues 49-57 in the HIV-1 Tat 
protein. Mutagenesis studies showed that a single arginine at position 52 makes the key 
contribution to the binding specificity (Figure 8).63 Studies with isolated peptides have 
shown that additional basic amino acids that surround this arginine help enhance the 
affinity and kinetic stability of the complex as well as improving binding specificity.64 
The arginine-rich domain of HIV Tat, like that of BIV, does not appear to adopt 
a stable structure in solution. Mutational studies suggest that the bound form of Tat is 
might be helical, but the actual bound conformation has so far not been proven.65 
 
BIV Tat 65SGPRPRGTRGKGRRIRR81 
HIV Tat 44GISYGRKKRQRRRPPQGS62 
 
Figure 8. Comparison of HIV-1 Tat and BIV Tat arginine-rich RNA-binding domains with the amino 
acids critical for binding TAR RNA in red. 
 
The TAR element varies in length and structure among lentiviruses. The BIV 
and HIV-1 TAR RNA form a stem-bulge-loop hairpin structure composed of 28 and 59 
nucleotides, respectively, which comprises the Tat binding site (Figure 9). Tat interacts 
in BIV transactivation with nucleotides G11-C25, G14-C23 and C15-G22 located in the 
stem of TAR, and it directly binds the bulge at U10. Then a base-triple RNA structure 
comprised of U10-A13-U24 is formed and is consolidated by hydrogen bonds.66,67 The 
central loop of BIV TAR RNA, comprising nucleotides CAUU, is not directly involved 
in the binding of BIV Tat, contrary to the situation in HIV.68,69  
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Figure 9. Comparison of the BIV and HIV-1 TAR RNA sequences. The nucleotides in red play a critical 
role in Tat recognition, the nucleotides in green for HIV-1 are critical for cyclin T1 binding.  
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Despite extensive efforts, a high-resolution structure of the HIV TAR-Tat 
complex has not yet been obtained. However, the NMR solution structures of the HIV 
TAR RNA and the Tat protein have been solved individually. Several NMR studies 
have investigated the HIV TAR RNA structural change that takes place upon binding to 
arginine70 (Figure 10), argininamide71 or Tat-derived peptides72,73 and they gave deeper 
insights into the principles of TAR RNA recognition by Tat. Together with extensive 
mutagenesis, chemical probing and peptide binding studies, the key elements required 
for TAR recognition by Tat have been defined, and it has been shown that the Tat 
binding site surrounds a UCU bulge located near the apex of TAR. In detail, it has been 
shown that a critical role in TAR recognition is played by U23, which forms a base 
triple with A27 and U38, and stacks on A22 and along G26. In addition, several 
phosphate groups adjacent to the bulge, including P21 (between G21 and A22), P22, 
and P40, are suggested to be essential for RNA recognition by HIV Tat. 
 
 
Figure 10. Major groove view of free HIV-1 TAR RNA (left, PBD 1ANR), and TAR-arginine complex 
(right, PDB 1ARJ). The nucleotides critical for binding are highlighted, in red U23, A27 and U38, which 
form a base triple, and in yellow A22 and G26. Arginine is shown in green. 
 
In both cases, HIV-1 and BIV, TAR-Tat complex formation induces global 
RNA conformational changes and alters the internal dynamics of the nucleotides 
surrounding the binding region in the TAR RNA. The bulge nucleotides help in 
widening of the major groove of the RNA, which is normally very narrow (~11Å) and 
resembles the minor groove of DNA in its interactions with proteins. 
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Figure 11. Schematic model of cyclin T1-Tat-TAR interaction shown on the left for BIV and right for 
HIV. Binding of HIV Tat and cyclin T1 to HIV TAR RNA is highly cooperative, while for BIV it occurs 
independently.74 
 
Although the TAR-dependent transactivation mechanism shares similarities 
among lentiviruses, there are differences in the Tat-pTEFb-TAR recognition event and 
the transactivation complex formation. HIV-1 Tat binds directly through its 
transactivation domain (amino acids 1-48) to the cyclin subunit of the pTEFb (cyclin 
T1), and induces loop sequence specific binding of this cyclin to TAR RNA.75 Cyclin 
T1 and Tat binding to HIV TAR RNA is highly cooperative. Cyclin T1 does not bind to 
TAR in the absence of Tat, and the HIV Tat RNA-binding domain binds TAR at least 
an order of magnitude more weakly in the absence of cyclin T1.72 The cyclin T1-Tat 
heterodimer directly binds to TAR RNA in the U-rich RNA budge, and this binding 
facilities the interactions of the cyclin T1-TAR RNA in the loop region (Figure 11, 
right).76 The interaction of HIV Tat with the human cyclin T1, increases greatly the 
affinity and specificity of the binding between HIV Tat and TAR. In sharp contrast, the 
BIV Tat may recognize the BIV TAR with high affinity in the presence or absence of 
cyclin T1 (Figure 11, left). Consequently, the BIV Tat-TAR interaction takes place in 
most mammalian cells, including murine, canine, rabbit and human cells, indicating 
flexibility for BIV Tat to recruit cyclin T1.68,74  
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2.1.3. Structure of the BIV Tat-TAR RNA complex solved by NMR 
 
Two decades of extensive studies on the Tat-TAR interaction have given deep 
insights into the principles of protein-RNA recognition and the transactivation 
mechanism in immunodeficiency lentiviruses. So far, only the structure of a BIV Tat 
derived peptide-TAR complex has been solved. In 1995 two independent groups 
determined NMR-structures of the BIV Tat RNA binding domain (residues 68-81 in 
one study26 and 65-81 in the other62) in complex with the BIV TAR RNA stem-bulge-
loop structure. Although using a different number of distance restraints, the two 
structures are globally in agreement, and the specific interactions seen in the complex 
explain the available in vitro and in vivo mutagenesis data. Both groups used a 28-
nucleotide fragment of BIV TAR RNA and the arginine-rich RNA binding domain of 
BIV Tat RNA (Figure 12). 
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  BIV Tat: 65SGPRPRGTRGKGRRIRR81 
Figure 12. Secondary structures of the BIV Tat and TAR RNA binding regions. Left: BIV TAR stem-
loop structure; Middle: arginine-rich TAR-binding domain of BIV Tat protein in a !-hairpin 
conformation. Nucleotides and amino acids important for binding are highlighted in both structures. 
Right: the three-dimensional structure of the complex between BIV Tat and TAR RNA (PDB 1MNB). 
 
Upon binding, the BIV Tat peptide, which is unstructured in aqueous solution, 
adopts a !-hairpin conformation and penetrates the widened (from ~10Å to 16Å) major 
groove of the RNA specifically (Figure 12, right). The !-hairpin structure is defined by 
an antiparallel !-sheet between the G71-T72-R73 and R77-R78-I79 segments. The !-
turn of type I is defined by Gly74 to Arg77 with a Gly76 promoting turn formation. 
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The formation of the base triple (U10-A13-U24) in the BIV Tat-TAR complex 
facilitates both the deformation of the backbone and the orientation of the phosphate 
between G9 and U10. This phosphate participates in a key intermolecular interaction 
with an Arg73 side chain. The guanidinium group forms hydrogen bonds with both the 
major groove edge of G11 and the phosphate oxygen atom. The aromatic ring of U10, 
positioned by formation of the base triple, interacts via van der Waals contacts with 
Ile79, whose side chain is packed into the major groove edge of the base triple. Thr72 is 
also involved in critical contacts with the ribose of G22. A hydrogen bond to the RNA 
backbone phosphate between G22 and C23 was suggested by Puglisi,26 whereas 
hydrogen bonds between the carbonyl oxygen and the amino group of C23, and 
hydroxyl oxygen and phosphate between C23 and U24 were suggested by Patel.62 The 
guanidinium groups of Arg70 and Arg77 make contacts with guanines at the major-
groove edge, Arg70-G14 via two hydrogen bonds and Arg77-G9 through two 
bifurcated hydrogen bonds. The intermolecular hydrogen bond between the amide 
proton of Gly71 and G22 leaves no room for any larger side chains, as it would point 
directly into A21. The G74 and G76 have no significance for binding to RNA but 
cannot be mutated without loss of activity, due to the steric hindrance that larger side 
chains would cause. 
 
 
2.1.4. Inhibition of TAR RNA-Tat protein interaction  
 
Among the earliest findings of ligands that bind to TAR RNA and prevent Tat 
TAR complex formation were the well known natural products, the aminoglycosides, 
already discussed in detail in paragraph 1.1.3. However, most aminoglycosides bind to 
a variety of RNA targets with lack of selectivity, which often results in severe toxicity, 
thus making them unattractive for drug development. 
During the last decade, a limited number of non-peptidic small-molecule ligands 
(following Lipinski’s rule, MW<500) have been reported to inhibit Tat-TAR complex 
formation. Many groups focused on the development of antagonists that posses a high 
and specific affinity for the bulge region of TAR RNA. 
By high-throughput in vitro screening of 150’000 compounds, Mei et al.77 
identified two promising candidates, 2,3-dioxo-8- [2-(5-tetrazolyl)]-2,3,4,7,8,9-
hexahydro-1H-6-nitrocyclopenta[f]quinoxaline (5) and 2,4,5,6-
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tetraaminoquinozaline (6). Studying their interaction with TAR RNA it was 
discovered that they bind to two different binding sites. Quinoxaline interacts with the 
bulge region, i.e. the Tat binding site, while tetraaminoquinozaline binds to the loop of 
the RNA, the cyclin T1 binding site.78 A promising class of 6-aminoquinolone TAR 
ligands, reported by Cecchetti et al.79 was discovered by testing antimicrobial quinolone 
DNA gyrase inhibitors. The lead compound, a 4-(2-pyridyl)-1-piperazinyl-substituted 
6-amino-quinolone (WM5) (7) exhibited submicromolar affinity to TAR RNA. WM5 
was able to inhibit Tat-TAR complex formation with an apparent Ki of 3.5 &M and 
exhibited inhibitory potency of HIV replication in infected cells in low micromolar 
range. It has been proven that this compound binds to the bulge region of the wild-type 
TAR RNA.80 
Well established in silico techniques were employed by the James’ group81 to 
predict potent Tat-TAR inhibitors, which then were tested in vitro. Apart from the 
ligands that were already known, e.g. aminoglycosides, many novel structures, such as 
anthraquinone (8) or trisamine-derivatives (9) were identified and exhibited an IC50 
value of approximately 1µM. The same group, in 2002,82 using computational 
screening of a 181,000-compound available chemicals directory against the three-
dimensional structure of TAR predicted 500 potential TAR ligands, from which 50 
were tested in vitro. Among these compounds, the most promising lead was 
acetylpromazine (10) (also known as acetopromazine or acepromazine), a 
phenothiazine derivative, which represents a new class of TAR ligands with ~270µM 
binding affinity, good bioavailability and low toxicity. NMR studies83 revealed that this 
compound binds to the bulge region of TAR, where the planar heteroaromatic ring 
system stacks between base pairs G26-C39 and A22-U40. It is noteworthy that 
acetylpromazine structurally resembles synthetic aminoacridine (11), a ligand of TAR 
that has been developed by Novartis Pharma using a rational design approach. These so 
called “In-PriNts”, inhibitors of protein-ribonucleotide sequences, should be tripartite 
and consist of i) a polyaromatic/heterocyclic moiety, with the potential for a stacking 
interaction inside the cavity of TAR, delimited by U23 as well as by bases below and 
above the bulge (A22 and G26, respectively), ii) a feature providing positive charges 
for interaction with the phosphate backbone of RNA, and iii) a spacer to connect the 
stacking entity with the RNA binding part.84 A similar rational approach was taken by 
Yuan et al.85 and resulted in the design of substituted purines (12) containing a side 
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chain with a terminal amino or guanidyl group. All the compounds effectively block 
TAR transactivation in human 293T cells, show low cytotoxity and interact with the 
bulge region of TAR. 
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Figure 13. Tat-TAR interaction inhibitors: (5) derivative of quinoxaline-2,3-dione, (6) 
tetraaminoquinozaline, (7) WM5, (8) anthraquinone, (9) trisamine-derivatives, (10) acetylpromazine, 
(11) substituted aminoacridine, (12) substituted purine. 
 
Peptides and peptidomimetics that specifically target RNA structures are 
potential antagonists of RNA-binding proteins and are therefore capable of controlling 
cellular functions. During the last decade, several peptidic structures have been 
developed that specifically interact with the bulge region of TAR. The starting point for 
many studies was the Tat sequence that is responsible for binding to TAR RNA. Tat-
derived oligocarbamate (13) and oligourea (14) contain basic side chains like those in 
the arginine-rich region of full length Tat protein and show inhibition in the low µM 
range.86 
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A combinatorial library of tripeptides of L- and D- natural amino acids was 
prepared by Hwang et al.87 Out of 24389 variations, eight sequences were found 
promising, among them two exhibit submicromolar affinity towards TAR RNA and 
inhibit transcriptional activation by Tat protein in human cells with an IC50 of $50 nM. 
The best binding tripeptide (15) was then incorporated into the cyclic structure (16) to 
improve pharmacokinetic properties, which showed increased inhibitory activity.88  
Another peptoid/peptide (17) was presented by Hamy et al.89 that was thought to 
inhibit the Tat/TAR association and block HIV-1 replication in primary human 
lymphocytes. However, later studies showed this whole cell inhibitory activity arises by 
a mechanism unrelated to Tat-TAR inhibition.90,91  
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Figure 14. Peptidic inhibitors of the Tat-TAR interaction: (13) Tat-derived oligocarbamate, (14) Tat-
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2.1.5. Previous work 
 
On the basis of the structural information obtained for the BIV Tat/TAR RNA 
presented a decade ago by Puglisi et al.26 followed by many further studies, it was 
possible to design the first peptidomimetic Tat-TAR interaction inhibitors. The first 
attempt to use the critical binding sequence of wild type Tat peptide was reported by 
Runyon.92 A cyclic 14-amino acid peptide derived from the arginine-rich BIV Tat 
motif, cyclo(dYGRGTRGKGRRIVN), showed a similar mode of action and almost the 
same affinity as the linear wild-type peptide. 
Following this observation, Athanassiou et al.54 reported a library of 8 cyclic 
peptidomimetics attached to a !-hairpin-inducing template. The starting point was a 
mimetic obtained by transplanting the residues 70-80 from BIV Tat onto a D-Pro-L-Pro 
template. In order to form a regular 2:2 !-hairpin conformation, the loop was extended 
to 12 amino acids, and the critical amino acids for TAR binding were kept constant 
(Figure 15).  
 
   
 
Figure 15. The design of BIV Tat mimetics. Left: the NMR structure of BIV Tat-TAR complex; middle: 
the conformation of the Tat bound to TAR RNA, moulded onto a D-Pro-L-Pro template; right: the 
representation of a typical 2:2 !-hairpin peptidomimetic. The residues 4-10 remain constant. 
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A set of cyclic peptidomimetics grafted onto a D-Pro-L-Pro template gave very 
promising results, summarized in Table 3. 
 
Mimetic Position Kd [µM] 
 1 2 3 4 5 6 7 8 9 10 11 12  
BIV0 - R G T R G K G R R I R 40 
BIV1 I R G T R G K R R I R V 30 
BIV2 R V R T R G K R R I R V 0.150 
BIV3 I Y R T R G K R R I R T nb 
BIV4 Y R G T R G K R R I Y V >50 
BIV5 R R G T R G K R R I G R 1-2 
BIV6 V R G T R G K R R I K Y >50 
BIV7 V R R T R G K R R I K Y nb 
BIV8 K R G T R G K R R I G Y >50 
Table 3. Sequences of !-hairpin peptidomimetics. Positions 1-12 refer to residues 1-12 as mounted on 
the D-Pro-L-Pro template (Figure 15, right). The dissociation constants (Kd) were determined for the 
interaction of each mimetic with BIV TAR4-31 RNA (EMSA) (nb=no binding detected). The 17-residue 
wild-type peptide Ac-65SGPRPRGTRGKGRRIRR81-NH2 (BIV Tat (65-81)) was used as a positive 
control in all binding studies, with a Kd value of 50 nM. 
 
 
Among the peptidomimetics, BIV2 showed a very high affinity to TAR RNA 
and proved to bind to it with high specificity, since the EMSA was performed in the 
presence of a large excess of tRNA [for details see Paragraph 2.2.3].  
In order to identify the amino acids important for the binding, each position of 
BIV2, except Gly at position 6, was mutated to Ala. Eleven new peptidomimetics, 
BIV2A1-BIV2A12, were produced in this way and assayed. The mutation of many 
amino acids to Ala was found to have a large detrimental effect on the binding (Table 
4). 
 
Table 4. Alanine scan of the BIV2 peptidomimetic. Kd values determined by EMSA (nb=no binding 
detected). 
Mimetic Position Kd [µM] 
 1 2 3 4 5 6 7 8 9 10 11 12  
BIV2 R V R T R G K R R I R V 0.150 
BIV2A1 A V R T R G K R R I R V nb 
BIV2A2 R A R T R G K R R I R V 0.3 
BIV2A3 R V A T R G K R R I R V nb 
BIV2A4 R V R A R G K R R I R V 0.3 
BIV2A5 R V R T A G K R R I R V nb 
BIV2A7 R V R T R G A R R I R V nb 
BIV2A8 R V R T R G K A R I R V nb 
BIV2A9 R V R T R G K R A I R V nb 
BIV2A10 R V R T R G K R R A R V 5 
BIV2A11 R V R T R G K R R I A V nb 
BIV2A12 R V R T R G K R R I R A 5 
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Furthermore, NMR spectroscopic studies on BIV2 free in solution revealed a 
stable !-hairpin conformation for this peptide and this feature facilitated the structure 
elucidation of the BIV2-TAR RNA complex. BIV2 induces a conformational change in 
TAR leading to a structure very similar to that seen in Tat-bound TAR RNA. The 
structure of the complex between the BIV2 peptide and BIV TAR RNA determined by 
NMR spectroscopy revealed that BIV2 binds to RNA in an orientation that is flipped 
upside-down compared to that expected based on a comparison to the wild-type Tat 
peptide, but the key intermolecular contacts that direct the RNA conformational change 
are maintained (Figure 16).93 
 
Figure 16. The structure of the complex between the BIV2 cyclic peptide and BIV TAR RNA 
determined by NMR spectroscopy.93 
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2.1.6. Project outline 
 
The successful design of the small library of cyclic Tat peptidomimetics that 
included a relatively potent inhibitor of BIV Tat-TAR, called BIV2, and determination 
of the structure of the complex of this ligand bound to BIV TAR opened the way for 
optimisation and further structural studies. On the basis of these findings, the purpose 
of this work was to optimise the lead compound, BIV2, and by doing so, to gain new 
insights into the origins of the high affinity and specificity of this ligand-RNA 
interaction. It was assumed that by introducing single mutations into BIV2 it would be 
possible to identify alternative side chains that would provide optimal contacts to the 
RNA, and that by combining individual changes and incorporating multiple mutations 
it would be possible to increase affinity by additive effects. Additionally, to evaluate if 
the interactions observed are specific, the peptidomimetics should be assayed with 
other related RNAs, namely HIV-1 TAR RNA and RRE RNA.  
Furthermore, since the transactivation mechanism for BIV and HIV shares many 
similarities, it seemed likely that the HIV Tat-TAR system could be mimicked by the 
BIV complex and the information derived from studies on BIV Tat inhibitors could be 
exported, at least in part, to derive inhibitors of the human virus. Therefore, all the 
previously prepared 14-amino acid BIV Tat peptidomimetics were assayed with HIV-1 
TAR RNA in order to identify lead compounds. Additionally, it was envisioned that 
introducing an additional four amino acids and increasing the number of residues in the 
sequence from 14 to 18 might enable the ligand to interact not only with the major 
groove, but additionally with the tip of the loop of the TAR RNA. This might then lead 
to inhibition of the cyclin T1-TAR RNA interaction, which is known to be necessary 
for effective transactivation. Moreover, it was reasoned that introducing a disulfide 
bridge into these 18-amino acid peptides might stabilize the !-hairpin conformation. 
The ultimate target was to evaluate the ability of the selected peptides to cross 
the cell membrane, to test their stability in biological settings, and to prove their 
activity using in vivo assays. 
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2.2. Results  
 
 
2.2.1. BIV Tat peptidomimetics 
 
• LIBRARY L1: Attempts to identify side chains optimal for RNA contacts by 
single mutations of the residues in BIV2. 
 
The sequence of BIV2, a sub-micromolar ligand (Kd=150 nM) of BIV TAR 
RNA with a stable !-hairpin conformation both free in solution and when bound to 
RNA, served as a lead for further optimisation. The !-hairpin structure of BIV2 bound 
to RNA allows us to identify the side chains interacting with the major groove (Arg1, 
Arg3, Arg5, Arg8, Ile10, Val12) and the residues exposed to the solvent (Val2, Thr4, 
Arg9, Arg11). The other two amino acids, Gly6 and Lys7, are at the tip of the !-hairpin 
and point toward the tip of the RNA.93 
 
 
Figure 17. !-Hairpin structure of BIV2 [cyclo-(D-Pro-L-Pro-Arg-Val-Arg-Thr-Arg-Gly-Lys-Arg-Arg-
Ile-Arg-Val)] bound to BIV TAR RNA. pink, red: the residues interacting with the major groove of 
RNA, green: the residues exposed to the solvent. The tip of the !-hairpin is at the top and the template D-
Pro-L-Pro at the bottom. 
 
In the first round of optimisation (Table 5), positions in the RNA-contacting 
face of BIV2 were targeted for mutation in an effort to identify alternative side chains 
that would provide optimal contacts to the RNA (see Figure 17). Arginine residues at 
positions 1 and 3, found from the complex structure to have hydrogen bonding 
interactions with TAR, were initially kept constant, with the exception of Arg3Lys, 
Arg3Cit, Arg3Orn to deliver more information on the nature of the Arg3 interaction 
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with the RNA. Arg5 and Arg8 were more freely mutated, as in the complex they show 
cation-% interactions rather than hydrogen bonding as observed in Arg1 and Arg3. 
Mutations of these residues to other charged amino acids would help to distinguish 
between the requirements for hydrogen bonding and electrostatic interactions. 
Hydrophobic residues (positions 10 and 12) were mutated to other hydrophobic or 
charged residues in an effort to optimise the intermolecular contacts at these positions. 
Positions 2, 4, 9, 11 on the solvent exposed face were also mutated in an effort to 
further increase the affinity by indirect conformational effects and to reduce the overall 
charge of the peptide. The residues at the tip of the !-hairpin were kept constant, as 
they were thought to be important for defining the !-turn and formation of a stable 
hairpin conformation. 
 
Table 5. Library L1 of BIV Tat mimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro template. 
Kd values [µM] were determined by EMSA (nb=no binding detected). 
Mimetic Position Kd BIV Kd HIV 
 1 2 3 4 5 6 7 8 9 10 11 12   
BIV2 R V R T R G K R R I R V 0.15 >5 
L1-01 R V R T R G K R R I R L 0.15 0.5 
L1-02 R V R T R G K R R I R I 0.05 0.5 
L1-03 R V R T R G K R R I R F 0.15 0.5 
L1-04 R V R T R G K R R I R T 0.5 0.5 
L1-05 R V R T R G K R R I R N 0.5 0.15 
L1-06 R V R T R G K R R I R R 0.15 0.15 
L1-07 R T R T R G K R R I R V 0.05 0.15 
L1-08 R N R T R G K R R I R V 0.15 0.25 
L1-09 R V R T R G K R R L R V 0.5 >10 
L1-10 R V R T R G K R R Cha R V 5 >10 
L1-11 R V R T R G K R R F R V 0.5 >5 
L1-12 R V R T R G K R R Y R V 0.5 1 
L1-13 R V R T R G K R R N R V 0.25 0.5 
L1-14 R V R T R G K R R Q R V 0.5 0.5 
L1-15 R V R Q R G K R R I R V 0.05 0.5 
L1-16 R V R V R G K R R I R V 0.1 0.5 
L1-17 R V R Y R G K R R I R V 0.1 1 
L1-18 R V R K R G K R R I R V 0.5 0.5 
L1-19 R V K T R G K R R I R V >5 5 
L1-20 R V U T R G K R R I R V >5 >10 
L1-21 R V O T R G K R R I R V 1.5 1 
L1-22 R V R T K G K R R I R V >5 >10 
L1-23 R V R T U G K R R I R V >5 >10 
L1-24 R V R T O G K R R I R V >5 2.5 
L1-25 R V R T N G K R R I R V >5 >10 
L1-26 R V R T Q G K R R I R V >5 >10 
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L1-27 R V R T I G K R R I R V >5 >10 
L1-28 R V R T L G K R R I R V >5 nb 
L1-29 R V R T Y G K R R I R V >5 nb 
L1-30 R V R T R G K K R I R V 2.5 2.5 
L1-31 R V R T R G K U R I R V >5 nb 
L1-32 R V R T R G K O R I R V 2.5 0.5 
L1-33 R V R T R G K N R I R V >5 nb 
L1-34 R V R T R G K F R I R V >5 nb 
L1-35 R V R T R G K Y R I R V >5 >10 
L1-36 R V R T R G K R K I R V 0.15 0.25 
L1-37 R V R T R G K R U I R V nb nb 
L1-38 R V R T R G K R O I R V 0.25 0.25 
L1-39 R V R T R G K R N I R V >5 nb 
L1-40 R V R T R G K R Q I R V >5 nb 
L1-41 R V R T R G K R R I K V 0.15 0.25 
L1-42 R V R T R G K R R I U V >5 nb 
L1-43 R V R T R G K R R I O V 0.1 0.25 
L1-44 R V R T R G K R R I N V 5 nb 
L1-45 R V R T R G K R R I Q V >5 nb 
 
 
2.2.2. Synthesis of Tat peptidomimetics 
 
All the Tat peptidomimetics described in this work were synthesised according 
to a mixed solid-phase solution-phase strategy developed earlier.94 Briefly, the first 
amino acid was coupled to freshly activated, acid-labile 2-chlorotrityl chloride resin 
with 4-equivalents DIEA in DCM. Generally, Fmoc-L-Pro-OH was chosen as the first 
amino acid to be attached to the resin, since this allowed for the synthesis of larger 
batches of preloaded resin that could be used for the synthesis of almost all the 
peptidomimetics. The linear, fully protected precursors were synthesised employing 
standard Fmoc-chemistry on a MultisynTech Syro II peptide synthesizer (parallel 
synthesis up to 48 peptides) on ~0.07 mmol scale or, when larger quantities were 
required, on an Applied Biosystems 433A peptide synthesizer on a 0.25 mmol scale. 
Generally, 4 equivalents of the appropriately side-chain protected N-Fmoc amino acid 
are activated with HBTU, HOBt (4 eq each) and DIEA (8 eq) in DMF. In the parallel 
synthesis every coupling was performed twice. Fmoc deprotection was carried out in 
20-40% piperidine in DMF solution. 
After completion of the peptide chain assembly, the linear peptides were 
cleaved from the resin with 0.8% TFA in DCM. The crude linear peptides were 
cyclized in DMF using HATU, HOAt and DIEA in DMF. The final deprotection was 
achieved with TFA:H2O:TIPS (95:2.5:2.5) cocktail and the crude cyclic peptides were 
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precipitated with ice-cold diethyl ether (Figure 18). The purification of the peptide 
libraries was performed by preparative RP-HPLC using H2O+0.1% TFA and 
MeCN+0.1% TFA and yielded the desired peptides of '95% purity and in 20-35% 
yield. All the peptides were characterised by analytical HPLC and LC-MS (see 
Appendix 2 for the analytical data). 
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Figure 18. Scheme of mixed solid-phase solution-phase peptide synthesis shown with L2-15 peptide as 
an example. 
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2.2.3. Electrophoretic mobility shift assay (EMSA) 
 
The in vitro evaluation of the Tat peptidomimetics by electrophoretic mobility 
shift assay (EMSA) was performed in cooperation with Prof. G. Varani from the 
Department of Chemistry at the University of Washington, and Dr. Zafiria Athanassiou 
and Amy Davidson. 
 
The electrophoretic mobility shift assay is one of the most common 
methodologies for identification and characterisation of protein complexes with nucleic 
acids. The EMSA technique is based on the observation that protein:DNA/RNA 
complexes migrate more slowly than free DNA/RNA molecules when subjected to non-
denaturing polyacrylamide or agarose gel electrophoresis.95,96 Because the rate of 
DNA/RNA migration is shifted or retarded upon protein binding, the assay is also 
referred to as a gel shift or gel retardation assay. For visualization purposes, the 
DNA/RNA fragment is usually radiolabeled with 32P by incorporating ["-32P]dNTPs 
during run-off transcription with T7 polymerase. After electrophoresis, the distribution 
of species containing nucleic acid is determined, usually by autoradiography of ["-32P]-
labeled nucleic acid. 
The specificity of the observed DNA/RNA binding reaction can be evaluated 
using competition assays in which an excess of unlabelled tRNA is added together with 
the labelled probe. Generally, non-specific competitors can be present in a large excess 
over the specific probe. Such a competitor, widely used in protein:RNA studies, is 
tRNA from yeast or E. coli. 
The strength of the binding is usually described using the dissociation constant 
(Kd). A low dissociation constant implies a high binding affinity. This number can be 
determined quantitatively by analysis of mobility shift assays. The dissociation constant 
is determined from the equation Kd=[RNA][P]/[P-RNA], where [RNA] is the free 
concentration of RNA, [P] is the concentration of free protein, peptide or other ligand, 
and [P-RNA] is the concentration of the complex. In practise, reactions are performed 
with an excess of protein (ligand) over the RNA. Assuming that upon binding the 
concentration changes insignificantly, the [P] can be taken as the protein (ligand) 
concentration used. The value of [RNA]/[P-RNA] is determined from the fraction of 
the RNA present in the unshifted (unbound) versus shifted (bound) bands in the 
mobility shift assay. If there is 1:1 binding stoichiometry, then Kd equals the 
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protein/peptide concentration, when 50% of the RNA is bound and present in the 
shifted band, so [RNA]=[P-RNA].  
To test the binding affinity of Tat peptidomimetics to BIV RNA and HIV RNA, 
radiolabelled RNAs were prepared using ["-32P] CTP and T7 polymerase by in vitro 
run-off transcription. The titration experiments were performed with varying 
concentrations of the Tat peptidomimetics, a constant concentration of radiolabelled 
TAR RNA (2nM) and unlabelled competitor tRNA (10’000-fold excess). The wide-
type linear BIV Tat (Ac-65SGPRPRGTRGKGRRIRR81-NH2 (BIV Tat (65-81)) or 
ADP-172 (Ac-37SFTTKALGISYGRKKRRQRRRPPQGSQTHQVSLSKQ72-NH2 (HIV-
1 Tat(37-72)) peptides were used as positive controls in all binding studies. The Kd 
determined by EMSA with a large excess of tRNA for BIV Tat (65-81) peptide is 
50 nM and 200 nM for ADP-1.  
 
Figure 19. Example of a visualised gel in a EMSA of one of the Tat peptidomimetics (L2-15). Lower 
band corresponds to the free radiolabelled TAR RNA and upper band stands for the peptide:RNA 
complex. The concentrations of the peptide are shown in nanomolar. The Kd of the interaction is 
estimated to be ~100 nM. 
 
The L1 peptidomimetics were assayed by electrophoretic mobility shift assay 
(EMSA) primarily with their target BIV TAR RNA, but in addition with HIV-1 TAR to 
investigate the selectivity and to identify interesting inhibitors of the HIV-1 Tat-TAR 
interaction. The results are reported in the Table 5. 
 
 
• LIBRARY L2: Attempts to mutate the residues critical for binding, and to tune 
the !-turn region, and then to introduce multiple mutations based on the results 
obtained with single mutations. 
 
In the second round of optimisation, further attempts were made to mutate the 
residues that are involved in the critical contacts with TAR RNA, such as Arg1, Arg3 
(Table 6). Furthermore, some amino acids that from the complex are not seen to be 
involved in binding, namely Val2, which is on the solvent exposed side, and Lys7 
involved in !-turn formation but not in contact with RNA, were mutated. Additionally, 
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the Gly6 and Lys7 were exchanged to evaluate the conformational effects of residues 
involved in !-turn formation. Finally, the knowledge gained from single mutations was 
used to combine multiple mutations in order to evaluate if the affinity improvements 
are additive. As the Val12Ile in the first library improved the affinity 3-fold (150 vs. 
50 nM) this mutation was introduced into all the L2 sequences. 
 
Table 6. Library L2 of BIV Tat mimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro template. 
Kd values [µM] were determined by EMSA (nd=not determined). 
Mimetic Position Kd BIV Kd HIV 
 1 2 3 4 5 6 7 8 9 10 11 12   
L2-01 R V R T R G K R R I R I 0.1 0.5 
L2-02 U V R T R G K R R I R I >10 nd 
L2-03 K V R T R G K R R I R I >10 0.1 
L2-04 O V R T R G K R R I R I >10 0.5 
L2-05 N V R T R G K R R I R I >10 >5 
L2-06 Q V R T R G K R R I R I 10 >5 
L2-07 Y V R T R G K R R I R I 5 5 
L2-08 L V R T R G K R R I R I >5 >5 
L2-09 W V R T R G K R R I R I >5 >5 
L2-10 R Q R T R G K R R I R I 0.2 0.5 
L2-11 R Y R T R G K R R I R I 0.2 1 
L2-12 R W R T R G K R R I R I 0.5 5 
L2-13 R L R T R G K R R I R I 0.2 5 
L2-14 R V R T R N G R R I R I 0.5 >5 
L2-15 R V R T R K G R R I R I 0.1 0.075 
L2-16 R V R T R G R R R I R I 0.2 1 
L2-17 R V R T R G Y R R I R I 0.2 >5 
L2-18 R V R T R G Q R R I R I 0.2 >5 
L2-19 R V R T R G N R R I R I 0.2 >5 
L2-20 R V R T R G O R R I R I 0.1 5 
L2-21 R V R T R G U R R I R I >10 >5 
L2-22 R V Q T R G K R R I R I >5 >5 
L2-23 R V N T R G K R R I R I >5 5 
L2-24 R T R T R G K R R I R I 0.05 0.5 
L2-25 R N R T R G K R R I R I 0.1 0.25 
L2-26 R V R T R G K R R I O I 0.05 5 
L2-27 R V R T R G K R R I K I 0.2 5 
L2-28 R V R T R G K R K I O I 0.1 5 
L2-29 R V R Q R G K R R I R I 0.2 >5 
L2-30 R V R V R G K R R I R I 0.2 >5 
L2-31 R V R Y R G K R R I R I 0.2 >5 
L2-32 R T R Q R G K R R I R I 0.1 5 
L2-33 R T R T R G K R R I O I 0.1 5 
L2-34 R T R T R G K R K I O I 0.1 5 
L2-35 R T R Q R G K R R I O I 0.1 1 
L2-36 R T R V R G K R R I O I 0.1 1 
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L2-37 R T R Y R G K R R I O I 0.2 5 
L2-38 R V R T R G K R R F R I 1 >5 
L2-39 R T R T R G K R R F R I 0.5 >5 
L2-40 R T R T R G K R R F O I 0.2 5 
L2-41 R V R Q R G K R R F O I 0.5 >5 
L2-42 R T R V R G K R K F O I 0.5 >5 
L2-43 R T R Y R G K R K F O I 0.5 >5 
 
The peptidomimetic library 2 was prepared using a standard Fmoc solid phase 
peptide synthesis protocol on a MultiSyn Tech Syro II peptide synthesiser as described 
previously in paragraph 2.2.2. After purification by HPLC, the desired peptidomimetics 
were typically obtained in 20-40% overall yield, and each was >95% pure as 
determined by analytical HPLC and gave ESI-MS data consistent with the calculated 
masses (see Appendix 2 for analytical data). 
The results of EMSA of peptides from both libraries established a structure-
activity-relationship for the BIV Tat peptidomimetics, which will be discussed in detail 
in the Discussion Section (Paragraph 2.3.1) It is noteworthy that these two rounds of 
optimisation gave peptides with only about 3-fold increased affinities to BIV TAR 
RNA (peptides L1-02, L1-07, L1-15, L2-24, L2-26) in comparison to lead compound 
BIV2. This shows that the concept used in the design of BIV0-BIV8 peptides delivered 
already a very potent, almost optimal RNA ligand (BIV2). The extensive mutational 
studies gave results consistent with the structural information obtained for the BIV2-
BIV TAR RNA complex. In general, only small changes in the character of amino acid 
residues in the BIV2 sequence were tolerated and the gain in the activity was not large. 
To provide a measure of the intrinsic affinities of these mimetics for BIV TAR, without 
competition from lower-affinity non-specific binding sites, as provided by tRNA, a 
standard used in EMSA, the binding assays were repeated in the absence of tRNA. 
Although several peptidomimetics exhibited high affinity for TAR RNA even in the 
presence of a large excess of tRNA, the Kd’s are typically lower (tighter binding) by at 
least 1 order of magnitude in the absence of tRNA (Table 7). These data demonstrate 
that nanomolar ligands of BIV TAR have been discovered that are capable of 
competing with a much larger protein for binding to the TAR RNA, and bind to their 
target even in the presence of a 10’000-fold excess of non-cognate tRNA.  
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Table 7. Kd values for selected mimetics binding to TAR RNA determined by EMSA in the presence and 
absence of tRNA. 
Mimetic Kd [µM] BIV TAR 
EMSA with tRNA 
Kd [µM] BIV TAR 
EMSA without tRNA 
BIV2 0.15 0.15 
L2-01 0.1 0.07 
L2-15 0.1 0.005 
L2-24 0.05 0.03 
L2-29 0.2 0.02 
L2-26 0.05 0.005 
L2-27 0.1 0.005 
L2-28 0.1 0.01 
L2-32 0.1 0.03 
L2-33 0.05 0.02 
L2-34 0.05 0.007 
L2-35 0.05 0.007 
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2.2.4. HIV Tat peptidomimetics 
 
By assaying the BIV Tat peptidomimetics with HIV-1 TAR RNA, several 
peptides, summarised in Table 8, that bind to the RNA with affinity comparable with 
ADP-1, were discovered. Importantly, peptides that bind the HIV and BIV TAR are 
distinct, and even small changes in peptide sequence lead to large losses in activity, 
proving the high specificity of the ligands. 
 
Table 8. BIV Tat peptidomimetics with high affinity to HIV-1 TAR. 
Mimetic Position Kd [nM] 
HIV-1 TAR 
 1 2 3 4 5 6 7 8 9 10 11 12  
L1-06 R V R T R G K R R I R R 150 
L1-07 R T R T R G K R R I R V 150 
L2-03 K V R T R G K R R I R I 100 
L2-15 R V R T R K G R R I R I 75 
 
 
2.2.4.1. 14-mer HIV-1 Tat peptidomimetics 
 
• LIBRARY L3: Further single mutations of the residues in BIV2 thought to be 
not critical for the binding to HIV TAR RNA. 
 
By assaying previously prepared BIV Tat peptidomimetics several peptides 
were discovered to be potent and specific ligands for HIV-1 TAR RNA (Table 5 and 
Table 6, summary in Table 8). Among them, L2-15 exhibits the highest affinity for 
HIV-1 TAR (75 nM), 3-fold higher than the peptide ADP-1 (200 nM), and this was 
used as a lead compound for further optimisation.  
L2-15 was the only peptide in the whole series with a !-turn defined by Lys6-
Gly7. This feature made it unique, suggesting that it is important for the interaction 
with HIV-1 TAR RNA. In an attempt to further investigate the turn region, the 
mutations Lys6Arg and Lys6hArg (peptides L3-04, L3-06) were studied (Table 9). By 
these changes the positive charge of the side chain was kept, but the guanidine group 
was introduced, and with two different lengths of side chain (Arg and hArg=homo-
Arg). The previous mutation studies suggested that the positive charge in the turn 
region is important for the interaction with HIV-1, but not for BIV TAR RNA. 
Additionally, in two peptides, L3-03 and L3-05, a disulfide bridge was introduced at 
positions 2 and 11 to stabilize a !-hairpin conformation. The positions 2 and 11 in the 
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!-hairpin conformation correspond to a non-hydrogen bonding site, and secondly in the 
BIV2-TAR RNA complex, they are solvent exposed and do not contact the RNA. To 
keep the overall charge of these peptides constant, in addition to incorporation of two 
cysteines, the amino acid at position 10 was mutated (Ile10Arg and Ile10Lys, for L3-03 
and L3-05, respectively). No structure is available of a ligand larger than arginamide in 
complex with HIV-1 TAR, so by the introduction of a disulfide bridge, which further 
stabilizes the !-hairpin conformation, we would evaluate if this conformation is 
important for the RNA recognition.  
It is noteworthy, that for the first time a single mutation was introduced in the D-
Pro-L-Pro template (D-Pro!D-Arg) in the peptide L3-01. In the structure of the BIV2-
TAR RNA complex, the template makes no significant contacts to the BIV TAR RNA, 
in particular D-Pro protrudes out of the binding site into the solvent. Once again, 
having little structural information on the ligand-HIV-RNA complex, it was 
hypothesized that the template region may be in closer proximity to the HIV RNA than 
in the BIV system. By introducing the long, positively charged side chain of D-Arg, it 
was hoped to test this hypothesis. Although introducing a DPro13DArg mutation may 
have a slightly destabilizing effect on the hairpin conformation (more freedom in the ( 
angle for Arg in comparison to Pro), this effect might be minimized or even overcome 
if the guanidine group interacts with the RNA. Importantly, the stereochemistry of the 
mutated amino acid was kept as D.  
 
Table 9. Library L3 of HIV-1 Tat mimetics. Kd values determined by EMSA. 
Mimetic Position Template Kd [nM] 
HIV-1 TAR 
 1 2 3 4 5 6 7 8 9 10 11 12   
L3-01 R V R T R K G R R I R I D-Arg-L-Pro 100 
L3-02 R V R T R K G R R R R I D-Pro-L-Pro 100 
L3-03 R C R T R K G R R R C I D-Pro-L-Pro 300 
L3-04 R V R T R R G R R I R I D-Pro-L-Pro 100 
L3-05 R C R T R K G R R K C I D-Pro-L-Pro 75 
L3-06 R V R T R hR G R R K R I D-Pro-L-Pro 100 
 
The peptidomimetic library 3 was prepared using a standard Fmoc solid phase 
peptide synthesis protocol on a MultiSyn Tech Syro II peptide synthesiser, as described 
previously in paragraph 2.2.2.  
In the case of peptides containing an intramolecular disulfide bridge, the 
oxidation was performed on the pre-purified cyclic peptides containing cysteine 
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residues protected with acetamidomethyl (Acm) protecting groups, in a mixture of 
AcOH:H2O (4:1) and 10 equivalents of iodine for 30 min. The quenching of the excess 
of iodine was achieved with 10 mM ascorbic acid in 50 mM citrate buffer (pH=5.0) 
(Figure 20). 
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Figure 20. Iodine oxidation of the cysteine residues protected with an Acm group. The scheme is shown 
for L3-03 peptide as an example. 
 
After purification by HPLC, the desired peptidomimetics were typically 
obtained in 20-40% overall yield, and each was >95% pure as determined by analytical 
HPLC and gave ESI-MS data consistent with the calculated masses (see Appendix 2 for 
analytical data). 
Unfortunately, the small library did not afford a peptide with affinity higher than 
the lead peptide, L2-15 (Kd=75 nM). The mutations introduced proved not to be 
critical, all the peptides remain active. Mutations of Lys6 into Arg and hArg led to a 
slight decrease of affinity, showing that the electrostatic interaction between the 
positively charged residue and the RNA is probably more important than the specific 
hydrogen bonding ability that a guanidinium group could facilitate. Furthermore, 
neither the introduction of the disulfide bridge nor the replacement of D-Pro by D-Arg, 
had any significant effects on the potency of the peptides.  
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2.2.4.2. Extended HIV-1 Tat peptidomimetics 
 
• Attempt to introduce more contacts to the HIV-1 TAR RNA by extending the 
length of the peptidomimetic 
 
The first library of peptidomimetics proved that 14-amino acid cyclic peptides 
with stable !-hairpin conformations can be potent binders to HIV-1 TAR RNA. 
However, all attempts at producing ligands with higher affinity than the lead 
compound, L2-15, have so far failed  
The mechanism of the Tat-TAR interaction in HIV-1, clearly shows that the 
cooperative binding of cyclin T1 to Tat protein and the TAR RNA loop region is 
necessary for effective transactivation. The cyclin T1-Tat heterodimer directly binds to 
the bulge region of TAR RNA, and this binding facilities the interactions of the cyclin 
T1-TAR RNA in the loop region.76 It was hypothesised that by extending the peptide 
sequences from 14 to 18 residues the surface of the intermolecular contacts between the 
mimetic and the RNA might be increased. Furthermore, it was envisioned that the 
contacts of this extended loop with the tip of the HIV-1 TAR RNA might result in 
inhibition of the cyclin T1 and TAR RNA interaction. The first peptide designed in this 
fashion was based on the sequence of BIV2, as its structure was at this point of the 
project the best studied one and its interaction with the RNA well understood. As the 
extension of the loop would bring more flexibility to the peptide structure, apart from 
the D-Pro-L-Pro template, a disulfide cross-link at a non-hydrogen bonding position (4 
and 13) was introduced to further stabilize a hairpin conformation (Figure 21). 
 
Figure 21. The first long loop peptide, called L4-01 (right), based on the BIV2 sequence (left). 
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The peptide L4-01 was prepared using a standard Fmoc solid phase peptide 
synthesis protocol on an ABI 433A peptide synthesiser, as described previously in 
paragraph 2.2.2. The formation of the disulfide cross-link was performed by oxidation 
on the pre-purified cyclic peptide containing cysteine residues protected with Acm 
groups, discussed in detail in paragraph 2.2.4.1. After purification by HPLC, the 
desired peptidomimetic was obtained in 38% yield. It was >95% pure as determined by 
analytical HPLC and gave ESI-MS data consistent with the calculated mass (see 
Appendix 2 for analytical data). 
The EMSA performed with this peptide revealed that this longer loop peptide 
was as potent as ADP-1 (Kd=200 nM) in binding to HIV-1 TAR RNA. L4-01 was a 
first attempt to increase the contact surface of the ligand and RNA and its sequence was 
based on BIV2, which was not the best ligand for HIV-1 TAR RNA (Kd=500 nM) 
Therefore this finding was very encouraging for further studies. 
 
 
• LIBRARY L4: Optimisation of the lead longer-loop peptide 
 
On the basis of the encouraging result obtained with the longer-loop peptide, 
L4-01, a new set of 18-residue peptides were designed and assayed. The sequences 
were based on that of L2-15, so far the most potent HIV-1 TAR RNA ligand 
(Kd=75 nM). Multiple mutations were made to the amino acids at positions 6-11, 
including the !-turn defining residues (Table 10). The cysteines forming the disulfide 
bridge, necessary for the stabilization of the !-hairpin conformation, were incorporated 
at two different non-hydrogen bonding positions: i) in the first 7 peptides, L4-02—L4-
08 at positions 4 and 13, the same as for L4-01, ii) in L4-09—L4-13 at positions 2 and 
15.  
 
Table 10. Library L4 of 18-mer HIV Tat peptidomimetics. Residues 1 and 16 are attached to the D-Pro-
L-Pro template. The Kd values were determined by standard EMSA. 
Mimetic Position Kd 
[µM] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  
L4-01 R V R C R T R G K R R R C A R V 0.2 
L4-02 R V R C R Q R K G R A R C I R I 0.2 
L4-03 R V R C R K L K G Q T R C I R I >5 
L4-04 R V R C R K R DR G Q T R C I R I 0.075 
L4-05 R V R C R Q R G P G K R C I R I >5 
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L4-06 R V R C R K Q G P G T R C I R I >5 
L4-07 R V R C R R K G P G Q R C I R I 0.15 
L4-08 R V R C R K R G P G Q R C I R I >5 
L4-09 R C R V R Q R K G R A R K I C I 0.15 
L4-10 R C R V R K Q G P G T R K I C I >5 
L4-11 R C R V R K Q G P G K R K I C I >5 
L4-12 R C R V R K R G P G Q R K I C I >5 
L4-13 R C R V R R K G P G A R K I C I 0.2 
 
The peptidomimetic library 4 was prepared using a standard Fmoc solid phase 
peptide synthesis protocol on a MultiSyn Tech Syro II peptide synthesiser, as described 
previously in paragraph 2.2.2. The intramolecular disulfide bridge, was formed by the 
oxidation of the pre-purified cyclic peptides containing cysteine residues protected with 
Acm groups, as previously described in detail in paragraph 2.2.4.1. After purification 
by HPLC, the desired peptidomimetics were typically obtained in 20-40% overall yield, 
and each was >95% pure as determined by analytical HPLC and gave ESI-MS data 
consistent with the calculated masses (see Appendix 2 for analytical data). 
The L4 library containing 18-amino acid hairpins gave some ligands with higher 
affinity for TAR RNA than L4-01, namely L4-04, L4-07 and L4-09. As multiple 
mutations have been made and the sequences vary extensively, it is not easy to discuss 
the importance of individual amino acid residues. However, some useful conclusions 
can be drawn, which might aid future work. The position of the disulfide bridge appears 
not to be of importance, as in both subgroups potent peptides are identified. Various !-
turn defining amino acids (KG, DRG, GP) were tested and all of the combinations gave 
active peptides. L4-03 and L4-04 vary only at positions 7 and 8 (LK vs. RDR) but this 
has a dramatic effect on the affinity (>5 µM vs. 75 nM). The only difference between 
L4-07 and L4-08 is the exchange of the amino acids at positions 6 and 7 (RK vs. KR) 
but again, the affinity diminishes drastically. Similar observations were made for L4-12 
and L4-13, however, Lys6-Arg7 present in L4-04 are apparently tolerated well in this 
peptide.  
In addition to the peptides containing 18 amino acid residues, it was decided to 
design several peptides with different loop lengths: i) 15-mers (L4-14!L4-19), and ii) 
16-mers (L4-20!L4-25), summarised in Table 11 and Table 12. Varying the loop 
length (15-mer, 16-mer vs. 18-mer) would help to evaluate the importance of this 
extension, and the possibility of picking up additional contacts with the tip of the RNA 
loop. 
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Table 11. Library L4 of 15-mer HIV Tat peptidomimetics. Residues 1 and 13 are attached to the D-Pro-
L-Pro template. The Kd values were determined by standard EMSA. 
Mimetic Position Kd 
[µ)] 
 1 2 3 4 5 6 7 8 9 10 11 12 13  
L4-14 R V R C R K K G K C I R I >5 
L4-15 R V R C R R R G R C I R I >5 
L4-16 R V R T R K K G K R I R I 1 
L4-17 R V R C R K K DP K C I R I >5 
L4-18 R V R T R K K DP K R I R I 0.75 
L4-19 R V R V R K K G R T I R I >5 
 
Analysis of binding of the 15-residue peptides to HIV TAR RNA by EMSA, 
showed that they do not bind, or bind weakly. Most likely the modified structure of the 
hairpin has significantly effected the hairpin stability and/or the interactions with the 
RNA.  
 
Table 12. Library L4 of 16-mer HIV Tat peptidomimetics. Residues 1 and 14 are attached to the D-Pro-
L-Pro template. The Kd values were determined by standard EMSA. 
Mimetic Position Kd 
[nM] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14  
L4-20 R V R C R K R K G R C I R I 500 
L4-21 R V R C R R K R G R C I R I 300 
L4-22 R V R T R Q R K G R R I R I 200 
L4-23 R V R V R K R K G R Q I R I 250 
L4-24 R V R Q R K R K G R V I R I 200 
L4-25 R V R C R K R K DP R C I R I 300 
 
All the 16-amino acid peptides exhibit moderate binding to TAR RNA, 
including peptides with and without the disulfide bridge present. So apparently, any 
additional stabilization of the !-hairpin has no significance on the interaction with the 
RNA. At positions 4 and 11 various amino acids were incorporated and the minor 
changes in affinity proved that these changes are not critical for binding. The 
replacement of Gly9 by D-Pro (L4-25), also brings no significant improvement in 
affinity.  
In summary, only peptides of 18-amino acid residues with the template, exhibit 
high potency among all the compounds tested and, therefore, they were chosen for 
further optimisation. 
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2.2.4.3. Structure-activity-relationship studies on lead compounds L4-04 and L2-15 
 
 
• Attempts to evaluate the importance of the template and disulfide bridge.  
 
L4-04 has been identified as the most potent peptide among the 18-amino acid 
ligands. Since there is no structure of the ligand/HIV-1 TAR RNA available, we 
performed systematic studies on this lead compound. In the first step, the importance of 
the template and disulfide bridge was evaluated. Three peptides were designed: i) L4-
04a, stabilized by a disulfide bridge but without the template, ii) L4-04b, stabilized by 
the template, but without a disulfide cross-link, and finally iii) L4-04c, without any of 
the constraints, i.e. a linear peptide. In the peptides without disulfide bridge, the 
cysteine residues were replaced by aminobutyric acid (Abu) (Table 13). 
These peptidomimetics were prepared using a standard Fmoc solid phase 
peptide synthesis protocol on an ABI 433A peptide synthesiser, as described previously 
in paragraph 2.2.2 and the intramolecular disulfide bridge was formed as described in 
paragraph 2.2.4.1. After purification by HPLC, the desired peptidomimetics were 
typically obtained in 20-40% overall yield, and each was >95% pure as determined by 
analytical HPLC and gave ESI-MS data consistent with the calculated masses (see 
Appendix 2 for analytical data). 
 
Table 13. Derivatives of L4-04 with and/or without D-Pro-L-Pro template and disulfide bridge. The Kd 
values were determined by standard EMSA. Abu=aminobutyric acid 
Mimetic Position Template Kd  
[nM] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16   
L4-04 R V R C R K R DR G Q T R C I R I D-Pro-L-Pro 75 
L4-04a Ac-R V R C R K R DR G Q T R C I R I-NH2 -- 200 
L4-04b R V R Abu R K R DR G Q T R Abu I R I D-Pro-L-Pro 100 
L4-04c Ac-R V R Abu R K R DR G Q T R Abu I R I-NH2 -- 200 
 
The peptides not stabilized by the template exhibit a reduced potency by more 
than 2-fold, which suggests that the stabilization by D-Pro-L-Pro is an important factor. 
The absence of the second constraint (the disulfide bridge) has a much smaller effect on 
the affinity; the Kd is only slightly worse in comparison to L4-04. 
 
 Peptidomimetics of the viral Tat Protein -50- 
A similar comparison was performed for L2-15, the most potent of the 14-mer 
peptides, where the linear peptide without template was synthesised and assayed (Table 
14). 
 
Table 14. Comparison between L2-15 and its derivate without the template, L2-15a. The Kd values were 
determined by standard EMSA. 
 
The linear peptide exhibits exactly the same affinity towards TAR RNA as the 
parent mimetic L2-15. This result suggests that the template in 14-mer peptides has no 
significance in contrast to the situation in the longer-loop peptides discussed above. 
However, the cyclic peptides are much more stable against proteolysis (Paragraph 
2.2.8.1) so it is important to keep the template, when considering other properties. 
 
 
• Attempts to evaluate the importance of arginine residues in L4-04 by single 
mutation to lysine. 
 
The single mutations of arginine residues to lysine residues in the lead 
compound, L4-04, was performed to evaluate the significance of the guanidinium 
groups, which can form specific hydrogen bonding with base pairs and/or the RNA 
backbone.  
 
Table 15. The HIV-1 Tat peptidomimetics of the L4-04K library. Single Arg!Lys mutations were 
introduced into the L4-04 lead compound. Residues 1 and 16 are attached to the D-Pro-L-Pro template. 
The Kd values were determined by standard EMSA. 
Mimetic Position Kd 
[nM] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  
L4-04 R V R C R K R DR G Q T R C I R I 75 
L4-04K01 K V R C R K R DR G Q T R C I R I 100 
L4-04K02 R V K C R K R DR G Q T R C I R I 50 
L4-04K03 R V R C K K R DR G Q T R C I R I 200 
L4-04K04 R V R C R K K DR G Q T R C I R I 200 
L4-04K05 R V R C R K R DR G Q T K C I R I 75 
L4-04K06 R V R C R K R DR G Q T R C I K I >1000 
L4-04K07 R V R C R K R DK G Q T R C I R I 75 
 
Mimetic 1 2 3 4 5 6 7 8 9 10 11 12 Template Kd [nM] 
L2-15 R V R T R K G R R I R I D-Pro-L-Pro 75 
L2-15a Ac-R V R T R K G R R I R I-NH2 -- 75 
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These peptides were synthesised, purified and characterised using the methods 
described above, for the analytical data see Appendix 2. 
The mutation Arg3Lys improves the affinity of the peptide, the positive charge 
of the lysine may produce a better fit in the complex than the guanidine group. The 
mutations Arg12Lys and DArg8DLys are perfectly tolerated and do not bring any 
improvement in affinity. Lysine replacements at positions 1, 5 and 7 seem to be well 
tolerated and bring only a small decrease in affinity. At these positions the guanidinium 
group is slightly preferred over the amine group. A dramatic drop in affinity is observed 
by the mutation Arg15Lys, where the affinity is completely lost. This result indicates 
that arginine with its guanidinium group at this position is critical for effective binding 
to the TAR RNA.  
 
 
• Attempts to evaluate the importance of the length of the arginine side chain 
in L4-04 and L2-15 by single mutations Arg!hArg. 
 
In addition to the Arg!Lys mutations described above, the single arginine 
residues were replaced stepwise by homoarginine (hArg) to evaluate the significance of 
the length of the side chain bearing guanidinium group. It was hypothesized that at 
some positions extending the side chain might bring an increase of affinity due to better 
contact with base pairs or the RNA backbone.  
 
Table 16. Single Arg!hArg mutations were introduced into the L4-04 lead compound. Residues 1 and 
16 are attached to the D-Pro-L-Pro template. The Kd values were determined by standard EMSA. 
hR=homoarginine. 
Mimetic Position Kd  
[nM] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  
L4-04 R V R C R K R DR G Q T R C I R I 75 
L4-04hR01 hR V R C R K R DR G Q T R C I R I 350 
L4-04hR02 R V hR C R K R DR G Q T R C I R I 150 
L4-04hR03 R V R C hR K R DR G Q T R C I R I 300 
L4-04hR04 R V R C R K hR DR G Q T R C I R I 100 
L4-04hR05 R V R C R K R DR G Q T hR C I R I 100 
L4-04hR06 R V R C R K R DR G Q T R C I hR I 150 
 
Synthesis of Fmoc-N,N’-bis-Boc-homoarginine (20). The Fmoc/Boc protected 
homoarginine (20) was prepared as shown in Figure 22. The Boc protection of 
commercially available guanidine hydrochloride to form N,N’-bis-Boc-guanidine (18) 
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was performed according to the procedure developed by Feichtinger.97 Introduction of 
the triflate group gave N,N’-bis-Boc-N’’-Tf-guanidine (19). This guanidinylating 
reagent was used in a reaction with the primary amine of Fmoc-protected lysine 
following the slightly modified description by Tamaki.98 The overall yield was 40%.  
 
H2N NH2
NH
BocHN NHBoc
NH
a) b)
BocHN NHBoc
N
Tf
COOHFmocHN
NH2
+
BocHN NHBoc
N
Tf
c)
COOHFmocHN
NH
NHBoc
BocN
18 19
20  
Figure 22. Scheme of synthesis of Fmoc-N,N’-bis-Boc-homoarginine. Reagents a) Boc2O, NaOH, 1,4-
dioxane; 66%, b) Tf2O, DIEA, DCM; 65%, c) TEA, DCM; 95%. 
 
The peptidomimetics with hArg incorporated were prepared using a standard 
Fmoc solid phase peptide synthesis protocol on a MultiSyn Tech Syro II peptide 
synthesiser, as described previously in paragraph 2.2.2. The coupling of the hArg was 
performed with a reduced amount of this amino acid (2 eq) and its completeness was 
monitored by the Kaiser test. The intramolecular disulfide bridge was formed by the 
oxidation of the pre-purified cyclic peptides containing cysteine residues protected with 
Acm groups, as previously described in detail in paragraph 2.2.4.1. After purification 
by HPLC, the desired peptidomimetics were typically obtained in 10-25% overall yield, 
and each was >95% pure as determined by analytical HPLC and gave ESI-MS data 
consistent with the calculated masses (see Appendix 2 for analytical data). 
In all the cases the peptides bearing mutations are slightly weaker binders to 
TAR RNA than the lead compound, L4-04. The decrease in affinity is pronounced for 
positions Arg1 and Arg5 (more than 3-fold). Peptides carrying mutations at positions 
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Arg7, Arg12 and Arg15 maintain good affinity. Probably these arginine residues, as in 
BIV2, are on the solvent exposed face of the peptide and therefore are more tolerant to 
the changes.  
The same approach was taken for the peptide L2-15. All the Arg!hArg 
mutations delivered peptides with slightly lower affinity compared to the parent 
peptide. Again, the arginine residues at positions 1, 3 and 5 are more affected by 
extension of the side chain, while the peptides with mutations of residues on the other 
side of the hairpin (Arg8, Arg9 and Arg11) retain the affinity (Table 17). 
 
Table 17. Single Arg!hArg mutations were introduced into the L2-15 lead compound. Residues 1 and 
12 are attached to the D-Pro-L-Pro template. The Kd values were determined by standard EMSA. 
hR=homoarginine. 
Mimetic Position Kd  
[nM] 
 1 2 3 4 5 6 7 8 9 10 11 12  
L2-15 R V R T R K G R R I R I 75 
L2-15hR01 hR V R T R K G R R I R I 150 
L2-15hR02 R V hR T R K G R R I R I 200 
L2-15hR03 R V R T hR K G R R I R I 200 
L2-15hR04 R V R T R K G hR R I R I 75 
L2-15hR05 R V R T R K G R hR I R I 100 
L2-15hR06 R V R T R K G R R I hR I 100 
 
The mutations of arginine to homoarginine introduced into both lead 
compounds, L2-15 and L4-04, show that extension of the side chain with an additional 
-CH2- group, does not facilitate any stronger contacts between guanidinium groups and 
TAR RNA. There are no significant changes in affinity, however, there is a trend 
noticeable - the mutations of the arginine residues 1, 3 and 5 are more affected by the 
extension, while other arginine residues are more tolerant with only a slight, if any, 
decrease in affinity. On the bases of these results we can suggest that the interaction 
between these peptides and HIV-1 TAR RNA is similar to that of BIV2-BIV TAR 
RNA and one side of the peptide predominantly contacts the RNA while the other side 
is rather solvent exposed.  
 
• LIBRARY L5: Further attempts to optimise the lead sequence of L4-04. 
 
From part of the L4 library containing 18-residue peptides, the lead compound, 
L4-04, has been identified. Attempts to evaluate the importance of intramolecular 
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constraints (the template and disulfide bridge) revealed that the template is more 
important for the binding affinity than the disulfide bridge, however, the linear peptide, 
L4-04c, still exhibits affinity to the RNA (Table 13).  
Studying the importance of arginine residues present in L4-04 has shown so far 
that most of the changes made are well tolerated, with the exception of Arg15Lys, 
which causes a complete loss in affinity. The length of the arginine side chain has no 
major significance on the strength of the interaction between the peptide and the RNA. 
Nonetheless, structural information on the complex is still lacking, so only careful 
stepwise optimisation will enable us to gather more insights into this ligand-RNA 
recognition and allow us to produce peptides with higher affinity for HIV-1 TAR RNA. 
One priority was to investigate the importance of the turn region. In L4-04, D-Arg in 
the !-turn seems to play an important role. To evaluate its importance the mutations 
DArg8Arg and DArg8Lys were introduced. The combination of Lys-Gly has been found 
in the 14-residue peptidomimetics to be favourable over any other combination in the 
interaction with HIV-1 TAR. Gly-Pro is also known to stabilize the !-hairpin 
conformation, so it was considered worthwhile to introduce these changes into L4-04. 
Peptide L4-04b showed that the disulfide bridge is not critical for the binding 
affinity (Table 13). It was therefore decided to replace the cysteine residues by 
threonine and alanine (L5-05), or to shift the disulfide to other non-hydrogen bonding 
positions (L5-06, L5-08 and L5-09). Additionally, multiple mutations were introduced 
at positions 6, 10, 11 and 15 combining the knowledge obtained from L4-01!L4-13 
peptides. Finally, it was decided to transplant the turn region of L2-15 into the “longer-
loop” peptides (L5-10!L5-12), to evaluate the effect on binding to HIV-1 TAR RNA. 
The peptidomimetic library L5 was prepared using a standard Fmoc solid phase 
peptide synthesis protocol on a MultiSyn Tech Syro II peptide synthesiser, as described 
previously in paragraph 2.2.2. The intramolecular disulfide bridge, present in the 
majority of the peptides, was formed by the oxidation of the pre-purified cyclic 
peptides containing cysteine residues protected with Acm groups, as previously 
described in detail in paragraph 2.2.4.1. After purification by HPLC, the desired 
peptidomimetics were typically obtained in 20-40% overall yield, and each was >95% 
pure as determined by analytical HPLC and gave ESI-MS data consistent with the 
calculated masses (see Appendix 2 for analytical data). 
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Table 18. The HIV-1 Tat peptidomimetics of the L5 library. Residues 1 and 16 are attached to the D-Pro-
L-Pro template. The Kd values were determined by standard EMSA. 
Mimetic Position Kd  
[nM] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  
L4-04 R V R C R K R DR G Q T R C I R I 75 
L5-01 R V R C R K R R G Q T R C I R I 100 
L5-02 R V K C R K R K G Q T R C I R I 100 
L5-03 R V R C R K L DR G Q T R C I R I 250 
L5-04 R V R C R R K DR G Q T R C I R I 100 
L5-05 R V R T R K R DR G Q T R A I K I 150 
L5-06 R C R V R K R DR G Q T R R I C I 200 
L5-07 R V R C R K R G P G A R C I K I >1000 
L5-08 R C R V R R K K G R A R K I C I 200 
L5-09 R C R V R Q R G P G A R K I C I >1000 
L5-10 R V R C R T R K G R A R C I K I 75 
L5-11 R V R C R Q R K G R R A C I R I 25 
L5-12 R V R C R Q R K G R R I C I R I 75 
 
The results of EMSA with the L5-01!L5-12 peptides, shown in Table 18, gives 
more information about the importance of several amino acid residues, and in 
combination with the results obtained with peptides L4-01!L4-13, allows new 
conclusions to be drawn. 
The comparison of the peptides with and without a disulfide bridge (L4-04, L4-
04b and L5-05) confirms that the additional stabilization of the conformation of the 18-
mer peptides leads to only minor changes in the binding affinity. The peptide without 
the bridge shows only a small decrease in affinity (2-fold). The position of the disulfide 
bridge is not a critical factor, but from all the peptides, the ones with the cysteines at 
positions 2 and 15 are generally 2 to 3-fold weaker binders to TAR RNA. 
The sequence defining the tip of the loop has been modified in several peptides 
without much impact on the affinity. The D-Arg at position 8 may be exchanged for L-
Arg and L-Lys, so neither the stereochemistry of the chiral centre, nor the guanidinium 
group are important at this position for the binding. Introduction of the Lys8-Gly9 at 
the turn (known from L2-15) results in retention or even an increase of potency 
(peptides L5-10, L5-11, L5-12). A !-turn defined by –8GPG10- works well with L4-07 
and L4-13 (affinity of 150 and 200 nM, respectively), but in combination of the other 
mutations, brings a complete loss in affinity (L5-07 and L5-09). 
Position 6 can accommodate different amino acid residues, including charged 
ones (lysine and arginine), and uncharged polar ones (glutamine or threonine). The 
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charge seems not to play a critical role; the peptides with Gln6 or Thr6 exhibit the same 
or even improved Kd’s. 
Similar behaviour is observed at position 12, which in L5-11 and L5-12 is 
mutated into alanine or isoleucine, respectively, and the affinity is retained or 
improved. Interestingly, the arginine residue at position 15, which from the lysine-
scanning library (Table 15) seems to be critical for binding and not exchangeable for 
lysine, in this library shows more tolerance towards this mutation (peptides L5-05 and 
L5-10). However, these peptides have other mutations, that may allow such a change 
and compensate for it by other contacts. It may be specially true for L5-05, which 
without the disulfide bridge exhibits more intrinsic flexibility than the constrained 
peptide, L4-04. 
Two of the peptides that exhibited up-to-date the highest affinity towards HIV-1 
TAR RNA in standard EMSA conditions with a large excess of tRNA, were assayed in 
EMSA in the absence of the tRNA (Table 19). The peptides exhibit affinities in the 
subnanomolar range and they are around 50-fold stronger in the absence of the 
unspecific competitor. These results show, that although we managed to design specific 
ligands of high affinity for TAR RNA, their partial binding to tRNA is unavoidable due 
to their cationic nature. However, it is noteworthy, that the binding affinities in the 
presence of 10’000-fold excess of competitor (tRNA) are still in the low nanomolar 
range, which makes them attractive leads for future development. 
 
Table 19. Kd values for selected mimetics binding to HIV-1 TAR RNA determined by EMSA in the 
presence and absence of tRNA. 
Mimetic Kd [nM] HIV-1 TAR 
EMSA with tRNA 
Kd [nM] HIV-1 TAR 
EMSA without tRNA 
L4-04K02 50 1 
L5-11 25 0.5 
 
 
2.2.4.4. Electrophoretic mobility shift inhibition assay  
 
In addition to the standard EMSA, the selected most potent HIV Tat 
peptidomimetics were assayed in competition with ADP-1, a native HIV-1 Tat-derived 
peptide, and a cyclin T1 bifunctional construct with Tat.99 The aim of this experiment 
was to prove that the peptidomimetics have an ability to inhibit: i) the interaction 
between the RNA-binding domain of Tat (ADP-1) and its cognate RNA, and ii) the 
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interaction between the chimera of human cyclin T1 (hCycT1) and Tat and HIV-1 TAR 
RNA. 
 
 
     
Figure 23. EMSA inhibition assay performed for L2-15. Left: Binding of L2-15 to HIV-1 TAR RNA 
(1 nM), right: Inhibition of the complex formation between the ADP-1 (150 nM) peptide and HIV-1 TAR 
RNA (1 nM) by L2-15.  
 
The peptides exhibit a high potency to inhibit the interaction between ADP-1 
and the hCytT1-Tat construct and its cognate TAR RNA (Figure 23and Table 20). That 
fact has a fundamental importance when considering the inhibition of viral transcription 
in vivo. Peptidomimetics are able to disturb not only the complex formation between 
HIV TAR RNA and ADP-1 but also the interaction of hCycT1 and Tat protein with the 
RNA. Since hCycT1 and Tat form a high-affinity complex with TAR RNA that results 
in the recruitment of Cdk9, formation of the positive transcription elongation factor-b 
complexes and reactivation RNA polymerase II, inhibition of this ternary complex 
formation is crucial for the inactivation of virus transcription. 
 
Table 20. Summary of EMSA experiments, the standard direct binding assay, inhibition assay with 
ADP-1, and the inhibition assay with a chimera of hCycT1 and Tat.99  
Mimetic Kd  
[nM] 
IC50 [nM] 
ADP-1 
IC50 [nM] 
Chimeric 
L2-15 75 100 250 
L2-15a 75 100 100 
L4-02 200 250 200 
L4-04 75 100 100 
L4-07 150 100 100 
L4-09 150 150 150 
L4-13 200 200 300 
T  L2-15 (µM)  
A 
R       0    0.05   0.1   0.2   0.5    1.0       2.0     5.0 
ADP-1 Complex 
 
 
 
 
 
 
L2-15 Complex 
 
TAR RNA 
L2-15 Complex 
 
TAR RNA 
T  L2-15 (µM) 
A 
R      0.025    0.05     0.1        0.2         0.3 
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2.2.5. NMR analysis of selected HIV Tat peptidomimetics 
 
The conformation of BIV2 was shown earlier to be a stable !-hairpin in aqueous 
solution.54,93 To verify, that the other highly active 14-residue HIV-1 Tat 
peptidomimetics retained the same structure, NMR was used to characterise their 
structure in the absence of RNA (peptides under study listed in Table 21).  
 
Table 21. Sequences of the selected 14-amino acid peptidomimetics, whose conformations have been 
studied in detail by NMR methods. Residues 1 and 12 are attached to the D-Pro-L-Pro template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 
BIV2 R V R T R G K R R I R V 
L1-07 R T R T R G K R R I R V 
L1-43 R V R T R G K R R I O V 
L2-15 R V R T R K G R R I R I 
 
All 1H-NMR spectra of selected peptides were measured in aqueous solution 
(10%D2O/H2O, pH=2.3) if not otherwise indicated. The strategy of proton assignment 
relied on the identification of spin systems using COSY and TOCSY, followed by 
analysis of NOESY spectra to establish the sequential connectivities. Furthermore, H/D 
exchange experiments and a temperature series of 1H and TOCSY experiments were 
performed to investigate intramolecular hydrogen bonding and the conformational 
stability of the structure. Calculations of peptide structures were performed by using 
NOE-derived upper-distance limits and JNH-H" coupling constants as restraints for a 
conformational search using DYANA.100 MOLMOL was used for structural analysis 
and visualisation of the molecular structures.101 These calculations were performed in 
collaboration with Dr. K. Moehle. 
The differences between C"H chemical shift values determined experimentally 
and the random coil values are widely used as an indicator of secondary structure 
formation. In regular secondary structures of proteins, an up-field shift of amide NHs 
and C"Hs are observed upon helix formation, and a down-field shift upon !-sheet 
formation.102 Down-field shifts of H" >0.1 ppm (*+), indicative of an extended !-sheet 
conformation, are observed for residues 1-5 and 8-12 in all the peptides studied (Figure 
24). 
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Figure 24. H" chemical shifts relative to random coil chemical shifts of residues in peptidomimetics 
BIV2 (black), L1-07 (red), L1-43 (yellow) and L2-15 (green).!
 
Peptides L1-07 and L1-43 (Table 21) vary from BIV2 only in one amino acid, 
but in both the !-turn is defined by Gly6-Lys7. L2-15 contains three mutations to the 
parent BIV2 sequence (Table 21). Especially the !-turn sequence is modified, which 
might significantly affect the hairpin stability and therefore this peptide has been 
studied in detail. It is well-known that the turn conformation plays a key role in the 
formation and stability of hairpin conformations in linear peptides. A comparison of 
1H-spectra in the linear L2-15a (Table 14) and cyclic L2-15 peptides shows a large 
difference in the amide NH region. The spread of the amide proton signals for cyclic 
L2-15 and linear L2-15a (1.85 vs 0.43 ppm) indicates clearly the highly organised 
structure of the cyclic peptide in contrast to that in the unstructured linear peptide 
(Figure 25). 
 Peptidomimetics of the viral Tat Protein -60- 
 
Figure 25. Comparison of the linear L2-15a peptide (without the template) [upper spectra] and the cyclic 
L2-15 [lower spectra]. 
 
The structure for L2-15 in aqueous solution was determined using 128 NOE 
upper distance limits. The ensemble of 20 structures had a backbone rmsd from the 
average structure of 0.75±0.36 Å (Table 22) indicating a highly structured molecule. 
Even prior to a formal structure calculation, conclusive evidence for a !-hairpin 
structure comes from the observation of long-range NOEs between residues on opposite 
strands of the hairpin, especially H"-H" NOEs between non-hydrogen bonding residue 
pairs and HN-HN NOEs between hydrogen bonding residue pairs on opposite strands. 
In L2-15, H"-H" NOEs are observed between Val2 and Arg11 and between Thr4 and 
Arg9; three HN-HN NOEs involve Arg1-Ile12, Arg3-Ile10, and Arg5-Arg8 
connections. Furthermore, cross-strand H"-HN NOEs were seen between Thr4 and 
Ile10 and between Val2 and Ile12. The average structures (Figure 26) confirm the 
predicted stable !-hairpin conformation in which the two strands of the antiparallel !-
sheet are connected by a type I' turn between Lys6 and Gly7, with Lys6 occupying the 
left-hand region of conformational space.  
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! !  
Figure 26. Left: Backbone superposition and representation of the final 20 NMR structures for L2-15 
with the template residues in red. Right: A typical NMR structure with the ribbon representation of the 
two strands.  
 
A semiquantitative estimate of the population of folded structures can be 
obtained from the intensities of the cross-strand H"-H" NOEs, relative to the intensity 
of the H"-H" NOE of Gly7, as a fixed reference distance.103 However, only the Thr4-
Arg9 NOE could be clearly resolved in the D2O spectra, because the Val2-Arg11 NOE 
is in the proximity of the diagonal. With reference to the H"-H" separation of 2.32 Å 
found in regular antiparallel !-sheets in proteins (100% folded hairpin), the estimated 
hairpin population in L2-15 is then ~90%. Another method of estimating folded !-
structures makes use of the "N(i,i+1)/" N(i,I) NOE intensity ratio.103 Values of ~2.3 
correlate with random coil conformations, whereas larger values of ~8 are predicted for 
an ideal antiparallel !-sheet. The intensity ratios for residues in the predicted !-strands 
of L2-15 (1-5 and 8-11) are in the range of 4.4-11.4 and thus provide further support for 
highly populated !-conformations. The intensity ratio of <1 for the same pair of NOEs 
observed for Lys6 and Gly7 is consistent with the left-handed ("L) population in a type 
I' turn. The predominant occurrence of the type I' !-turn, with the atypical left-handed 
helical orientation of Lys6, is confirmed by characteristic NOE connectivities, in 
particular, by the sequential HN-HN (Lys6-Gly7 and Gly7-Arg8) and H"-HN (Lys6-
Arg8) NOEs, as well as the strong intramolecular H"-HN NOEs of Lys6 and Gly7.  
Long-range NOEs consistent with the proximity of the two antiparallel !-
strands were also observed for other studied peptides L1-07, L1-43 and L2-15. They all  
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exhibit average !-hairpin structures in solution (Figure 27) that are very similar to those 
deduced earlier for BIV2 peptide (Figure 17). The results of the structural calculations 
of these peptides are summarised in Table 22 (see Appendix 6 for 1H-NMR 
assignments). 
 
Mimetic L1-07 L1-43 L2-15 
NOE upper-distance limits 84 102 138 
Intraresidue 31 37 56 
Sequential 39 43 59 
Medium and Long-Range 14 22 23 
Residual Target Function Value (Å2) 0.78±0.30 0.48±0.009 0.44±0.05 
Mean rmsd values (Å)    
All backbone atoms 1.39±0.68 0.87±0.40 0.75±0.36 
All heavy atoms 3.49±1.00 2.54±0.71 2.50±0.65 
Residual NOE violations    
Violation > 0.2 Å  13 6 none 
Maximum violation (Å) 0.44 0.24 none 
Table 22. Experimental distance restraints and statistics for the final 20 NMR structures calculated for, 
L1-07, L1-43 and L2-15. 
 
! ! !
! ! !
Figure 27. Left: Backbone superposition and representation of the final 20 NMR structures. Right: 
typical NMR structure with the ribbon representation of two strands for L1-07 and L1-43. 
L1-07 
 
 
 
 
 
 
 
 
 
 
 
 
L1-43 
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The temperature dependence of amide proton chemical shifts, as well as relative 
H/D exchange rates, provides complementary information about the involvement of 
amide NH groups in hydrogen bonding and/or their solvent accessibility.104 Relatively 
small temperature coefficients (<5) were observed for residues 1, 3, 5, 8, 10 and 12 for 
all the studied peptides as expected for residues in cross-strand hydrogen bonding 
positions (Figure 28).  
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Figure 28. Comparison of NH temperature coefficients (in parts per billion per Kelvin) determined over 
range the 278-328K. 
 
Further support for the strong network of cross-strand hydrogen bonding in L2-
15 came from the H/D exchange experiment. Peptide bonds involved in H-bonding, or 
otherwise shielded from the solvent, can be identified by their relatively slow rate of H-
D exchange. This effect is generally explained by the rate limiting breaking of the H-
bond prior to exchange with the solvent.105 Slowly exchanging amide protons in L2-15 
were detected by monitoring the signal intensities of amide proton resonances after 
dissolution in D2O at 298K. The experiment showed that the exchange rates of amide 
NHs are significantly slowed for Arg1, Arg3 and in particular Ile10 and Ile12. The very 
slow exchange rates of Ile10 (half-time, t1/2=32h) and Ile12 (half-time, t1/2=13h) NHs 
might be due not only to their involvement in cross-strand H-bonding, but also due to 
shielding from the solvent by their aliphatic side chains (Figure 29 and Table 23). 
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Lys6      Ile10          Ile12   Arg9  Gly7/Val2          Arg8 Arg1 
        Arg5/Arg3        Thr4/Arg11 
 
Figure 29. The H/D exchange experiment for L2-15 at 298K and pH=2.3. Hydrogen atoms of peptide 
bonds of Ile10, Arg3, Ile12 and Arg1 are the least susceptible to exchange in the experiment conditions. 
 
 
Table 23. H-D exchange rates and half-lives of peptide amide protons for L2-15. S-strong, M-medium 
and W-weak H-bonding, inferred from the exchange data. 
 
 
 
 
 
 
 
L2-15 Arg1 Val2 Arg3 Thr4 Arg5 Lys6 Gly7 Arg8 Arg9 Ile10 Arg11 Ile12 
k 
[min-1] 
0,0013 0,0032 0,0021 0,0142 0,0097 0,2916 0,0035 0,0041 0,0116 0,0005 0,0043 0,0009 
,1/2 
[min] 
533,6 216,6 330 48,8 71,5 2,4 198,1 169,1 59,8 1926,6 161,2 770,3 
H-bond S M M W W W M M M S M S 
23h 38min 
 
 
 
13h 37min 
 
 
 
 
3h 8min 
 
 
 
 
1h 28min 
 
 
 
6min after mixing 
with D2O 
Ile10 Arg3     Ile12      Arg1 
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The same set of experiments were performed for the selected “longer-loop” 
peptides exhibiting high affinity for HIV-1 TAR RNA, namely L4-01, L4-04, L4-07, 
L4-09 and L5-11 (Table 24). 
 
Table 24. Sequences of the selected 18-amino acid peptidomimetics, whose conformations were studied 
in detail by NMR methods. Residues 1 and 16 are attached to the D-Pro-L-Pro template. The Cys 
residues in each peptide are linked by a disulfide bond. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
L4-01 R V R C R T R G K R R R C A R V 
L4-04 R V R C R K R DR G Q T R C I R I 
L4-07 R V R C R R K G P G Q R C I R I 
L4-09 R C R V R Q R K G R A R K I C I 
L5-11 R V R C R Q R K G R R A C I R I 
 
The loop was extended to 16 amino acids stabilized by the template and by the 
disulfide bridge at the positions 2 and 15 for L4-09 and 4 and 13 for the other peptides. 
It was crucial to provide the experimental data to prove the conformational stability of 
the extended loop. The NMR experiments for 18-mer peptides were performed 
identically to the measurements for shorter peptides described above. The statistics 
important for the structural calculations are listed in Table 25 (see Appendix 6 for 1H-
NMR assignments). 
 
Table 25. Experimental distance restrains and statistics for the final 20 NMR structures calculated for  
L4-01, L4-04, L4-07, L4-09 and L5-11. 
Mimetic L4-01 L4-04 L4-07 L4-09 L5-11 
NOE upper-distance limits 149 167 120 183 152 
Intraresidue 59 59 39 62 62 
Sequential 61 71 60 78 67 
Medium and Long-Range 29 37 21 43 23 
Residual Target Function 
Value (Å2) 
0.67±0.00768 0.67±0.12 0.74±0.0088 0.8±0.0095 0.71±0.097 
Mean rmsd values (Å)      
All backbone atoms 1.09±0.47 1.53±0.60 1.63±0.53 1.48±0.98 1.40±0.41 
All heavy atoms 2.77±0.5 3.24±0.81 3.15±0.65 3.26±1.54 3.16±0.56 
Residual NOE violations      
Violation > 0.2 Å  none 5 11 7 7 
Maximum violation (Å) none 0.30 0.34 0.34 0.31 
 
Structures of the peptides studied are shown in Figure 30 and Figure 31. Structures of 
L4-04, L4-07, L4-09 and L5-11 exhibit less convergence than the structure of L4-01 
(seen also in increased backbone rmsd values, Table 25). This is due to the fact that 
visualised structures based on the calculations contain several NOE violations. 
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However, these violations are a minor component of all the NOE restraints and they are 
randomly distributed in all the 20-lowest energy final structures. 
! !  
! ! !
! !  
 
Figure 30. Left: Backbone superposition and representation of the final 20 NMR structures. Right: 
typical NMR structure with the ribbon representation of two strands for L4-01, L4-04 and L4-07. 
 
L4-01 
L4-04 
L4-07 
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! ! !  
Figure 31. Left: Backbone superposition and representation of the final 20 NMR structures. Right: 
typical NMR structure with the ribbon representation of two strands for L4-09 and L5-11. 
 
A comparison of the chemical shifts observed in these cyclic peptides with the 
random coil values (*+H" >0.1 ppm) indicates an extended !-sheet conformation for 
residues 1-7 and 10-16 in all the studied peptides (Figure 32). 
L4-09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L5-11 
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Figure 32. H" chemical shifts relative to random coil chemical shifts of residues in peptidomimetics L4-
01 (black), L4-04 (red), L4-07 (yellow), L4-09 (green) and L5-11 (blue). Residues 17 and 18 refer to D-
Pro-L-Pro template. 
 
The absolute values of temperature coefficients are shown in Figure 33. As 
expected, amide protons at positions 1, 3, 5 and 10 and to a smaller extent at positions 7 
and 16 exhibit smaller changes in chemical shifts upon temperature increase, which 
indicates the involvement of these protons in stable hydrogen bonds. 
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Figure 33. Comparison of NH temperature coefficients (in parts per billion per Kelvin) determined over 
the range 278-328K.!
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The H-D exchange experiments confirm the above mentioned results and the 
stability of the H-bonding pattern, especially in the smaller loop enclosed by the 
template and the disulfide bridge. Positions 1, 3 and 14, 16 exhibit very slow exchange 
rates, with half-times for exchange of up to 7 days or longer for L4-04 (Table 26). 
These values suggest that this peptide has an extremely stable conformation stabilized 
by persistent hydrogen bonds. The extremely slow exchange rates of amide protons of 
Ile14 and Ile16 in L4-04 might be due to shielding of peptide bonds by long, branched 
and unpolar side chains in addition to strong H-bonding.  
 
L4-01 Arg1 Val2 Arg3 Cys4 Arg5 Thr6 Arg7 Gly8 Lys9 Arg10 Arg11 Arg12 Cys13 Ala14 Arg15 Val16 
k 
[min-1] 
0,0015 0,125 0,0075 >0.4 >0.4 0,11 0,05 >0.4 >0.4 0,17 0,33 0,01 >0.4 0.00039 0.2 0.00059 
,1/2 
[min] 
672 8 133 >2.5 >2.5 9 20 >2.5 >2.5 6 3 99 >2.5 2552 5 1700 
H-
bond 
S W M W W W W W W W W M W S W S 
L4-04 Arg1 Val2 Arg3 Cys4 Arg5 Lys6 Arg7 DArg8 Gly9 Gln10 Thr11 Arg12 Cys13 Ile14 Arg15 Ile16 
k 
[min-1] 
8.11e-
05 
0,0025 7.1e-
05 
>0.2 >0.4 0,067 0,05 >0.5 >0.25 0,0033 0,0625 0,0014 >0.17 6.65e-
05 
0.0033 6.96e-
05 
,1/2 
[min] 
8546 
~6days 
277 9763 
~7days 
>5 >3 10 20 >2 >4 210 11 488 >6 10415 
>7days 
207 9948 
~7days 
H-
bond 
S M S W W W W W W W W M W S W S 
L4-07 Arg1 Val2 Arg3 Cys4 Arg5 Arg6 Lys7 Gly8 Pro9 Gly10 Gln11 Arg12 Cys13 Ile14 Arg15 Ile16 
k 
[min-1] 
7.59e-
04 
0,0082 0.0034 ~0.23 0.053 0,069 0,046 ~0.23 - 0,116 0,0630 0,0433 ~0.23 0.0014 0.0108 1.204e-
04 
,1/2 
[min] 
913 85 206 ~3 13 10 15 ~3 - 6 11 16 ~3 495 64 5756 
H-
bond 
S M M W W W W W - W W W W M W S 
Table 26. H-D exchange rates and half-lives of peptide amide protons for longer-loop peptides. S-strong, 
M-medium and W-weak H-bonding, inferred from the exchange rate data. 
 
 
 
 
 
 
 
 
 
 
 
 
 Peptidomimetics of the viral Tat Protein -70- 
At this point it was of interest to generate models of the RNA-bound forms of 
these cyclic peptides. The structures of the free HIV-1 TAR17-45 RNA106 and its Tat-
derived peptide-bound form72 have been determined at high resolution using NMR 
spectroscopy. The model complexes between potent representatives of the 14-mer 
peptides (L2-15) and 18-mer peptides (L4-04) were generated by superposition of the 
peptide structure determined in solution onto the previously solved structure of HIV-1 
TAR RNA. 
 
!  
Figure 34. Model of complex: left: L2-15-HIV-1 TAR RNA; right: L4-04-HIV TAR RNA. The NMR-
solved structures of L2-15 and L4-04 are superimposed on the HIV-1 TAR RNA NMR structure. 
 
The superposition of both peptides together on the HIV-1 TAR RNA shows that 
by extending the peptide chain, it is likely that more contacts between the RNA and the 
peptide would be present (Figure 34). The tip of the loop of the peptide is in close 
proximity to the tip of the loop of the RNA, and this fact has a high importance when 
considering the formation of the ternary complex between cyclin T1, Tat protein and 
RNA, which is necessary for the successful reactivation of RNA polymerase II. 
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Figure 35. Comparative model of the complexes between 14-mer peptide, L2-15 (pink), and 18-mer 
peptide, L4-04 (orange) with HIV-1 TAR RNA. 
 
The complexes between L2-15 and L4-04 and HIV-1 TAR RNA are currently 
under study by NMR spectroscopy in cooperation with Prof. G. Varani. 
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2.2.6. CD analysis 
 
CD spectroscopy provides preliminary qualitative information on the secondary 
structure of the peptides under study. Peptides assuming a high proportion of !-sheet 
secondary structure typically show spectra with a minimum at 218nm (%#>%* 
transition) and a maximum at 196nm (n->%* transition). 
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Figure 36. CD spectra of selected peptides: 14-mer L2-15 and 18-mer L4-01 and L4-04. Samples 
prepared in 10 mM phosphate buffer (pH=7.4), were measured in 0.1 mm quartz thermostatable cuvette 
at 25oC, using JASCO J-715 spectropolarimeter. A scan speed 5 nm/min, 2 seconds response and a 2 nm 
spectral band width were used. CD spectra are presented after subtraction of a blank containing only 
buffer and the optical activity is reported in units of mean residue ellipticity (deg cm2 dmol-1). Spectra 
presented as an average of five scans and results are given for a range 185-250 nm. 
 
All three peptides under study show a shape of the CD spectrum characteristic 
of a !-sheet conformation. L2-15 shows a maximum intensity of 14200 deg cm2 dmol-1 
at 194 nm and a minimum at 220 nm of -17400 deg cm2 dmol-1. These results are very 
close to the standard curves of molecules with 100% content of !-sheet secondary 
structure.107 The longer loop peptides exhibit a shift in the wavelength of the minima 
and maxima indicating a slightly lowered content of a regular !-sheet secondary 
structure but they still share high similarities to the standard curve.  
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2.2.7. Cell permeability studies  
 
Having found active Tat peptidomimetics, that bind tightly to the TAR RNA 
and therefore are potential antiviral agents, it is important to prove that the peptides can 
be delivered into cells, where their inhibitory action takes place. During the last decade, 
several peptides and proteins have been found to translocate through cellular 
membranes in a process called “protein transduction”. These translocatory proteins 
share several common biophysical features that may be related to their apparent 
permeability. All appear to be taken up into the cytoplasm in a punctuated manner 
without accumulation in the nucleus, despite earlier experiments with fixed cells, which 
due to fixation artefacts appeared to show nuclear accumulation.108 Each of them have a 
highly basic region that seems to mediate the ability of these proteins to bind to 
polyanions such as heparin/heparan sulfate, polysialic acid, and nucleic acids. These 
short sequences typically comprise less than 20 amino acids, which are highly rich in 
basic residues, and are called “protein transduction domains (PTDs)” or “cell 
penetrating peptides” (CPPs). These PTDs are responsible for the ability of the proteins 
to translocate across the plasma membrane. HIV Tat was one of the first membrane-
permeable arginine-rich proteins to be discovered in the late 1980’s.109 In 1997, Vivès 
et al. reported that the arginine-rich segment in the Tat protein (positions 48–60) is the 
critical component for translocation.110 Soon other arginine rich peptides were 
discovered that can internalise efficiently through the cell membrane, including the 
RNA-binding segments derived from HIV-1 Rev, the flock house virus (FHV) coat, the 
brome mosaic virus (BMV) Gag, and the human T-cell lymphotrophic virus (HTLV)-II 
Rex protein.111,112 There are no sequence similarities amongst them, except that these 
segments contained more than seven arginine residues. As the number of arginines in 
the segment becomes smaller, the internalization of the peptides becomes less efficient. 
Peptides containing less than five arginines lose the ability to transduce across cell 
membranes.113-115  
In the recent years, the translocation mechanism of major CPPs has been 
controversially discussed and is not yet fully understood. At early stages of such 
studies, it had been assumed that peptides such as Tat are delivered into the cell via 
direct, energy independent mechanisms and accumulate mainly in the nucleus.110 
Further studies proved this assumption to be wrong and the misleading results were 
explained by cell fixation artefacts and other experimental shortcomings. Recent studies 
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with life cells have demonstrated an energy and concentration dependent endocytic 
uptake mechanism.108,116,117  
BIV has been used in our studies as a model of the TAR RNA/Tat protein 
interaction. BIV Tat peptide has the same function as HIV Tat and similar properties, 
such as a high content of basic residues in the region responsible for RNA-binding. BIV 
Tat permeability has not yet been studied, but it could be presumed that it also can 
translocate through membranes. Hence it was decided to investigate the cell 
permeability of the BIV and HIV Tat mimetics described in the previous section. 
Peptidomimetics that target intracellular interactions must be efficiently 
delivered into the cell to perform their inhibitory action. BIV2 and L1-07 were chosen 
as representative examples of the !-hairpin peptidomimetics of BIV Tat and HIV-1, 
and the corresponding Tat-derived peptides were used as positive controls. The chosen 
peptides were fluorescently labelled in order to observe their uptake and cell 
localisation in HeLa cells by means of confocal microscopy (Table 27).  
A selection of three fluorescent probes was used: i) 5(6)-carboxyfluorescein 
($a= 494 nm and $e= 521 nm), ii) 5(6)-carboxyfluorescein diacetate ($a= 494 nm and 
$e= 521 nm), iii) 5(6)-carboxytetraethylrhodamine ($a= 554 nm and $e= 580 nm) 
(Figure 37).  
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Figure 37. Fluorescent probes used to label the selected peptides. Left: 5(6)-carboxyfluorescein, middle: 
5(6)-carboxyfluorescein diacetate, right: 5(6)-carboxytetraethylrhodamine. 
 
5(6)-Carboxyfluorescein is a very commonly used probe for permeability 
studies, however, it is negatively charged in physiological conditions. To evaluate if the 
charge of the probe has any influence on cell permeability we used in addition 5(6)-
carboxyfluorescein diacetate, which is non-polar and only after entering the cell is 
converted into the highly fluorescent dianionic 5(6)-carboxyfluorescein118 by 
intracellular esterase(s) (Figure 38). 
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Figure 38. Mechanism of the conversion of non-polar 5(6)-carboxyfluorescein diacetate into ionic 5(6)-
carboxyfluorescein. 
 
 
2.2.7.1. Synthesis of labelled peptides for cell permeability studies 
 
 
• Synthesis of the linear labelled peptides 
 
The positive controls for the permeability studies were chosen according to 
literature precedence: i) HIV-1 Tat arginine rich domain between Gly38 and Gln60 has 
been shown to be critical for permeability,110 ii) BIV Tat arginine rich domain between 
Ser65 and Lys82, which is assumed here to have the same permeability characteristic as 
the corresponding HIV Tat domain (Table 27). 
The linear Tat peptides were selectively labelled on the resin with 5(6)-
carboxyfluorescein or 5(6)-carboxyrhodamine at either the free N-terminal amino 
group, before other protecting groups were removed, or at the side chain of the Lys82 
in BIV Tat after selective removal of an Alloc-protecting group, and prior to removal of 
other side chain protecting groups. The free carboxyl groups in the fluorophores were 
coupled to the amino group of the peptide using standard coupling methodology with 
HATU/HOAt. The fluorescent labels performed very well in the solid phase peptide 
synthesis and they were stable in the standard final deprotection conditions. The 
labelled linear peptides were isolated in good yield after HPLC purification, and were 
characterized by MS (see experimental part 5.5.4 for synthesis and analytical data). 
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• Synthesis of the labelled cyclic peptides 
 
Labelling of the cyclic peptides requires an additional functionalisation of a 
chosen amino acid, since simply attaching it to the amine group of any lysine side chain 
present in the peptide may affect the binding affinity, as well as the cell permeability. 
Based on the structure of the BIV2/TAR RNA complex (Figure 39) D-Pro was chosen 
as a site for functionalisation and labelling, as it makes no direct contact with the RNA 
and therefore labelling at this residue should have minimal effects on binding. A 
hydrazino group at the 4-position of this D-Pro would provide a strongly nucleophilic 
site at which a selective ligation to the fluorophore could be performed. The first step, 
therefore, was the synthesis of an appropriately protected (2R,4S)-4-hydrazino-D-
proline. 
 
Figure 39. NMR-structure of the complex of BIV2-BIV TAR RNA. The D-Pro residue sticking out into 
solution is indicated with an arrow.  
Peptide Sequence Origins of the peptide 
Fl-BIV-Tat Fl-SGPRPRGTRGKGRRIRRK-NH2 BIV Tat protein residues 65-82 
Rh-BIV-Tat H-SGPRPRGTRGKGRRIRRK[Rh]-NH2 BIV Tat protein residues 65-82 
Fl-HIV-Tat Fl-GRKKRRQRRRPPQ-NH2 HIV Tat protein residues 48-60 
Rh-BIV2h cyclo(RVRTRGKRRIRVDP[Rh]P) earlier work 
Fl-BIV2h cyclo(RVRTRGKRRIRVDP[Fl]P) earlier work 
Rh-L1-07h cyclo(RTRTRGKRRIRVDP[Rh]P) L1 library 
Fl-L1-07h cyclo(RTRTRGKRRIRVDP[Fl]P) L1 library 
Fl-Ac-BIV2h cyclo(RVRTRGKRRIRVDP[Fl-Ac]P) earlier work 
Fl-Ac-L1-07h cyclo(RTRTRGKRRIRVDP[Fl-Ac]P) L1 library 
Table 27. Selection of peptides labelled with fluorescent probes, including linear positive controls 
derived from BIV and HIV-1 Tat arginine-rich domains and cyclic peptides BIV2 and L1-07. 
Fl=Fluorescein, Rh=Rhodamine, Fl-Ac=Fluorescein diacetate, h=indication that the peptide contains the 
4-hydrazino-D-Pro in the template  
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• Synthesis of (2R,4S)-4-[N,N,N’-tris-(tert-butyloxycarbonyl)]hydrazino-1-
[(9H-fluoren-9-yl)-methoxycarbonyl]-proline  
 
D-Proline was modified at position C. by a fully Boc-protected hydrazine 
group. This should allow a site-specific derivatization of a fully deprotected peptide, 
and is compatible with solid-phase peptide chemistry.119 The hydrazino group has been 
used previously, for example, in the chemoselective acylation of peptides by fatty acid 
succinimidyl esters, providing a valuable access to complex lipopeptides.120 
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Figure 40. Scheme of synthesis of Fmoc-4-(N,N,N’-tris-Boc)-hydrazino-D-proline. Reagents a) 
PhCH2OCOCl, NaOH, THF; 76%, b) BnBr, K2CO3, NaI, DMF; 97%, c) NosCl, TEA, DCM; 95%, d) 
BocNHNH2, Dioxan; 79%, e) Boc2O, DMAP, NEt3, DCM; 75%, f) H2, Pd/C 10%, MeOH; 75%, g) 
Fmoc-OSu, DIEA, DCM; 72%. 
 
The synthesis of the Fmoc/Boc protected 4-hydrazino-D-proline (27) is shown 
in Figure 40, starting from (2R,4R)-4-hydroxy-D-proline. Protection of the secondary 
amino group (21) and conversion into the benzyl ester (22) were performed according 
to established methods.121 Introduction of the nosyl group as an excellent leaving group 
(23) and its subsequent nucleophilic displacement by t-butylcarbazate (24) with a 
complete inversion of configuration was performed by slightly modifying the 
procedures of Hoffman et al.122 and Lerner et al.123 In the next step, the hydrazine 
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moiety was fully protected using di-tert-butyl dicarbonate to yield N-benzyl-4-[N,N,N’-
tris-tert-butyloxycarbonylhydrazino]-proline benzyl ester (25).119 
Hydrogenolysis of the fully protected derivative (25) removed the N"-Z and Bn 
protecting groups and gave the desired product, 4-[N,N,N’-tris-tert-butyloxycarbonyl-
hydrazino]-proline (26). The free amino group was then protected with Fmoc using 
Fmoc-OSu to deliver the amino acid (27) in overall yield of 22% in 7 steps, ready-to-
use in solid phase peptide synthesis.  
 
 
• Preparation of the fluorescently labelled cyclic peptides  
 
For the synthesis of fluorescently labelled BIV2 and L1-07, the Fmoc/Boc 
protected hydrazino-D-proline (27) was coupled manually to L-Pro preloaded 
chlorotrityl chloride resin. To ensure the coupling was complete, the chloranil test was 
performed. Subsequently, the peptides were assembled on the peptide synthesizer using 
standard Fmoc chemistry. Cyclization and the final deprotection yielded the desired 
peptides (Figure 41), which were purified by HPLC and characterized by MS (see 
paragraph 5.5.4 for synthesis and analytical data). 
The coupling of the fluorophores was performed in 50 mM citrate buffer 
pH=5.0-5.2. The pKa of the hydrazino group (~6)
120 should be about 4 units below that 
of the &-amino group of lysine (~10), therefore performing the reaction under pH 
controlled conditions should preferentially lead to a single acylation at the hydrazine 
group. To improve coupling efficiency the fluorescent probes were activated as N-
hydroxy succinimide esters, prepared freshly before reaction (reaction of fluorophore 
with N-hydroxysuccinimide and DIC) or purchased, if commercially available. To 
improve the solubility of the activated fluorophore, the probe was dissolved in DMF 
and then added to the buffered peptide solution.  
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Figure 41. An example of the cyclic 14-amino acid peptide, L1-07h, labelled with 5(6)-
carboxyfluorescein diacetate at the hydrazine moiety in D-proline. 
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By carefully adjusting the content of DMF to solubilize the succinimidyl ester 
of the fluorophore, the time of the reaction, and the ratio of peptide to fluorescent 
probe, the yield of the labelling reaction could be improved from 6% to above 50%. 
Figure 42 shows typical HPLC chromatograms of crude reaction products, before and 
after optimization. 
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Figure 42. HPLC chromatograms of the reaction mixtures of labelling reaction with L1-07 and 5(6)-
carboxyfluorescein-diacetate-succinimidyl ester. Semi-preparative Zorbax Eclipse column, C18, gradient 
10-90% MeCN in H2O+0.1%TFA. Flow 5 ml/min. The optimised reaction (bottom) was performed in 50 
mM citrate buffer (pH=5.0): DMF (5:1) over 5 days with 1.0 eq of the fluorophore. 
     Starting     Product     Double-Labelled  
     Peptide           Peptide 
Product 
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2.2.7.2. Cellular uptake of fluorescently labelled peptides into HeLa Cells 
 
The distribution of the fluorescently labelled peptides was followed in living 
unfixed HeLa cells. The cells were incubated with the peptides at 37oC for 30 min and 
with Hoechst 33341 for 5 min for nuclear staining, and after washing with PBS buffer 
inspected immediately under the confocal microscope. A separate set of experiments 
was prepared using fixed cells (mild fixation with 3% paraformaldehyde, 2% sucrose in 
BPS buffer) to evaluate the influence of fixation on the peptide distribution. In the case 
of experiments with fixed cells, the cells after fixation were incubated for 5 min with 
DAPI for nuclear staining, washed with PBS and mounted on microscope slides. 
Hoechst 33341 and DAPI are known to form fluorescent complexes with natural 
double-stranded DNA and they were used to visualize the nucleus. The transmission 
images were recorded to visualize the shape of the cells and prove their health.  
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Figure 43. Cellular uptake of peptides labelled with 5(6)-carboxyrhodamine in the fixed HeLa cells. 
5/104 cells seeded on coverglass were incubated with 500 nM peptide solution for 30 min at 37oC. 
Fixation was with 3% paraformaldehyde, 2% sucrose in BPS. Left: Rhodamine-peptide (red) with DAPI 
(blue) for nuclear staining; middle: Rhodamine-peptide (red), right: transmission image of the cells. 
A: corresponds to Rh-BIV2h, B: corresponds to Rh-L1-07h, C: corresponds to Rh-BIV Tat. 
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Figure 44. Cellular uptake of peptides labelled with 5(6)-carboxyfluorescein in the fixed HeLa cells. 
5/104 cells seeded on coverglass were incubated with 500 nM peptide solution for 30 min at 37oC. 
Fixation was with 3% paraformaldehyd, 2% sucrose in BPS. Left: Fluorescein-peptide (green) with 
DAPI (blue) for nuclear staining; middle: Fluorescein-peptide (green), right: transmission image of the 
cells. A: corresponds to Fl-BIV2h, B: corresponds to Fl-L1-07h, C: corresponds to Fl-HIV-Tat. 
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Figure 45. Cellular uptake of peptides labelled with 5(6)-carboxyrhodamine in live HeLa cells. 8/104 
cells seeded on coverglass were incubated with 1 µM peptide solution for 30 min at 37oC.  
Left: Rhodamine-peptide (red) with Hoechst 33341 (blue) for nuclear staining; middle: Rhodamine-
peptide (red), right: transmition image of the cells. 
A: corresponds to Rh-BIV-Tat, B: corresponds to Rh-L1-07h, C: corresponds to Rh-BIV2h. 
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Figure 46. Cellular uptake of peptides labelled with 5(6)-carboxyfluorescein (diacetate) in live HeLa 
cells. 8/104 cells seeded on coverglass were incubated with 1 µM peptide solution for 30 min at 37oC.  
Left: Fluorescein (diacetate) -peptide (green) with Hoechst 33341 (blue) for nuclear staining; middle: 
Fluorescein (diacetate)-peptide (green), right: transmition image of the cells. 
A: corresponds to Fl-HIV-Tat, B: corresponds to Fl-BIV-Tat, C: corresponds to Fl-Ac-L1-07h, D: Fl-Ac-
BIV2h. 
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Figure 47: (Continued) E: corresponds to Fl-BIV2h, F: corresponds to Fl-L1-07h. 
 
 
 All peptides studied showed a punctuated vesicular-type, cytoplasmic 
distribution of the labelled peptides (Figure 43-Figure 47). The peptides were localized 
in vesicular structures that were predominantly on one side of the nucleus. BIV Tat and 
HIV Tat peptides were analysed as controls and showed the same fluorescence 
distribution as the cyclic peptides. No nuclear localization was observed, as frequently 
reported as a common artefact in experiments with fixed cells.108,110 These observations 
are consistent with knowledge to-date on the endocytic translocation mechanism. The 
incubation time used in the experiments presented above was 30 min, although already 
after very short incubation times, such as 5 min, the internalisation was already taking 
place to visible levels. For the peptides labelled with fluorescein or fluorescein 
diacetate the quality of the images was mostly very good with a high resolution, while 
the images of the cells exposed to rhodamine most of the time could only be obtained 
with lower resolution. These problems might be due to spectroscopic differences 
between the two fluorophores. 
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2.2.8. Proteolytic and plasma stability of selected peptides 
 
The stability of drug candidates in a biological environment is essential for 
maintaining acceptable drug concentrations and half-life in order to achieve desirable 
pharmacological effects. Unstable compounds tend to have rapid clearance and short 
half-lives, resulting in poor in vivo performance. Except for “pro-drugs”, drug 
candidates undergoing rapid degradation by enzymes in plasma or tissue, generally 
have undesirable pharmacokinetic parameters and pose analytical challenges. 
Pharmaceutical companies tend to not advance the development of compounds that 
degrade rapidly, with the exception of prodrugs and special cases. 
 Cleavage by proteases is one of the main pathways for inactivation of peptides 
in biological settings. The major problem with therapy based on peptidic drugs is their 
susceptibility to extremely rapid enzymatic degradation after subcutaneous or oral 
administration. There is great demand for more stable peptidomimetic analogues, which 
would allow a patient-friendly way of administration, a reduction in dose and frequency 
of administration.  
 Selected Tat-derived peptides were studied here in two different assays to assess 
their rate of catabolism: i) in a trypsin digestion assay and, ii) in human and mouse 
plasma. 
 
 
2.2.8.1. Trypsin digestion assay 
 
 As proteases typically bind their substrates in a linear or an extended rather then 
folded conformation, inducing a stable !-hairpin secondary structure is expected to 
improve protease stability, leading to increased potency in vivo. To test this concept in 
vitro, selected peptides were treated with trypsin and the digestion process was 
analysed over time for up to 10 h. Trypsin is an endopeptidase (serine protease) that 
predominantly cleaves peptide chains at the carboxyl side of the amino acids lysine and 
arginine, except when either is followed by proline. The Tat peptidomimetics are rich in 
arginine and lysine residues. Therefore trypsin was chosen as a relevant proteolytic 
enzyme for the assay. L2-15, L4-01 and L4-04 were chosen for these studies, since 
their stable !-hairpin conformation has been confirmed by NMR studies (Paragraph 0). 
The linear version of the peptide L2-15 (L2-15a) was used to provide a comparative 
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study between linear and cyclic peptides in terms of their susceptibility to cleavage by 
trypsin. Trypsin activity was determined by methods published first by Erlanger124 and 
modified by Temporini.125  
 
Table 28. The results of the proteolytic digestion of peptides by trypsin. Peptides (0.33 mg/ml) were 
incubated with trypsin (2 µg/ml) in 50 mM Tris buffer (pH=8.2) containing 10 mM CaCl2. Reaction 
aliquots were taken at suitable time points. Digestion was stopped by addition of 30% AcOH. Samples 
were analysed by HPLC with L-Tryptophan (0.16 mM) as an internal control (method described by 
Wang et al.126) 
 
 As expected, the linear control peptide, L2-15a, is highly susceptible to 
cleavage by trypsin and was completely degraded within a few minutes under the assay 
conditions. The cyclic compounds L2-15 and L4-01 were completely digested in under 
60 min, while L4-04 was unexpectedly resistant to trypsin digestion and the complete 
degradation was detected only after more than 2 days. The half-lives (,1/2) of the 
peptides under the assay conditions are given in Table 28. As an example, the data 
points for L4-01 are shown in Figure 48. 
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Figure 48. The trypsin digestion experiment performed with L4-01. The experiments was repeated in 
triplicate and resulted in a half-life of 12.5±0.5min. 
Peptide Half-life ,1/2 [min] 
L2-15a 1.5±0.6 
L2-15 21±1 
L4-01 12.6±0.3 
L4-04 360±15 
 Peptidomimetics of the viral Tat Protein -88- 
 These results show that the cyclic peptides stabilized in a !-hairpin 
conformation, are less susceptible to proteolysis than their linear counterparts, and this 
is consistent with the common assumption that only extended or linear peptide 
conformations are recognized by trypsin and by other proteolytic enzymes. Presumably 
the cyclic form is tightly locked into a !-hairpin secondary structure and the peptide 
bonds are involved in a strong H-bonding network, which has an important influence 
on recognition by trypsin. For L2-15 and L4-01 the cleavage rate is decreased by 
around 10-fold, compared to the linear peptide L2-15a, consistent with the !-hairpin-
stabilizing effects noted above. In the case of L4-04, which is much more resistant to 
trypsin proteolysis, there is an interesting correlation with the NMR data of this peptide, 
which showed very slow H/D exchange rates, consistent with a very stable !-hairpin 
structure stabilized by strong hydrogen bonding. 
 
 
2.2.8.2. Plasma stability assay 
 
Compounds with certain functional groups are more susceptible to hydrolysis by 
plasma enzymes than others. These include esters, amides, lactones, lactams, 
carbamides, and sulfonamides. The plasma stability assay is designed to focus on these 
classes of compounds. Arg-containing peptides are potential substrates for the wide 
variety of trypsin-like proteases that are present in the blood and may have residual 
activity in the blood. The plasma stability of the Tat peptidomimetics may therefore be 
limited and this would have significant consequences related to development of 
antiviral Tat peptidomimetics as drug candidates. Due to species differences, screening 
of plasma stability in the most relevant animal species provides useful information for 
drug discovery. This information may help to prioritise compounds for in vivo studies 
and to alert researchers to the potential liabilities of key pharmacophores, so that 
structural modifications can be made to improve stability.  
 The stability of selected Tat-derived peptidomimetics was assessed by 
incubation experiments with the selected peptides (10 µM) in human and mouse plasma 
(90%), and collecting six data points over the course of 240 min. The experiments were 
repeated in triplicate. Propantheline was used as a positive control, which has a known 
degradation profile for both plasma species.127 The results are shown in Table 29.  
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Table 29. Summary of the results from plasma stability assays. The half-life (,1/2 [min]) and stability 
after 4 h (% remaining after 4 h) are presented for each peptide (10 µM in PBS) after incubation with 
human or mouse plasma (90%). 
Mimetic ,1/2 [min] 
in Human 
Plasma 
Stability after 4 h 
in Human Plasma 
[%] 
,1/2 [min] 
in Mouse 
Plasma 
Stability after 4h 
in Mouse Plasma 
[%] 
L1-06 >240 85.3 19.1 0 
L1-07 >240 74 79.2 1.9 
L2-15 90 24.8 178.7 42.7 
L4-01 240 50 99.1 38.4 
L4-04 104.5 30.4 152.9 45.1 
L5-11 >240 55.0 60 5 
 
 Although human plasma is of most interest, mouse plasma is also used to 
provide data relevant to lower mammals, which are often used in preclinical studies. All 
the peptides are relatively stable in human plasma, with a significant amount remaining 
after 4 h incubation (Table 29). Mouse plasma degrades the peptides generally faster 
than does human plasma. Similar observations have been made by Janssen et al. using 
hK2-selective peptide substrates.128 The difference between human and mouse plasma 
may be attributed to the large variability of the enzymes among different species. These 
results provide an indirect measure of the probable plasma half-life in humans, although 
in vivo plasma clearance will be faster due to clearance by the liver and kidneys.  
 The trypsin digestion and plasma stability experiments show that cyclization of 
the peptides and designing sequences that form stable !-hairpin conformations has a 
major effect on the proteolysis stability of the peptides, which is a very important factor 
when considering drug discovery. 
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2.3. Discussion 
 
 
2.3.1. BIV Tat peptidomimetics 
 
The previous results on the BIV Tat peptidomimetics described in detail in 
Section 2.2.1 provided us with the opportunity to use rational methods to optimise the 
activity of the lead peptide BIV2, thus demonstrating that this class of peptidomimetic 
inhibitors is both potent and specific. While it has been possible in the past to discover 
small molecule inhibitors of the Tat-TAR interaction, specificity has been difficult to 
achieve. In this work, we demonstrated that just a few rounds of optimisation led to the 
discovery of potent inhibitors of the BIV Tat-TAR interaction; remarkably the 
inhibitors are strongly selective over a structure as closely related as HIV-1 TAR, 
demonstrating that the structural rigidity imposed by the D-Pro-L-Pro template provides 
selectivity by locking the pharmacophore in a defined geometry at the peptide-RNA 
interface. 
The analysis of the large libraries L1 and L2 gave a detailed insight into 
determinants of affinity and specificity. Although the total number of peptides 
synthesised and tested is relatively large (~100), it represents a small fraction of the 
total sequence space potentially available to these peptides. The first step in designing 
the peptides was to mutate single amino acid residues. Then when the optimal residues 
for each position were found, the next step was to combine the favourable changes in 
order to verify if the positive results were additive. 
 
 
2.3.1.1. Summary of the structure-activity-relationship studies 
 
The guanidinium groups of Arg1, Arg3 and Arg5 with their positive charges 
and specific hydrogen bonding abilities are important for tight binding and any 
mutations at these positions, including lysine and ornithine, abolished binding to RNA. 
Side chains of these arginines are buried in the RNA major groove, and all three 
guanidinium groups are located in positions where strong hydrogen bonding with base 
pairs and/or the RNA backbone can occur. By comparing the complexes of BIV Tat-
TAR and BIV2-TAR, there is a clear positional overlap of Arg3 with Arg70, Arg1 with 
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Arg73 and to a smaller extent Arg5 with Arg77. All three arginine residues in the 
native BIV Tat peptide were found by mutagenesis studies to be crucial for binding.129 
The side chain of Val2 is on the solvent exposed side in the complex and 
possibly therefore mutations here are well tolerated (Table 5). Val2Thr yields a small 
improvement of affinity, probably since threonine is similar in size and shape to valine 
but is polar, which is important for the interaction with water. 
Thr4, similar to Val2, is also solvent exposed and does not contact the RNA – a 
variety of mutations were tested and proved to be well tolerated. Just in one case, the 
Thr4Gln mutation, a small increase of affinity was noticed. 
Gly6 and Lys7 are situated in the tip of the hairpin in BIV2 and do not contact 
RNA. The Lys7 side chain is pointing out into solution and the variations introduced at 
this position are well tolerated. Reversing the order of Lys and Gly has no significance 
on the affinity towards BIV TAR RNA. 
Arg8, Arg9, Arg11 can only be replaced by other positively charged amino 
acids (Lys, Orn) to produce peptides that can still bind to TAR RNA. The positive 
charge appears to play an important role in binding, while the guanidinium group with 
its specific hydrogen bonding ability seems to be less important. Arg8 is the most 
sensitive of all three positions to the changes, possibly because the guanidinium group 
of Arg8 contacts the base pairs at the tip of the RNA hairpin, however, it is not buried 
in the structure of the complex. 
The side chain of Ile10 is buried in the complex where it contacts RNA bases. 
Isoleucine can be exchanged by other hydrophobic residues without much loss of 
affinity in most of cases, but the side chain of isoleucine still remains as the optimal for 
hydrophobic contacts at the peptide-RNA interface.  
Ile12 (which replaced Val in the BIV2 sequence at an early stage of 
optimisation, as it produces consistently a small gain in affinity) points into the major 
groove of TAR. It could be replaced with polar and even aromatic residues, such as 
Asn, Thr, or Phe, with only small changes in activity.  
Peptidomimetics containing multiple substitutions in the BIV2 sequence, which 
combine the changes that individually resulted in increased affinity, gave several 
mutants exhibiting improved affinities towards TAR RNA in comparison to BIV2 (L2-
32—L2-36). 
 
 
 Peptidomimetics of the viral Tat Protein -92- 
2.3.1.2. Selectivity of the BIV Tat peptidomimetics 
 
The peptidomimetics in the libraries 1 and 2 were designed to target the Tat-
TAR RNA interaction in BIV. Since the lack of specificity of inhibitors of protein-
RNA interactions is a well-known problem, these peptides were also assayed against 
HIV-1 TAR and RRE RNA, in order to evaluate their ability to distinguish between 
these related RNAs. Remarkably, very large differences in affinity between BIV and 
HIV TAR were observed when even single amino acid mutations were introduced 
(Table 5 and Table 6). For example, peptides L2-03 and L2-04 bind to BIV TAR only 
weakly, while these peptides bind to HIV TAR strongly. Thus, the location of the Arg1 
side chain on the hairpin scaffold is an important feature not just of the affinity but also 
of the selectivity of these peptidomimetics. In contrast, peptides L1-09, L1-11—L1-12 
bind to HIV TAR weakly (or not at all) compared to BIV TAR, emphasizing the fact 
that position 10 can be occupied by different hydrophobic amino acids and retain 
binding to BIV TAR, although Ile seems to be the optimal residue. On the other hand, 
Ile was the only hydrophobic residue to retain affinity against HIV TAR; all other 
hydrophobic residues abrogated binding, while the activity with respect to HIV TAR 
was retained or even increased with the introduction of polar residues such as Asn and 
Gln in this position. Finally, significant differences in the binding profile between the 
two highly similar TAR sites were observed for mutants at the !-turn of the peptide 
loop (peptides L2-15—L2-20) and for peptides in which multiple mutations were 
combined, such as L2-11!L2-14 and L2-26!L2-43. For example, swapping Gly for 
Lys in L2-15 led to a 10-fold increase in the level of HIV TAR binding, mutating Lys 
to different residues (peptides L2-16—L2-20) abolished binding, but binding to BIV 
was not affected by any of these changes. Thus, this family of !-hairpin mimetics binds 
with nanomolar affinity and high selectivity to TAR RNAs and discriminates very 
effectively between the very closely related HIV and BIV structures. 
 
2.3.1.3. Summary 
 
This work demonstrates that peptidomimetic chemistry based on structure-
promoting scaffolds yields nanomolar inhibitors of viral protein-RNA interactions. In 
addition to being as potent as the complete Tat protein they were intended to mimic, 
these peptides are remarkably selective. Mutations that proved to be most favourable 
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for BIV TAR were not identical to those that led to optimal activity against HIV TAR, 
and vice versa; single and multiple substitutions allow the peptidomimetics to 
distinguish between two RNAs that are closely related in structure and sequence. The 
knowledge generated from the structural analysis and implemented in just a few cycles 
of design and testing led to a 100-fold improvement in activity compared to that of the 
lead molecule BIV2. The insight gained through this work into the origins of the 
affinity and selectivity of binding of peptidomimetics to BIV TAR has recently been 
exploited in the development of related mimetics that bind tightly to HIV TAR RNA. 
 
 
2.3.2. HIV-1 Tat peptidomimetics 
 
The ultimate goal of this project was to deliver potent, selective and 
proteolytically stable peptides that are capable of in vitro binding to HIV-1 TAR RNA 
and inhibiting the HIV-1 Tat protein-TAR RNA interaction, as well as being active in 
vivo, suppressing HIV replication. Studies on BIV Tat-TAR interaction inhibitors 
performed over the last few years have yielded a deeper understanding of their affinity 
and selectivity in binding TAR RNA. Furthermore, NMR studies of selected 
peptidomimetics and the structure of the BIV2-BIV TAR RNA complex allowed the 
successful targeting of the HIV-1 Tat-TAR interaction. 
From the collection of more than 100 peptides designed for the BIV project, it 
was possible to select some already very potent anti-HIV agents, namely L1-06, L1-07 
and L2-15 with affinities of 75 nM-150 nM for HIV TAR RNA. However, further 
optimisation of the lead compounds (library L3) did not yield any affinity 
improvement. Therefore, the next step was to extend the peptide sequence in order to 
reach the region of the RNA loop where the binding of cyclin T1 takes place. 
Following this approach, a series of peptides with different loop-lengths were produced, 
containing 15, 16 or 18 amino acids with sequences based on that of BIV2 peptide. In 
addition to the standard D-Pro-L-Pro template, the majority of peptides were stabilised 
by means of a disulfide bridge. The results showed that only the 18 amino acid peptides 
proved to be potent TAR binders, 16-mers were binding but with decreased affinities, 
while 15-mers failed to interact with the RNA target. Further studies of the longer loop 
peptides, by mutating single Arg amino acids in the lead compound, L4-04 (Arg!hArg 
and Arg!Lys), allowed the evaluation of their importance in TAR binding. The 
analysis of the mutations showed that most of the changes are well tolerated, with the 
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exception of the Arg15Lys mutation, which exhibits a complete loss of activity. 
Introducing hArg does not yield any improvement. Evaluation of the importance of the 
restraints (template and disulfide bridge) indicate that although the dual stabilisation is 
important for producing stable !-hairpin peptides, the disulfide bridge is not necessary 
for high binding affinity, whereas removal of the template always brings an increase in 
Kd value (2-4 fold).  
By testing various pairs of amino acids defining !-turn in library L5-01—L5-12, 
it was once more found that Lys-Gly is the best of the tested versions. This library 
delivered the strongest binder (L5-11) with a Kd value of 25 nM in a standard EMSA 
(with excess tRNA) and Kd=0.5 nM without excess of tRNA in the EMSA.  
 
Figure 49. Model of complex L5-11-HIV TAR RNA. The NMR-solved structure of L5-11 is 
superimposed on the HIV-1 TAR RNA NMR structure. 
 
A model of L5-11 complexed to HIV-1 TAR RNA, based on the solved 
structures of the free peptide (see Figure 49) and of HIV-1-TAR RNA,72,106 suggest that 
by extending the peptide loop it might be possible to increase the contact surface 
between the peptide and the RNA. Also, the interaction would then not only be 
restricted to the bulge region but would also extended to the RNA-loop region, where it 
might inhibit the native interaction with cyclin T1. 
In parallel to the structure-activity relationship studies and optimisation, 
selected potent peptides were tested for their stability in vitro by means of trypsin 
digestion assays and plasma stability assays. In comparison to linear peptides, the 
cyclic structured peptides have at least 10-fold higher stability in the trypsin assay. In 
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the best case, L4-04, the half-life time was ~360 min. The plasma stability assays, 
performed in human and mouse plasma, confirmed the former results and proved that 
the cyclic peptides with a stable !-hairpin conformation are proteolytically more stable, 
which makes them promising drug candidates. 
In the course of these studies, it was also possible to prove that the peptides are 
cell membrane permeable, which would allow them to perform their inhibitory action in 
infected cells. Up-take studies performed with fluorescently labelled peptides in HeLa 
cells demonstrated that the peptides are internalised in a manner similar to the positive 
control Tat peptides and are localized predominantly in the cytoplasm. Further studies 
to prove the activity of the peptides in vivo and their ability to suppress viral 
transcription are now being pursued in collaboration with Professor J. Karn, Case 
Western Reserve University, USA. 
Several peptides containing 14 and 18 amino acid residues were studied in detail 
by NMR techniques. All of them proved to form very stable !-hairpin conformations, 
as determined using NOE-derived distance restraints. Additional experiments, such as 
H/D exchange and determination of temperature coefficients for amide bonds suggest 
that the two antiparallel strands of the !-hairpin are stabilised by hydrogen bonding, 
especially between amide bonds at positions 1-12 in the 16-mer loop peptides and 3-9 
in the 12-mer loop peptides, which exhibit half-life times of exchangeable NHs of 
several days. The stability of the conformation is of dual importance. First it allows us 
to establish structure-activity relationships, and second it increases the proteolytic 
stability of the peptides, which is an important factor when therapeutic use is 
considered. 
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3. PEPTIDOMIMETICS OF THE HIV-1 REV PROTEIN 
 
 
3.1. Introduction 
 
 
3.1.1. The Rev protein-RRE RNA complex 
 
The virally encoded Rev protein of HIV-1 plays a critical role in viral 
replication by regulating the transport of unspliced and partially spliced viral RNA 
from the nucleus to the cytoplasm of infected cells. Rev is a 116 amino acid RNA-
binding phosphoprotein that binds a cis-acting RNA regulatory element located within 
the env mRNA, termed the Rev response element (RRE). Mutational analysis of Rev 
protein revealed several discrete domains: i) an amino-terminal domain that determines 
RRE binding and nuclear localization (NLS), ii) a multimerisation domain, flanking the 
RRE binding domain, and iii) a carboxy-terminal domain that includes a nuclear export 
signal (NES) and binding site for cellular proteins, known as the activation domain 
(Figure 50).130 
 
 
 
 
 
 
 
 
 
Figure 50. The 116 amino acid Rev protein harbours regions that: 1) mediate RRE RNA binding and 
nuclear localization [Arginine-Rich domain (ARD), brown box], 2) are required for protein 
multimerization (orange boxes), and 3) which function as the NES/activation domain (green box).130 
 
The NLS and RRE RNA-binding domain is rich in basic residues, which makes 
it, together with the Tat protein, another very prominent example of an RNA-binding 
protein containing an arginine-rich motif. The target of Rev binding, the RRE, is ca. 
350-nucleotides and forms an array of stem-loop structures present within the env 
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intron in all unspliced and singly spliced viral mRNAs. It has been demonstrated by 
various methods, including mutagenesis and chemical modification interference, that 
the Rev binding site is located in the 13-nucleotide bulge structure in stem-loop IIB 
(Figure 51). Although the stem-loop region is helical in nature, the local structure is 
substantially distorted by the formation of two non-Watson-Crick purine-purine base 
pairs (G47-A73 and G48-G71).131 These non-canonical base pairs open the major 
groove of the A-form RNA double helix, making the bases more accessible to the 
arginine rich, positively charged Rev peptide. 
 
Figure 51. Structure of the RRE RNA. The stem-loop IIB (shaded) contains the Rev binding site (in the 
box). The two non-canonical purine-purine base pairs are indicated.132 
 
In 1996 two independent groups succeeded in the determination of the three-
dimensional structure of the high affinity RRE site complexed with an arginine rich 
Rev-derived peptide (Figure 52).25,133 These NMR studies revealed the "-helical 
character of the Rev peptide binding in the major groove of the RNA near the purine-
rich bulge. The structure formed by the two purine-purine base pairs of the RRE creates 
a distinctive binding pocket for specific Rev peptide recognition. According to the 
structure of the complex, arginine side chains at positions 35, 39 and 44 make base-
specific contacts, and the side chain of Asp40 contacts a non-Watson-Crick G-A base 
pair (G47-A73). The side chain protons of Thr34, Arg38, Arg41, Arg42, Arg46, Arg48 
and Arg50 are within hydrogen bonding distance of the backbone phosphates. Ala37 is 
involved in a hydrophobic interaction by stacking of the methyl group with the sugar 
ring of G46 in the complex. These observations are in agreement with circular 
dichroism and mutation experiments, which indicate that Thr34, Arg35, Arg38, Arg39, 
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Asn40 and Arg44 are critical for specific high affinity RNA binding.134 The "-helical 
structure of the peptide is necessary for specific-RNA binding and is stabilized when 
bound to RRE RNA. The RRE RNA, like the TAR RNA (Paragraph 2.1.2) undergoes a 
conformational change upon binding, and the major groove is widened by ~5Å relative 
to the unbound form.135 
 
 
Figure 52. Structure of the Rev peptide (green) bound to HIV-1 RRE IIB. Prepared from protein data 
base file (PDB 1ETF). 
 
Initially, Rev binds to a high-affinity site within the RRE (stem–loop IIB). 
Subsequent to this initial binding event, approximately 10 additional Rev molecules 
oligomerize through protein-protein and protein-RNA interactions and coat the entire 
RRE.136  
 
 
3.1.2. Mechanism of action of Rev protein 
 
HIV-1 transcription yields ~2kb, ~4kb, and ~9kb RNAs. The fully spliced ~2kb 
transcript encodes the regulatory proteins Tat, Rev and Nef, the partially spliced ~4kb 
RNA encodes Env, Vif, Vpr and Vpu, and the full-length ~9kb transcript, in addition, 
encodes Gag (including the structural proteins for the capsid, nucleocapsid and matrix 
proteins) and Pol (encoding viral enzymes). During the early stages of virus expression, 
which correspond to no or low levels of Rev, only ~2kb transcripts are able to pass 
through the nuclear membrane and enter the cytoplasm, while unspliced mRNA 
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remains in the nucleus. Upon production in the cytoplasm, Rev enters the nucleus and 
activates the nuclear transport of ~9 and ~4 kb RNAs (Figure 53). 
 
 
Figure 53. Rev is required for cytoplasmic expression of intron-containing HIV-1 mRNA. Schematic 
representation of early (left) and late (right) phase of mRNA expression.137  
 
As the cellular concentration of Rev increases, additional molecules of Rev 
oligomerize cooperatively along the RRE by binding to adjacent low-affinity sites.136 
By interacting with the nuclear export factor, exportin 1, these multimeric Rev 
assemblies mediate the export of unspliced or partially spliced HIV-1 mRNAs to the 
cytoplasm before they can be fully spliced.130 Since this intron-containing mRNA 
subset encodes all of the protein components of the mature virus particle, the action of 
Rev is essential for the production of virions and the progress of HIV-1 infection.138  
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Figure 54. The Rev nuclear transport cycle (see text below).130 
 
After synthesis, the Rev protein directly interacts with importin ! (Imp !) via 
the nuclear localisation signal domain, located within the arginine-rich domain. The 
Imp !-mediated nuclear import is known to require energy and involves interaction 
with specific nucleoporins from the nuclear pore complex (NPC) and the small GTPase 
Ran. Transport through the nuclear pore complex is driven by a gradient of Ran/GTP, 
with a high concentration of Ran/GDP in the cytoplasm and a high concentration of 
Ran/GTP in the nucleus. Once the Imp !-Rev complex reaches the nucleus, the Rev is 
released from the complex. The next step in the Rev pathway involves the specific 
assembly of multiple Rev molecules onto RRE and recruitment of exportin-1 (known 
also as CRM1) via its nuclear export signal domain. The resultant ribonucleoprotein 
complex is recruited to the nuclear pore complex via direct interaction of exportin-1 
with nucleoporins. Once the HIV-1 RNA cargo reaches the cytoplasm, the complex is 
disassembled and HIV-1 mRNA is available for translation while Rev is free to return 
to the nucleus (Figure 54).137,138 
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3.1.3. Inhibitors of the Rev-RRE RNA interaction 
 
Because of its essential role in viral replication, the interaction between the Rev 
protein and the high-affinity RRE binding site represents an attractive yet unexploited 
target for antiviral therapy. Several steps are required for Rev function: binding to the 
RRE, oligomarization of Rev monomers, and interaction with cellular factors from the 
nuclear transport machinery. Each of these steps represents a potentially specific target 
for therapeutic intervention. The fact that structural information for Rev-RRE binding 
is available makes it a very attractive target for the development of HIV inhibitors.   
The first approaches towards anti-Rev drug discovery focused on the Rev-RRE 
interaction, as it is very specific and has no cellular counterparts. Because Rev binds to 
an RNA target, intercalating agents with specificity or preference towards RNA were 
first investigated as potential Rev-RRE inhibitors. The intercalating dye pyronin Y 
(28) was reported to completely block the formation of the Rev-RRE complex in vitro, 
at low µM concentrations. Despite the strong in vitro effect, the compound failed to 
inhibit HIV replication in cytoprotection assays and exhibited high levels of cellular 
toxicity.139 Other intercalating agents, such as derivatives of diphenylfuran (29),140 or 
proflavines (30)141 were also reported to inhibit the Rev-RRE interaction, by causing a 
conformational change in RRE. Although these agents can be useful as probes to 
investigate the precise mechanism of Rev-RRE binding, intercalating agents are clearly 
not attractive molecules from a therapeutic point of view, because of their toxic and 
mutagenetic effects. 
A second group of compounds shown to bind to RRE in vitro and inhibit its 
interaction with Rev are aminoglycosides. Binding studies with known antibiotics such 
as neomycin B (31) or tobramycin (32) showed their ability to bind to RRE at low µM 
concentrations and inhibit Rev binding to its target RNA.142 However, the selectivity of 
the aminoglycosides as RNA-binders is limited, which limits their usefulness as 
prospective anti-HIV drugs.  
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Figure 55. Relatively low molecular weight inhibitors of Rev function: (28) pyroninY, (29) 
diphenylfuran derivatives, (30) proflavine, (31) neomycin B, (32) tobramycin, (33) niruriside, (34) furan 
derative, (35) complex aromatic system, (36) "-helical constrained peptide, (37) Rev-derived backbone 
cyclic peptide. 
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A random screening approach has been utilized to discover compounds capable 
of inhibiting Rev function. A screening of natural products for their ability to inhibit 
binding of Rev protein to [32P]-labelled RRE RNA, reported by Qian-Cutrone,143 
delivered one novel compound, niruriside (33), which was isolated from the methanol 
extract of the dried leaf of Phyllanthus niruri (a plant widely used in Indian traditional 
medicine) by bioassay-guided fractionation. This compound was shown to inhibit 
binding of Rev to RRE with an IC50=3 µM. However, niruriside did not protect CEM-
SS cells from acute HIV infection.  
A high-throughput scintillation proximity assay with biotinylated Rev protein 
and RRE RNA was used by Chapman et al.144 to screen over 500'000 small molecules. 
Several inhibitors were identified, mostly aromatic-rich compounds e.g. disubstituted 
furan derivative (34) or a compound containing complex aromatic system (35). 
However, no compound demonstrated HIV antiviral activity in a relevant cell-based 
assay. 
The peptidomimetic approach to discover potent Rev-RRE inhibitors was 
reported by Chaloin145 and Mills.146 Mills et al. presented a set of "-helical arginine-
rich constrained peptides, among which one (36) exhibits a high affinity (Kd~40 nM) 
and specificity towards RRE RNA. It was also the most effective competitor 
(IC50~150 nM). 
Chaloin reported also a series of backbone cyclic peptides derived from the 
arginine rich motif of Rev (37). All of the peptides exhibit inhibition in the low µM 
range, and they were able to block HIV-1 replication in cell cultures in early and late 
stages of virus infection. Reported data suggest that these peptides represent an 
interesting approach for the design of novel antiviral compounds, however, the 
concentration required for complete inhibition has to be improved. 
All of these approaches are in an early phase of development, and these first 
attempts represent proof-of-principle experiments indicating that Rev-RRE interactions 
can be disrupted by small molecules, and that it is a valid molecular target for drug 
discovery.  
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3.1.4. Project outline 
 
Due to its essential role in the virus life cycle, the viral regulatory protein Rev 
and its highly specific interaction with the RRE RNA constitutes an attractive target for 
development of new antiviral molecules. With the experience gained in the field of 
viral protein-RNA interaction inhibitor (Chapter 2), and being encouraged by recent 
success in using !-hairpin structures to mimic an "-helical epitope in p53 and inhibit 
the p53-HDM2 interaction (Figure 56),147 a new approach to inhibitors of the Rev-RRE 
interaction was envisioned, based on conformationally constrained !-hairpin 
peptidomimetics.  
 
Figure 56. Using a !-hairpin to mimic an "-helical epitope. A model !-hairpin (yellow) superimposed 
on the p53 helical peptide (red). 
 
The RNA-binding sequence of Rev belongs to the same class of protein 
(arginine-rich domains) as the Tat proteins of BIV and HIV. Having successfully 
mimicked BIV Tat using macrocyclic ß-hairpin peptidomimetics, it was hypothesised 
that assaying selected Tat peptidomimetics, which display similarities in sequence with 
Rev-derived peptide, might provide new leads as Rev-RRE inhibitors. Furthermore, it 
was envisioned that a !-hairpin might provide a robust scaffold upon which the groups 
critical for RRE recognition could be displayed, just as the "-helical scaffold of the 
basic domain of Rev presents the energically important residues to the RNA. 
It was, therefore, decided to first assay selected !-hairpin peptides derived from 
the Tat peptidomimetic collection and, second to design hairpin peptides based on the 
sequence of the Rev protein, to enable the discovery of potent and specific Rev-RRE 
interaction inhibitors.  
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3.2. Results 
 
 
3.2.1. BIV Tat peptidomimetics as Rev-RRE inhibitors 
 
Owing to the high similarity of the arginine-rich regions of Tat and Rev 
proteins, the BIV Tat-derived !-hairpin peptidomimetics (BIV1-BIV8) were tested for 
in vitro binding to RRE, using EMSA. The Rev-derived linear peptide (H-
TRQARRNRRRRWRERQR-NH2 (Rev34-50)) was used as a positive control in all 
binding assays.148,149 The dissociation constant (Kd) of this Rev-derived peptide was 
determined by EMSA to be approximately 100 nM in the presence of a large excess of 
E. coli tRNA that was used as a control for non-specific binding (Figure 57, left). In the 
absence of excess tRNA, the Kd of Rev-RRE binding was about 20 nM, which is 
comparable to previous reports.149 
 
Table 30. Sequences of !-hairpin peptidomimetics BIV1—BIV8. Positions 1-12 refer to residues 1-12 as 
mounted on the D-Pro-L-Pro template. The dissociation constants (Kd) were determined for the 
interaction of each mimetic with HIV-1 RRE41-79 RNA (EMSA) (nb=no binding detected).  
Mimetic Position Kd [µM] 
 1 2 3 4 5 6 7 8 9 10 11 12  
Rev (34-50) H-TRQARRNRRRRWRERQR-NH2 0.1 
BIV1 I R G T R G K R R I R V nb 
BIV2 R V R T R G K R R I R V 5 
BIV3 I Y R T R G K R R I R T nb 
BIV4 Y R G T R G K R R I Y V nb 
BIV5 R R G T R G K R R I G R 0.3 
BIV6 V R G T R G K R R I K Y nb 
BIV7 V R R T R G K R R I K Y 5 
BIV8 K R G T R G K R R I G Y nb 
 
Among the peptidomimetics tested BIV-5 exhibited the highest affinity for RRE 
with a Kd of 300 nM in the presence of tRNA, only three-times higher than that 
measured for the wild-type Rev peptide under the same conditions. Two additional 
molecules, BIV-2 and BIV-7, were also found to bind to the RRE RNA with Kd values 
in the low micromolar range. The other mimetics failed to bind even at high 
micromolar concentrations. It was shown earlier that BIV-2 was the tightest-binding 
ligand for BIV TAR (Kd=0.15 µM), followed by BIV-5 (Kd=1-2 µM), whereas for 
BIV-7 no binding to TAR was detected (Paragraph 1.1.1). BIV-5, was also tested in an 
inhibition assay to measure its ability to displace Rev peptide in a preformed Rev-RRE 
complex. BIV-5 was found to displace the Rev peptide from the Rev-RRE complex 
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with an IC50 of about 300 nM (Figure 57, right), which is similar to the estimated Kd for 
direct binding to the RRE. 
 
 
Figure 57. Left: binding assay (EMSA) for the wild-type Rev peptide to RRE RNA (1 nM); Right: 
inhibition of Rev peptide (0.1 µM) from a preformed complex with RRE RNA (1 nM) by 
peptidomimetic BIV5 (all concentrations in µM). The lower band corresponds to free RNA, the upper to 
bound RNA. 
 
 
3.2.2. Design of Rev peptidomimetics as Rev-RRE inhibitors 
 
• LIBRARY R1: Initial design efforts 
 
These promising results prompted the synthesis of a dedicated library of !-
hairpin Rev peptidomimetics (R1-01 to R1-12), which were made to test the new 
design concept illustrated in Figure 58 and Figure 59. In the Rev-RRE complex the key 
RNA-interacting side chains are displayed around almost the entire circumference of 
the Rev "-helix. It was envisioned that a !-hairpin motif could be used as a structural 
platform to organise the amino acid side chains important for recognition of RRE RNA 
in a geometry similar to that present in Rev (Figure 58). 
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Figure 58. Left: Sequence of the "-helical RNA binding domain of Rev protein (Thr34-Trp45) with the 
amino acids important for binding highlighted, and a projection of a template-bound cyclic structure with 
12 residues overlaid on the Rev "-helix. Middle: a prototypical 2:2 !-hairpin mimetic (residues 1-12 
with D-Pro-L-Pro). Right: a model of !-hairpin (yellow) superimposed (the C(!) atoms of the side chains 
shown were used as the anchor points for the superimposition) on the Rev helical peptide (green). The !-
hairpin backbone can be used as a scaffold to pre-organize side chains in a geometry similar to that seen 
in the helical peptide. 
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!
Figure 59. A model !-hairpin (orange) superimposed on the Rev-helical peptide (green). 
 
Superimposing a model !-hairpin (Figure 59) on the Rev helical peptide, 
revealed that the side chains of residues 1, 12, 3, 10, 5, and 8 on one face of the 12-mer 
hairpin have approximately the same orientations as the side chains of residues W45, 
R44, R41, N40, A37, and Q36 in Rev, and residues T34, R35, R39, R38, R42, and R43 
in the Rev helix might be spatially mimicked by corresponding residues at positions 6, 
7, 9, 4, 2, and 11, respectively, on the other face of the hairpin (Figure 58, right). 
Moreover, the mimicry appears optimal when Arg7 in the hairpin (which should mimic 
Arg35 in Rev) has the D-configuration. Thus, the first mimetic (R1-01) has the 
sequence W1R2R3R4A5T6DR7Q8R9N10R11R12 mounted upon the D-Pro-L-Pro template. 
Other mimetics from this library (R1-02 to R1-12) differ in sequence mainly at the tip 
of the !-hairpin.  
Table 31. Sequences and binding affinities to RRE determined by EMSA of peptides from the R1 library 
of Rev peptidomimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro template. 
Mimetic Position Kd [µM] 
 1 2 3 4 5 6 7 8 9 10 11 12  
Rev H-TRQARRNRRRRWRERQR-NH2 0.1 
R1-01 W R R R A T DR Q R N R R 1 
R1-02 W R R R A P DR Q R N R R 1 
R1-03 W R R R G P DR Q R N R R 0.5 
R1-04 W R R R V P DR Q R N R R 1 
R1-05 W R R R A G DR Q R N R R 0.4 
R1-06 W R R R A G K Q R N R R 0.3 
R1-07 W R R R A T DR G R N R R 0.3 
R1-08 W R R R A P DR G R N R R 0.5 
R1-09 W R R R G P DR G R N R R 0.5 
R1-10 W R R R G T DR Q R N R R 0.7 
R1-11 W R R R V G DR Q R N R R 0.5 
R1-12 W R R R A S DR Q R N R R 0.4 
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The Rev mimetics were synthesized by first assembling a linear peptide chain 
on 2-chlorotrityl chloride resin using standard Fmoc solid phase peptide synthesis, as 
described previously in Paragraph 2.2.2. The linear precursors were cleaved from the 
resin without removing the side chain protecting groups. Macrocyclization was then 
performed in a dilute DMF solution. The side chain protecting groups were removed 
with TFA, and the products were purified by reverse phase HPLC. In a typical 
synthesis, the main component in the crude product was the desired Rev mimetic. After 
purification by HPLC, the desired peptidomimetics were typically obtained in 20-60% 
overall yield, and each was >95% pure as determined by analytical HPLC and gave ESI 
MS data consistent with the calculated masses (see Appendix 3 for analytical data). 
The wild-type linear peptide Rev (34-50) was used as a control in all binding 
studies. The Kd of this peptide determined by EMSA, described previously in 
Paragraph 2.2.3, in the presence of a large (10'000-fold) excess of tRNA, was found to 
be approximately 100 nM. The radiolabelled RRE RNA (and TAR RNA for specificity 
studies) for assays was prepared by in vitro transcription using T7 polymerase, 
synthetic oligonuclotide templates and nucleotides including a portion of ["-32P]CTP.  
All the peptides exhibited a strong affinity to RRE under the conditions tested 
(Table 31). The model sequence, R1-01, shows a Kd=1 µM, which is however lower 
than the value for BIV5. A single mutation in R1-01 at position 8 (Gln8Gly), as in 
peptide R1-07, improves the affinity 3-fold to a Kd $300 nM. The 4 different pairs of 
amino acids in the turn region were tested (Thr-DArg, Pro-DArg, Gly-DArg, Gly-Lys, 
Ser-DArg) and they all were equally well tolerated. However, NMR spectroscopic 
studies on several of these mimetics in free aqueous solution, suggested that few 
regular !-hairpin structures were present, that is, that they are disordered. For example, 
3
J(NH,C(")H) values were all in the range 6-8 Hz, and few characteristic long-range 
NOEs could be detected. Also, both cis and trans peptide bond rotamers at the Arg12-
D-Pro13 peptide bond can be detected in slow exchange in the NMR spectra. In the 
case of R1-06, at least one cis isomer (at the Arg12-D-Pro13) in equilibrium with the 
major trans isomer was observed, in an approximate 15:85 ratio. However, the peptide 
backbone NH and H-C(") resonances for the major major trans form could be assigned 
unambiguously (see Appendix 6), which enabled calculations of average solution 
structures calculations for the major isomer using the available restraints (for summary 
see Table 32). The resulting structures, shown in Figure 60, indicate that the loop of the 
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mimetic is disordered in free solution. Although the binding assays show high-affinity 
binding to the RNA, the lack of stable hairpin structure in these free ligands in solution 
prompted further studies aimed at stabilizing the hairpin fold. 
!!
Figure 60. Example of a poorly structured Rev peptidomimetic from the R1 library. Superposition of the 
template and representation of the final 20 NMR structures of R1-06. The structure calculation were 
performed only on the trans Arg12-D-Pro13 peptide bond isomer (for details see text). 
Mimetic R1-06 
NOE upper-distance limits 110 
Intraresidue 52 
Sequential 42 
Medium and Long-Range 16 
Residual Target Function Value (Å2) 0.59±0.09 
Mean rmsd values (Å)  
All backbone atoms 2.21±0.71 
All heavy atoms 4.52±1.00 
Residual NOE violations  
Violation > 0.22 Å  8 
Maximum violation (Å) 0.37 
Table 32. Experimental distance restraints and statistics for the final 20 NMR structures calculated for 
R1-06. 
 
 
• LIBRARY R2: Attempts to improve the !-hairpin stability of the 
peptidomimetics 
 
The second group of mimetics tested (R2-01 to R2-16) combine features of 
BIV-5 and peptides R1-01 to R1-12, and include a K6G7 motif at the hairpin tip, which 
was expected to promote a stable !-turn, as seen in closely related TAR-binding 
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mimetics. In addition, a disulfide bridge is present at a non-hydrogen-bonding position 
in R2-14, to further stabilize a !-hairpin structure.  
Table 33. Sequences and binding affinities to RRE determined by EMSA of peptides from the R2 library 
of Rev peptidomimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro template. 
Mimetic Position Kd [µM] 
 1 2 3 4 5 6 7 8 9 10 11 12  
Rev(34-50) H-TRQARRNRRRRWRERQR-NH2 0.1 
BIV5 R R G T R G K R R I G R 0.3 
R1-01 W R R R A T DR Q R N R R 1 
R2-01 W R R R A K G Q R N R R 0.2 
R2-02 W R L R A K G Q R N R R nd 
R2-03 W R Q R A K G Q R N R R nd 
R2-04 W R R R A K G Q R N R V 0.5 
R2-05 W R L R A DR K G R N R R 0.4 
R2-06 W R L R A K K G R N R R 0.3 
R2-07 W R K R A G K Q R N R R 0.4 
R2-08 W R K R A K G Q R N R R 0.2 
R2-09 W R R R A DR G Q R N R R 0.5 
R2-10 W R L R A DR G K R N R R 0.25 
R2-11 R R L R A DR G Q R N R R 0.1 
R2-12 R R L R A K G Q R N R R 0.1 
R2-13 R V R R A K G Q R N R R 0.3 
R2-14 R C R R A K G Q R R C R 0.1 
R2-15 K R Q R T K G R R L O R 0.1 
R2-16 W R R R A G R Q R N R R 0.15 
 
These peptides were prepared using methods described above. The 
intramolecular disulfide bridge present in R2-14, was formed by oxidation of the pre-
purified cyclic peptide containing cysteine residues protected with Acm groups, as 
previously described in detail in paragraph 2.2.4.1. After purification by HPLC, the 
desired peptidomimetics were typically obtained in 20-40% overall yield, and each was 
>95% pure as determined by analytical HPLC and gave ESI-MS data consistent with 
the calculated masses (see Appendix 3 for analytical data). 
The EMSA results for library R2 are summarised in Table 33. All the peptides, 
except R2-02 and R2-03, exhibit high affinity towards RRE RNA and many of them 
are more potent ligands than the peptidomimetics from the previous library. Generally 
incorporating the Lys6-Gly7 in the turn region brings an improvement in affinity, 
however, when combined with a mutation at position 3 (Arg3Leu, Arg3Gln), which 
reduces the total charge of the peptide, a complete loss in activity was observed. It is 
interesting to notice that these mutations are tolerated if the charge of the peptide is 
maintained by replacement of Trp by Arg in position 1, as in peptide R2-12. 
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Tryptophan at position 1 is not critical for the interaction with the RNA, it can be 
replaced by Arg or Lys, as shown in peptides R2-12—R2-15. Introduction of a 
disulfide bridge at a non-hydrogen-bonding position in peptide R2-14, apart from being 
an important stabilisation factor, produces a highly potent peptide. This together with 
peptides R2-11, R2-12, and R2-15 proved to be the best ligands for RRE RNA with 
Kd00.1 µ), similar to the Rev-derived peptide. When these molecules were assayed in 
the absence of excess tRNA, a Kd of 10 nM was observed for R2-11 (Table 34) and 
R2-12, whereas R2-14 showed a Kd of 1-2 nM. The affinity of this latter peptide for the 
RNA is thus significantly stronger than that of the Rev-derived "-helical peptide under 
these conditions.  
 
 
3.2.3. Specificity of the Rev peptidomimetics 
 
A further key issue in RNA ligand design is the specificity of RNA binding, 
which could clearly be influenced by the flexibility of the ligand as well as by the 
overall positive charge of this class of peptides. As a stringent test of binding specificity 
to RRE, binding of the mimetics to the structurally very similar HIV TAR RNA was 
also evaluated. As a control, binding of a peptide containing 7 consecutive Arg residues 
(Ac-Arg7-NH2) was also tested, which is expected to interact strongly but non-
specifically with both RNAs, mainly through electrostatic interactions.  
Table 34. Binding affinities (in µM) of selected peptides to HIV RRE and TAR RNAs. The Kd values 
were determined by EMSA in the absence of tRNA. 
Mimetic Kd (RRE) Kd (TAR) 
R2-11 0.010 0.005 
R2-12 0.010 0.010 
R2-13 0.005 0.010 
R2-14 0.002 0.100 
R2-15 0.002 0.010 
Ac-(Arg)7-NH2 0.002 0.002 
 
Consistent with this hypothesis, and demonstrated by EMSA, the Arg7 peptide 
binds non-specifically with a Kd of approximately 2 nM to both HIV TAR and RRE 
(Table 34). Among the ligands tested R2-13 and R2-15 discriminate only modestly 
(less than tenfold) between RRE and TAR. However, R2-14 discriminates by 
approximately 50-fold between the two closely related RNA structures. Given how 
closely related these RNA targets are, and the relatively poor specificity typically seen 
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in the interactions of other RNA-binding molecules with more diverse RNA targets, 
this result represents a notable level of RNA-binding specificity. 
 
 
3.2.4. NMR studies on the Rev peptidomimetics 
 
From the two libraries several peptidomimetics were selected for 2D 1H NMR 
experiments in aqueous solution (R1-01, R1-05, R1-06, R1-07, R2-11, R2-14 and R2-
16). Except for R2-14, all spectra showed at least two forms in solution with a 
percentage of minor species between 15-25%. As described previously54 for similar 
classes of cyclic peptidomimetics, the two forms are cis-trans isomers at the Xxx12-
DPro13 peptide bond with the trans form the major isomer. Except in the case of R2-14, 
the NMR spectra revealed predominantly random coiled non-!-hairpin structures in 
solution, as confirmed by a low amide proton chemical shift dispersion (0.6-0.8ppm), 
weak up-field shifts of C"H chemical shifts with respect to random coil values (Figure 
61), and the absence of characteristic long range NOEs. 
Figure 61. H" chemical shifts relative to random coil chemical shifts of residues in peptidomimetics R1-
06 (yellow), R2-11 (black), R2-14 (shaded). 
 
In R2-14, only the trans form is observed. The formation of the cis form appears 
to be prevented by the additional disulfide bridge restraint. The peptide backbone NH 
and H-C(") resonances for R2-14 could be assigned unambiguously (Appendix 6). 
Several long-range NOEs were observed, indicative of stable structure, which allowed 
the determination of average solution structures (Table 35). NMR spectroscopic studies 
on R2-14 in aqueous solution revealed a highly populated !-hairpin conformation in 
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solution (Figure 62) in which the two strands of antiparallel !-sheet are connected by a 
type I’-turn between Lys6 and Gly7. In particular, cross-strand NOEs characteristic of a 
!-hairpin are now observed, and the 3J(NH, C(")H) values are predominantly greater 
then 8Hz for residues within the !-strands. Thus the disulfide cross-link is clearly 
important in stabilizing the regular !-hairpin structure. 
! ! !
Figure 62. Left: Backbone superposition and representation of the final 20 NMR structures. Right: 
typical NMR structure with the ribbon representation of two strands for R2-14. 
 
Table 35. Experimental distance restraints and statistics for the final 20 NMR structures calculated for 
R2-14. 
Mimetic R2-14 
NOE upper-distance limits 109 
Intraresidue 44 
Sequential 50 
Medium and Long-Range 15 
Residual Target Function Value (Å2) 0.55±0.03 
Mean rmsd values (Å)  
All backbone atoms 1.02±0.37 
All heavy atoms 2.57±0.61 
Residual NOE violations  
Violation > 0.22 Å  2 
Maximum violation (Å) 0.30 
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3.3. Discussion 
 
Cyclic peptides containing a D-Pro-L-Pro template are an interesting class of 
protein mimetics due to the strong !-hairpin inducing properties of the heterochiral 
diproline. Here we have used this methodology to produce cyclic constrained peptides 
with the potential to be used as inhibitors of the binding of HIV-1 Rev protein to the 
RRE RNA. The RNA-binding domain of Rev protein adopts an "-helical conformation 
upon binding to its cognate RNA. We have used here a novel approach involving use of 
a model !-hairpin peptide as a scaffold to pre-organise side chains into a geometry 
similar to that seen in a helical peptide. As a starting point, already available cyclic, !-
hairpin peptides derived from the related, arginine rich, RNA-binding sequence of Tat 
protein were assayed. Identifying one peptide, BIV-5, able to bind to RRE RNA with 
Kd=0.3 µM and inhibit the Rev-RRE interaction (IC50=300 nM) encouraged further 
studies on this system. Transposing the RNA-binding domain displayed on a helical 
segment of Rev protein onto a hairpin scaffold, a potential Rev-RRE interaction 
inhibitor was designed (R1-01). The binding studies showed that this molecule binds to 
the RNA with Kd=1 µM. Further modifications of the sequence, specially in the turn 
region, led to the first library R1, and to the discovery of RRE-ligands with higher 
affinities (Kd $ 300 nM). However, the NMR studies on these peptides in free aqueous 
solution showed that they are largely unstructured, despite the influence of the D-Pro-L-
Pro template. 
In the second library, R2, the interest focused on stabilizing the !-hairpin 
conformation of the Rev peptidomimetics without loosing the activity of the peptides. 
For this purpose, information on the sequence of BIV-5 and the most potent peptides 
from the R1-library was combined. Furthermore, it was envisaged that using Lys6-Gly7 
in the turn and incorporating the disulfide bridge would help to stabilize a regular 
hairpin structure in solution. Most of the peptides from the second library exhibit higher 
affinities towards RRE RNA (100-500 nM) in standard EMSA than the ones from the 
previous library. However, the stabilization of the hairpin conformation proved to be a 
more difficult task than first thought. In the selection of the peptides studied by NMR 
techniques, only R2-14, stabilized by a disulfide bridge in addition to the template, 
showed a relatively stable !-hairpin structure in free solution. This peptidomimetic 
exhibits the highest affinity to RRE in the presence (Kd=100 nM), as well as in the 
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absence, of competitor tRNA in EMSA (Kd=2 nM). In addition, this compound exhibits 
good specificity for its target RNA. 
The structural and binding data together provide strong evidence supporting the 
hypothesis that this family of peptidomimetics can mimic the "-helical Rev peptide in 
its binding to RRE RNA. Although it is not yet possible to rationalize the quantitative 
effects of individual side-chain substitutions on the binding energy, it was possible to 
transplant the molecular interactions observed on the "-helical Rev-derived peptide 
onto a !-hairpin scaffold and rapidly discover potent RRE ligands. Furthermore, the 
results suggest that not just the number of positively charged groups, but also their 
relative orientations, as determined by the flexibility of the !-hairpin mimetic, have a 
decisive influence on the affinity and specificity of RNA binding.  
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4. RNASE P 
 
 
4.1. Introduction 
 
Ribonuclease P (RNase P) is an essential endonuclease involved in processing 
of precursor tRNA (ptRNA) into its mature form in all three kingdoms of life (Bacteria, 
Archaea, Eukarya). It has become the focus in the last decade of extensive interest as 
one of only two known ribozymes conserved in all life domains (the second one is the 
ribosome) that catalyze reactions with multiple turnovers. In contrast to other 
ribozymes (like the group I and II introns and the hammerhead RNA), which catalyse 
intramolecular phosphodiester bond cleavage, RNase P was the first trans acting 
ribozyme identified (i.e. substrate and catalyst are two separate RNA molecules). 
Although RNaseP catalyses the cleavage of multiple substrate RNAs in the cell, the 
preferred substrates are tRNAs precursors.150-152  
 
 
Figure 63. The RNase P reaction; processing of precursor tRNA.153 
 
RNase P is responsible for the endonucleolytic cleavage of 5’-leader sequences 
from all precursor tRNAs, producing a mature 5’-phosphate on the end of the tRNA 
and a hydroxyl group on the 3’-end of the leader sequence (Figure 63). RNase P 
consists of one RNA subunit and a variable number of protein subunits: only one is 
present in bacteria, but four are found in archea, nine in yeast and ten in mammalian 
RNase P.153  
The RNA component of bacterial RNase P can catalyse ptRNA cleavage in the 
absence of the protein subunit in vitro under conditions of high salt. The RNA subunit 
consists of separate domains determining specificity and catalysis. However, the protein 
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subunit is necessary in vivo and for the efficient reaction in vitro under physiological 
conditions of low ionic strength.154-156 The archeal and eucaryal holoenzymes are 
enriched in protein (70% of total mass of holoenzyme), relative to the bacterial enzyme 
(10%), which suggest that the protein subunits of these ribozymes perform more 
complex functions than their bacterial counterparts. It has been suggested that through 
the course of evolution, the proteins in eucarya and archea RNase P have evolved to 
play more fundamental roles and their functions might be to stabilize the active 
conformations of the RNA and to support substrate binding.150 Only very recently has it 
been shown that eucaryotic RNase P RNA can also mediate cleavage of a model 
hairpin-loop substrate as well as tRNA precursors in the absence of the protein 
subunits, however, the reaction rates and the affinities for the substrate are dramatically 
reduced.157 Since the protein component of RNase P is required to activate the 
ribozyme in vivo, it has been suggested that the primary function of the protein is to 
stabilize the active tertiary structure of RNase P RNA and contribute to high affinity 
substrate binding.158 
RNase activity absolutely requires divalent metal ions (preferably Mg2+), which 
probably fill both structural and functional roles in the catalytic cycle (Figure 64). 
 
Figure 64. The proposed mechanism of the RNase P reaction based on biochemical studies. On the left is 
a putative structure of the transition state of the reaction. The labile phosphodiester bond is encaged by 
Mg2+-hydrate complexes to form a trigonal bipyramidal transition state. The available biochemical data 
are consistent with a concerted SN2-like mechanism.
159 
 
The comparative analysis of RNA sequences has resulted in refined secondary 
structure models of the RNase P RNA’s for the bacterial type A and type B, as well as 
archeal RNA and eucaryal RNA. Archeal RNase P RNA tends to be similar in sequence 
and structure to the bacterial one and usually contains extra helices in comparison to 
eucaryal RNA. RNA sequences from eucaryal RNase P’s are simplified (~30% shorter) 
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in comparison to the other 2 types and lack the key stabilizing helices found in bacterial 
RNAs (Figure 65).160 
 
Figure 65. Representative secondary structures of RNase P RNA from all three domains of life, bacteria, 
type A (Eschericha coli, also termed M1 RNA), archaea (Pyrococcus furiosus), and eucarya (Homo 
sapiens). The blue area in the bacterial and archeal RNase P represents the substrate-specificity domain. 
Helices P4 and P6, which are disrupted in this representation are connected by line segments. Universally 
conserved nucleotides are depicted in the presented structures.160-162 
 
 
4.1.1. Bacterial RNase P 
 
Bacterial RNase P was one of the first catalytic ribozymes identified and 
thoroughly studied. The bacterial RNase P RNA component consists of ~300-450 
nucleotides and can be subdivided in two major types, A (ascestral-type, such as 
Eschericha coli) and B (e.g. Bacillus subtilis), on the basis of their sequence 
characteristics (Figure 66). 
 
Figure 66. Secondary structures of two types of bacterial RNase P RNAs: left E. coli (type A), right B. 
subtilis (type B).163 The red line separates the specificity domain and the catalytic domain. 
Specificity 
domain 
Catalytic 
domain 
TYPE A 
TYPE B 
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Since 2003 crystal structures have been available for one of the structural 
domains of the RNA component (the specificity domain) of RNase P from two bacteria, 
Bacillus subtilis
164 and Thermus thermophilus,165 and more recently for the entire RNA 
in RNase P from T. maritima166 and B. stearothermophilus.167 
The ternary structure of the protein subunit of B. subtilis, Staphylococcus aureus 
and T. maritima (representing both A- and B-types of RNase P) have been determined 
by X-ray crystallography and NMR.168-170 Although the sequences of these proteins are 
not highly conserved (20-30% amino acid identity), the overall three-dimensional 
structures are remarkably similar. The structural similarity results in functional 
similarity: RNase P RNA and proteins from different organisms can be reconstituted in 
vitro to form active heterologous complexes.155,171  
Three regions of the protein have been proposed to interact with RNase P RNA, 
a basic domain containing an RNR motif, the central cleft formed by one "-helix (C) 
and four !-sheets, and the negatively charged metal binding loop (Figure 67).168  
 
 
Figure 67. Ribbon plot of RNase P protein from B. subtilis;168 "-helices (A="1, B="2, C="3) and !-
strands labelled sequentially by letters and numbers, respectively. The basic amino acid-rich conserved 
RNA binding motif (RNR motif) is shown in red, a negatively charged metal binding loop is indicated as 
MBL, and the central cleft is indicated as CC. 
 
 
The RNR motif is a highly basic region located in an unusual left-handed !"! 
crossover connection from !-strand 3 to "-helix B to !-strand 4, and it is highly 
conserved among all bacterial RNase P proteins (Figure 68). 
 
 
 
RNR 
CC 
MBL 
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  52  54     59   62    66    70       
E. coli V A K K N V R R A H E R N R I K R L T R E S F R L R 
C. burnetti A S K R N V R K A V W R N R V R R V V K E A F R I R 
N. gonorrhoeae V G K K T A K R A N E R N Y M K R V I R D W F R L N 
S. bikiniensis V - S K A V G G A V V R N Q V K R R L R H L V C D R 
B. subtilis V - S K K I G N A V M R N R I K R L I R Q A F L E E 
Synechocystis V S Q K V S K K A T V R N R L K R Q I R A V I N H F 
B. burgdorferi F - S K G F R G S V K R N R I R R L F K E A F R K R 
C. pneumoniae V - S K K F G K A H E R N S F K R V V R E V F R H V 
T. maritima V - K R K F G K A T R R N K L K R W V R E I F R R N 
P. gingivalis V A K K R F R R A V K R N R V K R L V R E A Y R L N 
D. radiodurans V S K K T L K H A V K R N R A R R R V R E A L R T M 
C. tepidum V G K K L V P R A V D R N R I K R L M R E A Y R L E 
 
Figure 68. Alignment of the amino acid sequence around helix B ("2) in the protein subunit of RNase P 
from 12 different bacteria.172 Amino acids that are highly conserved are shown in red. 
 
Among all RNase P, the ones from bacteria, specially from E. coli (where the 
ribonuclease was first discovered173,174) and B. subtilis (the X-ray structures of the 
specificity domain of the RNA and the protein subunit are available) are the best 
characterised. As they consist of a single RNA and a single protein subunit they provide 
a simple model system to study the function of the protein in the ribonucleoprotein 
(RNP) complex. Although the structure of the E. coli RNase P protein subunit 
(commonly named as C5 protein) has so far not been solved, it is thought to be similar 
to the RNase P protein of B. subtilis, since the proteins from these bacterial RNase P 
can be functionally exchanged.171 Furthermore, there is a common subset of highly 
conserved basic and hydrophobic residues located in the central region, including the 
RNR motif, as well as a number of conserved hydrophobic amino acids in the N-
terminal and C-terminal domains (Figure 69). 
 
 
Figure 69. A comparison of the sequences of the protein of RNase P from E. coli and B. subtilis. The 
identical residues are highlighted in grey. The secondary structure elements are indicated above the 
sequences.175 
 
Although the ternary structures of RNA and protein subunits have been 
determined, a deeper understanding of the RNase mechanism and function requires 
detailed structural information of the entire holoenzyme, which is so far lacking. 
However, mutagenesis, photo-affinity cross-linking and nucleotide analogue 
"2 
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interference mapping (NAIM) studies have identified nucleotides essential for ptRNA 
binding and catalysis.152 Similar experiments were performed to understand the protein 
subunit function and to identify the regions that bind to either RNase P RNA or to the 
substrate. Thus cross-linking, affinity cleavage experiments, footprinting experiments, 
and mapping RNA-protein interactions using disulfide-linked EDTA-Fe have begun to 
reveal potential RNA-binding domains.176-178 Combining all the structural information 
available including the X-ray structural data and the results of various cross-linking 
techniques, has led in the last few years to many models of the holoenzyme alone or 
complexed with ptRNA (Figure 70), as suggested by Sharkady and Nolan,175 Rox at 
al.,179, Tsai et al.,180 Buck et al.,156 and Niranjanakumari et al.181 
 
Figure 70. Three-dimensional models of E. coli RNase P holoenzyme (left) and RNase P holoenzyme-
substrate complex (right) suggested by Tsai et al.180 The helical regions of the RNA are numbered P1-
P17. 
 
The above-mentioned studies allow general placement of the protein subunit in 
structural models of RNase P, and identify two important regions of RNA-protein 
interaction involving: i) the highly conserved region (~11 amino acids ) in the "2 helix 
comprising basic amino acid residues, including the RNR motif, which contacts the P2, 
P3 and P4 helices of the catalytic domain (Figure 70); ii) a hydrophobic central cleft 
formed by the "1-helix and the face of the central !-sheet, which contacts the 5’-leader 
sequence of the ptRNA at positions at least 4nt from the cleavage site, but does not 
interact directly with the RNase P RNA (Figure 71). Additionally, the so-called metal 
binding loop (between !2 and !3) containing a cluster of negatively charged residues is 
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proposed to be a third RNA-binding region. The acidic residues in this exposed region 
could mediate RNA contacts via co-ordinated metal ions.168 Deletion studies revealed 
that the C-terminal region and the RNR motif of the C5 protein are involved in binding 
to the RNA subunit of RNase P from E. coli (commonly named as M1 RNA). On the 
other hand, N-terminal deletions retained the M1 RNA binding ability. In spite of the 
lack of M1 RNA binding ability in the C-terminal deletion derivatives, they promote 
RNase P catalysis just like the N-terminal deletion derivatives.182 Very recently 
Niranjanakumari181 suggested that the RNR motif of the RNase P protein is located 
near (<15Å) the ptRNA cleavage site, the base of the ptRNA acceptor stem and the 
helix P4 of RNase P RNA. The P4 helix is a highly conserved RNA structure thought to 
be a part of the active site in the RNase P-ptRNA complex. 
 
Figure 71. Three-dimensional structure of B. subtilis RNase P. Summary of cross-linking and AOP 
(acetomido-1,10-o-phenathroline) cleavage experiments presented by Niranjanakumari et al.181 Labels 
indicate locations of the RNR motif, the metal binding loop (MBL) and the central cleft (CC). 
Highlighted amino acids indicate positions where cross-linking/cleavage occur to RNase P RNA only 
(green), to ptRNA only (red), or to both (blue). 
 
Functional roles assigned to the basic bacterial RNase P protein subunit in 
general include: i) electrostatic neutralisation effects on the RNA domain and 5’-
ptRNA backbone phosphates, ii) conformational stabilisation and fine-tuning of the 
active site structure, iii) increase in the binding affinity for ptRNA, which is linked to 
an increase in affinity for key metal ions involved in ptRNA binding and catalysis, and 
iv) mediation of RNase P dimer formation.183 
In agreement with previously mentioned biochemical studies showing that the 
B. subtilis protein can substitute for the protein component of E. coli RNase P, both in 
vivo and in vitro, the cross-linking and cleavage studies showed similar patterns of 
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interactions indicating that the position and orientation of the P protein is similar in 
both holoenzymes.156,158,181 
 
 
4.1.2. RNase P: A promising molecular target for the development of new drugs 
 
The recent increase in drug-resistant bacteria and pathogenic bacterial infections 
has motivated intense efforts to develop novel antibacterial compounds. For this, the 
selection of effective molecular targets is of utmost importance. Bacterial RNase P 
combines several favourable target features. It contains an essential catalytic RNA 
subunit. The RNase P is a highly efficient enzyme, with a generally low cellular 
abundance. Furthermore, the differences in structure between bacterial and eucaryotic 
RNase P should allow effective discrimination between humans and the bacterial 
pathogens. 
Some examples of RNase P inhibitors have already been discovered. 
Aminoglycosides, such as neomycin B, kanamycin, gentamycin have been reported to 
inhibit RNase P activity by a non-competitive mode of action.184,185 The studies on 
aminoglysides suggest a competition between Mg2+ ions and aminoglycoside antibiotic 
for the same binding sites on the enzyme. Gopalan and co-workers prepared 
aminoglycoside-arginine conjugates (NeoR), which combined the two different 
functionalities capable of RNA binding, and display a 500-fold increase in inhibitory 
efficiency (IC50=60 µM versus 125 nM for neomycin B and NeoR, respectively) and 
good discrimination between bacterial and human RNase P.186 Another approach was 
taken by Hori et al.187-189 by designing benzimidazole-derivatives and 
porphines/porphyrins, which act by binding to the substrate ptRNA. Bacterial RNase P 
seems to be also an attractive target for antisense-based strategies, as reported by 
Willkomm.190 
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4.1.3. Project outline 
 
The three-dimensional models of RNase P holoenzymes of B. subtilis and E. 
coli, which are based on extensive cross-linking and cleavage studies discussed above, 
have focused attention on the possible design of inhibitors of the RNA-protein 
interaction in this ribonuclease. The structural information available up-to-date shows 
the importance of the region containing the RNR-motif in helix "2 of RNase P protein, 
since it most probably contacts the catalytic domain of RNase P RNA. It was 
envisioned here, that it might be possible to mimic the "-helix of this critical region 
using a !-hairpin peptidomimetic and so to design novel inhibitors of this protein-RNA 
interaction in RNase P (Figure 72). 
  
Figure 72. Left: Structure of the protein unit of RNase P form B. subtilis (PDB 1A6F)168 with the "2-
helix at the front and the RNR motif highlighted (green, side chains shown); right: the superposition of a 
!-hairpin peptide (pink) on the RNR motif. The side chains of Arg60, Arg65 and Arg68 are shown (from 
top to bottom). 
 
It was reasoned that first assaying the existing library of Rev-RRE inhibitors, 
that share sequence similarities to the RNA-binding domain of RNase P protein subunit 
might deliver some preliminary leads. Furthermore, a library of mimetics might be 
designed to specifically target the RNase P. It was envisioned that this strategy might 
lead to the discovery of a novel class of RNase P inhibitors with potential utility in the 
search for new antibacterial agents.  
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4.2. Results 
 
 
4.2.1. Design of novel RNase P protein-RNA interaction inhibitors 
 
Encouraged by recent success in using a !-hairpin structure to mimic an "-
helical RNA-binding domain of Rev protein and inhibit the Rev-RRE RNA interaction, 
we explored here a new approach to inhibitors of the protein-RNA interaction in RNase 
P, based on conformationally constrained !-hairpin peptidomimetics. From structural 
studies, it was known that the "2-helix of the protein subunit plays a critical role in 
contacting its cognate RNA. We assumed that a !-hairpin peptide might provide a 
robust scaffold upon which the groups critical for RNase P RNA recognition could be 
displayed. The "-helical structure of the basic domain of the protein, containing the 
highly conserved RNR motif, presents the energetically important residues Phe71-
Arg60 to the RNA (Figure 73, left). According to this strategy, the hairpin mimetics 
should contain a twelve amino acid loop mounted on the D-Pro-L-Pro dipeptide 
template. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 73. Schematic representation of the amino acids in the "2-helix of RNase P protein subunit from 
B. subtilis (Arg60-Phe71) overlaid with a !-hairpin peptidomimetic (Template+ yellow arrow). Model of 
the template-bound !-hairpin peptidomimetic (orange) designed to mimic the "-helical RNA-binding 
domain of RNase P protein (grey). 
R60        N61 
 
I63        R62 
 
K64        R65 
 
I67        L66 
 
R68        Q69 
 
F71        A70 
TEMPLATE 
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The computational model (Figure 73, right) of the !-hairpin superimposed on 
the known crystal structure of the "2-helix from B. subtilis RNase P protein, suggests a 
good overlap of the amino acids side chains. The hairpin could act as a scaffold to pre-
organise these side chains to give a geometry similar to that seen in the helical motif. 
To test this hypothesis, we first assayed a small family of cyclic !-hairpin 
peptidomimetics (R-01 to R-27), prepared in earlier work, which fulfil the structural 
requirements and display similarities with the target sequence, for their ability to mimic 
the "2-helix of RNase P protein and to bind to the target RNA. 
 
 
4.2.2. Antimicrobial activity and selectivity of peptides R-01!R-27 
 
The R-01—R-27 peptidomimetics (from the R1 & R2 libraries) were tested first 
against E. coli to check their antimicrobial activity and then against other bacterial 
strains, including gram-positive bacteria, to investigate their selectivity (Table 36). 
Among the 27 compounds assayed, two R-17 and R-22, exhibit high 
antimicrobial activity towards E. coli, while being completely inactive against the other 
bacterial strains tested. The only difference between these peptides is at positions 7 and 
8, where two amino acids Lys and Gly are swapped (Table 36). From an analysis of the 
inactive sequences, it appears that Trp1, Leu3, DArg6 are important for the activity of 
these peptides. 
 
Table 36. The R-01—R-27 library. Residues 1 and 12 are attached to the D-Pro-L-Pro template. MIC 
values (in µg/ml) were measured against the bacterial strains indicated. 
Position Mimetic 
1 2 3 4 5 6 7 8 9 10 11 12 
MIC[µg/ml] 
E. coli  
ATCC25922 
MIC[µg/ml] 
P. aeruginosa 
ATCC27853 
MIC[µg/ml] 
P. aeruginosa 
PAOI   
MIC[µg/ml] 
S. aureus  
ATCC29213 
MIC[µg/ml] 
S. aureus   
ATCC25923 
R-01 W R R R A T DR Q R N R R >64 >64 >64 >64 >64 
R-02 W R R R A P DR Q R N R R >64 >64 >64 >64 >64 
R-03 W R R R G P DR Q R N R R >64 >64 >64 >64 >64 
R-04 W R R R V P DR Q R N R R >64 >64 >64 >64 >64 
R-05 W R R R A G DR Q R N R R >64 >64 >64 >64 >64 
R-06 W R R R A G K Q R N R R >64 >64 >64 >64 >64 
R-07 W R R R A T DR G R N R R >64 >64 >64 >64 >64 
R-08 W R R R A P DR G R N R R 32 >64 >64 >64 >64 
R-09 W R R R G P DR G R N R R 16 >64 >64 >64 >64 
R-10 W R R R G T DR Q R N R R 32 >64 >64 >64 >64 
R-11 W R R R V G DR Q R N R R >64 >64 >64 >64 >64 
R-12 W R R R A S DR Q R N R R >64 >64 >64 >64 >64 
R-13 W R R R A K G Q R N R R >64 >64 >64 >64 >64 
R-14 W R L R A K G Q R N R R 32 64 >64 >64 >64 
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R-15 W R Q R A K G Q R N R R >64 >64 >64 >64 >64 
R-16 W R R R A K G Q R N R V >64 >64 >64 >64 >64 
R-17 W R L R A DR K G R N R R 4 >64 >64 >64 >64 
R-18 W R L R A K K G R N R R >64 >64 >64 >64 >64 
R-19 W R K R A G K Q R N R R >64 >64 >64 >64 >64 
R-20 W R K R A K G Q R N R R >64 >64 >64 >64 >64 
R-21 W R R R A DR G Q R N R R >64 >64 >64 >64 >64 
R-22 W R L R A DR G K R N R R 4 >64 >64 >64 >64 
R-23 R R L R A DR G Q R N R R >64 >64 >64 >64 >64 
R-24 R R L R A K G Q R N R R >64 >64 >64 >64 >64 
R-25 R V R R A K G Q R N R R >64 >64 >64 >64 >64 
R-26 R C R R A K G Q R R C R >64 >64 >64 >64 >64 
R-27 K R Q R T K G R R L O R >64 >64 >64 >64 >64 
 
 
4.2.3. Biological activities and selectivities 
 
The primary criterion for the evaluation of antimicrobial peptides (AMPs) is 
their activity against micro-organisms. The RNase P peptidomimetics were assayed for 
antimicrobial activity using the NCCLS broth microdilution method. Briefly, two-fold 
serial dilutions of AMPs were prepared in Mueller-Hinton (MH) broth and inoculated 
with approximately 5x105 colony forming units (CFU/ml) of the appropriate organism. 
The minimal inhibitory concentrations (MIC) are reported as those concentrations of 
test compound that completely inhibit bacterial growth after an incubation period of 20 
h, as judged by visual inspection. The MIC of each mimetic was measured against the 
target organism Escherichia coli ATCC25922. Some peptidomimetics were assayed 
with other strains of Escherichia coli, as well as other micro-organisms, including 
Pseudomonas aeruginosa and Pseudomonas putida, representing Gram-negative 
bacteria, and Staphylococcus aureus and Bacillus subtilis, representing Gram-positive 
bacteria. 
 
 
4.2.4.  In vitro assay for inhibition of Escherichia coli RNase P 
 
The in vitro assay for inhibition of Escherichia coli RNase P was performed in 
cooperation with Professor V. Gopalan at the Department of Biochemistry at The Ohio 
State University. In preliminary studies with R-01—R-27, two peptides able to inhibit 
exclusively the growth of E. coli were discovered. In the next step, assays were 
performed to determine if any of these mimetics are able to inhibit RNase P in vitro.  
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Precursor tRNA was incubated with RNase P of E. coli and with the tested 
peptide. As a negative control only ptRNA was present in the assay, and as positive 
control the assay mixture contained no peptide inhibitor. Upon processing, the 
radiolabelled ptRNA is cleaved into mature tRNA and 5’-leader, both of which also 
contain radioactivity. The electrophoretic properties of the precursor, mature tRNA and 
5’-leader differ, so by EMSA it is possible to follow the course of the processing by 
RNase P (Figure 74). 
 
 
Figure 74. Principle of the RNase P-mediated processing of precursor tRNA, as monitored by EMSA. 
 
The initial screen was performed with the selected peptides at a concentration of 
5µM (Figure 75). The results of this initial EMSA are in close agreement with the 
information obtained from the antimicrobial assay. Peptides R-17 and R-22 show an 
inhibitory effect on RNase P from E. coli. The processing of the ptRNA takes place to a 
smaller extent in the presence of these two peptides, in comparison to the control lane 
and those for the other peptides. 
 
 
  ptRNA  Prod  R-02 R-03 R-04 R-05 R-06 R-08 R-10 R-11 R-12 R-13 R-14 R-15 R-16 R-17 R-18 R-19 R-20 R-22 R-26 
Figure 75. Initial EMSA assay of the inhibitory potential of the selected peptides, performed with E. coli 
RNase P and precursor tRNA. Prod = control without inhibitor present. 
Precursor 
tRNA 
 
Mature tRNA 
 
 
 
 
5’-Leader 
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  ptRNA Prod 0.6 1.5   4     10   0.6  1.5     4    10 
 
Figure 76. EMSA with a series of concentrations of R-17 and R-22 peptides. Assays were performed 
with RNase P from E. coli. Concentrations of cations: 200 mM NH4+ and 5 mM Mg2+. Prod = control 
without inhibitor present. 
 
The concentration-dependence of the inhibition by these two lead peptides was 
also investigated (Figure 76). Under the assay conditions, both peptides inhibit 
completely maturation of precursor tRNA at a concentration of 4 µM. The MIC value 
for these peptides is $ 4 µg/ml or approximately 2.2 µM. These values are very similar, 
which is at least consistent with the antimicrobial activity arising due to inhibition of 
RNase P. 
 
 
4.2.5. Alanine scan library P1 
 
Mimetics R-17 and R-22 are able to inhibit growth of E. coli with MIC values 
of $ 4 µg/ml. In order to identify the residues that are energetically important for 
antimicrobial activity of the peptides, a library of 11 mimetics was prepared, in which 
each residue in the sequence (R-22 was chosen) was replaced in turn by Ala (Table 37). 
The RNase P mimetics were synthesized, using methods described previously in 
Paragraph 2.2.2. In a typical synthesis, the main component in the crude product was 
the desired RNase P mimetic. After purification by HPLC, the desired peptidomimetics 
           R-17 [µM]                      R-22 [µM] 
Precursor tRNA 
 
Mature tRNA 
 
 
 
 
 
 
5’-Leader 
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were typically obtained in 20-40% overall yield, and each was >95% pure as 
determined by analytical HPLC and gave ESI MS data consistent with the calculated 
masses (see Appendix 4 for analytical data). 
The MIC values for the Ala-scanning library (Table 37) revealed that the 
replacement of Trp1 and Leu3 results in complete loss in activity in the range of 
concentration used. The DArg6Ala mutation produced a compound of 8-fold lower 
activity than the lead mimetic. Only mutations at positions 7 (Gly) and 10 (Asn) are 
unaffected in terms of activity. These findings support our design strategy, as in the 
model position 1 is occupied by Phe (Trp in R-22), at position 3 Ile is present (Leu in 
R-22), and position 6 is Arg (D-Arg in R-22). 
It seems that positions 1 and 3 have to be occupied by aromatic/large aliphatic 
groups, while Arg is important for the turn region. Reducing the positive charge of the 
mimetic most of the time has only a small influence on the activity (mimetics P1-08, 
P1-11, P1-12). Surprisingly, replacement of the polar residue Asn10 by Ala does not 
bring any changes in activity. This indicates that position 10 may accommodate 
residues of having different side chain properties. 
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4.2.6. Mimetic library P2: Attempts to optimise the lead compound 
 
Following the observations from the initial screen (peptides R-01-R-27) and Ala-
scanning of R-22, a new library was designed, in order to introduce amino acid residues 
that are present in the !-hairpin model (Figure 73). Previous results highlighted the 
importance of the Trp1, Leu3 and D-Arg6, therefore in this library mutations other than 
Ala were introduced at these positions. It was also established that the charge of 
peptides can be reduced, at least from +7 to +6. In the present approach some peptides 
have a total charge even lower (e.g. +4 in P2-22 and +3 in P2-24). P2-11 represents a 
sequence based entirely on the theoretical model (Figure 73). In other peptides 
single/multiple changes are introduced to follow the model sequence (P2-03—P2-10). 
Furthermore, all Arg residues were mutated in turn into Lys in order to determine the 
importance of the guanidine group (P2-12—P2-17). In one of the peptides, P2-21, a 
disulfide bridge was introduced at non-hydrogen bonding positions 2 and 11. 
These peptides were prepared using methods described previously. After 
purification by HPLC, the desired peptidomimetics were typically obtained in 20-40% 
overall yield, and each was >95% pure as determined by analytical HPLC and gave 
ESI-MS data consistent with the calculated masses (see Appendix 4 for analytical data). 
The antimicrobial activity of these peptides is summarised in the Table 38. This 
optimisation cycle produced many mimetics having improved activity (MIC <1 µg/ml) 
and very high selectivity for E. coli. The most potent peptidomimetic, P2-05, exhibits 
an  MIC of 0.06 µg/ml. This new lead compound represents a sequence that is a 
chimera between R-22 and the model sequence presented in P2-11. It appears, that the 
mutations Ala5Ile and Asn10Leu are of major importance for the antimicrobial activity. 
The results show that position 1 can accommodate neutral aromatic (Phe or Trp) or 
large aliphatic residues (Ile), however, Trp1Tyr brings a 16-fold loss of activity (P2-04 
vs. P2-10). This observation suggests that at this position large neutral amino acid 
residues, preferentially aromatic, are optimal, while introducing polarity possibly 
disturbs hydrophobic interactions. 
The results concerning mutations at position 6 in the turn region show that the 
stereochemistry at this position is more important than the character of the amino acid. 
The mutation DArg6Arg brings a 32-fold decrease in activity (P2-04 vs. P2-08), while 
the mutation DArg6DLys produces a peptide with retained activity (P2-04 vs. P2-14).  
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Peptides P2-12—P2-17 show that the replacement of Arg by Lys does not 
influence the activity of the peptides, therefore one can assume that the guanidinium 
groups are not critical for the interaction with the target. The mutations of Arg/Lys to 
Gln, which brings a reduction of the charge, when introduced singly, are very well 
tolerated (P2-06, P2-19, P2-20), but in multiple copies (P2-22, P2-23, P2-24), they 
bring a loss in activity. It is noteworthy, that reducing the charge from +7 to +5 
(peptides P2-11 and P2-07) does not have any influence on the peptide potency. This 
observation may be very important for further optimisation in terms of improving other 
properties and plasma stability. 
It is noteworthy, that all the peptides active against E. coli show also some, but 
strongly reduced, antimicrobial activity against B. subtilis. Interestingly, P2-11 
representing the model sequence based on the RNA-binding domain of the B. subtilis 
protein subunit, is the only peptidomimetic that inhibits more strongly growth of B. 
subtilis than of E. coli (0.12 vs 0.37 µg/ml). In addition, the peptides P2-05 and P2-11 
exhibit some inhibitory potency against other bacterial strains tested, however, the MIC 
values are at least 10-fold higher. 
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4.2.7. An evaluation of the importance of the D-Pro-L-Pro template 
 
In order to evaluate the importance of the template, the linear version of one of 
the active peptidomimetics, namely P2-04, was prepared (Table 39). 
 
Table 39. Sequences and MIC values for P2-04 and its linear derivative. Note, the N-terminus of P2-04a 
is acetylated, and the C-terminus is an amide. 
Mimetic Position Template MIC[µg/ml] 
E. coli  
ATCC25922 
MIC[µg/ml] 
B. subtilis  
3256 
 1 2 3 4 5 6 7 8 9 10 11 12    
P2-04 W R I R I DR N K R N R R DP-P 0.5 2 
P2-04a Ac-W R I R I DR N K R N R R-NH2 -- 16 4 
 
The 32-fold loss in antimicrobial activity of the linear peptide against E. coli in 
comparison to the cyclic one, suggests that either the constrained !-hairpin 
conformation or the template itself (or both) might be important for the activity. In 
sharp contrast, the inhibitory potency of the linear P2-04a determined against B. 
subtilis, a closely related bacterial strain, is only slightly influenced by removal of the 
template. 
 
 
4.2.8. The enantiomeric form of the peptide  
 
In the past, enantiomeric forms of antimicrobial peptides with all-D-amino acids 
were widely used to study the mechanism(s) of antimicrobial action.191,192 It has been 
suggested that the interactions between antimicrobial peptides and the cell membrane 
might not require from these class of peptides a specific chirality. Indeed, many studies 
have shown that for many membranolytic peptides the all-D-amino acid forms have 
equal activities to their all-L-enantiomers,193,194 suggesting that the antimicrobial 
mechanism of these peptides does not involve a stereoselective interaction with a chiral 
enzyme or protein receptor. In addition, all-D-peptides are resistant to proteolytic 
enzyme degradation, which enhances their potential as clinical therapeutics. Similar 
conclusions have been drawn with ligand-RNA interaction inhibitors, where the D-
forms of potent ligands exhibit only a slight decrease in affinities to the target RNAs, as 
discussed Paragraph 1.1.3.  
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However, there are some examples known of antimicrobial peptides from 
natural sources where the D-form is much less active than the L-form. These peptides 
typically do not show membranolytic activity, and must have a different mechanism of 
action.195,196 
Table 40. Sequences and MIC values for P2-04 and its enantiomeric form.  
Mimetic Position TEMPLATE MIC[µg/ml] 
E. coli  
ATCC25922 
MIC[µg/ml] 
B. subtilis  
3256 
 1 2 3 4 5 6 7 8 9 10 11 12    
P2-04 W R I R I DR N K R N R R DP-P 0.5 2 
P2-04b DW DR DI DR DI R DN DK DR DL DR DR P-DP 0.5 0.2 
 
The results of the antimicrobial assay (Table 40) show that the enantiomeric 
form of P2-04 has the same activity as the parent peptide against E. coli. Once again 
there is a clear difference in behaviour between E. coli and B. subtilis. P2-04b exhibits 
more than 10-fold higher inhibitory activity against B. subtilis than the parent peptide. 
It is also $3-fold more active against B. subtilis than E. coli.  
 
 
4.2.9. Mimetic library P3: Further optimisation of the lead compound 
 
The results form library P2 have shown that one strand of the !-hairpin (amino 
acids 1-6) is much more sensitive to changes than the other. In this library, the 
beneficial changes were combined in order to enhance the activity, as well as to 
decrease the total charge of the peptide.  
So far the model of the !-hairpin peptide was based on the sequence derived 
from B. subtilis, since the crystal structure of the RNA and the protein subunits are 
available. In this library, the sequence derived from the E. coli RNA-binding domain 
has been tested in order to evaluate if this approach would bring an improvement in 
activity and specificity against this strain of bacteria. The peptide derived from the 
sequence of the E. coli RNase P subunit, using the model shown in Figure 73, is 
represented by P3-04 (Table 41). 
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Table 41. Library P3 of RNase P peptidomimetics. MIC values (in µg/ml) of AMPs were measured 
against E. coli ATCC25922. 
Mimetic Position MIC [µg/ml] 
E. coli  
ATCC25922 
 1 2 3 4 5 6 7 8 9 10 11 12  
R-22 W R L R A DR G K R N R R 4 
P2-05 W R I R I DR N K R L R R 0.06 
P3-01 W R I R I DR N Q K L R R 0.37 
P3-02 W R I R I DR N Q K I R R 0.12 
P3-03 W R I R I DR N K O L R R 0.12 
P3-04 F R T R I DR N K R L E S 16 
P3-05 F R I R I DR N K R L R R 0.09 
P3-06 W R I R I DR N K R L R I 2 
P3-07 F R I R I DR N K R L R S 0.5 
P3-08 W R I R I DR N K R L Q A 0.25 
P3-09 Cha R I R I DR N K R L R R 0.12 
P3-10 W R I R I DR N Q R L Q A 0.75 
 
The results of MIC assays for the library P3 are reported in Table 41. Among 
the peptides tested no further gain in activity was achieved, however, almost all of the 
peptides exhibit very high potency. P2-05 represents so far the optimal sequence for 
inhibitory activity against E. coli. In agreement with previous studies, position 1 
appears to tolerate large aliphatic residues (as seen in P3-09, Trp1Cha). The 
incorporation of Leu at position 10 allows reduction of the total charge to +4 with much 
lower loss in activity compared to that seen in the previous library (i.e. 0.75 µg/ml vs. 
4 µg/ml in P3-10 and P2-22, respectively). Reduction of the total charge of the peptides 
might be important when considering the pharmacological properties of the 
compounds. Highly positively charged molecules are often found to be toxic (due to 
haemolytic activity and histamine release associated with their cationic nature). In 
addition, a replacement of the basic amino acid residues might also bring improvements 
in the stability against proteolytic degradation. 
It is noteworthy, that P3-04, whose sequence is derived from the RNA-binding 
domain of E. coli RNase P exhibits a dramatic loss in antimicrobial activity in 
comparison to the most active peptidomimetic P2-05 so-far (16 vs. 0.06 µg/ml). This 
suggests that the model of the RNA-binding domain derived from B. subtilis has more 
predictive value than the one for E. coli, perhaps due to the more detailed structural 
information available for B. subtilis. However, it might be that incorporation of just one 
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mutation (e.g. Thr3 or Glu11) has significant impact on activity, therefore further SAR 
studies are necessary. 
 
 
4.2.10. Effect of divalent cations (Ca2+ and Mg2+) on antimicrobial activity  
 
Many cationic antimicrobial peptides exhibit reduced potency in the presence of 
high concentrations of salt and, in particular, divalent cations. The Ca2+ concentration 
in the extracellular fluid is kept at approximately 10-3 M, and its concentration inside 
the cells is at approximately 10-6 M. The Mg2+ concentrations extracellular and 
intracellular are approximately 0.7-1.2 mM and 0.5 mM, respectively. Calcium remains 
almost wholly in plasma and very little in the cells, while magnesium is mostly found 
in the cells and less in plasma. It is thought that the presence of cations in the buffer 
reduces the affinity of cationic peptides to the negatively charged microbial 
membrane.197,198 In order to evaluate the effect of Ca2+ and Mg2+ on inhibitory activity, 
two peptides P2-04 and P2-22 were tested. 
 
Table 42. Summary of MIC values [µg/ml] for the assays performed in the presence of different 
concentrations of divalent cations. The peptides were assayed with the concentrations of calcium chloride 
and magnesium sulfate indicated or with a mixture of them both. 
Mimetic P2-04 P2-22 
Concentration 
Ca2+ /Mg2+ 
MIC [µg/ml] 
0mM Ca2+ / Mg2+ 0.5 4 
0.5mM CaCl2 0.5 12 
2mM CaCl2 4 >64 
5mM CaCl2 16 >64 
10mM CaCl2 64 >64 
20mM CaCl2 >64 >64 
40mM CaCl2 >64 >64 
5mM MgSO4 3 >64 
20mM Mg SO4 64 >64 
40mM Mg SO4 >64 >64 
5mM CaCl2/Mg SO4 64 >64 
20mM CaCl2/Mg SO4 >64 >64 
40mM CaCl2/Mg SO4 >64 >64 
 
The results of the assays with defined concentrations of divalent cations are 
reported in Table 42. Both peptides appear to be very sensitive to the presence of Ca2+ 
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and Mg2+. However, the effect is dependent on the total positive charge of the peptide; 
P2-04 has +7 positively charged guanidinium/amine groups under physiological 
conditions and is affected to lesser extent by the presence of cations than P2-22 with 4 
positive charges.  
This experiment shows that the RNase P mimetics share this sensitivity to 
divalent cations with other known cationic antimicrobial peptides, e.g. defensins.198 The 
sensitivity to cations might be a limiting factor for the potential use of this class of 
mimetics for pharmaceutical purposes. They could be effective in killing pathogens 
only at sites with low concentration of divalent cations.  
 
 
4.2.11. Activity of RNase P peptidomimetics on a selection of E. coli strains 
 
The previous experiments show that the peptidomimetics exhibit high 
antimicrobial activity and selectivity against an E. coli strain used commonly in 
laboratories, E. coli ATCC25922. To prove the ability to inhibit bacterial growth of 
pathogenic strains, 6 clinical isolates of E. coli were also tested in assays (Table 43). 
 
Table 43. Susceptibility of pathogenic strains of E. coli to selected RNase P peptidomimetics. MIC 
values are given in µg/ml. 
Mimetic E. coli  
ATCC25922 
E. coli 
2138E/2151 
E. coli 
2139E/2152 
E. coli 
2140E/2153 
E. coli 
2143E/2154 
E. coli 
2144E/2155 
E. coli 
3459E/2150 
R-17 4 8 16 24 16 3 32 
R-22 4 4 16 16 16 3 32 
P1-01 >64 >64 >64 >64 >64 >64 >64 
P1-06 4 4 6 8 8 6 8 
P2-01 0.5 0.25 0.5 0.75 0.25 3 0.375 
P2-03 0.5 0.375 0.25 0.375 0.125 0.75 0.25 
P2-04 0.125 0.125 0.125 0.125 0.09 0.75 0.125 
P3-10 0.75 1 1 1.5 0.5 0.5 1 
 
These results prove that the peptidomimetics tested are able to inhibit bacterial growth 
of several pathogenic E. coli strains present in the clinic. 
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4.2.12. Haemolytic activity of RNase P peptidomimetics 
 
In addition to antimicrobial activity, measured in MIC values, a second 
important criteria for the AMPs, with respect to their potential usefulness as therapeutic 
agents, is their haemolytic activity, i.e. the ability to lyse red blood cells. Such activity 
is often used as an indicator for the toxicity of AMPs towards (mammalian) host cells. 
Therefore, a low level of haemolysis is a pre-requisite for any systemic applications.  
 
Table 44. Haemolytic activity (% hemolysis) of RNase P peptidomimetics and a control antimicrobial 
agent, protegrin-1 (PG-1), against human red blood cells, each at a concentration of 100 µg/ml. 
Mimetic Haemolysis [%] 
R-17 1.35 
R-22 0.5 
P1-01 0.07 
P1-02 0.57 
P1-03 0.1 
P1-04 0.5 
P1-05 0.5 
P1-06 0.45 
P1-07 0.4 
P1-08 0.45 
P1-09 0.83 
P1-10 0.5 
P1-11 0.9 
P2-01 1.27 
P2-02 0.85 
P2-03 1.37 
P2-04 1.37 
P2-05 1.9 
P2-06 0.95 
P2-07 1.83 
P2-08 1.0 
P2-09 1.47 
P2-10 0.65 
P2-11 3.15 
P2-12 0.93 
P2-13 1.05 
P2-14 1.15 
P2-15 1.05 
P2-16 1.10 
P2-17 0.7 
P2-18 0.9 
P2-19 1.4 
P2-20 1.0 
P2-21 0.7 
P2-22 1.93 
P2-23 1.3 
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P2-24 1.5 
P2-04a 1.13 
P2-04b 1.3 
PG-1 45.35 
 
The haemolytic activity of the RNase peptidomimetics was determined by their 
ability to lyse human red blood cells (hRBC), typically at peptide concentration of 
100 µg/ml. The results of these experiments are expressed as percentage of haemolysis 
relative to 0.1% Triton-X 100TM, which is taken as a reference corresponding to 
complete lysis of the blood cells. Protegrin-1 (PG-1), a natural antimicrobial peptide 
with known haemolytic properties was used as a reference. The results summarised in 
Table 44 show that the peptides have a very low level of haemolytic activity, which 
supports their usefulness for therapeutic purposes. 
 
 
4.2.13. Plasma stability assays 
 
The proteolytic stability of the compounds in biological settings is a major 
challenge for using peptides as prospective therapeutics in drug discovery programmes, 
as discussed previously in Paragraph 2.2.7. The peptides were assayed in human and 
mouse plasma as described in Paragraph 2.2.8.2. The results of the experiments are 
summarised in Table 45. 
 
Table 45. Summary of the results from plasma stability assays. The half-life (,1/2 [min]) and stability 
after 4 h (% remaining after 4h) are presented for each peptide after incubation with human or mouse 
plasma. 
Mimetic ,1/2 [min] 
in Human 
Plasma 
Stability after 4 h 
in Human Plasma 
[%] 
,1/2 [min] 
in Mouse 
Plasma 
Stability after 4h 
in Mouse Plasma 
[%] 
R-22 140 29.2 114 16.2 
P2-04 >240 93.6 122 28.7 
P2-04b >240 100 >240 100 
P2-05 >240 90.3 >240 72.5 
P2-11 >240 100 >240 89.9 
 
The results indicate that under the assay conditions all the peptides exhibit a 
high stability against proteolytic enzymes present in plasma. The peptides are more 
susceptible to degradation in mouse plasma than in human plasma, and similar results 
were obtained for the Tat peptidomimetics (Paragraph 2.2.8.2). As expected, the 
mostly-D-amino acid-containing P2-04b is completely stable in these experiments.  
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4.3. Discussion 
 
The extensive structural, functional and sequence data available for the RNA 
and protein subunits of several bacterial RNase P ribonucleases, enabled in this work 
the design of a novel class of RNase P inhibitors. An initial assay of the !-hairpin 
peptides available from the Rev-RRE project delivered two compounds (R-17 and R-
22) with antimicrobial activity selective to E. coli. A similar observation was also made 
by EMSA with ptRNA and RNase P of E. coli. At the same time, a model !-hairpin 
peptide was designed and prepared by transpositioning the RNA-binding region 
displayed on an "-helical segment of the RNase P protein, onto a ß-hairpin scaffold to 
give mimetic P2-11.  
The alanine scan of lead peptide R-22, allowed the identification of residues 
important for the inhibitory activity. Based on this information and on the sequence of 
P2-11, the step-wise optimisation of the lead peptidomimetic was carried out, through 
the design, screening, and SAR analysis of peptides libraries. The analysis of the SAR 
data highlighted the importance of Trp/Phe1, a large aliphatic group at position 3 (Leu 
or Ile) and the D-Arg6 in the turn region.  
The most potent mimetic P2-05 represents a chimera between sequences 
derived from the model peptide P2-11 and R-22 (Figure 77). Although P2-11 
represents an optimal model sequence, it is not as potent as the best mimetic. This 
indicates that although the approach to the design of the !-hairpin mimetics was 
successful, as long as a crystal or NMR structure of the E. coli RNase P RNA-protein 
complex is not available, it is difficult to rationally design improved mimetics of the 
RNA-binding domain. 
Interestingly, only the model sequence derived using the B. subtilis RNase P, 
gave a peptide more active against B. subtilis than against E. coli (P2-11). Any other 
variants tested gave peptidomimetics with higher antimicrobial activity against E. coli 
than against B. subtilis. Using the sequence derived from the "2-helix of the protein 
domain of E. coli RNase P, P3-04, brought a 43-fold loss in activity in comparison to 
the model sequence (P2-11) from B. subtilis. This is again an indication that without 
detailed structural information on the complex from E. coli, it is difficult to rationally 
design inhibitors of this RNA-protein interaction. However, good progress has been 
made by exploiting this combinatorial approach to mimetic design and synthesis. 
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Figure 77. Representative examples of RNase P peptidomimetics, showing the stepwise improvements 
in antimicrobial activity against E. coli. 
 
Decreasing the total positive charge of the peptides, performed in the P2 and P3 
libraries, leads to the conclusion that in the case of these antimicrobial peptides the 
number of positively charged residues is not a critical factor for activity and, following 
the model and SAR studies, the charge can be reduced from +7 in R-22 to +5 in P2-11, 
or to +4 in P3-10. Furthermore, the character of the charged residue is also not critical, 
since mutations of Arg to Lys are very well tolerated.  
The experiments performed with different concentrations of divalent cations, 
Ca2+ and Mg2+, revealed that these peptides are sensitive to the presence of these 
cations. This might indicate that prior to internalisation they interact with the 
negatively-charged cell membrane, and high concentrations of cations disturb this 
interaction. However, it is also known that high concentrations of these divalent cations 
in in vitro assays reduces the activity of RNase P.199,200 
It is noteworthy that the most active peptidomimetic, P2-05, has an amphipathic 
character, having hydrophobic and hydrophilic faces (Figure 78), which makes it like 
many known antimicrobial peptides. The amphipathic character might mean that the 
RNase P peptidomimetics have a tendency to lyse red blood cells, however, this effect 
is fortunately not observed.  
 
W R L R A DR G K R N R R 4 µg/ml 
W R I R I DR N K R N R R 0.5 µg/ml F R I K I DR N R R L Q A 0.375 µg/ml 
W R I R I DR N K R L R R 0.06 µg/ml 
P2-04 
P2-05 
P2-11 (MODEL B.subtilis) 
16x 
8.3x 
R-22 
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Figure 78. Topology of P2-05. Illustration of its amphipathic character, in red are polar amino acid and 
in green the aliphatic/aromatic amino acids. 
 
The designed peptides are rich in arginine residues, which can make them 
susceptible to proteolytic degradation in biological settings. Selected peptides were 
tested in a plasma stability assay with human and mouse plasma, where they proved to 
be relatively stable under the experimental conditions. This stability might be 
attributable to the cyclic form of these peptides, which makes the peptide chain less 
accessible to the active sites of the proteolytic enzymes. 
To conclude, it has proven possible to design potent and selective inhibitors of 
E. coli RNase P, which inhibit directly the processing of ptRNA, as detected by EMSA. 
Moreover, these molecules also inhibit the growth of several strains of E. coli, 
including clinically active pathogens. In addition, it was demonstrated that the peptides 
do not exhibit significant haemolytic activity and that they are stable in plasma, which 
makes them very attractive as potential future therapeutics. Further on-going studies 
should include optimisation of the lead sequences in order to increase activity and/or 
reduce the positive charge. Most important, further studies are required to prove that 
RNase P inhibition is really the mechanism of their antimicrobial activity. 
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5. EXPERIMENTAL PART 
 
 
5.1. General notes 
 
Solvent and reagents. Reagents and solvents were purchased from Aldrich, 
Acros, Merck and Fluka. Ethyl acetate, diethyl ether, DCM, and cyclohexane were 
redistilled from K2CO3 or CaCl2. Dry DCM and dry toluene were obtained by 
distillation from CaH2. Other solvents or reagents were distilled, purified and/or dried 
using standard procedures.201  
 
Material and instrumentations. Flash chromatography was carried out on silica 
gel 60 (230-400mesh, 0.04-0.063mm) from Merck (Darmstadt, Germany) or Chemie 
Uetikon AG (Uetikon, Switzerland). Thin layer chromatography (TLC) was 
performed on silica gel 60 F254 plates from Merck. Melting points (m.p.) were 
measured on a Kofler apparatus connected to a NIKON YS 100 microscope (Egg, 
Switzerland). 
1H NMR and 13C NMR we measured at 300 MHz and 75MHz, respectively, on a 
Bruker ARX-300 specrometer (Bruker, Rheinstetten, Germany). Chemical shifts are 
given in ppm relative to the internal tetramethylsilane (TMS) in organic solvents or 
sodium 3-trimethylsilyl(2,2,3,3-D4)propionate (TSP) in H2O/D2O. 
MS spectra were measured by the MS service of the University of Zurich. ESI mass 
spectra were recorded either on a Waters Q-tof Ultima API Instrument (Milford, 
USA), on a Bruker ESQUIRE-LC quadrupole ion trap instrument or on a Finnigam 
TSQ-7- instrument. MALDI MS spectra were recorded on Bruker Autoflex I MALDI-
TOF. LC-MS analysis of the peptides was performed on a reverse-phase high 
performance liquid chromatography (RP-HPLC) system connected to a 
ThermoFinnegan Quadrupole-ESI Mass Spectrometer (Thermo Fisher Scientific, 
Waltham, USA). 
Purification and analysis of peptides were carried out by RP-HPLC using a dual pump 
Äkta purifier (Amersham Pharmacia Biotech) system. The columns used were: 
VydacTM GraceVydac 218TP54 (C18, 5µm, 4.6x250mm), Agilent Zorbax Eclipse 
XDB-C18 (5µm, 4.6x250mm) for analytical separations, Agilent Zorbax 300SB-C18 
(7µm, 21.2x250mm) and Waters XbridgeTM Prep-C18 (5µm, 19x50mm) for 
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preparative separations. UV detection was performed at $=226 nm and 278 nm. 
Solvents used were acetonitrile (Acros Organics) and distilled water, each containing 
0.1% trifluoroacetic acid (TFA).  
 
 
5.2. Peptide synthesis 
 
Solvents and amino acids.  NMP and piperidine were purchased from Acros 
Organics (Geel, Belgium) and used without further purification. DMF was purchased 
from Acros Organics and redistilled under vacuum from ninhydrin. DIEA was 
purchased from Acros Organics and redistilled under vacuum first from ninhydrin and 
subsequently from KOH. HBTU was purchased from Novabiochem and HOBt, 
HATU and HOAt were purchased from Fluka and used without further purification. 
Amino acids were purchased from Novabiochem, Bachem, NeoMPS, and Advanced 
ChemTech. Resins: 2-chlorotritylchloride resin (100-200mesh) with a loading of 
1.2mmol/g and Rink Amide MBHA resin with a loading of 0.69mmol/g were 
purchased from Novabiochem. The following N-"-Fmoc protected L/D-amino acids 
were used for routine Fmoc-SPPS: 
Fmoc-Ala-OH, Fmoc-Asp(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Cys(Acm)-OH, Fmoc-Gly-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-
OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Alloc)-OH, Fmoc-Phe-OH, 
Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-
Trp(Trt)-OH, Fmoc-Val-OH.  
Additionally some unnatural amino acids were used: cyclohexylalanine, Fmoc-Cha-
OH, (NeoMPS); diaminobutyric acid, Fmoc-Dab(Boc)-OH, (NeoMPS); 2-L-
aminobutyric acid, Fmoc-Abu-OH, (NeoMPS); !-phenyl-phenylalanine, Fmoc-Bpa-
OH (Sigma-Aldrich); pipecolic acid, Fmoc-Pip-OH, (NeoMPS); biphenylalanine, 
Fmoc-Bip-OH, (Advanced ChemTech); homo-L-phenylalanine, Fmoc-Hfe-OH, 
(Advanced ChemTech); 3-chloro-L-phenylalanine, Fmoc-Phe(3-Cl)-OH, (Advanced 
ChemTech); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, Fmoc-Tic-OH, 
(NeoMPS); 4-chloro-L-phenylalanine, Fmoc-Phe(4-Cl)-OH, (NeoMPS); ornithine, 
Fmoc-Orn(Boc)-OH (NeoMPS). 
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Loading of amino acid on the resin. For the coupling of the first amino acid to 
2-chlorotrityl chloride resin, a loading of 0.6 mmol of amino acid per gram of resin 
was typically used. The calculated amount of N-"-Fmoc protected amino acid was 
dissolved in dry DCM (10 ml per g of resin). To the pre-swollen resin (with dry 
DCM) the amino acid solution with 4 eq of DIEA was added. The reaction mixture 
was agitated for 120 min. The excess of unreacted resin was blocked by three 
consecutive washings with DCM/MeOH/DIEA (17:2:1) and then the resin was 
washed with dry DCM, DMF and DCM. The resin was dried overnight under vacuum 
over KOH. Estimation of the level of loading was performed by measuring the UV 
absorption at 290 nm after Fmoc-deprotection of ~1-2 mg dry resin in 25% 
piperidine/DMF for ~15 min. The blank sample contained only the 25% 
piperidine/DMF. The loading was calculated according to the equation: 
Loading (mmol/g)=(Abssample)/(mg of resin x 1.75)
202 
 
Rink amide MBHA resin was used directly in the SPPS procedure, with Fmoc 
deprotection as the first step of the synthesis. 
 
 
Peptide synthesis. 
Automated single peptide synthesis.  Peptides were synthesised on an Applied 
Biosystems ABI433A automated synthesiser coupled to a Perkin Elmer UV/VIS 
detector using the FastMoc® chemistry protocol on a 0.25 mmol scale. In 0.25 mmol 
FastMoc chemistry, 4 eq of Fmoc-protected amino acid and 4 eq of coupling reagents: 
HBTU/HOBt (0.45 M in DMF), DIEA (2 M in NMP) are used for each coupling 
reaction. Deprotection is performed in 20% piperidine in NMP, monitored by UV and 
repeated if needed.  
Automated parallel peptide synthesis. Synthesis of peptide libraries was carried 
out on a MultiSynTech Syro II peptide synthesiser on ~0.07 mmol scale using 4 eq of 
Fmoc-protected amino acid (0.3 M in DMF) and of coupling reagents HBTU/HOBt 
(0.45 M in DMF), DIEA (2 M in NMP). The coupling reactions were performed twice 
for 45 min. The deprotection was carried out twice in 40% piperidine/DMF for 5 min.  
Manual coupling of amino acids. Coupling of non-standard amino acids was 
carried out manually with 2 eq of the Fmoc-protected amino acid activated with 
1.9 eq of HATU/HOAt and 4 eq of DIEA in 10 ml dry DMF/g resin. The coupling 
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reactions were carried out for 4 h under vigorous agitation, and completion of the 
coupling reaction was monitored by the Kaiser test for primary amines203 or chloranil 
test for secondary amines.204 
 
Cleavage from the resin.  The linear, side chain-protected peptides 
assembled on the 2-chlorotrityl resin were cleaved from the resin by treatment up to 
10 times with 0.8% TFA/DCM for 2 min. The TFA filtrates were collected into 
separate flasks containing a few drops of DIEA to neutralise the acid and the solutions 
were evaporated under reduced pressure to yield crude linear fully protected peptides. 
The cleavage from the rink amide MBHA resin was carried out together with the 
final deprotection step using a cocktail of TFA:H2O:TIPS [95:2.5:2.5 (v/v)] for 4 h. 
The filtrate was concentrated on a rotary evaporator and then the precipitation of 
crude fully-deprotected peptide was performed with ice-cold ether.  
 
Acetylation of N-terminal amine group. The acetylation of N-terminal amine 
groups was performed with peptides assembled on the rink amide MBHA resin. After 
the last Fmoc deprotection, the resin with fully-protected peptide was incubated twice 
with a solution of acetic anhydride (19 ml), DIEA (9 ml), and HOBt (0.8 g) in NMP 
(372 ml) (capping solution). The acetylation was monitored by a standard Kaiser test. 
 
Cyclisation and deprotection . Linear precursors (after cleavage from the 
chlorotrityl resin) were cyclised in DMF with 1.5 eq of HATU/HOAt and 6 eq of 
DIEA over 4 h. Concentrations of ~5 mg of crude precursor per ml DMF were used. 
After the reaction the mixture was concentrated under vacuum, yielding a 
yellow/brown oil containing a crude cyclic fully protected peptide. The final 
deprotection was performed in TFA/H2O/TIPS (95:2.5:2.5) cocktail (10 ml) for 4 h. 
The solution was concentrated under vacuum and precipitation with ice-cold ether 
yielded a crude fully deprotected cyclic peptide. 
 
Disulfide bridge formation.  The cysteines to be oxidised were protected with 
Acm protecting groups, which are stable to the standard final deprotection procedure. 
Pre-purified, fully deprotected (except for the Acm groups on Cys residues) cyclic 
peptides were dissolved in 4:1 AcOH:H2O mixture and treated with 10 eq of I2 in 
methanol. The reaction was stirred for 30 min, then the excess of iodine was quenched 
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with a solution of ascorbic acid (50 mM) in citrate buffer (10 mM, pH=5.0). The 
reaction mixture was lyophilised. A dry crude product was redissolved in water and 
purified by RP-HPLC. 
 
 
5.3. EMSA 
 
Run-Off Transcription of BIV TAR RNA.           The synthetic oligodeoxynucleotide 
(“bottom strand”) with a sequence complementary to that of BIV TAR, followed by a 
sequence complementary to the DNA-top-strand, 5’-GGC TCG GAG CTA ATG 
AGC TAC ACG CCT ATA GTG AGT CGT ATA A-3’, was bought from IDT-DNA 
technologies (Iowa, USA) on a 1 µM scale. The DNA template provided was 
OD260=11.1 (24.29 nmoles). The template was dissolved in sterile water (200 µl) and 
NaOAc (3 M, 35 µl) and absolute EtOH (600 µl) were added. The solution was kept 
at –20oC overnight and then centrifuged at 12'000 rpm, 4oC for 30 min. The DNA 
pellet was washed with 70% EtOH, centrifuged and dried. Then, the pallet was 
dissolved in sterile water, a UV260 absorbance of a 100-fold diluted sample was 
measured, which gave OD260=7.04 (15 mmol). The “bottom strand” oligonucleotide 
was dissolved in sterile water (1.875 ml) to give an 8 µM solution. The “top strand” 
(5’-TAA TAC GAC TCA CTA TAG-3’, IDT-DNA technologies) was prepared in the 
same way to give an 8 µM stock solution. The BIV TAR RNA was prepared by run-
off transcription. The run-off transcription was performed on a 100 µl scale in an 
Eppendorf tube. For this, sterile water (20 µl), “bottom strand” BIV TAR RNA 
(8 µM, 10 µl), “top strand” (8 µM, 10 µl), and Mg2Cl (1 M, 5.6 µl) were mixed in an 
Eppendorf tube, vortexed shortly and heated to 80oC for 2-3 min. The reaction 
mixture was left to cool down to rt for ~10 min, then NTPs (20 mM of each; 20 µl of 
a mixture of ATP, GTP, CTP, UTP (40 µl, 100 mM each, Pharmacia)), water (40 µl), 
PEG (20 µl, 8 K, 40%, Axygen Biosciences), ["-32P]-CTP (40 µl, 3000 Ci/mmol, 
Amersham), a transcription buffer (5 µl; 20x Tris-HCl (800 mM, pH=8.1), spermidine 
(20 mM, Sigma-Aldrich), Triton X-100 (0.2%, Sigma), and DTT (150 µl, 100 mM), 
were added and heated for 2-3 min at 37oC. T7 RNA polymerase (20 U/ml, 10 µl, 
Ambion) was added, the mixture was vortexed shortly and incubated at 37oC for 4h. 
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 Afterwards, the transcription reaction was passed through a Sephadex G-25 
column (Sigma-Aldrich) to remove most of the unincorporated ["-32P]-CTP. To the 
eluted RNA, denaturing loading dye (TBE 2x, in 7 M urea, ~80 µl) was added and the 
mixture was loaded on a 20% denaturing polyacrylamide gel (20 cm x 52 cm) [75 ml 
of 40% polyacrylamide:bisacrylamide 19:1 (Acros), 63 g urea, 15 ml TBE 10x (890 
mM Tris-base, 890 mM boric acid, 890 mM Na4EDTA), 1500 µl APS (0.1 g/ml, 
Acros), 150 µl TEMED (Acros)]. The gel was run for ~24 h with 1x TBE (until the 
xylene cyanol dye in the loading dye had reached almost the bottom of the gel), at 900 
V, 500 mA, 30 Watts (constant power). The gel was then removed (marked for 
reference with radioactive CTP and ink) and exposed on a phosphor image screen 
(Molecular Dynamics) for 30 min. The phosphor image screen was then scanned on a 
phosphor image scanner (Molecular Dynamics), and the autoradiogram was analysed 
with Image Quant 5.0. The wet gel was overlapped with the scanned autoradiogram 
(with the aid of the marker reference radioactive ink), and the RNA band was excised 
accurately. The main product band (N=28 mer) appeared at the expected height 
relative to the xylene cyanol dye (above the second, slower band of dye) indicating 
that the expected product (N): 
5’-GGC UCG UGU AGC UCA UUA GCU CCG AGC C-3’ 
had been transcribed and was well separated from N+1 side product (above the 
intensive product band). The gel band was cut into small pieces and crashed gently 
into small pieces in a Falcon sterile tube and left mixing overnight with eluting buffer 
(1 ml, H2O:NaOAc(3 M):Na2PO4 (pH=7.5, 0.5 M) (v/v 3:1:1)). The procedure was 
repeated 3 times, every time the eluting buffer was removed and a fresh portion of it 
was added to the pieces of the gel. All 3 portions of the elutant buffer were combined 
and passed through a 0.2 µl Millipore™ filter to remove any remaining gel pieces. 
The eluate was divided into Eppendorfs (400 µl in each), NaOAc (40 µl, 3 M) and 
absolute EtOH (900 µl) were added to each one and the solutions were kept at –20oC 
overnight for the RNA to precipitate, and then centrifuged at 12’000 rpm, at 4oC for 
45 min. The solvent was decanted from above the pellet of the RNA, the pellet was 
washed with 70% EtOH, centrifuged again, solutions decanted again, dried on a high 
speed rotary vacuum and redissolved in sterile H2O (1 ml). The solution was dialysed 
against phosphate buffer (1 l, 10 mM, pH=6.6) overnight at 6oC. The dialyzed RNA 
was speed-vacced to dryness and dissolved again in sterile H2O (1 ml). A UV260 
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absorbance was measured to calculate the final concentration of the BIV TAR RNA. 
The BIV TAR solution of 0.9 µM was prepared. 
Gel retardation assay . For each RNA-peptide binding reaction, a peptide at 
different dilutions was mixed in a sterile Eppendorf tube with 5 µl of assay buffer 
(100 µl contains: Tris (0.5 M, pH=8.0, 10 µl), KCl (0.5 M, 10 µl), DTT (1 M, 20 µl), 
tRNA (E. coli, 10 mg/ml, 0.28 µl), Triton X-100 (10%, 2 µl), sterile H2O (48 µl) and 
RNA stock solution (10 µl)). The mixture was incubated in ice for 30 min. Then, a 
native loading dye (5 µl, 10% glycerol, 0.1% bromophenol blue, 0.1% xylene cyanol) 
was added to each binding reaction, vortexed, centrifuged and loaded on a 0.4 mm, 
12% native gel (prepared from sterile H2O (30 ml), acrylamide:bisacrylamide (29:1, 
40%, 16.25 ml), TB [10x (890 mM Tris-base, 890 mM boric acid), 25 ml], Triton X-
100 (10%, 0.5 ml), APS (0.1 g/ml, 0.5 ml) and TEMED (500 µl)). The gel should be 
left for at least 6 h to polymerise before electrophoresis. The native gels were run at 
500 V, 150 mA, 15 Watts, at 4oC for 3.5 h. Then, they were dried at 70oC for 30 min, 
exposed on a phosphor image screen overnight and scanned on a phosphor scanner. 
The autoradiograms were analysed with Image Quant 5.0. 
 
 
5.4. NMR analysis of peptides 
 
Data collection and analysis. 1D and 2D spectra were recorded at 600 MHz on 
a Brucker DRX-600 or Bruker AV-600 spectrometer, or at 700 MHz on a Bruker AV-
700 spectrometer. Typically the spectra were recorded at a peptide concentration of 8 
mg/ml or (if less) with the maximum material available. The solvent systems used 
were H2O/D2O 9:1 pH=2.3 or D2O pH=2.3. The pH (uncorrected for isotope effect) 
for aqueous solutions was adjusted with 0.01 M solution of HCl or NaOH in 
H2O/D2O 9:1. Water suppression was performed by presaturation using a power level 
of 5dB for the suppression. Spectral assignments were based on DQF-COSY, TOCSY 
and NOESY or ROESY spectra. Distance restraints were obtained from NOESY 
spectra with a mixing time of 250 ms. Spectra were typically collected with 1024x256 
complex data points zero-filled prior to Fourier transformation to 2048x1024, and 
transformed with a cosine-bell weighting function. Data processing was carried out 
with TOPSPIN-NMR (Bruker) and XEASY.205 The chemical shift values are given in 
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ppm relative to internal sodium 3-trimethylsilyl(2,2,3,3-D4)propionate (TSP). The 
coupling constants J are given in Hz. 
Structure calculations. To derive NOE distance restraints, it was assumed that 
the initial rate approximation is valid and that each peptide rotates as a single isotropic 
rotor. The NOEs were determined from NOESY spectra measured with mixing times 
of 250 ms for all the peptides in H2O/D2O 9:1 and D2O, at temperatures of 298 and 
278 K (to resolve C"H-1"2 NOE cross-peaks close to the water signal). Cross-peak 
volumes were determined by integration using XEASY software. The relative cross-
peak volumes were assumed to be proportional to r-6 and were used to derive distance 
restraints. The structure calculations were performed using the program DYANA, 
which is based on restrained molecular dynamics in torsion angle space.100 Starting 
from 100 randomised conformations a bundle of 20 conformations are selected, which 
have the lowest DYANA target energy function. The program MOLMOL was used 
for structural analysis and visualisation of the molecular models.101 
H" chemical shifts relative to random coil chemical shifts. The differences 
between the C"H chemical shift values determined experimentally on the bases of 1H 
NMR recorded at 298K in H2O/D2O 9:1 for each peptide and the random coil values 
were calculated following the protocol from Maynard and Griffiths-Jones.102,103 
H-D exchange experiments.  The dry sample of the peptide (8-10 mg/ml, ~ 
4.5 mM) was dissolved in a solution of D2O. The experiments were carried out at 298 
K. The first 1H NMR spectrum was recorded immediately after dissolving, and then 
the spectra were recorded every 3 min for the first hour, then after every 5 min for the 
second hour, then after every 15 min for the next 2 h. Then up to 24 spectra were 
recorded every one hour. If necessary measurements were repeated once a day until 
all the signals disappeared. The intensity of each signal was normalized relative to the 
corresponding value for a non-exchangeable peak for each data set. First order rate 
constants, were calculated following the protocol of Seebach et al.206 {gradient of the 
plot: ln[I(NHexchangeable)/I(NHnon-exchangeable) vs time } 
The temperature dependence of amide proton chemical shifts. 1H 1D and TOCSY 
NMR spectra were recorded for peptides at a concentration of 8-10 mg/ml in 
H2O/D2O 9:1 (pH=2.3) using at least 6 different temperatures in the range of 278-
328K.  
 
 
 Experimental Part -153- 
 
5.5. Cell up-take studies 
 
 
5.5.1. Materials 
 
HeLa cells were obtained from the American Type Culture Collection ATCC 
(Rockville, MD). RPMI 1640 Medium with GlutaMax, foetal calf serum (FCS), 
trypsin-EDTA (10x), penicillin-streptomycin, sodium pyruvate (100mM), HEPES 
buffer (1M, pH 7.4) and Dulbecco's phosphate-buffered saline (D-PBS, pH 7.4) 
without calcium and magnesium were purchased from Gibco® (Invitrogen). Hoechst 
33342, DAPI were from Molecular Probes (Leiden, The Netherlands). Dako 
fluorescent mounting medium was purchased from DAKO Corp. (Carpinteria, CA). 
5(6)-Carboxyfluorescein was from Fluka (Buchs, Switzerland), and 5(6)-
Carboxyrhodamine was obtained as Rhodamine WT from Abbey Color (Philadelphia, 
PA), as a 20% aq. sodium salt solution. This solution was acidified and the acid form 
was purified on reverse-phase HPLC. Cell culturing flasks (75 cm2) and 24-well 
plates were from TPP (Trasadingen, Switzerland). Round coverslips (no.1.5) were 
purchased from Hecht (Glaswarenfabrik Karl Hecht, Germany) and microscope slides 
and squared cover glasses were obtained from Menzel (Braunschweig, Germany).  
 
5.5.2. Cell culture 
 
HeLa cells were cultured as exponentially growing subconfluent monolayers at 37oC 
under 5% CO2. The cell culture was in 75 cm
2 culture flasks in RPMI 1640 medium 
(high glucose) supplemented with 10% heat-inactivated FCS, 1% 
penicillin/streptomycin, 1% HEPES (1 M, pH=7.4), and 1% sodium pyruvate 
(100 mM). The medium was exchanged two times per week. Exponentially growing 
HeLa cells were seeded at a constant density of about 5-8x104 cells/cm2 on glass 
cover glasses (12 mm) in 24-well plates. For experiments, cells were used 24 h post-
seeding.  
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5.5.3. Confocal laser scanning microscopy (CLSM) 
 
HeLa cells were seeded on coverslips in 24-well plates as described above. The 
culture medium was discarded, and the cells were washed three times with D-PBS 
(pH 7.4). The cell monolayer was incubated for 30 min at 37oC with the peptides 
dissolved in the medium at the appropriate concentration. Subsequently, cells were 
washed three times with PBS and incubated with Hoechst 33342 for nuclear staining. 
Cells were washed three times with PBS and inspected immediately in a medium 
solution without any fixation. For the fixed cells, the protocol was the same except for 
the incubation with Hoechst 33342, which was omitted. The cells were fixed using a 
solution of 2% formaldehyde/3% sucrose (v/v) in PBS for 5 min at rt. After fixation, 
cells were incubated for 5 min with DAPI for nuclear staining, washed three times 
with PBS and mounted with the fluorescent mounting medium. The distribution of 
fluorescence was analysed using a high-resolution TCS-SP2 laser scanning confocal 
microscope (Leica Microsystems, Mannheim, Germany) with a 63!, 1.4 NA plan 
apochromatic lens using HeNe 594 nm, HeNe 543 nm, Ar 488 nm, and Ar UV 
405 nm lasers. To avoid cross talk, emission signals were collected independently. 
Image processing was performed using IMARIS software (Bitplane AG, Zurich, 
Switzerland).  
 
5.5.4. Peptide synthesis 
 
A selection of fluorescently labelled peptides was prepared for the up-take studies 
(Table 46). 
 
Peptide 
 
Sequence 
 
Origin of the 
peptide 
 
Fl-BIV-Tat Fl-SGPRPRGTRGKGRRIRRK-NH2 BIV Tat protein 
Rh-BIV-Tat H-SGPRPRGTRGKGRRIRRK[Rh]-NH2 BIV Tat protein 
Fl-HIV-Tat Fl-GRKKRRQRRRPPQ-NH2 HIV Tat protein 
Rh-BIV2h cyclo(RVRTRGKRRIRVDP[Rh]P) BIV library 
Fl-BIV2h cyclo(RVRTRGKRRIRVDP[Fl]P) BIV library 
Rh-L1-07h cyclo(RTRTRGKRRIRVDP[Rh]P) L1 library 
Fl-L1-07h cyclo(RTRTRGKRRIRVDP[Fl]P) L1 library 
Fl-Ac-BIV2h cyclo(RVRTRGKRRIRVDP[Fl-Ac]P) BIV library 
Fl-Ac-L1-07h cyclo(RTRTRGKRRIRVDP[Fl-Ac]P) L1 library 
Table 46. Fluorescently labelled peptides synthesized for this study. Fl=5(6)-carboxyfluorescein, 
Rh=5(6)-carboxyrhodamine; Fl-Ac= 5(6)-carboxyfluorescein diacetate, h=indication that the peptide 
contains the 4-hydrazino-D-Pro in the template.  
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• Synthesis of Rh-BIV-Tat 
 
H-Ser65-Gly-Pro-Arg-Pro-Arg-Gly-Thr-Arg-Gly-Lys-Gly-Arg-Arg-Ile-Arg-Arg-
Lys82(Rh)-NH2 
 
Rink amide resin (Novabiochem) (0.6 mmol/g) was used for the synthesis of 
the linear peptide. The chain assembly was performed using an ABI433A peptide 
synthesizer on a 0.25 mmol scale using the standard SPPS protocol described in 
Paragraph 5.2. For Lys82 Fmoc-Lys(Alloc)-OH was used. After completion of the 
synthesis, without removing the Fmoc-group on Ser65, the resin was washed with 
DCM and DMF. Alloc removal from Lys82 was carried out using Pd(PPh3) (1 eq), 
PhSiH3 (60 eq) in dry DCM (15 ml) under argon for 3 h. After completion of the 
reaction, the resin was washed with DCM and DMF several times. 5(6)-Carboxy-
rhodamine (1.5 eq) was coupled overnight manually to the free side chain amine 
group of Lys82 using HATU/HOAt (1.5 eq) and DIEA (6 eq) in dry DMF (20 ml).  
 The Fmoc-group of the N-terminus of the peptide was removed under 
standard conditions: 20% piperidine in DMF twice for 20 min. Cleavage of the 
peptide from the resin and deprotection was performed using standard conditions 
(cleavage cocktail TFA:H20:TIPS, 95:2.5:2.5) for 4 h. The reaction mixture was then 
evaporated almost to dryness and the fully deprotected peptide was precipitated by 
addition of ice-cold ether. The resulting crude material was purified by PR-HPLC 
(Vydac 218TP1022 C18 column, gradient 10-60% MeCN in H2O + 0.1%TFA) to give 
the fully deprotected linear peptide. 
Rh-BIV-Tat: 12mg (6% yield), ESI-MS m/z [M+6H+] 427.4. 
 
 
• Synthesis of Fl-BIV-Tat and Fl-HIV-Tat 
 
Fl-BIV-Tat: Fl-Ser65-Gly-Pro-Arg-Pro-Arg-Gly-Thr-Arg-Gly-Lys-Gly-Arg-Arg-Ile-
Arg-Arg-Lys82-NH2 
Fl-HIV-Tat: Fl-Gly48-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln60-NH2 
 
Rink amide resin (Novabiochem) (0.6 mmol/g loading) was used for the 
synthesis of the linear peptides. The chain assembly was performed using an 
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ABI433A peptide synthesizer on a 0.25 mmol scale using the standard SPPS protocol 
described in Paragraph 5.2. 5(6)-Carboxyfluorescein-N-succinimidyl ester 
(0.11 mmol, 1.3 eq, Fluka), was coupled overnight to the resin in DMF with DIEA 
(10 eq). A final cleavage from the resin was performed using a solution containing 
95% TFA, 2.5% H2O, 2.5% TIPS for 4 h at rt. Evaporation and precipitation by ice-
cold ether gave the crude linear fully deprotected peptide. The peptides were purified 
by PR-HPLC (C18 column, Vydac 218TP1022, gradient 10-60% MeCN in H2O + 
0.1%TFA) and analysed by ESI-MS or MALDI-MS. 
Fl-BIV-Tat: 13mg, 6% yield, ESI-MS m/z [M+6H+]=409.1 
Fl-HIV-Tat: 68mg, 38% yield, MALDI-MS m/z [M+H+]=2189 
 
 
• Synthesis of BIV2h and L1-07h (peptides containing 4-hydrazino-D-Pro) 
 
BIV2h: cyclo(Arg-Val-Arg-Thr-Arg-Gly-Lys-Arg-Arg-Ile-Arg-Val-(4-NH2NH)DPro-Pro) 
L1-07h: cyclo(Arg-Thr-Arg-Thr-Arg-Gly-Lys-Arg-Arg-Ile-Arg-Val-(4-NH2NH)DPro-Pro) 
 
Chlorotrityl resin preloaded with L-Pro (0.52 mmol/g) was used for the 
synthesis of both peptides. The resin (0.25 mmol) was first swelled with DMF and 
then treated with 20% piperidine in DMF to remove the Fmoc protecting group. The 
first two couplings were performed manually (2 eq HATU/HOAt, 6 eq DIEA in 
DMF) and monitored by the chloranil test. The further chain elongation was 
performed sequentially on an ABI433A with an appropriately protected amino acid (4 
eq, extended coupling time), HBTU/HOBt for activation, DIEA as a base and NMP 
as a solvent. A solution of 20% piperidine in DMF was used for Fmoc-deprotection. 
After completion of the synthesis, the resin was washed with DCM and DMF and 
treated with 1% TFA in DCM (15 ml, 5 times). The filtrate was neutralized with 
DIEA and evaporated to dryness to yield the linear protected peptides. The peptides 
were then cyclized overnight at rt in DMF solution (10 mg/ml) with HATU/HOAt (3 
eq) and DIEA (10 eq). After evaporation of the DMF, the products were dissolved in 
DCM, washed with 10% MeCN in water and dried to give the crude cyclic protected 
peptides. The cyclic protected peptides were treated with a standard final cleavage 
cocktail at rt for 4 h. Evaporation and precipitation with ice-cold ether gave crude 
cyclic deprotected peptides. The peptides were purified by RP-HPLC (Zorbax Eclipse 
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XDB-C18 column, gradient 10-60% MeCN in H2O+ 0.1% TFA) and analysed by 
LC-MS: 
BIV2h: 155mg (35% yield), ESI-MS m/z (M+4H+) 440.7. 
L1-07h: 145mg (33% yield), ESI-MS m/z (M+4H+) 441.5. 
 
 
• Chemoselective labelling of BIV2h and L1-07h with 5(6)-
carboxyfluorescein, 5(6)-carboxyfluorescein-diacetate, and 5(6)-
carboxyrhodamine 
 
Each peptide BIV2h and L1-07h (~ 6 mg, 3.4 µmol) was dissolved in citrate 
buffer (0.5 ml, 50 mM, pH=5.0) and 5(6)-carboxyfluorescein-diacetate-succinimidyl 
ester (1.0 eq), 5(6)carboxyfluorescein-succinimidyl ester (1.0 eq) [both from Fluka] 
or 5(6)carboxyrhodamine-succinimidyl ester (1.0 eq) [freshly prepared with DIC and 
N-hydroxysuccinimide] dissolved in DMF (0.1 ml) was added to the solution. The 
reaction was stirred for 5 d at rt and its progress was followed by LC-MS. After 
completion the reaction mixture was frozen and lyophilised. The crude residue was 
dissolved in water and purification was performed on the RP-HPLC (semi-preparative 
Zorbax Eclipse, C18, gradient 10-90%MeCN in H2O+0.1%TFA) to give the desired 
product.  
Fl-BIV2h: 3.7 mg, 52% yield, MALDI m/z (M+H+) 2118. 
Fl-L1-07h: 4.2 mg, 59% yield, MALDI m/z (M+H+) 2120. 
Fl-Ac-BIV2h: 4.1 mg, 54% yield, MALDI m/z (M+H+) 2201. 
Fl-Ac-L1-07h: 3.9 mg, 52% yield, MALDI m/z (M+H+) 2203. 
Rh-BIV2h: 2.3 mg, 23% yield, MALDI m/z (M+H+) 2228. 
Rh-L1-07h: 2.9 mg, 38% yield, MALDI m/z (M+H+) 2230. 
 
 
5.6. Bacteriological experiments 
 
Materials.  For the preparation of all solutions and media, water was 
purified using an Elgastat® UHP-UF water purification system. Unless noted 
otherwise, all experiments with bacterial cultures were carried out in Difco™ Mueller 
Hinton broth (Becton Dickinson, Sparks, MD). For solid media Difco™ Mueller 
Hinton Agar (containing 17.0 g/l of agarose) was used. All media were prepared 
 Experimental Part -158- 
 
according to the manufacturer’s instructions and sterilised by autoclaving for 20 min 
at 121oC. The microorganisms used were Escherichia coli (ATCC 25922, 2138E, 
2139E, 2140E, 2143E, 2144E, 3459E), Pseudomonas aeruginosa (ATCC 27853, 
PAO1), Staphylococcus aureus (ATCC 29213, ATCC 25923) and Bacillus subtilis 
(Nr. 3256). 
 
Bacterial cultures.  Bacterial cultures were incubated at 37oC in conical 
flasks and agitated under orbital shaking at 200 rpm. Overnight bacterial cultures 
were inoculated with single colonies from agar plates freshly incubated overnight and 
used in turn to inoculate sterile Muller-Hinton broth, typically at ratio of ~1:100 (v/v). 
To estimate growth, the cell density was estimated photometrically via the turbidity 
of the bacterial cell suspensions at 600 nm with a UV/Vis spectrometer. For short 
term storage, bacterial strains were stored on Mueller Hinton agar plates at 4oC and 
were used to inoculate fresh agar plates weekly. For long term storage, bacterial 
cultures were stored in 30% glycerol solution at -80 oC. 
 
MIC determination.  The determination of MICs was carried out according to 
a standard protocol207 with modifications of Steinberg et. al.208 to account for 
unspecific adsorption of AMPs onto reaction vessel surfaces. Lyophilised AMPs were 
dissolved in 0.01% AcOH at a concentration of 1 mg/ml. For routine MIC 
determination, colony material from agar plates incubated freshly overnight was 
taken with an inoculation loop and transferred into aqueous NaCl (3 ml of 0.9%). The 
turbidity of the bacterial suspension was adjusted to McFarland standard 0.5, and 100 
µl of this bacterial suspension was transferred into Mueller Hinton broth (10 ml) 
supplement with 0.02% BSA. In 96-well microtitre plates, two-fold serial dilutions of 
AMPs were prepared in Mueller Hinton broth. The broth was supplemented with 
0.02% BSA and the final volume of each dilution was 50 µl. Finally, 50 µl of the 
bacterial suspension were used to inoculate the microtitre plates to give a final cell 
density of approximately 5x105 CFU/ml in a final volume of 100 µl in each well. 
Alternatively, for MIC determinations corresponding to higher cell density of the 
inoculum, overnight cultures of bacteria were diluted ~1:100 into fresh Mueller 
Hinton broth and incubated for 105 min under standard conditions to yield 
approximately 2x108 CFU/ml (for P. aeruginosa PAO1). These bacterial suspensions 
were then used to inoculate the two-fold series of dilutions of test compounds, which 
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were prepared in Mueller Hinton broth supplemented with 0.04% BSA. The 
microtitre plates were covered and incubated overnight at 37oC in an orbital shaker at 
200 rpm. The MIC is determined by visual inspection as the minimum concentration 
at which no visible growth occurs after 18 to 20 h of incubation and it is expressed in 
µg/ml.  
 
Haemolytic activity.  The haemolytic activities of AMPs and a control 
compound (protegrin-1, PG-1) against human red blood cells (hRBCs) were tested by 
a photometric assay. Fresh hRBCs were washed with PBS and centrifuged three times 
for 10 min at 2000 g. Test compounds at concentrations of 100 µg/ml were incubated 
with 20% (v/v) of hRBCs (final erythrocyte concentration of ~0.9x109/ml) at 37oC for 
one hour. The samples were centrifuged at 2000 g, the supernatant was diluted 
twenty-fold in PBS, and the optical density was measured at 540 nm. The values 
corresponding to 0% and 100% lysis were determined by incubation of hRBCs with 
PBS or 0.1% Triton X-100 in water, respectively. The OD540nm corresponding to 
100% lysis typically ranges from 1.6 to 2.0 and the haemolytic activity obtained for 
the test compounds is expressed as a percentage relative to the 100% value. 
 
 
5.7. Proteolytic stability 
 
5.7.1. Trypsin digestion assay 
 
Materials. A standard procedure was conducted in Tris buffer (50 mM, pH=8.0) 
containing 10 mM CaCl2 (assay buffer). Trypsin (from Bovine Pancrease, 
13500 BAEE units/mg solid) was purchased from Sigma-Aldrich. BAPNA (benzoyl-
Arg-p-nitroanilide) was purchased from Fluka. DL-Tryptophan, an internal control for 
HPLC integration, was obtained from Fluka. An analysis of the assay mixture was 
performed by analytical RP-HPLC (Agilent Zorbax Eclipse XDB-C18, 5 µm, 4.6x250 
mm, gradient 10-50%, 6CV, MeCN in H2O+0.1%TFA).  
 
Trypsin activity. Trypsin activity was tested by the method published first by F. 
Erlanger et al.124 and modified by C.Temporini et al.125 and L. Ocampo and J.M. 
Ezquerra.209 BAPNA (43.5 mg) was dissolved in DMSO (1 ml) and the solution was 
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diluted to 100 ml with assay buffer to give a 1 mM stock solution. To BAPNA 
(2.5 ml, 1 mM) was added water (0.5 ml) and the mixture was allowed to equilibrate 
in a thermostatically controlled bath at 25oC. At zero time, 50 µl of trypsin solution 
(0.1 mg/ml in 1 mM HCl) was added, and the reaction was allowed to run for 1800 
sec (the UV absorption at 410 nm was collected every second). A suitable control 
without enzyme was also used. The reaction was terminated by addition of 30% acetic 
acid (0.5 ml). The controls showed no self-hydrolysis of substrate. The BAPNA-unit 
(U) of trypsin activity is defined as the amount of enzyme that hydrolyses 1 µmol of 
substrate per minute at pH=8.0. The BAPNA-units of assayed trypsin were calculated 
by means of a calibration curves in which UV410nm was plotted against concentration 
of released p-nitroaniline (p-NA). The *A410nm/min from the fitted curves was used in 
following equation: 
U (µmol/min)= *A410nm/min x 1000 x reaction volume (ml) 
8800 x mg of protein 
 
where 8800 is the extinction coefficient of p-NA at 410nm. The average trypsin 
activity was found to be 0.4023 U. 
 
Trypsin digestion assay.  A standard procedure was conducted at 37oC in 
Tris buffer. A solution of trypsin (1 mg/ml) in 1 mM HCl was prepared, and then 
diluted 10x with the assay buffer. A typical experiment was performed by adding of 
trypsin solution (20 µl, 0.1 mg/ml in the assay buffer) to a solution of peptide (300 µl, 
1mg/ml in H2O), followed by addition of tryptophan (300 µl, 0.5 mM in the assay 
buffer) and the assay buffer (380 µl) to obtain a final reaction volume of 1 ml. At the 
time points (typically 0, 1, 2, 5, 10, 15, 30, 60, 120, 240 min) 100 µl of the reaction 
mixture was removed and the trypsin was inactivated by addition of 30% AcOH/H2O 
solution (50 µl). Samples were analysed by RP-HPLC with integration of the peptide 
and tryptophan peaks. 
 
5.7.2. Plasma stability studies 
 
Materials. Human plasma was obtained from Basler Blutspendedienst, and mouse 
plasma from Harlan Sera Lab, UK. The 1 mM peptide solutions were prepared from 
lyophilised samples in water. Assays were performed at 37oC in PBS buffer, pH=7.4. 
To terminate the assay, the assay solution was transferred to Millipore Filtration 
 Experimental Part -161- 
 
Plates (MSRPN0410) filled with acetonitrile (HPLC-grade, +2% Formic Acid) and 
then filtered. For this, the Millipore MultiScreen HTS Vacuum Manifold 
(MSVMHTS00), Deep Well Collar (MSVMHTS0D) and Millipore Receiver Plates 
PP (MDCPN2M50) were used. 
Plasma stability assay. The peptide solution (35 µl, 0.1 mM in PBS) was added 
to freshly thawed plasma (315 µl), and incubated at 37oC. At five time points (0, 15, 
30, 60, 120, 240 min), 50 µl of the reaction mixture was transferred into filtration 
plate wells containing 150 µl of MeCN. After 2 min of shaking (700 rpm) on a 
microplate shaker, the plate was placed on a Millipore receiver plate and a vacuum of 
~-50 cmHg was applied until the filtration was completed. 100 µl of the filtrate was 
transfered to the microtiter plate and was subjected to LC-MS analysis. The assays 
were completed in triplicate. 
Assay assessment. The peak area counts from LC-MS analysis are used for 
the calculations. The triplicate values were averaged, unless obvious deviations were 
observed (and disregarded from calculations). The stability is expressed as a percent 
remaining after the initial time point 0 min (100% x Tx/T0) and plotted graphically 
over time. Using Excel, the data are used to determine t1/2 and a T240 min parameter 
(the fitted amount of peptide remaining after 240 min). 
 
 
5.8. Circular dichroism spectra measurements 
 
CD spectra were recorded on a Jasco J-715 spectropolarimeter (Jasco, Tokyo, Japan) 
at 25oC. A cylindrical, thermostated, quartz cell with 0.1 cm path length was used for 
measurements. The peptides were dissolved in PBS (10 mM, pH=7.4) to obtain a 
peptide concentration of approximately 20-30 µM. For further investigations, accurate 
concentrations were determined by amino acid analysis. Far-UV CD experiments 
were carried out in the wavelength range of 185 to 250 nm. Five scans were averaged 
for each sample, and the blank was subtracted from all spectra. The sample solutions 
were stored at rt for 30 min before measurements. The results are expressed as the 
mean residue ellipticity (') with units of degrees cm2 dmol"1. Other experimental 
settings were 5 nm/min scan speed, 2.0 nm band width, and 2 sec response time. 
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5.9. Synthesis of Fmoc-N,N’-di-Boc-L-homoarginine (Fmoc-
hArg(Boc)2-OH) 
 
N, N’-Bis(tert-butoxycarbonyl)-guanidine (18). 1,4-Dioxane (50 ml) was added to 
a solution of guanidine hydrochloride (2.39 g, 25 mmol) and sodium hydroxide (4.0 g, 
0.1 mol) in water (25 ml) and the resulting mixture was cooled to 0oC. Di-tert-butyl 
pyrocarbonate (12.0 g, 55 mmol) was added in one portion and the reaction mixture 
was allowed to warm to rt within 2 h. After stirring for 14 h (overnight) the mixture 
was concentrated in vacuo to one third of its original volume. The resulting 
suspension was diluted with water (50 ml) and extracted three times with ethyl 
acetate. The combined extracts were washed with 10% citric acid, water and brine, 
and dried over magnesium sulfate. After filtering and removal of the solvent under 
reduced pressure the crude product was purified by flash chromatography on silica gel 
(eluent: first DCM 100%, then DCM:MeOH 97:3). N, N’-Bis(tert-butoxycarbonyl)-
guanidine (4.2 g, 64%) was obtained as a colourless powder, m.p.=139-141oC (lit. 
m.p.14497); Rf=0.34 (DCM:MeOH 97:3); 
1H NMR (300 MHz, DMSO-d6) 10.5-10.0 
(broad s, 1H), 8.5-8.3 (broad s, 2H), 1.39 (s, 18H); ESI-MS: m/z [M+Na+] 282.1. 
 
N,N’-Di-Boc-N’’-trifluoromethanesulfonylguanidine (19). A solution of N, 
N’-bis(tert-butoxycarbonyl)-guanidine, (18) (1.8 g, 6.95 mmol) and triethylamine 
(1.16 ml, 6.8 mmol) in anhydrous DCM (25 ml) was cooled to –78oC under an 
atmosphere of Ar. Triflic anhydride (1.12 ml, 6.8 mmol) was added dropwise at such 
a rate that the reaction temperature did not exceed –65oC. When the addition was 
complete, the mixture was allowed to warm to rt within 4 h. The solution was washed 
with 1M sodium bicarbonate and water, and dried with magnesium sulfate. After 
filtering and removal of the solvent under reduced pressure the crude product was 
purified by flash chromatography on silica gel (eluent: DCM 100%). N,N’-di-Boc-
N’’-Trifluoromethanesulfonylguanidine (1.74 g, 65%) was obtained as a white 
powder, m.p.=117-119oC (lit. m.p.=11597); Rf=0.71 (DCM 100%); 
1H NMR (300 
MHz, DMSO-d6) 11.0 (broad s, 1H), 1.4 (s, 18H); 
13C NMR (75 MHz, CHCl3) 154.3, 
152.7 (C=O urethane, Boc), 83.2 (C(CH3)3), 27.4 (C(CH3)3). ESI-MS: m/z [M+Na
+] 
314.1. 
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Fmoc-N,N’-di-Boc-homoarginine (20). Fmoc protected lysine (393 mg, 1.07 
mmol) was suspended in anhydrous DCM (25 ml) under Ar. To the amino acid 
suspension triethylamine (178 µl, 1.28 mmol) was added followed by addition of 
N,N’-di-Boc-N’’-trifluoromethanesulfonylguanidine (500 mg, 1.28 mmol). The 
reaction was stirred overnight at rt, then another portion of Fmoc-Lys-OH (100 mg) 
was added to ensure completeness of the reaction. After 12 h, the reaction mixture 
was washed with 1M citrate buffer (pH=5.0) and brine, and dried over magnesium 
sulfate. After filtering and removal of the solvent under reduced pressure the crude 
product was purified by flash chromatography on silica gel (eluenting first with 
AcOEt:Hexane 1:1 + 1% AcOH, then 99.5% AcOEt+0.5% AcOH). Fmoc-N,N’-di-
Boc-homoarginine was obtained as a white powder, m.p.=79-83oC (decomposition) 
(lit. m.p.=155210); Rf=0.23 (99.5% AcOEt + 0.5% AcOH); "
25
D= +2.0 (c 0.04, 
MeOH); 1H NMR (300 MHz, CDCl3) 8.80 (broad s, 1H, NH), 7.85 (d, J 7.8 Hz, 2H, 
Fmoc), 7.69 (d, J 7.8 Hz, 2H, Fmoc), 7.38 (t, J 7.4 Hz, 2H, Fmoc), 7.30 (t, J 7.4 Hz, 
2H, Fmoc), 5.60 (broad d, J 8.2 Hz, 1H, NH), 4.40 (d, J 7.9 Hz, 2H, -OCH2-(Fmoc)), 
4.35 (m, 1H, CH"), 4.25 (t, J 7.9 Hz, 1H, CH(Fmoc)), 3.30-3.45 (m, 2H, CH2(&)) 
1.85-1.98 (m, 2H, CH2(!)), 1.65 (m, 2H, CH2(+)), 1.49 (s, 3H, CH3), 1.47 (s, 3H, 
CH3), 1.45-1.55 (m, 2H, CH2(.));); 
13C NMR (75MHz, CHCl3) 176.2 (C=O acid), 
163.2 (C=N), 157.2 155.3, 152.7 (C=O urethane, Boc, Fmoc), 144.6, 142.2, 128.6, 
128.0, 126.0, 120.8 (aromat, Fmoc) 84.2, 80.7 (C(CH3)3), 67.0 (-OCH2-(Fmoc), 50.5 
(CH(Fmoc), 40.5 (C"), 33.2 (C&), 31.2 (C+), 29.8 (C.), 29.1-28.9 (C(CH3)3), 22.5 (C!). 
ESI-MS: m/z [M+H+] 611.7. 
 
 
5.10. Synthesis of (2R,4S)-4-[N,N,N’-tris-(tert-butyloxycarbonyl)]-
hydrazine-1-[(9H-fluoren-9-yl)-metoxycarbonyl]-proline 
 
(2R,4R)-N-Benzyloxycarbonyl-4-hydroxyproline (21). To a cooled solution 
(ice/water bath) of (2R,4R)-hydroxyproline (10 g, 60.4 mmol) in 1M NaOH (70 ml) 
and THF (60 ml), a solution of benzyl chloroformate (1.25 eq, 11.4 ml, 75.5 mmol) in 
THF (60 ml) was added, followed by addition of 1M NaOH (70 ml). The reaction was 
allowed to reach rt and was stirred overnight. The reaction mixture was diluted with 
water and 1M NaOH (~100 ml) was added to pH=12. The aqueous layer was washed 
with diethyl ether (3 x 50 ml), acidified to pH~3 with concentrated HCl, and extracted 
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with ethyl acetate (3 x 75 ml). The combined organic layers were washed with water 
(40 ml), brine (40 ml) and dried over Na2SO4. The solvent was removed in vacuo to 
give a colourless oil which precipitated from ether/hexane to give a white powder 
(12.1 g, 76%). m.p.=107oC (lit. 110.5-111.5 oC211), Rf=0.1 (AcOEt/Hexane 1:1); 
"25D=+42.1
o (c 0.05, MeOH) (lit. ["]D=+26.3
211); 1H NMR (300 MHz, D2O) 7.3-7.45 
(5H, aromat), 5.12 (s, 1H, -OCH2-), 5.08 (d, J 6.2 Hz, 1H, -OCH2-) 4.4-4.5 (m, 2H, 
CH("), CH(.)), 3.55-3.7 (dd, J1 5.0 Hz, J2 11.0 Hz, 1H, CH(+)), 3.32-3.45 (t, J 12.0 
Hz, 1H, CH(+)), 2.35-2.55 (m, J 5.0 Hz, 1H, CH(!)), 2.05-2.15 (d, J 12.0 Hz, 1H, 
CH(!)); 13C-NMR (75 MHz, D2O): 176.0 (C=O acid), 155.9 (C=O urethane), 135.9, 
128.6, 128.2, 127.5 (aromat), 69.0 (C(.)), 67.5 (benzyl), 57.9 (C(")), 54.0 (C(+)), 37.3 
(C(!)). ESI-MS: m/z [M+H+] 266.2. 
 
(2R,4R)-N-Benzyloxycarbonyl-4-hydroxyproline benzyl ester (22).  To a 
solution of (2R,4R)-N-benzyloxycarbonyl-4-hydroxyproline (21) (12 g, 45.2 mmol) in 
DMF, anhydrous potassium carbonate (2 eq, 12.47 g, 135.6 mmol), sodium iodine 
(0.1 eq, 0.72 g, 4.6 mmol) and benzyl bromide (3 eq, 16.26 ml, 135.6 mmol) were 
added under nitrogen. The mixture was stirred overnight at rt. The reaction mixture 
was diluted with water (100 ml) and extracted with ethyl acetate (3x60 ml). The 
organic layers were combined and washed with water (50 ml), brine (50 ml) and dried 
over Na2SO4. The solvent was removed in vacuo and the crude product was purified 
by flash chromatography (30% AcOEt/Hexane) to give the desired product as a 
colourless oil (15.7 g, 98%), Rf=0.32 (AcOEt/Hexane 1:1); "
25
D=+19.8
o (c 0.01, 
MeOH) (lit. ["]D=+34.2 (0.5 MeOH)
212); 1H NMR (300 MHz, CHCl3) 7.25-7.45 
(10H, aromat), 5.0-5.3 (m, 4H, 2x -OCH2Ph), 4.4-4.52 (dd, J1 19.1 Hz, J2 10.9 Hz, 
1H, CH(.), 4.35 (broad s, 1H, (CH(")), 3.72 (t, J 12.7, 1H, CH(+)), 3.55-3.68 (td, J1 
3.6 Hz, J2 12.7 Hz, 1H, CH(+)), 2.30-2.55 (m, 1H, CH(!)), 2.05-2.12 (dd, J1 8.1 Hz, 
J2 12.7 Hz, 1H, CH(!)); 
13C-NMR(75MHz, CDCl3) 172.9 (C=O ester), 154.9 (C=O 
urethane), 128.0, 128.2, 128.3, 128.6, 128.8, 135.5, 135.8 (aromat), 69.3 (C.), 68.9, 
67.0 (-OCH2Ph), 58.0 (C"), 54.8 (C+), 38.3 (C!). ESI-MS: m/z [M+Na
+] 378.1. 
 
(2R,4R)-N-Benzyloxycarbonyl-4-O-(p-nitrophenylsulfonyl)-proline benzyl ester 
(23). To a cooled solution (ice/water bath) of (2R,4R)-N-Benzyloxycarbonyl-4-
hydroxyproline benzyl ester (17.7 g, 50 mmol) in DCM (150ml), NosCl (1.3 eq, 14.3 
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g, 65 mmol) and Et3N (1.5 eq, 10.4 ml, 75mmol) were added under nitrogen. The 
reaction was allowed to reach rt and was stirred overnight. The orange solution was 
extracted with 1M HCl (3 x 50 ml) and with saturated NaHCO3, (3 x 50 ml). The 
organic layers were combined and washed with water (50 ml), brine (50 ml) and dried 
over Na2SO4. The solvent was removed in vacuo and the crude product was purified 
by flash chromatography (AcOEt/Hexane 1:2) to give the desired product as a pale 
yellow oil (25.7 g, 96%). Rf=0.4 (AcOEt/Hexane 40:60); "
25
D =+26.3
o (c 0.1, CHCl3); 
1H NMR (300 MHz, CHCl3) 8.25-8.35 (t, J 9.0, 2H, Nos) 7.95-8.05 (dd, J1 3.6, J2 9.0, 
2H, Nos) 7.2-7.4 (10H, aromat), 5.05-5.35 (m, 5H, 2x -OCH2-, CH(.)), 4.55-4.7 (ddd, 
J1 2.7 Hz, J2 8.2 Hz, J3 25.5 Hz, 1H, CH(")), 3.75-3.85 (m, 2H, CH(+)), 2.4-2.6 (m, 
2H, CH(!)); 13C NMR (75MHz, CHCl3) 171.5 (C=O ester) 154.6 (C=O urethane), 
143.0, 135.9, 128.8, 128.5, 128.4, 127.9, 124.4 (aromat), 79.2 (C.) 67.5, 67.1 (-
OCH2Ph), 57.6 (C"), 52.1 (C+), 37.1 (C!). ESI-MS: m/z [M+Na
+] 563.2. 
 
(2R,4S)-N-Benzyloxycarbonyl-4-[N-(tert-butyloxycarbonyl)hydrazino]-proline 
benzyl ester (24). To a solution of (2R,4R)-N-benzyloxycarbonyl-4-O-(p-
nitrophenylsulfonyl)-proline benzyl ester (25.4 g, 47 mmol) in dioxane (180 ml), tert-
butylcarbazate (8 eq, 49.7 g, 376 mmol) was added. The reaction was refluxed for 40 
h. The solution was diluted with water (300 ml) and extracted with DCM (5 x 80 ml). 
The organic layers were combined and washed with water (50 ml), brine (50 ml) and 
dried over Na2SO4. The solvent was removed in vacuo and the crude product was 
purified by flash chromatography (eluting first with AcOEt/Hexane 1:3, then 
AcOEt/Hexane 1:2) as a preliminary purification and then by Kugelrohr distillation, 
(80oC, 0.1 atm) to give the desired product as a pale yellow oil (25.7 g, 96%). Rf=0.53 
(AcOEt/Hexane 3:4); "25D =+24.9
o (c 0.1, MeOH); 1H NMR (300 MHz, CHCl3) 7.1-
7.35 (10H, aromatic), 6.1-6.3 (broad d, J 31.8 Hz, 1H, NH), 5.05-5.2 (m, 2H,-OCH2-), 
4.95-5.05 (d, 2H, -OCH2-), 4.35-4.55 (m, J 10.9 Hz, 1H, CH(.)), 3.7-3.85 (m, 2H, 
CH("), NH), 3.4-3.6 (m, 2H, CH(+)), 2.1-2.2 (m, 1H, CH(!)), 1.9-2.0 (m, 1H, C(!)), 
1.4-1.5 (3x s, 9H, 3x CH3, Boc);
 13C NMR (75 MHz, CHCl3) 172.4 (C=O ester), 
156.8 (C=O urethane, Boc), 154.9, (C=O urethane, Bn), 136.5, 135.5, 128.4, 128.3, 
128.1, 128.0, 127.8 (aromat), 80.9 (C(CH3)3), 67.0, 66.8 (-OCH2Ph), 58.2 (C"), 57.9 
(C.), 50.9 (C+), 34.9 (C!), 28.2 (C(CH3)3). ESI-MS: m/z [M+Na
+] 492.2. 
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(2R,4S)-N-Benzyloxycarbonyl-4-[N,N,N’-tris-(tert-butyloxycarbonyl)-hydrazino]-
proline benzyl ester (25). To a solution of (2R,4S)-N-benzyloxycarbonyl-4-[N-
(tert-butyloxycarbonyl)-hydrazino]-proline benzyl ester (7 g, 15 mmol) in DCM 
(100ml), di-tert-butyl dicarbonate (5 eq, 16.4 g, 74.5 mmol), DMAP (0.5 eq, 0.91 g, 
74.5 mmol) and Et3N (5 eq, 4.7 ml, 74.5 mmol) were added. The reaction was stirred 
at rt for 4 h and its progress was followed by TLC. The solvent from the reaction 
mixture was removed in vacuo and the crude product was purified by flash 
chromatography (AcOEt/Hexane 1:3) to give the desired product as a yellowish oil 
(6.49g, 62%). Rf=0.34 (AcOEt/Hexane 1:3); "
25
D=+32.0
o (c 0.05, MeOH); 1H NMR 
(300 MHz, CHCl3) 7.2-7.5 (10H, aromatic), 5.0-5.3 (m, 2H, 2x -OCH2-), 4.65-4.8 (m, 
J 7.2 Hz, 1H, CH(")), 4.4-4.65 (ddd, J1 3.6, Hz, J2 9.1, Hz, J3 19.0 Hz, 1H, CH(.)), 
3.8-3.9 (m, 1H, CH(+)), 3.45-4.65 (m, 1H, CH(+)), 2.52-2.35 (m, 1H, CH(!)), 2.08-
2.15 (m, 1H, C(!)) 1.3-1.4 (27H, 9x CH3, Boc); 
13C NMR (75 MHz, CHCl3) 173.5 
(C=O, ester), 157.0 (C=O urethane, Boc), 153.0 (C=O urethane, Bn), 152.0 (C=O 
urethane Boc), 136.5, 135.5, 128.5-127.7 (aromat), 83.6, 81.7 (C(CH3)3), 67.0, 66.9 (-
OCH2Ph), 57.6 (C"), 56.3 (C.), 47.5 (C+), 33.2 (C!), 28.0-27.8 (C(CH3)3). ESI-MS: 
m/z [M+Na+] 692.3. 
(2R,4R)-N-Benzyloxycarbonyl-4-[N,N’-bis-(tert-butyloxycarbonyl)-hydrazino-proline 
was isolated as a minor product (2.6g, 31%).  
 
(2R,4S)-4-[N,N,N’-tris-(tert-butyloxycarbonyl)hydrazino]-proline (26).  To a 
solution of (2R,4S)-N-benzyloxycarbonyl-4-[N,N,N’-tris-(tert-butyloxycarbonyl)-
hydrazino]-proline benzyl ester (19.7 g, 29 mmol) in MeOH (300 ml), a spatula of 
10% Pd/C (~200 mg) was added. The mixture was stirred for 30 h under hydrogen. 
The catalyst was removed by filtration through celite and the solvent was removed in 
vacuo. The crude product was precipitated from AcOEt to give a white powder (9.7 g, 
75%). m.p.=204oC; Rf=0.185 (DCM:MeOH 9:1); "
25
D =+9.2
o (c 0.09, MeOH); 1H 
NMR (300 MHz, CHCl3) 4.45-4.55 (t, J 7.3 Hz, 1H, CH(.)), 4.32-4.4 (t, J 7.7 Hz, 1H, 
CH(")), 3.8-3.9 (dd, J1 7.4 Hz, J2 11.8 Hz, 1H, CH(+)), 3.45-3.55 (dd, J1 7.4 Hz, J2 
12.0, 1H, CH(+)) 2.4-2.5 (m, 2H, CH(!)) 1.35-1.55 (27H, 9x CH3); 
13C NMR (75 
MHz, CHCl3) 174.8 (C=O acid), 155.3, 155.2, 155.0 (C=O urethane, Boc), 84.2, 82.6 
(C(CH3)3), 59.6 (C"), 57.3 (C.), 47.1 (C+), 32.8 (C!), 28.0-27.8 (C(CH3)3). ESI-MS: 
m/z [M+H+] 446.2. 
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(2R,4S)-4-[N,N,N’-tris-(tert-butyloxycarbonyl)-hydrazine]-1-[(9H-fluoren-9-yl)-
metoxycarbonyl]-proline (27). To a solution of (2R,4S)-4-[N,N,N’-tris-(tert-
butyloxycarbonyl-)hydrazino]-proline, (9 g, 20 mmol) in DCM (150 ml), Fmoc-O-
succinimide (1.3 eq, 8.8 g, 26 mmol) and DIEA (2.2 eq, 7.2 ml, 44 mmol) were 
added. The reaction mixture was stirred overnight at rt. The solvent was removed in 
vacuo and the crude product was purified by flash chromatography 
(AcOEt/Hexane/AcOH 2:1/1%) to give a white powder (12.8 g, 72%). m.p.=89oC; 
Rf=0.46 (AcOEt/Hexane/AcOH 2:1/1%); "
25
D=+23.3
o (c 0.07, MeOH); 1H NMR (300 
MHz, MeOH) 7.70-7.78 (t, J 7.3 Hz, 2H, aromatic), 7.54-7.62 (t, J 7.3 Hz, 2H, 
aromatic), 7.29-7.37 (t, J 7.5 Hz, 2H, aromatic), 7.22-7.28 (t, J 7.5 Hz, 2H, aromatic), 
4.65-4.75 (m, 1H, CH(.)), 4.1-4.5 (m, 4H, CH("),-OCH2-(Fmoc), CH(Fmoc)), 3.55-
3.85 (m, 2H, CH(+)), 2.4-2.6 (m, 1H, CH(!)), 2.15-2.35 (m, 1H, CH(!)) 1.4-1.6 (27H, 
9x CH3); 
13C NMR (75 MHz, CHCl3) 174.3 (C=O acid), 155.3 (C=O urethane, 
Fmoc), 153.1, 150.7 (C=O urethane, Boc), 143.6, 141.1, 127.6, 127.0, 125.0, 119.9 
(aromat, Fmoc) 84.0, 82.0 (C(CH3)3), 68.2 (-OCH2-(Fmoc), 57.8 (C"), 56.4 (C.), 48.2 
(C+), 47.0 (CH(Fmoc)), 31.2 (C!), 28.0-27.8 (C(CH3)3). ESI-MS: m/z [M+Na
+] 690.3. 
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Appendix 1: Abbreviations 
 
AIDS ……………………………………………..…....acquired immunodeficiency syndrome 
AMP …………………………………………...…...……….…………...antimicrobial peptide 
AMPM ……………………...…………………………...……..antimicrobial peptidomimetics  
APS ...........................................................................................…………ammonium persulfate  
ARM ……………………………………………………………………..…arginine rich motif 
BIV ……………………………………………………………bovine immunodeficiency virus 
BSA ..........................................................................................................bovine serum albumin 
Boc ………………………………………………………………………tert-butyloxycarbonyl 
CD …………………………………………………………………………...circular dichroism 
CDK …………………………………………………………………cyclin dependent kinase 
CFU …………………...………………………………………………….colony forming units 
CTD ………………………………………………………………..carboxy terminal domain 
DCM ………………………………………………………………………….dichloromethane 
DIEA …………………………………………………...……………….diisopropylethylamine 
DMF ………………………………………………………….…….N,N-dimethylformamide 
DMSO …………………………………………………….……………….dimethylsulfoxide 
DNA …………………………………………………………………….deoxyribonucleic acid 
DQF-COSY ……………………………….double quantum filtered correlated spectroscopy 
dsRNA ……………………………………………….double stranded RNA-binding domain 
Fl ………………………………………………………...………………………….fluorescein 
EMSA …………………………………………………….electrophoresis mobility shift assay 
eq …………………………………………………………………………………….equivalent 
ESI …………………………..………………………………………….electrospray ionisation 
Fmoc ………………………………….………………….N-9H-fluoren-2-ylmethoxycarbonyl 
Fmoc-OSu ……………………………….N-(9H-fluoren-2-ylmethoxycarbonyl)succinimide 
HATU …….O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
HBTU ………….O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
HEPES ………………………………….4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIV ………………………………………………………….human immunodeficiency virus 
hnRNPs ………………………………………….heterogeneous ribonucleoprotein particles 
hnRNA ………………………………………………………….heterogeneous nuclear RNA 
HOAt …………………………………………………………1-hydroxy-7-azabenzotriazole 
 Appendix 1: Abbreviations -169- 
 
HOBt …………………………………………………………………1-hydroxybenzotriazole 
HPLC …………….…………………………………high performance liquid chromatography 
hRBC ………………………………………………………..……human red blood corpuscles 
Kd …………………………………………………………………………dissociation constant 
KH ………………………………………………………………………K-homology domain 
LC-MS ……………………………………………liquid chromatography-mass spectroscopy 
LTR ………………………………………………………………….……long terminal repeat 
MALDI ……………………………………………matrix-assisted laser desorption/ionisation 
MIC …………………………………………………………minimal inhibitory concentration 
MH broth/agar …………………………………………………….Mueller-Hinton broth/agar 
m.p. ………………………………………………………………………………melting point 
mRNA ………………………………………………………………………messenger RNA 
MS …………………………………………………………………………mass spectroscopy 
NHS ………………………………………………..…………………N-hydroxysuccinimide 
NMP …………………………………………………………………N-methylpyrrolidinone 
NMR ………………………………………………………………nuclear magnetic resonance 
NES ………………………………………………………………………nuclear export signal 
NOESY ………………………………………nuclear Overhauser enhancement spectroscopy 
NTPs …………………………………………………………………nucleotide triphosphate 
Pbf …………………………………………………pentamethyldihydrobenzofuran-5-fulfonyl 
PDB ………………………………..…………………………………………protein data base 
PEG ………………………………………………………………………polyethylene glycol 
PG-1 …………………...……………………………………………………………protegrin-1 
p-TEFb ……………………………………………positive transcription elongation factor b 
RBD ……………………………………………………………………RNA-binding domain 
Rev ………………………………………………………………………Regulator of Virion 
Rf ……………………….………………………………………………………reference factor 
Rh ...…………………………………………………………………………………rhodamine 
RNA …………………………………………………………………………...ribonucleic acid 
RNAi ………………………………………………………………………RNA interference 
RNP ………………………………………………………………………….ribonucleoprotein 
RP …………….…………………………………………………………………..reverse phase 
RRE ……………………………………………………………………..Rev response element 
RRM ……………………………….………………………………….RNA-recognition motif 
rRNA ..................................................................................................................ribosomal RNA 
RT ………………………………………………………….……………..reverse transcriptase 
rt …………………………………………………………………………….room temperature 
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SAR ……………………………………………………………..structure activity relationship 
siRNAs ………………………………………………………………small interfering RNAs 
SPPS ………….………………………………………………….solid phase peptide synthesis 
TAK ……………………………………………………………………..Tat-activated kinase 
TAR …………………………………………………………transactivator response element 
Tat ………………………..………………………………………transcriptional transactivator 
TEMED ……………………….…………………….N,N,N!,N!-tetramethyl ethylene diamine 
TF …………………………………………………………………………..transcription factor 
Tf …………………………………………………………………..trifluoromethane sulfonyl 
TFA ………………………………………………………………………trifluoroacetic acid 
TIPS ………………………………………………………………………..triisopropylsilane 
THF …………………………………………………………...……………….tetrahydrofuran 
TLC ……………………………………………….………………..thin layer chromatography 
tRNA ………………………………………………………………………..transporter RNA 
TOCSY ………………………..……………………………………..totally correlated spectra 
Tris …………………………………………………….tris-(hydroxymethyl)-aminomethane 
Trt …………………………………………………………………………………………trityl 
wt ……………………………………………………………………………………wild type 
ZnF ………………………………………………………………………………….zinc finger 
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Table 47. Summary of the HPLC and MS analytical data of BIV Tat peptidomimetics. Amino acids 1 
and 12 are attached to a D-Pro-L-Pro template (with an exception for wt BIV Tat). MWcalc.= 
theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc. 
m/z ESI-MS 
 
MW 
obser. 
ES-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
wt BIV 
Tat 
                         Ac-SGPRPRGTRGKGRRIRR-NH2 2004.3 669.2[M+3H]3+ 
502.1[M+4H]4+ 
2004.4 5.87* 
BIV-2 R V R T R G K R R I R V 1729.1 577,6[M+3H]3+ 
433,7[M+4H]4+ 
1729,8 7,33* 
L1-01 R V R T R G K R R I R L 1743.2 581.8[M+3H]3+ 
436.7[M+4H]4+ 
1742.4 4.57** 
L1-02 R V R T R G K R R I R I 1743.2 581.8[M+3H]3+ 
436.8[M+4H]4+ 
1742.4 4.39** 
L1-03 R V R T R G K R R I R F 1777.2 593.0[M+3H]3+ 
445.0[M+4H]4+ 
1776.0 4.68** 
L1-04 R V R T R G K R R I R T 1731.1 577.8[M+3H]3+ 
433.8[M+4H]4+ 
1730.4 3.55** 
L1-05 R V R T R G K R R I R N 1744.1 582.1[M+3H]3+ 
437.0[M+4H]4+ 
1743.3 3.32** 
L1-06 R V R T R G K R R I R R 1786.2 596.0[M+3H]3+ 
447.3[M+4H]4+ 
1785.2 3.36** 
L1-07 R T R T R G K R R I R V 1731.1 577.9[M+3H]3+ 
433.7[M+4H]4+ 
1730.7 4.04** 
L1-08 R N R T R G K R R I R V 1744.1 582.1[M+3H]3+ 
437.0[M+4H]4+ 
1743.3 4.07** 
L1-09 R V R T R G K R R L R V 1729.1 577.0[M+3H]3+ 
433.2[M+4H]4+ 
1728.0 4.28** 
L1-10 R V R T R G K R R X R V 1769.0 590.5[M+3H]3+ 
443.3[M+4H]4+ 
1768.5 4.87** 
L1-11 R V R T R G K R R F R V 1763.1 588.5[M+3H]3+ 
441.9[M+4H]4+ 
1762.5 4.36** 
L1-12 R V R T R G K R R Y R V 1779.1 593.8[M+3H]3+ 
445.8[M+4H]4+ 
1778.4 3.98** 
L1-13 R V R T R G K R R N R V 1730.1 577.4[M+3H]3+ 
433.5[M+4H]4+ 
1729.2 3.68** 
L1-14 R V R T R G K R R Q R V 1744.1 582.4[M+3H]3+ 
437.0[M+4H]4+ 
1744.2 3.62** 
L1-15 R V R Q R G K R R I R V 1756.1 586.4[M+3H]3+ 
440.1[M+4H]4+ 
1756.2 4.19** 
L1-16 R V R V R G K R R I R V 1727.1 576.4[M+3H]3+ 
432.6[M+4H]4+ 
1726.2 4.17** 
L1-17 R V R Y R G K R R I R V 1791.2 597.8[M+3H]3+ 
448.7[M+4H]4+ 
1790.4 4.07** 
L1-18 R V R K R G K R R I R V 1756.2 586.4[M+3H]3+ 
440.0[M+4H]4+ 
1756.2 4.18** 
L1-19 R V K T R G K R R I R V 1701.1 567.9[M+3H]3+ 
426.4[M+4H]4+ 
1700.7 4.04** 
L1-20 R V U T R G K R R I R V 1730.1 577.5[M+3H]3+ 
433.4[M+4H]4+ 
1729.5 4.10** 
L1-21 R V O T R G K R R I R V 1687.2 563.6[M+3H]3+ 
422.7[M+4H]4+ 
1686.8 5.79* 
L1-22 R V R T K G K R R I R V 1701.1 567.9[M+3H]3+ 
426.4[M+4H]4+ 
1700.7 4.07** 
L1-23 R V R T U G K R R I R V 1730.1 577.4[M+3H]3+ 
433.5[M+4H]4+ 
1729.2 4.08** 
L1-24 R V R T O G K R R I R V 1687.1 563.2[M+3H]3+ 
422.7[M+4H]4+ 
1686.6 4.07** 
L1-25 R V R T N G K R R I R V 1687.0 563.1[M+3H]3+ 
422.8[M+4H]4+ 
1686.3 4.09** 
L1-26 R V R T Q G K R R I R V 1701.1 567.9[M+3H]3+ 1700.7 4.04** 
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426.3[M+4H]4+ 
L1-27 R V R T I G K R R I R V 1686.1 562.8[M+3H]3+ 
422.5[M+4H]4+ 
1685.4 5.07** 
L1-28 R V R T L G K R R I R V 1686.1 526.9[M+3H]3+ 
422.5[M+4H]4+ 
1685.7 5.13** 
L1-29 R V R T Y G K R R I R V 1736.1 579.4[M+3H]3+ 
435.0[M+4H]4+ 
1735.2 4.72** 
L1-30 R V R T R G K K R I R V 1701.1 567.9[M+3H]3+ 
426.4[M+4H]4+ 
1700.7 4.01** 
L1-31 R V R T R G K U R I R V 1730.1 577.5[M+3H]3+ 
433.5[M+4H]4+ 
1729.5 4.16** 
L1-32 R V R T R G K O R I R V 1687.1 563.2[M+3H]3+ 
422.6[M+4H]4+ 
1686.6 3.98** 
L1-33 R V R T R G K N R I R V 1687.0 563.1[M+3H]3+ 
422.7[M+4H]4+ 
1686.3 4.26** 
L1-34 R V R T R G K F R I R V 1720.1 540.6[M+3H]3+ 
405.7[M+4H]4+ 
1618.8 5.10** 
L1-35 R V R T R G K Y R I R V 1736.1 579.4[M+3H]3+ 
435.0[M+4H]4+ 
1735.2 4.89** 
L1-36 R V R T R G K R K I R V 1701.1 567.9[M+3H]3+ 
426.4[M+4H]4+ 
1700.7 
 
4.12** 
L1-37 R V R T R G K R U I R V 1730.1 577.5[M+3H]3+ 
433.4[M+4H]4+ 
1729.5 4.26** 
L1-38 R V R T R G K R O I R V 1687.1 563.1[M+3H]3+ 
422.7[M+4H]4+ 
1686.3 4.36** 
L1-39 R V R T R G K R N I R V 1687.0 563.2[M+3H]3+ 
422.8[M+4H]4+ 
1686.6 4.12** 
L1-40 R V R T R G K R Q I R V 1701.1 567.9[M+3H]3+ 
426.4[M+4H]4+ 
1700.7 4.24** 
L1-41 R V R T R G K R R I K V 1701.1 567.9[M+3H]3+ 
426.5[M+4H]4+ 
1700.7 4.02** 
L1-42 R V R T R G K R R I U V 1730.1 577.4[M+3H]3+ 
433.4[M+4H]4+ 
1729.2 4.24** 
L1-43 R V R T R G K R R I O V 1687.1 563.1[M+3H]3+ 
422.7[M+4H]4+ 
1686.3 3.99** 
L1-44 R V R T R G K R R I N V 1687.0 563.1[M+3H]3+ 
422.7[M+4H]4+ 
1686.3 4.26** 
L1-45 R V R T R G K R R I Q V 1701.1 567.8[M+3H]3+ 
426.4[M+4H]4+ 
1700.4 4.30** 
L2-01 R V R T R G K R R I R I 1743.2 581.8[M+3H]3+ 
436.8[M+4H]4+ 
1742.4 4.39** 
L2-02 U V R T R G K R R I R I 1744.2 582.5[M+3H]3+ 
437.2[M+4H]4+ 
1774.5 7.84* 
L2-03 K V R T R G K R R I R I 1715.1 573.1[M+3H]3+ 
429.9[M+4H]4+ 
1715.6 7.60* 
L2-04 O V R T R G K R R I R I 1701.4 568.0[M+3H]3+ 
426.6[M+4H]4+ 
1701.0 7.38* 
L2-05 N V R T R G K R R I R I 1701.1 568.3[M+3H]3+ 
426.3[M+4H]4+ 
1701.9 7.67* 
L2-06 Q V R T R G K R R I R I 1715.1 572.7[M+3H]3+ 
429.8[M+4H]4+ 
1715.1 7.80* 
L2-07 Y V R T R G K R R I R I 1750.1 584.2[M+3H]3+ 
438.6[M+4H]4+ 
1749.6 9.03* 
L2-08 L V R T R G K R R I R I 1700.1 567.6[M+3H]3+ 
426.1[M+4H]4+ 
1699.8 9.38* 
L2-09 W V R T R G K R R I R I 1773.2 592.2[M+3H]3+ 
444.4[M+4H]4+ 
1773.6 9.98* 
L2-10 R Q R T R G K R R I R I 1772.2 591.9[M+3H]3+ 
444.2[M+4H]4+ 
1772.7 7.60* 
L2-11 R Y R T R G K R R I R I 1807.2 603.4[M+3H]3+ 
453.0[M+4H]4+ 
1807.2 7.42* 
L2-12 R W R T R G K R R I R I 1830.2 611.2[M+3H]3+ 
458.7[M+4H]4+ 
1830.6 7.49* 
L2-13 R L R T R G K R R I R I 1757.2 587.2[M+3H]3+ 
440.5[M+4H]4+ 
1758.0 7.73* 
L2-14 R V R T R N G R R I R I 1729.1 577.6[M+3H]3+ 
433.5[M+4H]4+ 
1729.8 7.04* 
L2-15 R V R T R K G R R I R I 1743.2 582.2[M+3H]3+ 1743.6 7.24* 
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436.8[M+4H]4+ 
L2-16 R V R T R G R R R I R I 1771.2 591.3[M+3H]3+ 
444.0[M+4H]4+ 
1770.9 7.20* 
L2-17 R V R T R G Y R R I R I 1778.2 593.8[M+3H]3+ 
445.7[M+4H]4+ 
1778.4 7.65* 
L2-18 R V R T R G Q R R I R I 1743.1 582.1[M+3H]3+ 
436.9[M+4H]4+ 
1743.3 7.36* 
L2-19 R V R T R G N R R I R I 1729.1 577.5[M+3H]3+ 
433.4[M+4H]4+ 
1729.5 7.26* 
L2-20 R V R T R G O R R I R I 1729.1 577.3[M+3H]3+ 
433.4[M+4H]4+ 
1728.9 7.55* 
L2-21 R V R T R G U R R I R I 1772.2 591.8[M+3H]3+ 
444.2[M+4H]4+ 
1772.4 7.99* 
L2-22 R V Q T R G K R R I R I 1715.1 572.5[M+3H]3+ 
429.9[M+4H]4+ 
1714.5 7.60* 
L2-23 R V N T R G K R R I R I 1701.1 567.8[M+3H]3+ 
426.3[M+4H]4+ 
1700.4 7.81* 
L2-24 R T R T R G K R R I R I 1745.1 582.8[M+3H]3+ 
437.6[M+4H]4+ 
1745.4 7.84* 
L2-25 R N R T R G K R R I R I 1758.1 587.1[M+3H]3+ 
440.7[M+4H]4+ 
1758.3 7.81* 
L2-26 R V R T R G K R R I O I 1701.1 568.1[M+3H]3+ 
426.4[M+4H]4+ 
1701.3 7.57* 
L2-27 R V R T R G K R R I K I 1715.1 572.8[M+3H]3+ 
430.0[M+4H]4+ 
1715.4 7.54* 
L2-28 R V R T R G K R K I O I 1673.1 559.2[M+3H]3+ 
419.4[M+4H]4+ 
1673.6 7.33* 
L2-29 R V R Q R G K R R I R I 1770.2 591.1[M+3H]3+ 
443.6[M+4H]4+ 
1770.3 7.53* 
L2-30 R V R V R G K R R I R I 1741.2 581.4[M+3H]3+ 
436.4[M+4H]4+ 
1741.2 7.49* 
L2-31 R V R Y R G K R R I R I 1805.2 603.0[M+3H]3+ 
452.3[M+4H]4+ 
1806.0 7.41* 
L2-32 R T R Q R G K R R I R I 1772.2 591.6[M+3H]3+ 
444.1[M+4H]4+ 
1771.8 7.53* 
L2-33 R T R T R G K R R I O I 1703.1 568.5[M+3H]3+ 
426.9[M+4H]4+ 
1702.5 7.73* 
L2-34 R T R T R G K R K I O I 1675.1 559.1[M+3H]3+ 
419.9[M+4H]4+ 
1674.3 7.31* 
L2-35 R T R Q R G K R R I O I 1730.1 577.9[M+3H]3+ 
433.7[M+4H]4+ 
1730.7 7.30* 
L2-36 R T R V R G K R R I O I 1701.1 568.5[M+3H]3+ 
426.4[M+4H]4+ 
1701.6 7.35* 
L2-37 R T R Y R G K R R I O I 1765.1 589.8[M+3H]3+ 
442.1[M+4H]4+ 
1764.4 7.30* 
L2-38 R V R T R G K R R F R I 1777.2 593.4[M+3H]3+ 
445.4[M+4H]4+ 
1777.2 7.64* 
L2-39 R T R T R G K R R F R I 1779.1 594.7[M+3H]3+ 
446.0[M+4H]4+ 
1800.0 7.78* 
L2-40 R T R T R G K R R F O I 1737.1 580.2[M+3H]3+ 
435.6[M+4H]4+ 
1737.6 7.30* 
L2-41 R V R Q R G K R R F O I 1762.2 588.4[M+3H]3+ 
441.6[M+4H]4+ 
1762.2 7.58* 
L2-42 R T R V R G K R K F O I 1707.1 570.0[M+3H]3+ 
428.1[M+4H]4+ 
1707.0 7.55* 
L2-43 R T R Y R G K R K F O I 1771.1 591.5[M+3H]3+ 
444.0[M+4H]4+ 
1771.5 7.50* 
* analytical column: Agilent, Zorbax Eclipse XDB-C18 4.6 x 250 mm (5 µm), 1 ml/min, 5CV, 10-90% 
MeCN in H2O +0,1%TFA; ** analytical column: Phenomenex, Jupiter Proteo 90A, 
2.0 x 50 mm(4 µm), 0,5 ml/min, 8 min, 5-60% MeCN in H2O +0,1%TFA 
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Table 48. Summary of the HPLC and MS analytical data of HIV Tat peptidomimetics. Amino acids 1 
and 12 are attached to a D-Pro-L-Pro template (with an exception for wt HIV Tat). MWcalc.= 
theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position Template MW 
calc 
m/z  
ESI-MS 
MWobs 
ES-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12 13-14     
wt HIV-1 
Tat 
Ac-SFTTKALGISYGRKKRRQRRRPPQGSQTHQVSLSKQ-NH2 4210.9 1404.4[M+3H]
3+
1054.0[M+4H]4+
4210.2 8.00 
L3-01 R V R T R K G R R I R I DR-LP 1802.2 601.5[M+3H]3+ 
451.5[M+4H]4+ 
1801.5 6.40 
L3-02 R V R T R K G R R R R I DP-LP 1786.2 893.7[M+2H]2+ 
596.5[M+3H]3+ 
1786.5 7.06 
L3-03 R C R T R K G R R R C I DP-LP 1735.2 868.6[M+2H]2+ 
579.4[M+3H]3+ 
1734.4 7.43 
L3-04 R V R T R R G R R I R I DP-LP 1771.2 886.4[M+2H]2+ 
592.0[M+3H]3+ 
1770.8 7.67 
L3-05 R C R T R K G R R K C I DP-LP 1707.1 854.3[M+2H]2+ 
569.7[M+3H]4+ 
1706.6 7.22 
L3-06 R V R T R hR G R R K R I DP-LP 1800.2 900.8[M+2H]2+ 
600.8[M+3H]3+ 
1799.6 7.10 
Analytical column: Agilent, Zorbax Eclipse XDB-C18 4.6 x250 mm (5 µm), 5CV, 1 ml/min; 10-90% 
MeCN in H2O +0,1%TFA 
 
Table 49 The HPLC and MS analytical data of L2-15a. 
Mimetic Position MW 
calc 
m/z 
MALDI 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12    
L2-15a Ac-R V R T R K G R R I R I-NH2 1608 1608.0 6.94 
Analytical column: Agilent, Zorbax Eclipse XDB-C18 4.6 x250 mm (5 µm), 5CV, 1 ml/min; 10-90% 
MeCN in H2O +0,1%TFA 
 
Table 50. Summary of the HPLC and MS analytical data of L2-15hR peptidomimetics [Single 
mutations of Arginine to homoArginine (hR) in L2-15 peptide]. Amino acids 1 and 12 are attached to a 
D-Pro-L-Pro template. MWcalc.= theoretical MW calculated from molecular formula, MWobs.=MW 
from MS. 
Mimetic Position MW 
calc 
m/z  
ESI-MS 
MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
L2-15hR01 hR V R T R K G R R I R I 1757.2 587.1[M+3H]3+ 
440.4[M+4H]4+ 
1757.6 15.46 
L2-15hR02 R V hR T R K G R R I R I 1757.2 587.0[M+3H]3+ 
440.4[M+4H]4+ 
1758.0 15.29 
L2-15hR03 R V R T hR K G R R I R I 1757.2 587.1[M+3H]3+ 
440.8[M+4H]3+ 
1758.3 15.01 
L2-15hR04 R V R T R K G hR R I R I 1757.2 587.1[M+3H]3+ 
440.8[M+4H]4+ 
1758.3 15.39 
L2-15hR05 R V R T R K G R hR I R I 1757.2 586.4[M+3H]3+ 
440.4[M+4H]4+ 
1756.2 15.22 
L2-15hR06 R V R T R K G R R I hR I 1757.2 586.4[M+3H]3+ 
440.4[M+4H]4+ 
1756.2 15.38 
Analytical column: Agilent, Zorbax Eclipse XDB-C18 4.6 x 250 mm (5 µm), 6CV, 1 ml/min; 10-50% 
MeCN in H2O +0,1%TFA 
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Table 51. Summary of the HPLC and MS analytical data of HIV Tat peptidomimetics [L4-Library]. Amino acids 1 and 16 (13/14) are attached to a D-Pro-L-Pro template. 
MWcalc.= theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z ES-MS MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16     
L4-01 R V R C R T R G K R R R C A R V 2203.7 552.1[M+4H]4+ 
442.0[M+5H]5+ 
2204.4 7.20 
L4-02 R V R C R Q R K G R A R C I R I 2201.7 551.5[M+4H]4+ 
441.5[M+5H]5+ 
2202.0 8.52 
L4-03 R V R C R K L K G Q T R C I R I 2160.7 721.4[M+3H]3+ 
541.5[M+4H]4+ 
2161.2 8.32 
L4-04 R V R C R K R DR G Q T R C I R I 2231.8 744.7[M+3H]3+ 
559.3[M+4H]4+ 
2231.1 8.63 
L4-05 R V R C R Q R G P G K R C I R I 2128.6 710.1[M+3H]3+ 
533.2[M+4H]4+ 
2128.8 7.93 
L4-06 R V R C R K Q G P G T R C I R I 2073.6 692.4[M+3H]3+ 
519.4[M+4H]4+ 
2074.2 7.91 
L4-07 R V R C R R K G P G Q R C I R I 2128.6 711.2[M+3H]3+ 
533.4[M+4H]4+ 
2129.6 7.48 
L4-08 R V R C R K R G P G Q R C I R I 2128.6 710.7[M+3H]3+ 
533.5[M+4H]4+ 
2129.1 7.93 
L4-09 R C R V R Q R K G R A R K I C I 2173.7 726.8[M+3H]3+ 
544.8[M+4H]4+ 
2175.2 7.99 
L4-10 R C R V R K Q G P G T R K I C I 2045.5 683.3[M+3H]3+ 
512.3[M+4H]4+ 
2045.2 7.61 
L4-11 R C R V R K Q G P G K R K I C I 2072.6 692.5[M+3H]3+ 
519.6[M+4H]4+ 
2074.4 7.96 
L4-12 R C R V R K R G P G Q R K I C I 2100.6 701.7[M+3H]3+ 
526.5[M+4H]4+ 
2102.0 7.70 
L4-13 R C R V R R K G P G A R K I C I 2043.6 682.5[M+3H]3+ 
511.9[M+4H]4+ 
2044.5 8.44 
L4-14 R V R C R K K G K C I R I    1790.3 597.8[M+3H]3+ 
449.4[M+4H]4+ 
1790.4 7.84 
L4-15 R V R C R R R G R C I R I    1874.4 625.9[M+3H]3+ 
470.1[M+4H]4+ 
1874.7 7.90 
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L4-16 R V R T R K K G K R I R I    1843.3 615.7[M+3H]3+ 
462.2[M+4H]4+ 
1844.1 7.62 
L4-17 R V R C R K K DP K C I R I    1830.4 611.5[M+3H]3+ 
459.1[M+4H]4+ 
1831.5 7.82 
L4-18 R V R T R K K DP K R I R I    1883.4 629.0[M+3H]3+ 
472.2[M+4H]4+ 
1884.0 7.54 
L4-19 R V R V R K K G R T I R I    1814.3 606.0[M+3H]3+ 
454.9[M+4H]4+ 
1815.0 8.37 
L4-20 R V R C R K R K G R C I R I   1974.5 659.6[M+3H]3+ 
494.9[M+4H]4+ 
1975.6 8.25 
L4-21 R V R C R R K R G R C I R I   2002.5 668.4[M+3H]3+ 
501.7[M+4H]4+ 
2002.2 8.29 
L4-22 R V R T R Q R K G R R I R I   2027.5 676.9[M+3H]3+ 
508.1[M+4H]4+ 
2027.7 8.10 
L4-23 R V R V R K R K G R Q I R I   1997.5 666.9[M+3H]3+ 
500.7[M+4H]4+ 
1997.7 8.25 
L4-24 R V R Q R K R K G R V I R I   1997.5 666.9[M+3H]3+ 
500.6[M+4H]4+ 
1997.7 8.02 
L4-25 R V R C R K R K DP R C I R I   2014.6 673.5[M+3H]3+ 
504.8[M+4H]4+ 
2015.2 8.25 
Analytical column: Agilent, Zorbax Eclipse XDB-C18 4.6 x 250 mm (5 µm), 6CV, 1 ml/min 10-50% MeCN in H2O +0,1%TFA 
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Table 52. Summary of the HPLC and MS analytical data of HIV Tat peptidomimetics [L5-Library]. Amino acids 1 and 16 are attached to a D-Pro-L-Pro template. MWcalc.= 
theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z ESI-MS MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16     
L5-01 R V R C R K R R G Q T R C I R I 2233.8 745.3[M+3H]3+ 
559.0[M+4H]4+ 
2232.9 15.10 
L5-02 R V K C R K R K G Q T R C I R I 2203.8 735.9[M+3H]3+ 
552.3[M+4H]4+ 
2204.7 15.02 
L5-03 R V R C R K L DR G Q T R C I R I 2188.7 730.9[M+3H]3+ 
548.5[M+4H]4+ 
2189.7 16.42 
L5-04 R V R C R R K DR G Q T R C I R I 2233.8 745.4[M+3H]3+ 
559.2[M+4H]4+ 
2233.2 14.93 
L5-05 R V R T R K R DR G Q T R A I K I 2171.6 725.4[M+3H]3+ 
544.3[M+4H]4+ 
2173.2 14.66 
L5-06 R C R V R K R DR G Q T R R I C I 2231.8 744.3[M+3H]3+ 
558.6[M+4H]4+ 
2229.9 15.62 
L5-07 R V R C R K R G P G A R C I K I 2043.6 682.5[M+3H]3+ 
512.1[M+4H]4+ 
2044.5 15.56 
L5-08 R C R V R R K K G R A R K I C I 2175.8 725.9[M+3H]3+ 
544.8[M+4H]4+ 
2174.7 15.59 
L5-09 R C R V R Q R G P G A R K I C I 2043.5 682.8[M+3H]3+ 
512.3[M+4H]4+ 
2045.2 16.32 
L5-10 R V R C R T R K G R A R C I K I 2146.7 717.1[M+3H]3+ 
538.0[M+4H]4+ 
2148.0 15.39 
L5-11 R V R C R Q R K G R R A C I R I 2201.7 735.2[M+3H]3+ 
551.5[M+4H]4+ 
2202.6 15.35 
L5-12 R V R C R Q R K G R R I C I R I 2243.8 748.7[M+3H]3+ 
561.6[M+4H]4+ 
2243.1 17.75 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x250 mm (5 µm), 6CV, 1 ml/min 10-50% MeCN in H2O +0,1%TFA 
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Table 53. Summary of the HPLC and MS analytical data of HIV Tat peptidomimetics [Single mutations of arginine to homoarginine (hR) or arginine to lysine in L4-04]. 
Amino acids 1 and 16 are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z ES-MS MWobs 
ES-MS 
rt [min] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16     
L4-04hR01 hR V R C R K R DR G Q T R C I R I 2245.8 749.9[M+3H]3+ 
562.8[M+4H]4 
2246.7 16.76 
L4-04hR02 R V hR C R K R DR G Q T R C I R I 2245.8 749.9[M+3H]3+ 
562.7[M+4H]4 
2246.7 16.53 
L4-04hR03 R V R C hR K R DR G Q T R C I R I 2245.8 749.9[M+3H]3+ 
562.7[M+4H]4 
2246.7 16.49 
L4-04hR04 R V R C R K hR DR G Q T R C I R I 2245.8 749.6[M+3H]3+ 
562.8[M+4H]4+ 
2245.8 16.51 
L4-04hR05 R V R C R K R DR G Q T hR C I R I 2245.8 750.4[M+3H]3+ 
562.7[M+4H]4 
2246.2 16.57 
L4-04hR06 R V R C R K R DR G Q T R C I hR I 2245.8 750.3[M+3H]3+ 
562.7[M+4H]4 
2246.2 16.63 
L4-04K01 
 
K V R C R K R DR G Q T R C I R I 2203.8 736.1[M+3H]3+ 
552.0[M+4H]4+ 
2204.4 17.52 
L4-04K02 
 
R V K C R K R DR G Q T R C I R I 2203.8 735.9[M+3H]3+ 
551.9[M+4H]4+ 
2202.0 17.46 
L4-04K03 R V R C K K R DR G Q T R C I R I 2203.8 735.9[M+3H]3+ 
551.7[M+4H]4+ 
2161.2 17.44 
L4-04K04 
 
R V R C R K K DR G Q T R C I R I 2203.8 735.9[M+3H]3+ 
552.0[M+4H]4+ 
2204.4 17.34 
L4-04K05 
 
R V R C R K R DR G Q T K C I R I 2203.8 736.0[M+3H]3+ 
552.3[M+4H]4+ 
2204.4 17.27 
L4-04K06 
 
R V R C R K R DR G Q T R C I K I 2203.8 736.2[M+3H]3+ 
552.0[M+4H]4+ 
2202.0 16.92 
L4-04K07 
 
R V R C R K R DK G Q T R C I R I 2203.8 735.8[M+3H]3+ 
551.8[M+4H]4+ 
2204.4 15.74 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x250 mm (5 µm), 6CV, 1 ml/min 10-50% MeCN in H2O +0,1%TFA 
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Table 54. Summary of the HPLC and MS analytical data of HIV Tat peptidomimetics [Derivatives of L4-04]. MWcalc.= theoretical MW calculated from molecular formula, 
MWobs.=MW from MS. Abu=aminobutyric acid. 
Mimetic Position  MW 
calc 
m/z ESI-MS MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17-18     
L4-04a Ac-R V R C R K R DR G Q T R C I R I-NH2 - 2096.6 700.5[M+3H]
3+ 
525.3[M+4H]4+ 
2097.2 13.68 
L4-04b R V R Abu R K R DR G Q T R Abu I R I DP-LP 2197.6 733.3[M+3H]3+ 
550.8[M+4H]4+ 
2196.9 16.01 
L4-04c Ac-R V R Abu R K R DR G Q T R Abu I R I-NH2 - 2062.5 688.8[M+3H]
3+ 
517.0[M+4H]4+ 
2063.4 14.97 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x 250 mm (5 µm), 6CV, 1 ml/min 10-50% MeCN in H2O +0,1%TFA 
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Table 55. Summary of the HPLC and MS analytical data of Rev peptidomimetics. Amino acids 1 and 12 
are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW calculated from molecular formula, 
MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z  
ESI-MS 
MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
BIV-5 R R G T R G K R R I G R 1645.0 549.4[M+3H]3+ 
412.3[M+4H]4+ 
1645.2 6.56 
R1-01 W R R R A T DR Q R N R R 1888.2 630.4[M+3H]3+ 
472.9[M+4H]4+ 
1888.2 7.45 
R1-02 W R R R A P DR Q R N R R 1884.2 628.8[M+3H]3+ 
471.9[M+4H]4+ 
1883.4 7.52 
R1-03 W R R R G P DR Q R N R R 1870.2 624.3[M+3H]3+ 
468.5[M+4H]4+ 
1869.9 7.48 
R1-04 W R R R V P DR Q R N R R 1912.3 638.5[M+3H]3+ 
479.0[M+4H]4+ 
1912.5 7.69 
R1-05 W R R R A G DR Q R N R R 1844.1 615.8[M+3H]3+ 
461.9[M+4H]4+ 
1844.4 7.40 
R1-06 W R R R A G K Q R N R R 1816.1 606.2[M+3H]3+ 
455.0[M+4H]4+ 
1815.6 7.28 
R1-07 W R R R A T DR G R N R R 1817.1 606.3[M+3H]3+ 
455.3[M+4H]4+ 
1815.9 7.43 
R1-08 W R R R A P DR G R N R R 1813.1 605.3[M+3H]3+ 
454.3[M+4H]4+ 
1812.9 7.51 
R1-09 W R R R G P DR G R N R R 1799.1 600.7[M+3H]3+ 
450.8[M+4H]4+ 
1799.1 7.10 
R1-10 W R R R G T DR Q R N R R 1874.2 625.7[M+3H]3+ 
469.5[M+4H]4+ 
1874.1 6.94 
R1-11 W R R R V G DR Q R N R R 1872.2 625.2[M+3H]3+ 
469.0[M+4H]4+ 
1872.0 7.04 
R1-12 W R R R A S DR Q R N R R 1874.2 625.4[M+3H]3+ 
469.5[M+4H]4+ 
1874.0 6.88 
R2-01 W R R R A K G Q R N R R 1816.1 #1816.7[M+H]+ 1815.7 7.32 
R2-02 W R L R A K G Q R N R R 1773.1 887.3[M+2H]2+ 1772.6 8.07 
R2-03 W R Q R A K G Q R N R R 1788.1 894.7[M+2H]2+ 
597.2[M+3H]3+ 
1787.4 6.94 
R2-04 W R R R A K G Q R N R V 1759.1 880.3[M+2H]2+ 1758.6 7.12 
R2-05 W R L R A 
DR K G R N R R 1801.2 901.5[M+2H]2+ 1801.0 7.84 
R2-06 W R L R A K K G R N R R 1773.1 887.8[M+2H]2+ 1773.6 7.96 
R2-07 W R K R A G K Q R N R R 1788.1 894.8[M+2H]2+ 1787.6 7.00 
R2-08 W R K R A K G Q R N R R 1788.1 894.8[M+2H]2+ 1787.6 7.10 
R2-09 W R R R A 
DR G Q R N R R 1844.1 922.8[M+2H]2+ 1843.6 7.32 
R2-10 W R L R A 
DR G K R N R R 1801.2 901.2[M+2H]2+ 1800.4 8.12 
R2-11 R R L R A 
DR G Q R N R R 1771.1 886.6[M+2H]2+ 1771.2 7.41 
R2-12 R R L R A K G Q R N R R 1743.1 871.9[M+2H]2+ 1741.8 6.45 
R2-13 R V R R A K G Q R N R R 1729.1 865.5[M+2H]2+ 1729.0 5.98 
R2-14 R C R R A K G Q R R C R 1720.1 #1720.7[M+H]+  1719.7 6.31 
R2-15 K R Q R T K G R R L O R 1745.1 873.9[M+2H]2+ 1745.8 6.79 
R2-16 W R R R A G R Q R N R R 1844.1 615.7[M+2H]3+ 
462.1[M+3H]4+ 
1844.1 7.37 
Arg7                       Ac-(Arg)7-NH2 1152.4 #1152.7[M+H]
+ 1152.7 5.48 
# Matrix Assisted Laser Desorption Ionization (MALDI), Bruker Autoflex. 
Analytical column: Agilent, Zorbax Eclipse XDB-C18 4.6 x250 mm (5 µm), 1 ml/min 10-90% MeCN in 
H2O+0,1% TFA over 21.4 min (6CV). 
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Table 56. Summary of the HPLC and MS analytical data of RNase P peptidomimetics [Library P1-
Alanine scan of R2-10]. Amino acids 1 and 12 are attached to a D-Pro-L-Pro template. MWcalc.= 
theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z ESI-MS MWobs 
ESI-
MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
P1-01 A R L R A DR G K R N R R 1686.2 563.5[M+3H]3+ 
423.2[M+4H]4+ 
1687.5 14.24 
P1-02 W A L R A DR G K R N R R 1716.2 573.0[M+3H]3+ 
430.4[M+4H]4+ 
1716.0 16.95 
P1-03 W R A R A DR G K R N R R 1759.2 587.8[M+3H]3+ 
439.8[M+4H]4+ 
1760.4 14.57 
P1-04 W R L A A DR G K R N R R 1716.2 573.4[M+3H]3+ 
430.3[M+4H]4+ 
1717.2 17.37 
P1-05 W R L R A A G K R N R R 1716.2 573.4[M+3H]3+ 
430.1[M+4H]4+ 
1717.2 16.30 
P1-06 W R L R A DR A K R N R R 1815.2 605.7[M+3H]3+ 
454.7[M+4H]4+ 
1814.8 15.26 
P1-07 W R L R A DR G A R N R R 1744.1 582.8[M+3H]3+ 
437.3[M+4H]4+ 
1745.4 16.35 
P1-08 W R L R A DR G K A N R R 1716.2 573.1[M+3H]3+ 
430.4[M+4H]4+ 
1716.3 16.40 
P1-09 W R L R A DR G K R A R R 1758.1 587.4[M+3H]3+ 
440.4[M+4H]4+ 
1759.2 16.60 
P1-10 W R L R A DR G K R N A R 1716.2 573.3[M+3H]3+ 
430.2[M+4H]4+ 
1716.6 16.51 
P1-11 W R L R A DR G K R N R A 1716.2 573.5[M+3H]3+ 
430.4[M+4H]4+ 
1717.5 18.25 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x 250 mm (5 µm), 6CV, 1 ml/min 10-50% 
MeCN in H2O +0,1%TFA. 
 
Table 57. Summary of the HPLC and MS analytical data of RNase P peptidomimetics [Library-P2]. 
Amino acids 1 and 12 are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW calculated from 
molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z  
ESI-MS 
MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
P2-01 W R I R I DR G K R N R R 1686.2 563.5[M+3H]3+ 
423.2[M+4H]4+ 
1687.5 14.24 
P2-02 W A I R A DR G K R N R R 1716.2 573.0[M+2H]3+ 
430.4[M+3H]4+ 
1716.0 16.95 
P2-03 W R L R I DR G K R N R R 1759.2 587.8[M+2H]3+ 
440.9[M+3H]4+ 
1760.4 14.57 
P2-04 W R I R I DR N K R N R R 1900.3 634.9[M+3H]3+ 
476.4[M+4H]4+ 
1901.4 19.10 
P2-05 W R I R I DR N K R L R R 1899.3 634.7[M+3H]3+ 
476.0[M+4H]4+ 
1900.0 20.38 
P2-06 W R I R I DR N K R N Q R 1872.2 625.3[M+3H]3+ 
469.4[M+4H]4+ 
1872.9 19.55 
P2-07 W R I R I DR N K R N Q A 1787.1 597.2[M+3H]3+ 
448.2[M+4H]4+ 
1788.6 22.88 
P2-08 W R I R I R N K R N R R 1900.3 635.0[M+3H]3+ 
476.5[M+4H]4+ 
1902.0 18.10 
P2-09 F R I R I DR N K R N R R 1861.3 621.9[M+3H]3+ 
466.8[M+4H]4+ 
1862.7 19.31 
P2-10 Y R I R I DR N K R N R R 1877.3 627.3[M+3H]3+ 
470.7[M+4H]4+ 
1878.9 16.24 
P2-11 F R I K I DR N R R L Q A 1747.1 583.4[M+3H]3+ 1747.2 26.77 
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436.8[M+4H]4+  
P2-12 W K I R I DR N K R N R R 1872.3 625.5[M+3H]3+ 
469.2[M+4H]4+ 
1872.8 18.48 
P2-13 W R I K I DR N K R N R R 1872.3 625.6[M+3H]3+ 
469.4[M+4H]4+ 
1873.6 18.50 
P2-14 W R I R I DK N K R N R R 1872.3 625.6[M+3H]3+ 
469.4[M+4H]4+ 
1873.6 17.85 
P2-15 W R I R I DR N K K N R R 1872.3 625.6[M+3H]3+ 
469.5[M+4H]4+ 
1873.8 17.79 
P2-16 W R I R I DR N K R N K R 1872.3 625.6[M+3H]3+ 
469.5[M+4H]4+ 
1873.8 17.82 
P2-17 W R I R I DR N K R N R K 1872.3 625.7[M+3H]3+ 
469.4[M+4H]4+ 
1873.6 17.45 
P2-18 I R I R I DR N K R N R R 1827.2 610.5[M+3H]3+ 
457.9[M+4H]4+ 
1827.6 17.18 
P2-19 W Q I R I DR N K R N R R 1872.2 625.6[M+2H]3+ 
469.5[M+3H]4+ 
1873.8 17.51 
P2-20 W R I R I DR N Q R N R R 1900.2 634.7[M+2H]3+ 
476.5[M+3H]4+ 
1901.1 17.69 
P2-21 W C I R I DR N K R N C R 1792.2 896.6[M+2H]2+ 
598.1[M+3H]3+ 
1791.1 17.33 
P2-22 W R I R I DR N Q R N Q A 1787.1 597.2[M+3H]3+ 
447.7[M+4H]4+ 
1788.6 22.20 
P2-23 W R I R I DR N Q R N Q R 1872.2 625.6[M+3H]3+ 
469.5[M+4H]4+ 
1873.8 18.28 
P2-24 W R I R I DR N Q Q N Q A 1759.1 881.1[M+2H]2+ 
587.8[M+3H]3+ 
1760.2 22.50 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x 250 mm (5 µm), 6CV, 1 ml/min, 10-50% 
MeCN in H2O +0,1%TFA. 
 
Table 58. Summary of the HPLC and MS analytical data of derivatives of P2-04. In P2-04b amino acids 
1 and 12 are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW calculated from molecular 
formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z ESI-MS MWobs  
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
P2-04a Ac-W R I R I DR N K R N R R-NH2 1765.1 589.9[M+3H]
3+ 
442.4[M+4H]4+ 
1766.7 17.12 
P2-04b DW DR DI DR DI R DN DK DR DN DR DR 1900.3 634.2[M+3H]3+ 
475.9[M+4H]4+ 
1899.6 18.64 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x 250 mm (5 µm), 6CV, 1 ml/min, 10-50% 
MeCN in H2O +0,1%TFA. 
 
Table 59. Summary of the HPLC and MS analytical data of RNase P peptidomimetics [Library-P3]. 
Amino acids 1 and 12 are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW calculated from 
molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z ESI-MS MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
P3-01 W R I R I DR N Q K L R R 1871.3 936.7[M+2H]2+ 
624.9[M+3H]3+ 
1871.4 19.19 
P3-02 W R I R I DR N Q K I R R 1871.3 936.5[M+2H]2+ 
625.2[M+3H]3+ 
1871.0 19.03 
P3-03 W R L R I DR N K O L R R 1857.3 929.2[M+2H]2+ 
619.7[M+3H]3+ 
1856.4 18.87 
P3-04 F R T R I DR N R R L E S 1780.1 890.7[M+2H]2+ 
594.0[M+3H]3+ 
1779.4 20.52 
P3-05 F R I R I DR N K R L R R 1860.3 621.7[M+3H]3+ 
466.8[M+4H]4+ 
1862.1 19.24 
P3-06 W R I R I DR N K R L R I 1856.3 620.4[M+3H]3+ 
465.3[M+4H]4+ 
1857.2 26.10 
P3-07 F R I R I DR N K R L R S 1791.2 598.3[M+3H]3+ 1791.9 21.83 
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447.8[M+4H]4+ 
P3-08 W R I R I R N K R L Q A 1786.2 597.0[M+3H]3+ 
447.6[M+4H]4+ 
1788.0 24.84 
P3-09 Cha R I R I DR N K R L R R 1866.3 623.7[M+3H]3+ 
468.2[M+4H]4+ 
1868.1 20.33 
P3-10 W R I R I DR N Q R L Q A 1786.2 596.9[M+3H]3+ 
447.7[M+4H]4+ 
1787.7 28.08 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x250 mm (5 µm), 6CV, 1 ml/min, 10-50% 
MeCN in H2O +0,1%TFA. 
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The growing problem of resistance to established antibiotics has stimulated 
intense interest in the development of novel antimicrobial agents with new modes of 
action. One emerging class of antibiotics is based on naturally occurring cationic 
peptides, which have been discovered in many animal species, where they are thought 
to constitute ancient evolutionary elements of immunity.213,214 These include disulfide-
bridged !-hairpin and !-sheet peptides (for example, the protegrins, tachyplesins,215 
and defensins216), amphipatic "-helical peptides (for example, cecropins, dermaseptins, 
magainins, and mellitins),217 as well as other linear and loop-structured peptides.218 The 
primary site of interaction of these cationic peptides is the microbial cell 
membrane.214,218 Upon exposure to these agents, the cell membrane undergoes 
permeabilization, which leads to rapid cell death. 
Structural studies by NMR spectroscopy have shown that protegrin219 and 
tachyplesin220 adopt well-defined !-hairpin structures in water, as a result of the 
constraining effect of the two disulfide cross-links. In protegrin analogues that lack one 
or both of the disulfide bridges, the stability of the !-harpin conformation is diminished 
and the membranolytic activity is reduced.193 Similar observations were made for 
tachyplesin,221 which indicates that the !-hairpin structure plays an important role in the 
activity of these molecules. 
The starting point for the antimicrobial peptidomimetic design in our group was 
the naturally occurring antimicrobial peptide protegrin I (PG-I), one of the family of 
five homologous peptides first isolated from porcine leucocytes.222 PG-I is an 18-amino 
acid peptide containing two disulfide cross-links (Cys6-15 and Cys8-13). These 
disulfide bridges constrain the peptide into a !-hairpin conformation, with a !-turn 
formed by residues 9-12. PG-I typically kills susceptible microorganisms within 
minutes,208 consistent with a bactericidal effect caused by disruption of the cell 
membrane.221,223 
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Figure 79. Naturally occurring cationic !-hairpin antimicrobial peptide, PG-I (top), served as a starting 
point for the design of template-bound antimicrobial peptidomimetics, shown below. 
 
The design of PG-I mimetics was performed by grafting the hairpin sequence 
onto an D-Pro-L-Pro template whose function is to restrain the peptide loop termini in a 
!-hairpin geometry (Figure 79). The extensive SAR studies conducted with the 14-mer 
peptidomimetics led to the development of the very potent antimicrobial agents (D and 
M18A11, Table 60) with high selectivity and low haemolytic activity in comparison to 
PG-I and other first generation peptides (e.g. A).224,225  
 
Table 60. Antimicrobial and haemolytic activities of antimicrobial peptidomimetics derived from 
protegrin-1. The values for protegrin-1 and mimetics A and B are taken from Shankaramma et al.,225 and 
the others are taken from PhD Thesis of N. Srinivas.224 nd=not determined, % haemolysis at a peptide 
concentration of 100 µg/ml. 
MIC[µg/ml] 
P. aeruginosa S. aureus 
Peptide Sequence 
E. coli 
25922 27853 PAO1 25923 29213 
C. albicans 
% H 
hRBC 
PG-I Protegrin-1 3 3 nd 6 nd 6 37 
A LRLQYRRFQYRVpP 6 12 nd 12 nd 6 27 
B LRLKKRRWKYRVpP 12 6 nd 12 nd 12 1 
C RWLKKQRWKYYRpP 16 0.25 nd >64 >64 nd 0 
D TWLKKRRWKKVKpP 64 0.03 0.06 32 >64 nd 0 
M18A11 TWLKKRRWKKAKpP 64 0.015 0.004 >64 >64 nd 0 
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The peptidomimetics from library KP1 (Table 61) and KP2 (Table 63) were 
designed based on the sequence of the most potent antimicrobial peptide produced so 
far, M18A11, with the goal to investigate the effect of changing the nature of the 
positively charged residues. In these libraries the arginine residues present in the 
sequence were mutated to lysines followed by the single/mutiple mutations of Arg/Lys 
to the unnatural amino acids ornithine (O) and diaminobutyric acid (Dab). It was 
hypothesised that introduction of these unnatural amino acids will increase the stability 
of the peptides in biological settings, due to their resistance to proteolytic degradation. 
 
Table 61. Summary of the HPLC and MS analytical data of antimicrobial peptidomimetics in library 
KP1. Amino acids 1 and 12 are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW 
calculated from molecular formula, MWobs.=MW from MS. O=Ornithine 
Mimetic Position MW 
calc 
m/z  
ESI-MS 
MWobs 
ESI-MS 
rt [min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
KP1-01 T W L K K R R W K K A K 1805.3 602.7[M+3H]3+ 
452.6[M+4H]4+ 
1805.1 18.63 
KP1-02 T W L K K K R W K K A K 1777.5 593.7[M+3H]3+ 
445.3[M+4H]4+ 
1778.1 18.25 
KP1-03 T W L K K R K W K K A K 1777.5 593.7[M+3H]3+ 
445.5[M+4H]4+ 
1778.1 18.49 
KP1-04 T W L K K K K W K K A K 1749.2 583.9[M+3H]3+ 
438.6[M+4H]4+ 
1748.7 18.05 
KP1-05 T W L O K K K W K K A K 1735.1 579.8[M+3H]3+ 
435.1[M+4H]4+ 
1736.4 18.06 
KP1-06 T W L K O K K W K K A K 1735.1 579.7[M+3H]3+ 
435.1[M+4H]4+ 
1736.1 18.35 
KP1-07 T W L K K K K W O K A K 1735.1 579.8[M+3H]3+ 
435.1[M+4H]4+ 
1736.4 18.21 
KP1-08 T W L K K K K W K O A K 1735.1 579.8[M+3H]3+ 
434.9[M+4H]4+ 
1736.4 18.00 
KP1-09 T W L K K K K W K K A O 1735.1 579.6[M+3H]3+ 
435.0[M+4H]4+ 
1735.8 18.02 
KP1-10 T W L K K O O W K K A K 1720.9 575.0[M+3H]3+ 
431.4[M+4H]4+ 
1722.0 18.09 
KP1-11 T W L O O K K W O O A O 1678.3 561.0[M+3H]3+ 
420.8[M+4H]4+ 
1680.0 18.08 
KP1-12 T W L O O O O W O O A O 1650.0 551.6[M+3H]3+ 
413.8[M+4H]4+ 
1651.8 18.01 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x 250 mm (5 µm), 6CV, 1 ml/min, 10-50% 
MeCN in H2O +0,1%TFA 
 
 
Table 62. Antimicrobial activity (MIC) measured for peptidomimetics from the KP1 library. 
Mimetic P. putida 2442 
MIC [µg/ml] 
P. aeruginosa PAOI 
MIC [µg/ml] 
KP1-01 0.25 0.006 
KP1-02 0.12 0.002 
KP1-03 0.12 0.003 
KP1-04 0.12 0.002 
KP1-05 0.25 0.003 
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KP1-06 2 0.002 
KP1-07 0.03 0.006 
KP1-08 0.03 0.002 
KP1-09 0.25 0.006 
KP1-10 0.004 0.003 
KP1-11 1 0.002 
KP1-12 0.75 0.002 
 
 
Table 63. Summary of the HPLC and MS analytical data of antimicrobial peptidomimetics in library 
KP2. Amino acids 1 and 12 are attached to a D-Pro-L-Pro template. MWcalc.= theoretical MW 
calculated from molecular formula, MWobs.=MW from MS. Dab=diaminobutyric acid, O=ornithine 
Mimetic Position MW 
calc 
m/z  
ESI-MS 
MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
KP2-01 T W L O O O O W O O A O 1650.0 551.6[M+3H]3+ 
413.8[M+4H]4+ 
1651.8 18.01 
KP2-02 T W L Dab O O O W O O A O 1636.2 547.0[M+3H]3+ 
410.7[M+4H]4+ 
1638.0 16.08 
KP2-03 T W L O Dab O O W O O A O 1636.2 546.9[M+3H]3+ 
410.6[M+4H]4+ 
1637.7 15.87 
KP2-04 T W L O O Dab O W O O A O 1636.2 547.0[M+3H]3+ 
410.7[M+4H]4+ 
1638.0 15.83 
KP2-05 T W L O O O Dab W O O A O 1636.2 547.1[M+3H]3+ 
410.6[M+4H]4+ 
1638.3 16.03 
KP2-06 T W L O O O O W Dab O A O 1636.2 547.0[M+3H]3+ 
410.6[M+4H]4+ 
1638.0 16.09 
KP2-07 T W L O O O O W O Dab A O 1636.2 546.7[M+3H]3+ 
410.8[M+4H]4+ 
1637.1 16.01 
KP2-08 T W L O O O O W O O A Dab 1636.2 547.0[M+3H]3+ 
410.7[M+4H]4+ 
1638.0 16.10 
KP2-09 T W L Dab Dab Dab Dab W Dab Dab A Dab 1552.2 518.9[M+3H]3+ 
388.1[M+4H]4+ 
1553.7 16.10 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 4.6 x 250 mm (5 µm), 6CV, 1 ml/min, 10-50% 
MeCN in H2O +0,1%TFA 
 
Table 64. Antimicrobial activity (MIC) measured for peptidomimetics from the KP2 library. 
Mimetic P. putida 2442 
MIC [µg/ml] 
P. aeruginosa PAOI 
MIC [µg/ml] 
KP2-01 0.25 0.006 
KP2-02 0.12 0.001 
KP2-03 16 0.02 
KP2-04 0.33 0.005 
KP2-05 0.12 0.001 
KP2-06 1 0.001 
KP2-07 0.02 0.001 
KP2-08 0.09 0.001 
KP2-09 4 0.1 
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Table 65. Trypsin digestion assay. Shown are the half-lives of the peptides in the trypsin digestion assay 
(for detail see paragraph 2.2.8.1). 
Peptide Half-life ,1/2 [min] 
KP1-01 <5 min 
KP1-12 >13 days (after 3 days, 90%left; after 
13 days, 65%left) 
KP2-09 5 days 
 
 
The results of the antimicrobial activities presented in Table 62 and Table 64 
indicate that replacement of the arginine and lysine residues does not bring much 
change in the antimicrobial activity against P. aeruginosa, while larger changes were 
observed for P. putida. Only the peptide containing only Dab residues, KP2-09, shows 
a 20-fold reduced inhibitory potency against P. aeruginosa in comparison with KP1-
01. Some of the peptides exhibit an increase of 2- to 4-fold in inhibitory activity, which 
might be due to their improved stability towards proteolysis. The lead peptide, 
M18A11 (called here KP1-01) is digested completely in 30 min whereas the two 
peptides having exclusively ornithine residues (KP1-12), or diaminobutyric acid (KP2-
09) are stable in the assay conditions for at least a few days (Table 65). 
The first part of the KP3 library (KP3-02—KP3-12) represents an alanine scan 
prepared for M18A11 (KP3-01), and performed in order to investigate the importance 
of the single amino acid residues for the antimicrobial activity. The second part of the 
library, with peptides KP3-13—KP3-34, represents single mutations of the two 
tryptophan residues present in the sequence of M18A11 peptide. It was performed to 
assess the tolerance to the replacement of these critical amino acids for other 
hydrophobic or aromatic side chains. 
 
Table 66. Summary of the HPLC and MS analytical data of antimicrobial peptidomimetics [Alanine scan 
and mutations of tryptophan in M18A11]. Amino acids 1 and 12 are attached to a D-Pro-L-Pro template. 
MWcalc.= theoretical MW calculated from molecular formula, MWobs.=MW from MS. 
Mimetic Position MW 
calc 
m/z  
ESI-MS 
MWobs 
ESI-MS 
rt 
[min] 
 1 2 3 4 5 6 7 8 9 10 11 12     
KP3-01 T W L K K R R W K K A K 1805.3 602.7[M+3H]3+ 
452.6[M+4H]4+ 
1805.1 17.07 
KP3-02 A W L K K R R W K K A K 1775.5 592.9[M+3H]3+ 
445.1[M+4H]4+ 
1775.7 17.66 
KP3-03 T A L K K R R W K K A K 1690.1 564.5[M+3H]3+ 
423.8[M+4H]4+ 
1690.5 15.35 
KP3-04 T W A K K R R W K K A K 1763.2 589.0[M+3H]3+ 
442.1[M+4H]4+ 
1764.0 14.38 
KP3-05 T W L A K R R W K K A K 1748.2 583.8[M+3H]3+ 
438.1[M+4H]4+ 
1748.4 17.59 
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KP3-06 T W L K A R R W K K A K 1748.2 583.8[M+3H]3+ 
438.1[M+4H]4+ 
1748.4 17.90 
KP3-07 T W L K K A R W K K A K 1720.2 574.7[M+3H]3+ 
431.3[M+4H]4+ 
1721.1 16.54 
KP3-08 T W L K K R A W K K A K 1720.2 574.8[M+3H]3+ 
431.3[M+4H]4+ 
1721.4 17.66 
KP3-09 T W L K K R R A K K A K 1690.1 564.8[M+3H]3+ 
423.8[M+4H]4+ 
1691.4 15.57 
KP3-10 T W L K K R R W A K A K 1748.2 583.9[M+3H]3+ 
438.1[M+4H]4+ 
1748.7 17.94 
KP3-11 T W L K K R R W K A A K 1748.2 583.4[M+3H]3+ 
438.1[M+4H]4+ 
1747.2 16.86 
KP3-12 T W L K K R R W K K A A 1748.2 583.9[M+3H]3+ 
438.1[M+4H]4+ 
1748.7 18.18 
KP3-13 T F L K K R R W K K A K 1766.2 590.0[M+3H]3+ 
442.6[M+4H]4+ 
1767.0 17.95 
KP3-14 T Y L K K R R W K K A K 1782.2 595.4[M+3H]3+ 
446.8[M+4H]4+ 
1783.2 16.35 
KP3-15 T L L K K R R W K K A K 1732.2 578.7[M+3H]3+ 
434.2[M+4H]4+ 
1733.1 17.07 
KP3-16 T Cha L K K R R W K K A K 1772.3 592.1[M+3H]3+ 
444.4[M+4H]4+ 
1773.3 19.29 
KP3-17 T 1-
Nal 
L K K R R W K K A K 1816.3 606.4[M+3H]3+ 
455.3[M+4H]4+ 
1816.2 19.23 
KP3-18 T 2-
Nal 
L K K R R W K K A K 1816.3 606.7[M+3H]3+ 
455.4[M+4H]4+ 
1817.1 19.76 
KP3-19 T Hfe L K K R R W K K A K 1780.3 594.7[M+3H]3+ 
446.1[M+4H]4+ 
1781.1 18.78 
KP3-20 T 3Cl-
F 
L K K R R W K K A K 1800.7 601.4[M+3H]3+ 
451.5[M+4H]4+ 
1801.2 18.74 
KP3-21 T 4Cl-
F 
L K K R R W K K A K 1800.7 601.7[M+3H]3+ 
451.2[M+4H]4+ 
1802.1 18.31 
KP3-22 T Bip L K K R R W K K A K 1842.4 615.4[M+3H]3+ 
461.9[M+4H]4+ 
1843.2 20.51 
KP3-23 T Tpi L K K R R W K K A K 1817.1 - - - 
KP3-24 T W L K K R R F K K A K 1766.2 590.1[M+3H]3+ 
442.6[M+4H]4+ 
1767.3 17.16 
KP3-25 T W L K K R R Y K K A K 1782.2 595.4[M+3H]3+ 
446.8[M+4H]4+ 
1783.2 16.25 
KP3-26 T W L K K R R L K K A K 1732.2 578.8[M+3H]3+ 
434.2[M+4H]4+ 
1733.4 16.99 
KP3-27 T W L K K R R Cha K K A K 1772.3 592.1[M+3H]3+ 
444.2[M+4H]4+ 
1773.3 17.78 
KP3-28 T W L K K R R 1-
Nal 
K K A K 1816.3 606.8[M+3H]3+ 
455.3[M+4H]4+ 
1817.4 17.95 
KP3-29 T W L K K R R 2-
Nal 
K K A K 1816.3 606.7[M+3H]3+ 
455.2[M+4H]4+ 
1817.1 18.24 
KP3-30 T W L K K R R Hfe K K A K 1780.3 594.7[M+3H]3+ 
446.2[M+4H]4+ 
1781.1 17.45 
KP3-31 T W L K K R R 3Cl-
F 
K K A K 1800.7 601.7[M+3H]3+ 
451.2[M+4H]4+ 
1802.1 17.88 
KP3-32 T W L K K R R 4Cl-
F 
K K A K 1800.7 601.0[M+3H]3+ 
451.5[M+4H]4+ 
1800.0 17.69 
KP3-33 T W L K K R R Bip K K A K 1842.4 615.3[M+3H]3+ 
461.9[M+4H]4+ 
1842.9 19.20 
KP3-34 T W L K K R R Tpi K K A K 1817.1 - - - 
Cha=Cyclohexylalanine                                                                             
3Cl-F=3-chloro-phenylalanine, 4Cl-F=4-chloro-phenylalanine 
Bip = 4-Phenyl-phenylalanine 
Hfe = Homophenylalanine 
1(2)-Nal=1(2)-Naphthylalanine 
 
Analytical column: Agilent, Zorbax Eclipse XDB-C18, 
4.6 x 250 mm (5 µm), 6CV, 1 ml/min, 10-50% MeCN in H2O 
+0,1%TFA 
N
H
N
CO2H
Fmoc
Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid
Fmoc-L-Tpi-OH
Appendix 5: Antimicrobial peptides-derivates of M18A11 -190- 
 
The syntheses of peptides containing 1,2,3,4-tetrahydronorharman-3-carboxylic acid 
(KP3-23 and KP3-34) failed. 
 
Table 67. Antimicrobial activity (MIC) for the peptides from the KP3 library. 
Mimetic P. aeruginosa PAOI 
MIC [µg/ml] 
KP3-01 0.02 
KP3-02 0.02 
KP3-03 >16 
KP3-04 0.09 
KP3-05 0.05 
KP3-06 0.09 
KP3-07 0.02 
KP3-08 0.04 
KP3-09 >16 
KP3-10 0.04 
KP3-11 0.04 
KP3-12 0.02 
KP3-13 0.04 
KP3-14 0.04 
KP3-15 1 
KP3-16 0.25 
KP3-17 0.2 
KP3-18 0.09 
KP3-19 3 
KP3-20 0.03 
KP3-21 0.04 
KP3-22 0.04 
KP3-24 0.09 
KP3-25 0.25 
KP3-26 0.2 
KP3-27 0.08 
KP3-28 0.05 
KP3-29 0.005 
KP3-30 0.04 
KP3-31 0.2 
KP3-32 0.05 
KP3-33 0.8 
 
The results of the antimicrobial assays of the alanine-scanning library prove the 
importance of the two tryptophan residues in the sequence. Therefore, the single 
replacements of these critical amino acids were performed using natural (Phe, Leu, Tyr) 
and unnatural amino acids (homophenylalanine; cyclohexylalanine; 3-, 4-chloro-
phenyalanine; 4-phenyl-phenylalanine; 1-,2-naphtylalanine). Overall the changes are 
were tolerated, but generally with a slight decrease in potency. A significant decrease is 
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noticed only for the Trp3Leu and Trp3Hfe mutants (40 and 80-fold). More than 10-fold 
reduction in activity is observed for the mutants of Trp3Cha, Trp8Tyr and Trp8Bip. 
Only one mutation, of Trp8 to 2-Naphthylalanine, brings an increase in the 
antimicrobial activity (4-fold, MIC=0.005 vs 0.02 µg/ml) in comparison to M18A11 
(KP3-01). 
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Appendix 6: NMR data for BIV/HIV Tat and Rev peptidomimetics 
 
The peptide backbone NH, C(")H and side chain resonances for all the studied cyclic 
peptides were assigned unambiguously. 
 
Table 68. 1H-NMR assignment of L1-07. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1).  
L1-07 NH " ! Others 
Arg1 7.754 4.676 1.853 CH2(.) 1.622; CH2(+) 3.214; NH(&) 7.282 
Thr2 8.501 5.009 3.923 CH3(.) 1.041 
Arg3 9.086 4.722 1.675 1.830 CH2(.) 1.532; CH2(+) 3.159; NH(&) 7.242 
Thr4 8.641 4.933 4.029 CH3(.) 1.073 
Arg5 8.726 4.507 1.588 1.747 CH2(.) 1.476, 1.589; CH2(+) 3.160  
Gly6 9.139 3.697, 3.996 - - 
Lys7 8.913 4.231 1.751 2.016 CH2(.) 1.427, 1.464; CH2(+) 1.673; CH2(&) 
2.985 
Arg8 7.905 4.502 1.863 CH2(.) 1.591, 1.687; CH2(+) 3.209   
Arg9 8.531 4.515 1.579 1.707 CH2(.) 1.472, 1.582; CH2(+) 3.109   
Ile10 8.958 4.443 1.758 CH2(.) 1.031, 1.320; CH3(.
2) 0.831 CH3(+
1) 
0.753 
Arg11 8.681 4.691 1.736 1.829 CH2(.) 1.548, 1.637; CH2(+) 3.158; NH(&) 
8.716 
Val12 8.716 4.455 1.938 CH3(.) 0.816, 0.879 
Pro13 - 4.734 1.914 2.293 CH2(.) 2.004, 2.124; CH2(+) 3.479, 3.849 
Pro14 - 4.562 2.124 2.245 CH2(.)1.890, 2.107; CH2(+) 3.744, 3.975  
 
 
 
Table 69. 1H-NMR assignment of L1-43. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1).  
L1-43 NH " ! Others 
Arg1 7.734 4.657 1.833 CH2(.) 1.611; CH2(+) 3.207; NH(&)  
Val2 8.453 4.725 1.860 CH3(.) 0.771, 0.852 
Arg3 9.120 4.750 1.667, 1.841 CH2(.) 1.519, 1.575; CH2(+) 3.146, 3.178;  
Thr4 8.633 4.953 4.027 CH3(.) 1.073 
Arg5 8.704 4.517 1.586, 1.744 CH2(.) 1.473; CH2(+) 3.171  
Gly6 9.150 3.690, 3.993 - - 
Lys7 8.926 4.231 1.757, 2.031 CH2(.) 1.425, 1.452; CH2(+) 1.671; CH2(&) 
2.990 
Arg8 4.490 4.491 1.862 CH2(.) 1.593, 1.697; CH2(+) 3.211   
Arg9 8.507 4.801 1.568, 1.680 CH2(.) 1.464; CH2(+) 3.111   
Ile10 8.988 4.416 1.746 CH2(.) 1.033, 1.338; CH3(.
2) 0.834 CH3(+
1) 
0.759 
Orn11 8.734 4.690 1.716, 1.995 CH2(.) 1.715; CH2(+) 2.914, 3.002; NH(&)  
Val12 8.832 4.490 1.937 CH3(.) 0.833, 0.885 
Pro13 - 4.755 1.926, 2.300 CH2(.) 2.017, 2.137; CH2(+) 3.517, 3.870 
Pro14 - 4.568 2.141, 2.234 CH2(.)1.888, 2.110; CH2(+) 3.739, 3.957  
 
 
 
 
 Appendix 6: NMR data for BIV/HIV Tat and Rev peptidomimetics -193- 
 
Table 70. 1H-NMR assignment of L2-15. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1).  
L2-15 NH " ! Others 
Arg1 7.751 4.604 1.809 CH2(.) 1.603; CH2(+) 3.204; NH(&) 7.272 
Val2 8.461 4.733 1.867 CH3(.) 0.844, CH3(.) 0.784 
Arg3 8.971 4.737 1.624 1.846 CH2(.) 1.555, 1.524;  
Thr4 8.585 5.092 3.928 CH3(.) 1.002 
Arg5 8.976 4.549 1.733, 1.623 CH2(.) 1.622, 1.439; 
Lys6 9.590 3.900 2,012, 1.804 CH2(.) 1.412, CH2(&) 2.993, 
Gly7 8.477 4.125, 3.564 - - 
Arg8 7.840 4.617 1.845, 1.785 CH2(.) 1.639, 1.588;  
Arg9 8.630 4.690 1.706 1.582 CH2(.) 1.581, 1.456; CH2(+) 3.110; NH(&) 
7.166 
Ile10 9.072 4.444 1.788 CH3(.) 1.256, 1.061 CH3(.
2) 0.841 CH3(+
1) 
0.782 
Arg11 8.582 4.822 1.828 1.669 CH2(.) 1.568, 1.484;  
Ile12 8.750 4.552 1.774 CH3(.) 1.387, 1.060 CH3(.
2) 0.854  
Pro13 - 4.733 1.909 2.287 CH2(.) 2.006, 2.121; CH2(+) 3.521, 3.860 
Pro14 - 4.547 2.119, 2.233 CH2(.)1.880, 2.104; CH2(+) 3.738, 3.970  
 
 
 
Table 71. 1H-NMR assignment of L4-01. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1).  
L4-01 NH " ! Others 
Arg1 7.658 4.667 1.805 CH2(.) 1.589; CH2(+) 3.200; NH(&) 7.276 
Val2 8.536 4.478 1.887 CH3(.
2) 0.809, 0.861 
Arg3 8.865 4.754 1.727, 1.846 CH2(.) 1.511, 1.659; CH2(+) 3.176; NH(&) 7.256 
Cys4 9.129 5.616 2.580, 3.046 - 
Arg5 8.857 4.673 1.763, 1.839 CH2(.) 1.605; CH2(+) 3.201; NH(&) 7.197 
Thr6 8.797 4.869 4.003 CH3(.) 1.033 
Arg7 8.529 4.516 1.685, 1.784 CH2(.) 1.516, 1.611; CH2(+); NH(&)  
Gly8 9.161 3.734, 3.968 - - 
Lys9 8.862 4.159 1.788, 2.020 CH2(.) 1.397, 1.440; CH2(+) 1.673; CH2(&) 2.985; 
NH(&) 7.276 
Arg10 7.847 4.560 1.855 CH2(.) 1.580, 1.662; CH2(+) 3.206; NH2(&) 7.590 
Arg11 8.668 4.840 1.636, 1.747 CH2(.) 1.427; CH2(+) 3.092; NH2(&) 7.159 
Arg12 8.729 4.703 1.743, 1.827 CH2(.) 1.561, 1.632; CH2(+) 3.186; NH(&)  
Cys13 9.027 5.516 2.634, 2.988 - 
Ala14 8.831 4.615 1.366 - 
Arg15 8.724 4.667 1.709 CH2(.) 1.500, 1.562; CH2(+) 3.183 
Val16 8.828 4.484 1.955 CH3(.
2) 0.886 
Pro17 - 4.759 1.911, 2.292 CH2(.) 2.015, 2.136; CH2(+) 3.529, 3.877 
Pro18 - 4.559 2.130, 2.238 CH2(.) 1.876, 2.102; CH2(+) 3.747, 3.975  
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Table 72. 1H-NMR assignment of L4-04. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1). 
L4-04 NH " ! Others 
Arg1 7.747 4.609 1.826 CH2(.) 1.596; CH2(+) 3.199; NH(&) 7.280 
Val2 8.488 4.687 1.880 CH3(.
2) 0.832, 
Arg3 8.905 4.725 1.658, 1.805 CH2(.) 1.479, 1.656; CH2(+) 3.156; NH(&) 7.230 
Cys4 9.171 5.620 2.610, 3.015 - 
Arg5 8.798 4.646 1.789 CH2(.) 1.586; CH2(+) 3.134, 3.194; NH(&) 7.230 
Lys6 8.827 4.947 1.636, 1.702 CH2(.) 1.214, CH2(+) 1.551; CH2(&) 2.872; NH2(() 
7.480 
Arg7 8.717 4.542 1.708, 1.763 CH2(.) 1.505, 1.622; CH2(+) 3.173; NH(&) 7.240 
D-
Arg8 
9.208 4.118 1.821 CH2(.) 1.629, 1.713, CH2(+) 3.220 NH(&) 7.210 
Gly9 8.987 3.944 - - 
Gln10 7.728 4.703 2.020, 2.117 CH2(.) 2.301, 2.356; NH2(&) 7.590, 6.920 
Thr11 8.941 4.625 3.960 CH3(.) 1.078 
Arg12 8.740 4.716 1.770, 1.827 CH2(.) 1.554, 1.633; CH2(+) 3.181; NH(&) 7.200 
Cys13 9.076 5.591 2.607, 2.983 - 
Ile14 8.858 4.516 1.828 CH2(.) 1.140, 1.422; CH3(.
2) 0.895; CH3(+
1) 0.834 
Arg15 8.586 4.846 1.675 1.814 CH2(.) 1.471, 1.555; CH2(+) 3.117, 3.194 
Ile16 8.821 4.546 1.779 CH2(.) 1.068, 1.415 CH3(.
2) 0.859; CH3(+
1) 0.815 
Pro17 - 4.747 1.916, 2.286 CH2(.) 2.014, 2.130; CH2(+) 3.521, 3.862 
Pro18 - 4.547 2.129, 2.235 CH2(.)1.889, 2.106; CH2(+) 3.740, 3.975  
 
 
 
Table 73. 1H-NMR assignment of L4-07. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1). 
L4-07 NH " ! Others 
Arg1 7.751 4.603 1.836 CH2(.) 1.600; CH2(+) 3.199; NH(&) 7.280 
Val2 8.475 4.664 1.894 CH3(.
2) 0.837, 
Arg3 8.918 4.716 1.665, 1.812 CH2(.) 1.490; CH2(+) 3.156; NH(&) 7.230 
Cys4 9.183 5.508 2.796, 2.985 - 
Arg5 8.653 4.585 1.823, 1.901 CH2(.) 1.678; CH2(+) 3.134, 3.194; NH(&) 7.230 
Arg6 8.621 4.354 1.802, 1.878 CH2(.) 1.613, 1.670; CH2(+) 3.151; NH2(&) 7.480 
Lys7 8.186 4.442 1.652, 1.734 CH2(.) 1.317, 1.354; CH2(+) 1.641; CH2(&) 2.972 
Gly 9.713 3.802, 4.307 - - 
Pro9 - 4.554 2.042, 2.260 CH2(.)1.989; CH2(+) 3.794, 3.654 
Gly10 8.136 3.882, 4.158 - - 
Gln11 8.330 4.581 1.883, 2.020 CH3(.) 2.229; NH2(&) 7.525 
Arg12 8.644 4.517 1.768, 1.886 CH2(.) 1.674; CH2(+) 3.181; NH(&) 7.200 
Cys13 8.906 5.466 2.613, 3.045 - 
Ile14 8.758 4.494 1.843 CH2(.) 1.150, 1.433; CH3(.
2) 0.896; CH3(+
1) 0.849 
Arg15 8.599 4.327 1.682 1.819 CH2(.) 1.471, 1.555; CH2(+) 3.117 
Ile16 8.800 4.552 1.781 CH2(.) 1.077, 1.424, CH3(.
2) 0.866; CH3(+
1) 0.824 
Pro17 - 4.747 1.914, 2.286 CH2(.) 2.010, 2.129; CH2(+) 3.528, 3.865 
Pro18 - 4.539 2.110, 2.232 CH2(.)1.897, 2.104; CH2(+) 3.735, 3.978  
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Table 74. 1H-NMR assignment of L4-09. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1). 
L4-09 NH " ! Others 
Arg1 7.696 4.505 1.898 CH2(.) 1.557, 1.650; CH2(+) 3.222; NH(&) 7.308 
Cys2 8.962 5.499 2.584, 3.083 - 
Arg3 8.769 4.629 1.773, 1.820 CH2(.) 1.524, 1.641; CH2(+) 3.156; NH(&) 7.230 
Val4 8.694 4.520 1.904 CH3(.
2) 0.810, 0.877 
Arg5 8.952 4.629 1.804, 1.848 CH2(.) 1.549, 1.655; CH2(+) 3.144, 3.199; NH(&) 
7.334 
Gln6 8.891 4.653 1.920, 1.967 CH2(.) 2.244; NH2(&) 7.564 
Arg7 8.804 4.497 1.731, 1.760 CH2(.) 1.494, 1.616; CH2(+) 3.165, 3.235; NH(&) 
7.370 
Lys8 9.382 4.030 1.775, 1.958 CH2(.) 1.406; CH2(+) 1.686; CH2(&) 2.975 
Gly9 8.732 3.703, 4.112 - - 
Arg10 7.918 4.573 1.749, 1.825 CH2(.) 1.615; CH2(+) 3.165, 3.235; NH(&) 7.370 
Ala11 8.638 4.508 1.274 - 
Arg12 8.748 4.540 1.727, 1.792 CH2(.) 1.607; CH2(+) 3.181; NH(&) 7.200 
Lys13 8.805 4.628 1.667, 1.775 CH2(.) 1.257, CH2(+) 1.630; CH2(&) 2.895 
Ile14 8.972 4.400 1.797 CH2(.) 1.194, 1.429; CH3(.
2) 0.874; CH3(+
1) 0.803 
Cys15 9.117 5.393 2.953, 3.099 - 
Ile16 8.670 4.563 1.891 CH2(.) 1.142, 1.522; CH3(.
2) 0.904; CH3(+
1) 0.873 
Pro17 - 4.756 1.846, 2.313 CH2(.) 2.004, 2.106; CH2(+) 3.609, 3.902 
Pro18 - 4.519 2.134, 2.238 CH2(.)1.906, 2.095; CH2(+) 3.727, 3.928  
 
 
Table 75. 1H-NMR assignment of L5-11. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1). 
L5-11 NH " ! Others 
Arg1 7.755 4.611 1.835 CH2(.) 1.603; CH2(+) 3.203; NH(&) 7.270 
Val2 8.473 4.708 1.883 CH3(.
2) 0.839, 
Arg3 8.897 4.732 1.656, 1.807 CH2(.) 1.489; CH2(+) 3.164; NH(&) 7.227 
Cys4 9.155 5.659 2.628, 3.047 - 
Arg5 8.855 4.633 1.804, 1.851 CH2(.) 1.528, 1.659; CH2(+) 3.135, 3.198; NH(&) 
7.190 
Gln6 8.727 4.72 1.933 CH2(.) 2.190, 2.212 
Arg7 8.888 4.527 1.672, 1.779 CH2(.) 1.472, 1.618; CH2(+) 3.160; NH(&) 7.250 
Lys8 9.379 3.949 1.804, 1.993 CH2(.) 1.405; CH2(+) 1.690; CH2(&) 2.989 
Gly9 8.623 3.669, 4.118 - - 
Arg10 7.793 4.635 1.766, 1.858 CH2(.) 1.597; CH2(+) 3.214; NH(&) 7.189 
Arg11 8.651 4.513 1.700, 1.760 CH3(.) 1.477 CH2(+) 3.146; NH(&) 7.206 
Ala12 8.842 4.722 1.361 - 
Cys13 8.891 5.555 2.634, 2.995 - 
Ile14 8.863 4.523 1.813 CH2(.) 1.143, 1.435; CH3(.
2) 0.904; CH3(+
1) 0.845 
Arg15 8.563 4.864 1.679 1.816 CH2(.) 1.472, 1.563; CH2(+) 3.129, 3.201, NH(&) 
7.255 
Ile16 8.816 4.550 1.784 CH2(.) 1.070, 1.416; CH3(.
2) 0.867; CH3(+
1) 0.813 
Pro17 - 4.762 2.290, 2.013 CH2(.) 2.013, 2.129; CH2(+) 3.523, 3.863 
Pro18 - 4.550 2.111, 2.240 CH2(.)1.895, 2.108; CH2(+) 3.741, 3.975  
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Table 76. 1H-NMR assignment of R1-06. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1). 
R1-06 NH " ! Others 
Trp1 8.044 4.469 3.311 CH2(+) 7.291; CH(&3) 7.587; CH(&1) 10.160, 
CH(33) 7.119; CH(32) 7.480; CH(42) 7.221 
Arg2 7.772 4.028 1.537, 1.685 CH2(.) 1.302; CH2(+) 3.086; NH(&) 7.153 
Arg3 7.895 4.209 1.695 1.882 CH2(.) 1.541, 1.581; CH2(+) 3.173; NH(&) 7.2 
Arg4 7.903 4.328 1.575, 1.876 CH2(.) 1.598; CH2(+) 3.115; NH(&) 7.14 
Ala5 8.249 4.370 1.389 -  
Gly6 8.380 3.886, 4.126 - - 
Lys7 8.439 4.283 1.744 1.860 CH2(.) 1.393, 1.450; CH2(+) 1.669; CH2(&) 
2.990 
Gln8 8.370 4.297 1.966, 2.115 CH2(.) 2.358, 1.687; CH2(&) 7.484, 6.870   
Arg9 8.392 4.221 1.718 1.789 CH2(.) 1.569; CH2(+) 3.147; NH(&) 7.16 
Asn10 8.215 4.641 2.716, 2.793 CH2(.) 7.525, 6.870 
Arg11 8.224 4.168 1.618  CH2(.) 1.243, 1.450; CH2(+) 2.947; NH(&) 
7.003 
Arg12 8.181 4.455 1.747, 1.867 CH2(.)1.611, 1.651; CH2(+) 3.202; NH(&) 7.19 
Pro13 - 4.718 1.947, 2.337 CH2(.) 2.080, 2.127; CH2(+) 3.747 
Pro14 - 4.441 1.753, 2.092 CH2(.)1.605, 1.925; CH2(+) 3.636, 3.808  
 
 
 
Table 77. 1H-NMR assignment of R2-14. Chemical shifts obtained relative to the internal TSP 
standard at 298K and pH=2.3 in H2O/D2O (9:1). 
R2-14 NH " ! Others 
Arg1 7.693 4.450 1.911 CH2(.) 1.605; 1.667; CH2(+) 3.234; NH(&) 
7.260 
Cys2 8.584 5.247 2.737, 2.994 - 
Arg3 8.638 4.532 1.818,  CH2(.) 1.562, 1.624; CH2(+) 3.208; NH(&) 
7.200 
Arg4 8.577 4.699 1.685, 1.773 CH2(.) 1.445, 1.536; CH2(+) 3.132; NH(&) 
7.217 
Ala5 8.423 4.515 1.340 - 
Lys6 9.004 4.056 1.825, 1.926 CH2(.) 1.420; CH2(+) 1.694; CH2(&) 3.001 
Gly7 8.615 3.720, 4.119 - - 
Gln8 7.946 4.529 1.965, 2.108 CH2(.) 2.324; CH2(&) 7.572, 6.905 
Arg9 8.693 4.514 1.662, 1.834 CH2(.) 1.508; CH2(+) 3.163; NH(&) 7.205 
Arg10 8.677 4.582 1.759, 1.840 CH2(.) 1.583, 1.637; CH2(+) 3.149, 3.187; 
NH(&) 7.174 
Cys11 8.786 5.215 2.940, 3.128 - 
Arg12 8.592 4.869 1.747, 1.839 CH2(.) 1.578, 1.664; CH2(+) 3.223; NH(&) 7.2 
Pro13 - 4.722 1.890, 2.303 CH2(.) 2.015, 2.097; CH2(+) 3.618, 3.812 
Pro14 - 4.483 2.089, 2.274 CH2(.)1.931, 2.090; CH2(+) 3.719, 3.925  
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Appendix 7: EMSA images for BIV/HIV Tat and Rev 
peptidomimetics 
 
Table 78. Library L1 of BIV Tat mimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 
BIV2 R V R T R G K R R I R V 
L1-01 R V R T R G K R R I R L 
L1-02 R V R T R G K R R I R I 
L1-03 R V R T R G K R R I R F 
L1-04 R V R T R G K R R I R T 
L1-05 R V R T R G K R R I R N 
L1-06 R V R T R G K R R I R R 
L1-07 R T R T R G K R R I R V 
L1-08 R N R T R G K R R I R V 
L1-09 R V R T R G K R R L R V 
L1-10 R V R T R G K R R Cha R V 
L1-11 R V R T R G K R R F R V 
L1-12 R V R T R G K R R Y R V 
L1-13 R V R T R G K R R N R V 
L1-14 R V R T R G K R R Q R V 
L1-15 R V R Q R G K R R I R V 
L1-16 R V R V R G K R R I R V 
L1-17 R V R Y R G K R R I R V 
L1-18 R V R K R G K R R I R V 
L1-19 R V K T R G K R R I R V 
L1-20 R V U T R G K R R I R V 
L1-21 R V O T R G K R R I R V 
L1-22 R V R T K G K R R I R V 
L1-23 R V R T U G K R R I R V 
L1-24 R V R T O G K R R I R V 
L1-25 R V R T N G K R R I R V 
L1-26 R V R T Q G K R R I R V 
L1-27 R V R T I G K R R I R V 
L1-28 R V R T L G K R R I R V 
L1-29 R V R T Y G K R R I R V 
L1-30 R V R T R G K K R I R V 
L1-31 R V R T R G K U R I R V 
L1-32 R V R T R G K O R I R V 
L1-33 R V R T R G K N R I R V 
L1-34 R V R T R G K F R I R V 
L1-35 R V R T R G K Y R I R V 
L1-36 R V R T R G K R K I R V 
L1-37 R V R T R G K R U I R V 
L1-38 R V R T R G K R O I R V 
L1-39 R V R T R G K R N I R V 
L1-40 R V R T R G K R Q I R V 
L1-41 R V R T R G K R R I K V 
L1-42 R V R T R G K R R I U V 
L1-43 R V R T R G K R R I O V 
L1-44 R V R T R G K R R I N V 
L1-45 R V R T R G K R R I Q V 
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Figure 80. Gel band shift assay of mimetics from library L1. Peptides and BIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Figure 81. Gel band shift assay of mimetics from library L1. Peptides and HIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Table 79. Library L2 of BIV Tat mimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 
L2-01 R V R T R G K R R I R I 
L2-02 U V R T R G K R R I R I 
L2-03 K V R T R G K R R I R I 
L2-04 O V R T R G K R R I R I 
L2-05 N V R T R G K R R I R I 
L2-06 Q V R T R G K R R I R I 
L2-07 Y V R T R G K R R I R I 
L2-08 L V R T R G K R R I R I 
L2-09 W V R T R G K R R I R I 
L2-10 R Q R T R G K R R I R I 
L2-11 R Y R T R G K R R I R I 
L2-12 R W R T R G K R R I R I 
L2-13 R L R T R G K R R I R I 
L2-14 R V R T R N G R R I R I 
L2-15 R V R T R K G R R I R I 
L2-16 R V R T R G R R R I R I 
L2-17 R V R T R G Y R R I R I 
L2-18 R V R T R G Q R R I R I 
L2-19 R V R T R G N R R I R I 
L2-20 R V R T R G O R R I R I 
L2-21 R V R T R G U R R I R I 
L2-22 R V Q T R G K R R I R I 
L2-23 R V N T R G K R R I R I 
L2-24 R T R T R G K R R I R I 
L2-25 R N R T R G K R R I R I 
L2-26 R V R T R G K R R I O I 
L2-27 R V R T R G K R R I K I 
L2-28 R V R T R G K R K I O I 
L2-29 R V R Q R G K R R I R I 
L2-30 R V R V R G K R R I R I 
L2-31 R V R Y R G K R R I R I 
L2-32 R T R Q R G K R R I R I 
L2-33 R T R T R G K R R I O I 
L2-34 R T R T R G K R K I O I 
L2-35 R T R Q R G K R R I O I 
L2-36 R T R V R G K R R I O I 
L2-37 R T R Y R G K R R I O I 
L2-38 R V R T R G K R R F R I 
L2-39 R T R T R G K R R F R I 
L2-40 R T R T R G K R R F O I 
L2-41 R V R Q R G K R R F O I 
L2-42 R T R V R G K R K F O I 
L2-43 R T R Y R G K R K F O I 
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Figure 82. Gel band shift assay of mimetics from library L2. Peptides and BIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Figure 83. Gel band shift assay of mimetics from library L2. Peptides and HIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Figure 84. Inhibition assay. Inhibition of the complex formation between the ADP-1 peptide (150 nM) 
and HIV-1 TAR RNA (1 nM) by L2-15 at the peptide concentrations shown (nM and µM). 
 
 
Table 80. Library L3 of HIV Tat peptidomimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position Template 
 1 2 3 4 5 6 7 8 9 10 11 12  
L3-01 R V R T R K G R R I R I D-Arg-L-Pro 
L3-02 R V R T R K G R R R R I D-Pro-L-Pro 
L3-03 R C R T R K G R R R C I D-Pro-L-Pro 
L3-04 R V R T R R G R R I R I D-Pro-L-Pro 
L3-05 R C R T R K G R R K C I D-Pro-L-Pro 
L3-06 R V R T R hR G R R K R I D-Pro-L-Pro 
 
Figure 85. Gel band shift assay of mimetics from library L3. Peptides and HIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Table 81. Library L4 (18-mer) of HIV Tat peptidomimetics. Residues 1 and 16 are attached to the D-
Pro-L-Pro template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
L4-01 R V R C R T R G K R R R C A R V 
L4-02 R V R C R Q R K G R A R C I R I 
L4-03 R V R C R K L K G Q T R C I R I 
L4-04 R V R C R K R DR G Q T R C I R I 
L4-05 R V R C R Q R G P G K R C I R I 
L4-06 R V R C R K Q G P G T R C I R I 
L4-07 R V R C R R K G P G Q R C I R I 
L4-08 R V R C R K R G P G Q R C I R I 
L4-09 R C R V R Q R K G R A R K I C I 
L4-10 R C R V R K Q G P G T R K I C I 
L4-11 R C R V R K Q G P G K R K I C I 
L4-12 R C R V R K R G P G Q R K I C I 
L4-13 R C R V R R K G P G A R K I C I 
 
Figure 86. Gel band shift assay of mimetics from library L4 (18-mer). Peptides and HIV TAR RNA 
(~2 nM) were incubated at the peptide concentrations shown. 
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Table 82. Library L4 (15-mer) of HIV Tat peptidomimetics. Residues 1 and 13 are attached to the D-
Pro-L-Pro template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
L4-14 R V R C R K K G K C I R I 
L4-15 R V R C R R R G R C I R I 
L4-16 R V R T R K K G K R I R I 
L4-17 R V R C R K K DP K C I R I 
L4-18 R V R T R K K DP K R I R I 
L4-19 R V R V R K K G R T I R I 
 
Figure 87. Gel band shift assay of mimetics from library L4 (15-mer). Peptides and HIV TAR RNA 
(~2 nM) were incubated at the peptide concentrations shown. 
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Table 83. Library L4 (16-mer) of HIV Tat peptidomimetics. Residues 1 and 14 are attached to the D-
Pro-L-Pro template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
L4-20 R V R C R K R K G R C I R I 
L4-21 R V R C R R K R G R C I R I 
L4-22 R V R T R Q R K G R R I R I 
L4-23 R V R V R K R K G R Q I R I 
L4-24 R V R Q R K R K G R V I R I 
L4-25 R V R C R K R K DP R C I R I 
 
Figure 88. Gel band shift assay of mimetics from library L4 (16-mer). Peptides and HIV TAR RNA 
(~2 nM) were incubated at the peptide concentrations shown. 
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Table 84. Library L4-04K of HIV Tat mimetics. Residues 1 and 16 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
L4-04 R V R C R K R DR G Q T R C I R I 
L4-04K01 K V R C R K R DR G Q T R C I R I 
L4-04K02 R V K C R K R DR G Q T R C I R I 
L4-04K03 R V R C K K R DR G Q T R C I R I 
L4-04K04 R V R C R K K DR G Q T R C I R I 
L4-04K05 R V R C R K R DR G Q T K C I R I 
L4-04K06 R V R C R K R DR G Q T R C I K I 
L4-04K07 R V R C R K R DK G Q T R C I R I 
 
Figure 89. Gel band shift assay of mimetics from library L4-04K. Peptides and HIV TAR RNA (~2 
nM) were incubated at the peptide concentrations shown. 
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Table 85. Library L2-15hR of HIV Tat mimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 
L2-15 R V R T R K G R R I R I 
L2-15hR01 hR V R T R K G R R I R I 
L2-15hR02 R V hR T R K G R R I R I 
L2-15hR03 R V R T hR K G R R I R I 
L2-15hR04 R V R T R K G hR R I R I 
L2-15hR05 R V R T R K G R hR I R I 
L2-15hR06 R V R T R K G R R I hR I 
 
 
Figure 90. Gel band shift assay of mimetics from library L2-15hR. Peptides and HIV TAR RNA (~2 
nM) were incubated at the peptide concentrations shown. 
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Table 86. Derivatives of L4-04 of HIV Tat mimetics.  
Mimetic Position Template 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  
L4-04 R V R C R K R DR G Q T R C I R I D-Pro-L-Pro 
L4-04a Ac-R V R C R K R DR G Q T R C I R I-NH2 -- 
L4-04b R V R Abu R K R DR G Q T R Abu I R I D-Pro-L-Pro 
L4-04c Ac-R V R Abu R K R DR G Q T R Abu I R I-NH2 -- 
 
Figure 91. Gel band shift assay of derivates of L4-04 peptide. Peptides and HIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Table 87. Library L5 of BIV Tat mimetics. Residues 1 and 16 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
L5-01 R V R C R K R R G Q T R C I R I 
L5-02 R V K C R K R K G Q T R C I R I 
L5-03 R V R C R K L DR G Q T R C I R I 
L5-04 R V R C R R K DR G Q T R C I R I 
L5-05 R V R T R K R DR G Q T R A I K I 
L5-06 R C R V R K R DR G Q T R R I C I 
L5-07 R V R C R K R G P G A R C I K I 
L5-08 R C R V R R K K G R A R K I C I 
L5-09 R C R V R Q R G P G A R K I C I 
L5-10 R V R C R T R K G R A R C I K I 
L5-11 R V R C R Q R K G R R A C I R I 
L5-12 R V R C R Q R K G R R I C I R I 
 
Figure 92. Gel band shift assay of mimetics from library L5. Peptides and HIV TAR RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Figure 93. Gel band shift assay of selected mimetics. Peptides and HIV TAR RNA (~2 nM) were 
incubated at the peptide concentrations shown. EMSA was performed in the absence of tRNA. 
 
Table 88. Library L4-04hR of HIV Tat mimetics. Residues 1 and 16 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
L4-04 R V R C R K R DR G Q T R C I R I 
L4-04hR01 hR V R C R K R DR G Q T R C I R I 
L4-04hR02 R V hR C R K R DR G Q T R C I R I 
L4-04hR03 R V R C hR K R DR G Q T R C I R I 
L4-04hR04 R V R C R K hR DR G Q T R C I R I 
L4-04hR05 R V R C R K R DR G Q T hR C I R I 
L4-04hR06 R V R C R K R DR G Q T R C I hR I 
Figure 94. Gel band shift assay of mimetics from library L4-04hR. Peptides and HIV TAR RNA (~2 
nM) were incubated at the peptide concentrations shown. 
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Table 89. Library R1 of Rev peptidomimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 
Rev Ac-RQARRNRRRRWRERNR-NH2 
BIV5 R R G T R G K R R I G R 
R1-01 W R R R A T DR Q R N R R 
R1-02 W R R R A P DR Q R N R R 
R1-03 W R R R G P DR Q R N R R 
R1-04 W R R R V P DR Q R N R R 
R1-05 W R R R A G DR Q R N R R 
R1-06 W R R R A G K Q R N R R 
R1-07 W R R R A T DR G R N R R 
R1-08 W R R R A P DR G R N R R 
R1-09 W R R R G P DR G R N R R 
R1-10 W R R R G T DR Q R N R R 
R1-11 W R R R V G DR Q R N R R 
R1-12 W R R R A S DR Q R N R R 
 
Figure 95. Gel band shift assay of mimetics from library R1. Peptides and HIV RRE RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Table 90. Library R2 of Rev peptidomimetics. Residues 1 and 12 are attached to the D-Pro-L-Pro 
template. 
Mimetic Position 
 1 2 3 4 5 6 7 8 9 10 11 12 
R2-01 W R R R A K G Q R N R R 
R2-02 W R L R A K G Q R N R R 
R2-03 W R Q R A K G Q R N R R 
R2-04 W R R R A K G Q R N R V 
R2-05 W R L R A DR K G R N R R 
R2-06 W R L R A K K G R N R R 
R2-07 W R K R A G K Q R N R R 
R2-08 W R K R A K G Q R N R R 
R2-09 W R R R A DR G Q R N R R 
R2-10 W R L R A DR G K R N R R 
R2-11 R R L R A DR G Q R N R R 
R2-12 R R L R A K G Q R N R R 
R2-13 R V R R A K G Q R N R R 
R2-14 R C R R A K G Q R R C R 
R2-15 K R Q R T K G R R L O R 
R2-16 W R R R A G R Q R N R R 
 
Figure 96. Gel band shift assay of mimetics from library R2. Peptides and HIV RRE RNA (~2 nM) 
were incubated at the peptide concentrations shown. 
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Figure 97. Gel band shift assay of selected Rev peptidomimetics and Ac-Arg7-NH2. Peptides and HIV 
RRE RNA (~2 nM) were incubated at the peptide concentrations shown. EMSA was performed in 
the absence of tRNA. 
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Zusammenfassung 
 
 
Diese Arbeit befasst sich mit der Entwicklung neuer antiviraler und 
antimikrobieller !-Haarnadel-Peptidmimetika (!-Hairpin). Das Ziel dabei war die 
Inhibition von wichtigen viralen Protein-RNA-Wechselwirkungen zwischen den 
Regulator-Proteinen Tat und Rev und ihren Ziel-RNAs TAR und RRE, und zwischen 
der RNA- und Protein-Domäne der bakteriellen RNase P. RNA und RNA/Protein- 
Wechselwirkungen haben in den letzten Jahrzehnten immer mehr an Bedeutung 
gewonnen. Die steigende Resistenz gegen antivirale Medikamente macht diese neuen 
Ziele interessant. Im Allgemeinen wird angenommen, dass es für Pathogene schwierig 
ist, RNA mit wichtigen Funktionen zu mutieren. Es wurde hier versucht die RNA-
bindenden Domänen der oben genannten Proteine durch zyklische Peptide 
nachzuahmen, welche ein heterochirales Diprolin-Templat enthalten. Diese Peptide 
bilden eine interessante Klasse von Peptidmimetika, da das D-Pro-L-Pro Motiv zur 
Bildung von !-Hairpins führt. Diese Mimetika können aus kommerziellen 
Aminosäuren über standardisierte Festphasensynthese oder in Lösung hergestellt 
werden. 
Die Wechselwirkung des viralen Tat-Proteins und seiner TAR-RNA 
(transactivator response element) spielt eine entscheidende Rolle im viralen 
Lebenszyklus. Die argininreiche RNA-bindende Domäne vom Rinder 
Immundefizienzvirus (BIV) Tat-Protein nimmt nach der Bindung an TAR-RNA eine 
!-Hairpin-Konformation an. Bisherige Studien von BIV Tat-Peptidmimetika haben 
die Identifikation eines sehr potenten BIV Tat-TAR Inhibitor, genannt BIV2, 
ermöglicht. Seine stabile !-Hairpin-Konformation und seine hohe Affinität für BIV 
TAR-RNA haben die Strukturaufklärung des Komplexes mit BIV TAR durch NMR-
Analysen ermöglicht. In dieser Arbeit wurden ausgedehnte Struktur-Aktivitäts-
Beziehungs-Studien (structure-activity-relationship, SAR) mit diesen 12-mer Loop 
BIV Tat-Peptidmimetika durchgeführt, welche weitere sehr potente und selektive 
Liganden lieferten. Weiterhin diente die BIV Tat-TAR Wechselwirkung als ein 
Modell, aus welchem wichtige Informationen über RNA-Erkennung gewonnen und 
auf den humanen Immundefizienzvirus Typ-1 (HIV-1) Tat-TAR übertragen werden 
konnten, was das Design neuer HIV Tat-Inhibitoren erleichterte. Durch Studien an 
einer umfangreichen Bibliothek aus BIV Tat-Peptidmimetika konnten einige potente 
 Zusammenfassung -240- 
 
und selektive Liganden für HIV-1 TAR-RNA identifiziert werden. Der beste Ligand, 
L2-15, weist eine Dissoziationskonstante (Kd) von ca. 75 nM und einen IC50 von ca. 
100 nM für die Hemmung der ADP-1 Binding an TAR auf.  
Analog zur BIV Anordnung, bindet das HIV Tat-Protein an die Wölbung 
(bulge) der TAR RNA Stamm-Schleife Struktur. Um die Funktion zu gewährleisten, 
muss ein ternärer Komplex zwischen Tat-TAR und Cyclin T1 gebildet werden, in 
welchem Cyclin T1 mit Tat und der Spitze des TAR-RNA-Loops wechselwirkt. 
Aufgrund von Computermodelling und SAR-Studien, wurden neue 16-mer Loop 
HIV-1 Tat-Peptidmimetika entwickelt, welche eine stabile !-Hairpin-Konformation in 
Wasser besitzen, mit hoher Affinität an TAR-RNA binden und fähig sind, die Tat-
TAR Wechselwirkung zu hemmen. Das beste Peptid in dieser Klasse, L5-11, weist 
einen Kd-Wert von ca. 25 nM in Gegenwart eines grossen Überschusses an tRNA und 
ca. 0.5 nM in Abwesenheit der Konkurrenz-tRNA auf. Weil die Struktur des HIV-1 
Tat-TAR-Komplexes noch nicht bekannt ist, wurden ausgedehnte SAR-Studien mit 
den 16-mer Loop Mimetika durchgeführt, um das Verständnis der 
Erkennungprinzipen dieser Protein/RNA-Wechselwirkung zu vertiefen. Weitere 
Studien mit HIV Tat-Peptidmimetika haben ihre Fähigkeit die Zellmembranen zu 
passieren und ihre Stabilität in biologischer Umgebung aufgezeigt. 
Der zweite kritische Schritt in der viralen Replikation ist die Bindung des Rev-
Proteins an RRE-RNA (Rev Response Element), welche den Transport ungespleisster 
und partiell gespleisster viraler RNA aus dem Zellkern in das Zytoplasma reguliert. 
Die RNA-bindende Domäne des Rev-Proteins nimmt im Komplex mit RRE eine "-
helikale Konformation an. Im zweiten Teil dieser Arbeit wurde ein neues Konzept 
angewandt, um diese "-helikale Struktur in !-Hairpin-Peptidmimetika nachzuahmen. 
Diese Peptidmimetika haben ein robustes Strukturgerüst, das die für die RRE-
Erkennung wichtigen Gruppen präsentiert. Durch Studien einer kleinen Familie 
zyklischer !-Hairpin-Peptidmimetika basierend auf BIV Tat-Peptidmimetika, und 
durch das Design einer neuen Serie von Peptiden basierend auf der Sequenz der 
RNA-bindenden Domäne des Rev-Proteins, wurde es ermöglicht, ein Set potenter 
RRE-Liganden zu entwickeln, welche vergleichbare Kd-Werte zu denen des Rev-
Peptids aufzeigten. Die !-Hairpin-Konformation der Peptide wurde durch den Einbau 
einer Disulfidbrücke stabilisiert, was zu einem sehr aktiven Rev-Peptidmimetikum, 
R2-14, mit stabiler !-Hairpin-Struktur in wässriger Lösung führte.  
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Ein ähnlicher Ansatz wurde auch für das Design neuer Peptidinhibitoren der 
E. coli RNase P, einem Ribonucleoprotein verwendet, welches die Reifung der 
Precursor-tRNA in allen drei Lebensdomänen reguliert. Ausgedehnte biochemische 
Untersuchungen an zwei verwandten Bakterienstämmen, E. coli und B. subtilis, 
ergaben, dass "-helikale, hoch konservierte und argininreiche Domänen des 
Proteinteils von RNase P mit dem katalytisch aktiven RNA-Teil wechselwirken. 
Durch Testen der Rev-Peptidmimetika, welche Sequenzähnlichkeit mit der RNA-
bindenden Domäne von RNase P haben, wurden zwei potente, gegen E. coli selektive, 
antimikrobielle Wirktstoffe gefunden. Die Informationen dieser besten 
Peptidmimetika und die Entwicklung eines Computermodells eines !-Hairpins, 
welches mit dem helikalen Epitop überlagert, führten zur Entwickelung sehr aktiver 
Inhibitoren von E. coli RNAse P. Der beste Inhibitor, P2-05, weist einen MIC-Wert 
(minimal inhibitory concentration) von 0.06 µg/ml auf. Diese Klasse von Peptiden hat 
günstige pharmakologische in vitro-Eigenschaften. Dazu gehören eine geringe 
haemolitische Aktivität und hohe Plasmastabilität. Diese Eigenschaften machen 
solche Peptidmimetika als zukünftige antimikrobielle Wirkstoffe interessant. 
Die drei beschriebenen Konzepte zur Herstellung von Inhibitoren von Protein-
RNA Wechselwirkungen führten zur Entdeckung sehr potenter und selektiver 
antiviraler und antimikrobieller Wirkstoffe, die sehr interessante Startpunkte für die 
Entwicklung von Medikamenten sind. Zusätzlich zu ihrem pharmakologischen 
Potenzial brachten ausgedehnte SAR-Studien wichtige Informationen über die 
Chemie und die Prinzipen der RNA-Erkennung durch diese strukturell und 
konformationell eingeschränkten Peptidmimetika. Diese könnten bei der Optimierung 
von anderen bekannten RNA-Liganden und in Zukunft bei der Entwicklung von 
Wirkstoffen gegen andere funktionelle RNAs helfen. 
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